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 Glioblastoma	  multiforme	  (GBM)	  is	  a	  malignant	  primary	  brain	  tumour	  that	  is	  almost	  always	  fatal.	  Conventional	  treatment	  modalities	  are	  limited	  by	  toxicity.	  T	  cell-­‐based	  immunotherapy	  is	  a	  promising	  alternative	  that	  has	  the	  potential	  to	  specifically	  target	  tumour	  cells.	  	  	  The	  author	  of	  this	  thesis	  was	  a	  principal	  investigator	  for	  a	  recently	  completed	  Phase	  I	  clinical	  trial	  in	  which	  patients	  with	  recurrent	  GBM	  were	  treated	  with	  surgery,	  dendritic	  cell-­‐based	  immunotherapy	  and	  chemotherapy.	  In	  addition	  to	  conducting	  the	  trial	  in	  collaboration	  with	  others,	  the	  author	  used	  peripheral	  blood	  mononuclear	  cells	  from	  trial	  participants	  to	  assess	  anti-­‐tumour	  immune	  responses	  before	  and	  after	  treatment.	  	  A	  broad	  correlation	  was	  observed	  between	  clinical	  outcome	  and	  anti-­‐tumour	  immunity,	  with	  sustained	  progression-­‐free	  survival	  occurring	  in	  two	  patients	  with	  baseline	  responses	  that	  persisted	  or	  increased	  after	  treatment.	  However,	  the	  overall	  clinical	  benefit	  was	  modest.	  For	  progress	  to	  be	  made,	  there	  is	  a	  need	  to	  develop	  a	  more	  potent	  vaccine.	  	  With	  this	  in	  mind,	  a	  novel	  “Glioma-­‐Gal”	  vaccine	  was	  devised	  and	  tested	  in	  an	  orthotopic	  mouse	  model	  of	  glioma,	  This	  simple	  vaccine	  consisted	  of	  irradiated	  autologous	  tumour	  cells	  pulsed	  with	  the	  glycolipid	  alpha-­‐galactosylceramide,	  an	  immunoadjuvant	  that	  induces	  invariant	  Natural	  Killer	  T	  cells	  to	  licence	  endogenous	  dendritic	  cells.	  The	  vaccine	  was	  shown	  to	  be	  effective	  in	  a	  therapeutic	  setting	  when	  accompanied	  by	  depletion	  of	  regulatory	  T	  cells.	  Mechanistically,	  vaccine	  efficacy	  was	  dependent	  on	  CD4	  T	  cells	  and	  the	  mediastinal	  lymph	  node	  was	  shown	  to	  be	  an	  important	  site	  of	  T	  cell	  priming.	  It	  was	  further	  shown	  that	  components	  of	  the	  immune	  system	  necessary	  for	  the	  vaccine	  to	  work	  were	  present	  and	  competent	  in	  a	  cohort	  of	  GBM	  patients.	  	  	  	  The	  final	  chapters	  explore	  the	  idea	  of	  enhancing	  the	  therapeutic	  benefit	  of	  this	  vaccine	  by	  targeting	  certain	  tumour	  cell	  subsets	  or	  phenotypes.	  Cancer	  stem	  cells	  (CSC)	  are	  proposed	  to	  be	  a	  subset	  of	  tumour	  cells	  with	  a	  unique	  capacity	  for	  initiating	  and	  maintaining	  tumours.	  	  Eliminating	  these	  cells	  may	  therefore	  be	  both	  necessary	  and	  sufficient	  to	  achieve	  cure.	  Using	  
 4 
the	  same	  mouse	  model,	  a	  variety	  of	  methods	  were	  assessed	  for	  their	  ability	  to	  isolate	  or	  enrich	  for	  a	  CSC	  subset.	  Of	  these,	  culture	  in	  serum-­‐free	  medium	  in	  the	  presence	  of	  certain	  growth	  factors	  was	  shown	  to	  enrich	  for	  a	  more	  stem	  cell-­‐like	  phenotype.	  However,	  a	  vaccine	  constructed	  from	  these	  stem	  cell-­‐like	  cells	  was	  not	  more	  effective	  than	  the	  standard	  vaccine.	  Next,	  the	  author	  tested	  the	  hypothesis	  that	  a	  vaccine	  manipulated	  to	  target	  chemoresistant	  cells	  would	  be	  more	  effective	  than	  standard	  vaccine	  when	  used	  in	  combination	  with	  chemotherapy.	  However,	  the	  modified	  vaccine	  showed	  no	  advantage	  over	  standard	  vaccine	  in	  this	  model.	  In	  the	  course	  of	  these	  experiments,	  synergy	  was	  observed	  between	  the	  vaccine	  and	  the	  chemotherapy	  agent	  doxorubicin.	  The	  mechanism	  responsible	  for	  this	  supra-­‐additive	  effect	  remains	  undetermined	  but	  is	  most	  likely	  due	  to	  an	  immunomodulatory	  effect	  of	  low	  dose	  doxorubicin.	  	  	  The	  Glioma-­‐Gal	  vaccine	  design	  holds	  promise	  but	  more	  studies	  are	  needed	  to	  realise	  the	  full	  potential	  of	  this	  approach.	  The	  data	  presented	  in	  the	  thesis	  did	  not	  support	  targeting	  CSC	  or	  chemoresistant	  cells	  as	  ways	  of	  achieving	  this.	  In	  contrast,	  combining	  the	  vaccine	  with	  immunomodulation	  was	  effective	  and	  merits	  further	  exploration.	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   Endoplasmic	  reticulum	  FACS	   Fluorescence-­‐activated	  cell	  sorting	  FasL	   Fas	  ligand	  FBC	   Full	  blood	  count	  FC	   Flow	  cytometry	  FCS	   Foetal	  calf	  serum	  FNSC	   Foetal	  neural	  stem	  cell	  GAA	   Glioma-­‐associated	  antigen	  GFP	   Green	  fluorescent	  protein	  GBM	   Glioblastoma	  multiforme	  GM-­‐CSF	   Granulocyte	  Macrophage	  colony-­‐stimulating	  factor	  gp100	   Glycoprotein	  100	  HIV	   Human	  immunodeficiency	  virus	  HLA	   Human	  leucocyte	  antigen	  HMGB1	   High	  mobility	  group	  box	  1	  i.c.	   Intracranial	  i.d.	   Intradermal	  i.p.	   Intraperitoneal	  i.v.	   Intravenous	  ICAM-­‐1	   Intercellular	  adhesion	  molecule-­‐1	  IDH1	   Isocitrate	  dehydrogenase	  1	  IDO	   Indoleamine	  2,3-­‐dioxygenase	  1	  IFN-­‐γ	  	   Interferon-­‐gamma	  Ig	   Immunoglogbulin	  IL-­‐	   Interleukin-­‐	  IMDM	   Iscove’s	  modified	  Dulbecco’s	  medium	  iNKT	   Invariant	  Natural	  Killer	  T	  [cell]	  iNOS	   Inducible	  Nitric	  Oxide	  synthase	  iTreg	   Induced	  regulatory	  T	  cell	  IQR	   Interquartile	  range	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KLH	   Keyhole	  limpet	  haemocyanin	  LAK	   Lymphokine-­‐activated	  killer	  [cell]	  LC	   Langerhans	  cell	  LLC	   Lewis	  Lung	  Carcinoma	  LN	   Lymph	  node	  mAb	   Monoclonal	  antibody	  MdLN	   Mediastinal	  lymph	  node	  MDR-­‐1	   Multidrug	  resistance	  protein	  -­‐	  1	  MDSC	   Myeloid-­‐derived	  suppressor	  cell	  MGMT	   O6-­‐methylguanine-­‐DNA	  methyltransferase	  MHC	   Major	  histocompatibility	  molecule	  MPEC	   Memory	  precursor	  effector	  cell	  MR	   Mannose	  receptor	  MRI	  	   Magnetic	  resonance	  imaging	  mRNA	   Messenger	  RNA	  MRP	   Multidrug	  resistance-­‐associated	  protein	  Msi-­‐1	   Musashi-­‐1	  MTD	   Maximally	  tolerated	  dose	  NCI	  CTC	   National	  Cancer	  Institute	  Common	  Terminology	  Criteria	  NF1	   Neurofibromatosis	  type	  1	  NK	  	   Natural	  Killer	  [cell]	  NKT	   Natural	  Killer	  T	  [cell]	  NO	   Nitric	  oxide	  NOD/SCID	   Non-­‐obese	  diabetic/severe	  combined	  immunodeficiency	  NSC	   Neural	  stem	  cell	  nTreg	   Natural	  regulatory	  T	  cell	  OS	   Overall	  survival	  OVA	   Ovalbumin	  PAMP	   Pathogen-­‐associated	  molecular	  pattern	  PBMC	   Peripheral	  blood	  mononuclear	  cell	  PBS	   Phosphate-­‐buffered	  saline	  PCR	   Polymerase	  chain	  reaction	  PD	   Progressive	  disease	  PD-­‐1	   Programmed	  cell	  death	  protein	  1	  PD-­‐L1	   B7	  family	  member,	  ligand	  for	  PD-­‐1	  pDC	   Plasmacytoid	  dendritic	  cell	  PDGR	   Platelet-­‐derived	  growth	  factor	  PDGFR	   Platelet-­‐derived	  growth	  factor	  receptor	  PEG-­‐Dox	   Pegylated	  liposomal	  doxorubicin	  PFS	   Progression-­‐free	  survival	  PFS6MO	   Progression-­‐free	  survival	  at	  6	  months	  PGE2	   Prostaglandin	  E2	  PI3K	   Phosphatidylinositol	  3-­‐kinase	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PR	   Partial	  response	  PRR	   Pattern-­‐recognition	  receptor	  PTEN	   Phosphatase	  and	  tensin	  homolog	  PVDF	   Polyvinyl	  difluoride	  RBC	   Red	  blood	  cell	  rhX	   Recombinant	  human	  X	  RNA	   Ribonucleic	  acid	  ROS	   Reactive	  oxygen	  species	  RPA	   Recursive	  partitioning	  analysis	  RT-­‐PCR	   Reverse	  transcription	  polymerase	  chain	  reaction	  s.c.	   Subcutaneous	  SC	   Stem	  cell	  SD	   Stable	  disease	  SDS	   Sodium	  dodecyl	  sulfate	  SEM	   Standard	  error	  of	  the	  mean	  SLCC	   Stem-­‐like	  cancer	  cell	  SLEC	   Short-­‐lived	  effector	  cell	  SLP	   Synthetic	  long	  peptide	  SOX2	   Sex	  determining	  region	  Y-­‐box	  2	  SP	   Side	  population	  STAT-­‐3	   Signal	  transducer	  and	  activator	  of	  transcription-­‐3	  TAA	   Tumour-­‐associated	  antigen	  TAM	   Tumour	  associated	  macrophage	  TAP	   Transporter	  associated	  with	  antigen	  processing	  	  TCM	   Central	  memory	  T	  cell	  TCR	   T	  cell	  receptor	  TEM	   Effector	  memory	  T	  cell	  TFH	   Follicular	  helper	  T	  cell	  TGF-­‐β	   Transforming	  growth	  factor-­‐beta	  TH	  	   T	  helper	  [cell]	  	  TIDC	   Tumour-­‐infiltrating	  dendritic	  cell	  TIL	   Tumour-­‐infiltrating	  leucocyte	  TLR	   Toll-­‐like	  receptor	  TMZ	   Temozolomide	  TNF-­‐α	   	   Tumour	  Necrosis	  Factor-­‐alpha	  Topo	  II	   Type	  2	  topoisomerase	  	  TRAIL	   TNF-­‐related	  apoptosis	  inducing	  ligand	  Treg	   Regulatory	  T	  cell	  TRP-­‐2	   Tyrosinase-­‐related	  protein-­‐2	  VEGF	   Vascular	  endothelial	  growth	  factor	  WT	   Wild	  type	  WHO	   World	  Health	  Organisation	  YB-­‐1	   Y-­‐box	  binding	  protein	  1	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CHAPTER	  1:	  GENERAL	  INTRODUCTION	  
	  
1.1	  THE	  CLINICAL	  PROBLEM:	  GLIOBLASTOMA	  MULTIFORME	  Glioblastoma	  multiforme	  (GBM)	  is	  a	  highly	  malignant	  primary	  brain	  tumour	  that	  is	  almost	  universally	  fatal.	  It	  is	  the	  most	  common	  form	  of	  primary	  brain	  tumour	  in	  adults.	  A	  study	  of	  patients	  referred	  to	  the	  Wellington	  neurosurgery	  unit	  found	  an	  incidence	  of	  4.1	  new	  cases	  per	  year	  per	  100,000	  population	  that	  was	  similar	  for	  Maori	  and	  non-­‐Maori	  when	  adjusted	  for	  age	  (Alexander	  et	  al.	  2010).	  The	  median	  age	  at	  first	  presentation	  was	  62	  years	  with	  males	  outnumbering	  females	  by	  a	  ratio	  of	  1.5	  to	  1.	  These	  tumours	  almost	  always	  arise	  in	  the	  deep	  white	  matter	  of	  the	  cerebral	  hemispheres.	  Patients	  present	  with	  symptoms	  of	  raised	  intracranial	  pressure,	  seizures	  or	  focal	  neurological	  deficits.	  Imaging	  with	  Magnetic	  Resonance	  Imaging	  (MRI)	  or	  Computerised	  Tomography	  (CT)	  typically	  shows	  a	  mass	  lesion	  surrounded	  by	  a	  zone	  of	  oedema	  that	  exerts	  pressure	  on	  the	  surrounding	  brain	  and,	  after	  administration	  of	  an	  intravenous	  contrast	  agent,	  tumours	  typically	  have	  necrotic	  centre	  surrounded	  by	  a	  contrast-­‐enhancing	  rim.	  	  GBM	  tumours	  are	  locally	  invasive.	  Location	  in	  a	  critical	  organ	  combined	  with	  a	  poorly-­‐defined	  infiltrative	  border	  means	  that	  surgery	  alone	  is	  never	  curative.	  Until	  recently,	  standard	  management	  consisted	  of	  maximum	  safe	  surgical	  debulking	  followed	  by	  external	  beam	  radiotherapy.	  	  Post-­‐operative	  radiotherapy	  is	  effective	  and	  doubles	  median	  survival	  compared	  with	  surgery	  alone,	  but	  recurrence	  is	  inevitable	  (M.	  D.	  Walker	  et	  al.	  1979).	  In	  a	  landmark	  paper	  published	  in	  2005,	  Stupp	  and	  colleagues	  reported	  the	  results	  of	  a	  Phase	  III	  randomised	  controlled	  trial	  showing	  a	  statistically	  significant	  survival	  benefit	  when	  the	  alkylating	  agent	  temozolomide	  (TMZ)	  is	  added	  to	  surgery	  and	  radiotherapy,	  and	  this	  combined	  regimen	  has	  now	  been	  adopted	  as	  the	  standard	  management	  for	  newly-­‐presenting	  patients	  (Stupp	  et	  al.	  2005).	  Although	  TMZ	  is	  the	  most	  important	  advance	  in	  the	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treatment	  of	  GBM	  for	  more	  than	  50	  years,	  median	  survival	  is	  still	  only	  15	  months,	  five	  year	  survival	  is	  less	  than	  10	  %,	  and	  long	  term	  survival	  remains	  an	  extremely	  rare	  event	  (Stupp	  et	  al.	  2009).	  In	  clinical	  practice	  the	  diagnosis	  of	  GBM	  is	  histopathological,	  and	  requires	  the	  presence	  of	  atypical	  pleomorphic	  cells	  of	  astrocytic	  morphology,	  evidence	  of	  mitotic	  activity,	  and	  either	  areas	  of	  necrosis	  or	  vascular	  proliferation	  (D.	  N.	  Louis	  et	  al.	  2007).	  It	  is	  now	  widely	  accepted	  that	  these	  microscopic	  appearances	  are	  a	  common	  morphology	  shared	  by	  a	  set	  of	  tumours	  that	  are	  different	  at	  a	  molecular	  level.	  Under	  the	  World	  Health	  System	  (WHO)	  for	  classifying	  central	  nervous	  system	  (CNS)	  tumours,	  GBM	  is	  classified	  as	  the	  most	  aggressive	  form	  of	  diffuse	  astrocytoma	  (“Grade	  IV”),	  with	  the	  cell	  of	  origin	  presumed	  to	  be	  an	  oncologically-­‐transformed	  astrocyte.	  	  (Note:	  The	  commonly	  used	  term	  “high	  grade	  glioma”	  encompasses	  both	  GBM	  and	  the	  less	  common	  anaplastic	  astrocytoma,	  itself	  a	  synonym	  for	  WHO	  Grade	  III	  Diffuse	  Astrocytoma).	  	  However,	  there	  is	  some	  support	  for	  the	  idea	  that	  neural	  stem	  cells	  or	  early	  progenitor	  cells	  may	  the	  cells	  of	  origin	  of	  at	  least	  some	  GBM	  (The	  concept	  of	  “cancer	  stem	  cells”	  is	  discussed	  in	  detail	  in	  Chapter	  5).	  The	  aetiology	  of	  most	  GBM	  tumours	  is	  unknown.	  Some	  inherited	  mutations	  increase	  the	  risk	  of	  high	  grade	  glioma	  (reviewed	  in	  Schwartzbaum	  et	  al.	  2006)	  but	  these	  account	  for	  only	  a	  small	  minority	  of	  patients.	  The	  only	  proven	  environmental	  risk	  factor	  is	  high	  dose	  radiation	  (Schwartzbaum	  et	  al.	  2006).	  Several	  studies	  have	  suggested	  an	  association	  with	  exposure	  to	  petrochemicals,	  pesticides,	  and	  other	  chemicals	  but	  this	  has	  not	  been	  a	  consistent	  finding	  (reviewed	  in	  Schwartzbaum	  et	  al.	  2006).	  	  Studies	  on	  the	  effect	  of	  cell	  phone	  usage	  on	  the	  incidence	  of	  brain	  tumours	  have	  also	  reached	  conflicting	  conclusions	  (Corle	  et	  al.	  2012).	  A	  causal	  link	  with	  infection	  is	  unproven.	  Although	  human	  cytomegalovirus	  (CMV)	  is	  detectable	  in	  over	  90	  %	  of	  GBM	  tumours	  and	  in	  the	  peripheral	  blood	  of	  80	  %	  of	  patients	  with	  newly	  diagnosed	  GBM,	  it	  remains	  unclear	  whether	  this	  is	  due	  to	  reactivation	  of	  latent	  infection	  due	  to	  tumour-­‐induced	  immunosuppression	  or	  whether	  the	  virus	  plays	  a	  role	  in	  oncogenesis	  (Mitchell	  et	  al.	  2008b).	  The	  possibility	  of	  exploiting	  CMV	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infection	  of	  glioma	  tumour	  cells	  by	  targeting	  CMV	  antigens	  with	  immunotherapy	  is	  under	  investigation	  (Mitchell	  et	  al.	  2015b;	  Prins	  et	  al.	  2008)	  Interestingly,	  an	  inverse	  correlation	  between	  the	  incidence	  of	  GBM	  and	  infection	  by	  the	  Herpes	  virus	  Varicella-­‐Zoster	  has	  been	  reported	  (Wrensch	  et	  al.	  2005).	  	  Clinically,	  most	  patients	  with	  GBM	  present	  with	  a	  rapidly	  progressive	  illness	  and	  their	  resected	  tumours	  satisfy	  the	  histological	  criteria	  for	  GBM	  at	  this	  first	  presentation	  (“de	  novo”	  or	  primary	  GBM).	  Others	  evolve	  over	  time	  from	  a	  lower	  grade	  astrocytoma	  (secondary	  GBM).	  These	  two	  clinical	  subtypes	  of	  GBM	  are	  associated	  with	  different	  patterns	  of	  genetic	  abnormality.	  Primary	  GBM	  commonly	  have	  gain-­‐of-­‐function	  epidermal	  growth	  factor	  receptor	  (EGFR)	  mutations	  or	  amplifications	  or	  deletion	  of	  phosphatase	  and	  tensin	  homolog	  (PTEN),	  while	  secondary	  tumours	  commonly	  lack	  EGFR	  mutations	  but	  have	  deletions	  of	  the	  tumour	  suppressor	  gene	  p53	  (Ohgaki	  and	  Kleihues	  2007;	  Schwartzbaum	  et	  al.	  2006).	  Although	  these	  differences	  demonstrate	  different	  pathways	  to	  the	  formation	  of	  tumours	  with	  identical	  morphology,	  a	  simple	  “two-­‐pathway”	  model	  does	  not	  account	  for	  the	  significant	  proportion	  of	  GBM	  tumours	  that	  do	  not	  fit	  into	  either	  of	  these	  two	  patterns	  (Schwartzbaum	  et	  al.	  2006).	  	  More	  recently,	  sub-­‐classifications	  based	  on	  gene	  expression	  “signatures”	  (Freije	  et	  al.	  2004;	  Nutt	  et	  al.	  2003;	  H.	  S.	  Phillips	  et	  al.	  2006)	  or	  a	  combination	  of	  gene	  expression	  and	  patterns	  of	  genetic	  mutation	  (Verhaak	  et	  al.	  2009)	  have	  been	  described	  that	  propose	  the	  existence	  of	  three	  or	  four	  molecular	  subgroups	  of	  GBM.	  Although	  these	  studies	  have	  reached	  slightly	  different	  conclusions,	  this	  kind	  of	  molecular	  classification	  holds	  promise	  for	  more	  accurate	  prognostic	  stratification	  and	  refinement	  of	  treatment	  selection.	  A	  “proneural”	  tumour	  signature	  is	  characterised	  by	  p53	  mutation,	  platelet-­‐derived	  growth	  factor	  receptor	  (PDGFR)	  amplification,	  isocitrate	  dehydrogenase-­‐1	  (IDH-­‐1)	  mutations,	  and	  expression	  of	  oligodendroglial	  (Verhaak	  et	  al.	  2009)	  or	  neuronal	  (H.	  S.	  Phillips	  et	  al.	  2006)	  markers,	  and	  is	  clinically	  associated	  with	  younger	  age,	  secondary	  tumours,	  and	  a	  slightly	  better	  overall	  prognosis.	  	  A	  “mesenchymal”	  signature	  is	  characterised	  by	  the	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expression	  of	  mesenchymal	  markers	  and	  genes	  associated	  with	  angiogenesis	  such	  as	  vascular	  endothelial	  growth	  factor	  (VEGF),	  as	  well	  as	  mutations	  or	  deletion	  of	  neurofibromatosis	  type	  1	  (NF1).	  Another	  group	  of	  tumours	  termed	  “proliferative”	  (H.	  S.	  Phillips	  et	  al.	  2006)	  or	  “classical”	  (Verhaak	  et	  al.	  2009)	  harbour	  mutations	  or	  amplifications	  of	  EGFR	  and	  deletions	  of	  PTEN,	  leading	  to	  constitutive	  overactivity	  of	  the	  phosphatidylinositol	  3-­‐kinase	  (PI3K)/Akt	  signalling	  pathway	  that	  drives	  proliferation.	  The	  potential	  usefulness	  of	  this	  kind	  of	  molecular	  classification	  to	  immunotherapists	  is	  illustrated	  by	  the	  recent	  report	  of	  a	  clinical	  trial	  of	  dendritic	  cell	  vaccination	  in	  which	  prolonged	  survival	  was	  seen	  only	  in	  the	  group	  of	  patients	  with	  tumours	  of	  the	  “mesenchymal”	  type	  (Prins	  et	  al.	  2011).	  	  There	  is	  no	  standard	  treatment	  for	  recurrent	  GBM.	  The	  range	  of	  treatment	  options	  includes	  further	  surgical	  debulking,	  second-­‐line	  chemotherapy	  regimens	  and	  additional	  focused	  irradiation.	  	  However,	  these	  treatment	  modalities	  are	  often	  restricted	  by	  local	  or	  systemic	  toxicity	  or	  a	  risk	  of	  unacceptable	  neurological	  deficits.	  Survival	  benefit	  is	  limited	  and	  the	  emphasis	  of	  management	  is	  on	  symptom	  palliation.	  Median	  survival	  from	  time	  of	  progression	  or	  recurrence	  is	  just	  6.9	  months	  (Stupp	  et	  al.	  2005).	  Motivating	  this	  thesis	  is	  the	  clear	  need	  to	  develop	  more	  effective	  treatments	  for	  this	  lethal	  disease.	  One	  promising	  alternative	  approach	  is	  to	  exploit	  the	  power	  of	  the	  patient’s	  own	  immune	  system.	  Immunotherapies	  have	  the	  potential	  to	  specifically	  eliminate	  cancer	  cells	  without	  the	  unacceptable	  collateral	  damage	  associated	  with	  standard	  modalities	  (Palucka	  et	  al.	  2011;	  Pardoll	  2012).	  Furthermore,	  by	  inducing	  long-­‐lived	  memory	  cells,	  vaccines	  can	  potentially	  have	  anti-­‐tumour	  effects	  that	  persist	  long	  after	  the	  completion	  of	  treatment.	  	  In	  this	  chapter	  I	  will	  start	  by	  introducing	  the	  immune	  system	  and	  cancer	  immunotherapy	  in	  general	  and	  then	  focus	  on	  the	  particular	  field	  of	  therapeutic	  vaccination	  for	  glioma.	  	  
1.2	  INTRODUCTION	  TO	  THE	  IMMUNE	  SYSTEM:	  REQUIREMENTS	  FOR	  ANTI-­‐
TUMOUR	  IMMUNE	  RESPONSES	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1.2.1	  The	  innate	  and	  adaptive	  immune	  systems	  The	  immune	  system	  has	  evolved	  primarily	  to	  provide	  protection	  against	  pathogenic	  microorganisms	  (K.	  Murphy	  2008).	  The	  innate	  and	  adaptive	  immune	  systems	  work	  in	  an	  interconnected	  way	  to	  achieve	  this	  purpose.	  The	  innate	  system	  is	  a	  first	  line	  of	  defence	  that	  responds	  rapidly	  to	  pathogens	  that	  have	  succeeded	  in	  breaching	  epithelial	  barriers.	  An	  innate	  response	  is	  triggered	  by	  the	  recognition	  of	  non-­‐specific	  signals	  that	  alert	  the	  immune	  system	  to	  the	  presence	  of	  foreign	  microorganisms	  and/or	  tissue	  damage.	  Innate	  effector	  cells	  include	  phagocytic	  cells	  such	  as	  macrophages	  and	  neutrophils,	  and	  Natural	  Killer	  (NK)	  cells	  that	  are	  specialised	  to	  recognise	  “altered	  self”.	  The	  innate	  system	  also	  includes	  a	  range	  of	  soluble	  factors	  elaborated	  by	  non-­‐immune	  cells	  such	  as	  antibacterial	  defensin	  proteins	  secreted	  by	  mucosal	  cells	  of	  the	  gut	  and	  the	  components	  of	  the	  complement	  system	  produced	  by	  the	  liver.	  	  In	  some	  cases	  the	  innate	  system	  alone	  is	  capable	  of	  clearing	  a	  pathogen	  but,	  failing	  this,	  the	  innate	  system	  serves	  to	  control	  the	  infection	  until	  a	  more	  potent	  and	  pathogen-­‐specific	  adaptive	  immune	  response	  has	  time	  to	  fully	  develop.	  The	  key	  effectors	  of	  this	  second	  line	  of	  defence	  are	  T	  cells	  and	  B	  cells,	  responsible	  for	  cell-­‐mediated	  and	  antibody-­‐mediated	  responses	  respectively.	  With	  few	  exceptions,	  adaptive	  responses	  are	  controlled	  by	  dendritic	  cells	  (DC),	  specialised	  antigen-­‐presenting	  cells	  (APC)	  that	  take	  up	  and	  present	  antigen	  to	  T	  cells.	  The	  adaptive	  system	  is	  also	  responsible	  for	  the	  phenomenon	  of	  immunological	  memory,	  whereby	  subsequent	  encounters	  with	  the	  same	  pathogen	  elicit	  a	  faster	  and	  more	  potent	  response.	  The	  two	  arms	  of	  the	  immune	  system,	  innate	  and	  adaptive,	  are	  closely	  integrated.	  For	  example,	  cells	  of	  the	  adaptive	  system	  may	  exert	  some	  of	  their	  effector	  functions	  indirectly	  through	  the	  actions	  of	  innate	  cells.	  Conversely,	  the	  innate	  system	  has	  an	  important	  role	  in	  determining	  whether	  the	  threshold	  for	  triggering	  an	  adaptive	  response	  is	  reached.	  	  In	  addition	  to	  its	  primary	  role	  of	  providing	  protection	  against	  infections,	  the	  immune	  system	  is	  also	  capable	  of	  mediating	  anti-­‐tumour	  effects.	  Whereas	  cells	  of	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the	  innate	  immune	  system	  are	  rapidly	  activated	  by	  the	  recognition	  of	  generic	  pathogen-­‐	  or	  danger-­‐associated	  molecules,	  the	  lymphocytes	  of	  the	  adaptive	  system	  provide	  a	  more	  specific	  line	  of	  defence	  that	  is	  also	  more	  potent.	  B-­‐lymphocytes	  are	  responsible	  for	  humoral	  immunity,	  namely	  the	  production	  and	  secretion	  of	  soluble	  antibodies.	  Antibodies	  are	  primarily	  concerned	  with	  binding	  to	  extracellular	  antigens,	  such	  as	  extracellular	  pathogens	  and	  toxins.	  However,	  antibodies	  can	  also	  bind	  to	  antigens	  on	  cancer	  cell	  surfaces,	  thereby	  opsonising	  cells	  for	  phagocytosis	  by	  macrophages,	  triggering	  antibody-­‐dependent	  cellular	  cytotoxicity	  (ADCC),	  or	  blocking	  the	  activity	  of	  a	  surface	  molecule	  that	  promotes	  tumour	  progression	  (Heo	  et	  al.	  2012).	  Circulating	  antibodies	  to	  tumour-­‐associated	  antigens	  (TAA)	  have	  been	  widely	  reported	  in	  patients	  with	  cancer	  (reviewed	  in	  Heo	  et	  al.	  2012)	  and	  have	  proved	  a	  useful	  means	  of	  identifying	  potential	  antigen	  targets	  for	  immunotherapy	  (Ueda	  et	  al.	  2004).	  However,	  although	  the	  presence	  of	  TAA-­‐specific	  antibodies	  proves	  that	  an	  adaptive	  response	  exists,	  the	  importance	  of	  endogenous	  humoral	  responses	  to	  effective	  anti-­‐tumour	  immunity	  is	  unclear	  (Heo	  et	  al.	  2012).	  In	  contrast,	  animal	  experiments	  have	  firmly	  established	  a	  role	  for	  T	  cells	  anti-­‐tumour	  immunity	  (K.	  Murphy	  2008)	  and	  generating	  tumour-­‐specific	  T	  cells	  has	  been	  the	  goal	  of	  most	  cancer	  vaccines.	  	  	  	  
1.2.2	  T	  cells	  in	  anti-­‐cancer	  immune	  responses	  1.2.2.1	  T	  cell	  development:	  diversity	  and	  clonal	  selection	  T	  cells	  recognise	  peptide	  antigens	  using	  T	  cell	  receptors	  (TCR)	  on	  the	  cell	  surface.	  Unlike	  antibodies,	  TCR	  do	  not	  bind	  to	  free	  antigen	  but	  instead	  recognise	  a	  complex	  of	  peptide	  bound	  to	  a	  Major	  Histocompatibility	  Complex	  (MHC)	  molecule	  on	  the	  surface	  of	  another	  cell.	  There	  are	  two	  main	  T	  cell	  subsets.	  CD8	  T	  cells	  recognise	  peptides	  of	  8-­‐10	  amino	  acids	  in	  length	  that	  are	  bound	  to	  MHC	  class	  I	  molecules.	  CD4	  T	  cells	  recognise	  peptides	  of	  12-­‐16	  amino	  acids	  presented	  by	  MHC	  class	  II.	  The	  specificity	  of	  each	  TCR	  (i.e.	  the	  specific	  peptide-­‐MHC	  complex	  it	  will	  recognise)	  is	  determined	  by	  its	  variable	  region,	  the	  region	  of	  the	  TCR	  that	  binds	  to	  the	  peptide-­‐
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MHC	  complex.	  Immature	  T	  lymphocytes	  are	  produced	  in	  the	  bone	  marrow	  throughout	  life	  and	  travel	  via	  the	  circulation	  to	  the	  thymus	  to	  complete	  differentiation.	  In	  the	  thymus,	  genes	  encoding	  the	  amino	  acid	  sequence	  of	  the	  variable	  region	  undergo	  a	  process	  of	  rearrangement	  that	  in	  turn	  generates	  T	  cells	  with	  different	  TCR	  variable	  regions	  and	  hence	  diverse	  specificities.	  The	  purpose	  of	  this	  diversity	  is	  to	  generate	  T	  cells	  capable	  of	  recognising	  a	  wide	  range	  of	  foreign	  antigens.	  However,	  before	  leaving	  the	  thymus,	  T	  cells	  undergo	  a	  process	  of	  negative	  and	  positive	  selection.	  The	  essentially	  random	  process	  of	  gene	  rearrangement	  inevitably	  produces	  cells	  that	  are	  of	  no	  use	  (because	  they	  bind	  too	  weakly	  to	  MHC)	  or	  are	  too	  dangerous	  (because	  they	  bind	  too	  strongly	  to	  MHC	  complexed	  to	  “self”	  peptides	  derived	  from	  normal	  tissues).	  These	  cells	  are	  deleted.	  The	  deletion	  of	  strongly	  self-­‐reactive	  T	  cells	  is	  termed	  	  “central	  tolerance”.	  	  In	  order	  to	  be	  positively	  selected,	  T	  cells	  must	  receive	  a	  survival	  signal	  through	  the	  TCR	  when	  it	  successfully	  binds	  to	  a	  peptide-­‐MHC	  complex	  expressed	  by	  specialised	  thymic	  epithelial	  cells.	  It	  is	  pertinent	  to	  note	  that	  the	  peptides	  presented	  to	  T	  cells	  in	  the	  thymus	  are	  derived	  from	  normal	  tissues	  –	  thus	  all	  T	  cells	  that	  survive	  clonal	  selection	  are	  to	  some	  extent	  self-­‐reactive.	  This	  is	  reassuring	  for	  tumour	  immunotherapy,	  where	  the	  aim	  is	  usually	  to	  target	  over-­‐expressed	  self-­‐antigens.	  However,	  it	  also	  means	  that	  “central	  tolerance”	  must	  be	  backed	  up	  by	  another	  set	  of	  “peripheral	  tolerance”	  mechanisms	  to	  prevent	  auto-­‐reactivity	  (described	  below).	  Mature	  T	  cells	  that	  have	  survived	  the	  process	  of	  clonal	  selection	  leave	  the	  thymus	  to	  join	  a	  pool	  of	  naïve	  lymphocytes	  that	  continuously	  circulate	  through	  the	  blood	  stream	  and	  secondary	  lymphoid	  organs	  (lymph	  nodes	  and	  spleen)	  searching	  for	  their	  “cognate”	  antigen,	  namely	  a	  peptide-­‐MHC	  combination	  that	  binds	  strongly	  enough	  to	  the	  TCR	  to	  trigger	  downstream	  signalling.	  	  	  	  	  1.2.2.2	  CD8	  T	  cell	  effector	  functions	  Naïve	  CD8	  T	  cells	  are	  primed	  in	  secondary	  lymphoid	  organs	  when	  they	  encounter	  cognate	  antigen	  on	  the	  surface	  of	  a	  DC	  along	  with	  other	  activating	  signals.	  Primed	  CD8	  T	  cells	  (also	  termed	  “Cytotoxic	  T	  cell”	  or	  CTL)	  re-­‐enter	  the	  circulation	  and	  home	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to	  the	  target	  site	  guided	  by	  chemokines,	  chemokine	  receptors	  and	  adhesion	  molecules.	  	  CTL	  that	  encounter	  cognate	  antigen	  at	  the	  target	  site	  are	  capable	  of	  direct	  killing	  in	  a	  number	  of	  ways.	  The	  release	  of	  lytic	  granules	  containing	  perforin	  (which	  creates	  pores	  in	  the	  plasma	  membrane	  of	  the	  target	  cell)	  and	  granzyme	  B,	  a	  protease	  that	  enters	  the	  target	  cell	  and	  initiates	  an	  enzyme	  cascade	  within	  the	  cytosol	  that	  leads	  to	  apoptosis	  (or	  programmed	  cell	  death).	  An	  alternative,	  perforin-­‐independent	  mechanism	  of	  inducing	  apoptosis	  involves	  the	  binding	  of	  Fas	  ligand	  on	  the	  CTL	  surface	  with	  the	  “death	  receptor”	  Fas	  (CD95)	  on	  the	  target	  cell.	  Tumour	  Necrosis	  Factor-­‐related	  apoptosis-­‐inducing	  ligand	  (TRAIL)	  is	  another	  death	  receptor	  ligand	  that	  has	  been	  shown,	  for	  example,	  to	  be	  required	  for	  the	  graft-­‐
versus-­‐leukaemia	  effect	  of	  CTL	  in	  mouse	  models	  of	  allogeneic	  bone	  marrow	  transplant	  (Schmaltz	  et	  al.	  2002).	  	  CTL	  also	  release	  the	  cytokines	  Interferon-­‐γ	  (IFN-­‐γ)	  and	  Tumour	  Necrosis	  Factor-­‐α	  (TNF-­‐α).	  IFN-­‐γ	  inhibits	  tumour	  angiogenesis	  and	  has	  a	  wide	  range	  of	  immunomodulatory	  effects	  including	  upregulation	  of	  MHC	  class	  I	  expression	  by	  target	  cells	  and	  enhanced	  macrophage	  function	  (Kane	  and	  Yang	  2010).	  	  In	  addition	  to	  a	  number	  of	  pro-­‐inflammatory	  effects,	  TNF-­‐α	  was	  named	  for	  its	  ability	  to	  directly	  induce	  apoptosis	  in	  tumour	  cell	  lines.	  However,	  the	  ability	  of	  TNF-­‐α	  to	  directly	  kill	  tumour	  cells	  in	  vivo	  seems	  to	  be	  limited	  to	  certain	  tumour	  types,	  notably	  sarcoma	  (Starnes	  1992).	  In	  the	  clinic,	  recombinant	  TNF-­‐α	  has	  been	  used	  most	  successfully	  to	  improve	  delivery	  of	  chemotherapeutic	  agents	  by	  increasing	  vascular	  permeability	  or	  for	  its	  property	  of	  selectively	  inducing	  endothelial	  necrosis	  in	  tumour	  neo-­‐vasculature	  (Lejeune	  et	  al.	  2006;	  van	  Horssen	  et	  al.	  2006).	  	  	  1.2.2.3	  CD4	  T	  cell	  helper	  and	  effector	  functions	  All	  cells	  (except	  erythrocytes	  in	  humans)	  express	  MHC	  class	  I	  and	  are	  therefore	  potential	  targets	  for	  CTL.	  In	  contrast,	  CD4	  T	  cells	  recognise	  cognate	  antigen	  bound	  to	  MHC	  class	  II	  molecules	  (they	  are	  thus	  MHC	  class	  II-­‐restricted).	  In	  the	  steady	  state,	  MHC	  class	  II	  is	  expressed	  at	  low	  levels	  by	  most	  cells.	  The	  exceptions	  are	  the	  antigen-­‐
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presenting	  cells:	  DC,	  macrophages	  and	  B	  cells.	  Thus,	  CD4	  T	  cells	  mainly	  interact	  with	  these	  cell	  types.	  	  The	  term	  T	  cell	  help	  was	  first	  used	  to	  describe	  the	  process	  by	  which	  CD4	  T	  cells	  promote	  B	  cell	  responses.	  Subsequently,	  it	  was	  discovered	  that	  CD4	  T	  cells	  also	  provide	  “help”	  to	  CD8	  T	  cell	  responses	  (Husmann	  and	  Bevan	  1988)	  by	  providing	  activation	  signals	  to	  DC	  that	  licence	  the	  DC	  to	  prime	  CD8	  T	  cells.	  This	  process	  (discussed	  below	  in	  more	  detail)	  requires	  the	  CD4	  T	  cell	  to	  recognise	  its	  cognate	  antigen	  bound	  to	  MHC	  class	  molecules	  on	  the	  DC	  cell	  surface	  and	  is	  predominantly	  mediated	  by	  CD40	  ligand	  (CD40L)	  on	  T	  cells	  binding	  to	  CD40	  on	  DC.	  CD4	  T	  cells	  not	  only	  provide	  help	  to	  DC	  but	  may	  be	  reciprocally	  activated	  to	  develop	  effector	  functions.	  Depending	  on	  the	  local	  cytokine	  milieu	  at	  the	  time	  of	  priming,	  naïve	  CD4	  T	  cells	  have	  an	  ability	  to	  differentiate	  into	  a	  number	  of	  different	  effector	  phenotypes	  (J.	  Zhu	  and	  Paul	  2008;	  Mosmann	  et	  al.	  1986;	  K.	  M.	  Murphy	  and	  Reiner	  2002).	  Interleukin	  12	  (IL-­‐12)	  released	  by	  DC	  drives	  expression	  of	  the	  transcription	  factor	  T-­‐bet	  which	  induces	  a	  type	  1	  T-­‐helper	  (TH1)	  phenotype.	  TH1	  cells	  secrete	  IL-­‐2,	  TNF-­‐α	  and	  IFN-­‐γ	  (W.	  E.	  Paul	  and	  Seder	  1994).	  TH1	  cells	  that	  traffic	  to	  the	  site	  of	  inflammation	  can	  provide	  help	  to	  local	  innate	  cells.	  IFN-­‐γ	  and	  CD40-­‐CD40L	  interactions	  boost	  the	  ability	  of	  macrophages	  to	  kill	  intracellular	  pathogens	  and	  tumour	  cells	  (Corthay	  et	  al.	  2005;	  Grewal	  and	  Flavell	  1996;	  Mumberg	  et	  al.	  1999;	  Y.	  Suzuki	  et	  al.	  1988).	  IFN-­‐γ	  also	  promotes	  antigen	  presentation	  by	  upregulating	  MHC	  class	  I	  and	  class	  II	  expression	  on	  immune	  and	  non-­‐immune	  cells	  (reviewed	  in	  Kane	  and	  Yang	  2010).	  TH1	  cells	  are	  also	  able	  to	  kill	  immune	  cells	  directly	  via	  Fas-­‐FasL	  interactions,	  which	  provides	  another	  way	  of	  killing	  infected	  cells	  and	  is	  an	  important	  regulatory	  mechanism	  for	  dampening	  immune	  responses	  (Janssens	  et	  al.	  2003).	  	  	  	  TH2	  cell	  differentiation	  is	  promoted	  by	  IL-­‐4	  and	  the	  transcription	  factor	  GATA-­‐3	  (K.	  M.	  Murphy	  and	  Reiner	  2002;	  J.	  Zhu	  and	  Paul	  2008).	  TH2	  cells	  secrete	  IL-­‐4,	  IL-­‐5,	  IL-­‐10	  and	  IL-­‐13	  and	  support	  certain	  humoral	  immune	  responses,	  particularly	  IgE-­‐mediated	  responses	  directed	  at	  extracellular	  parasites	  (W.	  E.	  Paul	  and	  Seder	  1994;	  J.	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Zhu	  and	  Paul	  2008).	  TH2	  cells	  are	  major	  mediators	  of	  asthma	  and	  allergic	  responses.	  TH1	  and	  TH2	  cells	  counter-­‐regulate	  each	  other	  so	  that	  IL-­‐4	  inhibits	  IFN-­‐γ	  signalling	  and	  vice	  versa	  (W.	  E.	  Paul	  and	  Seder	  1994).	  TFH	  (follicular	  helper)	  cells	  have	  a	  specialised	  role	  in	  supporting	  humoral	  responses	  in	  germinal	  centres	  (Vinuesa	  et	  al.	  2005).	  	  TH17	  cells	  develop	  in	  the	  combined	  presence	  of	  transforming	  growth	  factor-­‐β	  (TGF-­‐β)	  and	  IL-­‐6	  (at	  least	  in	  mice),	  and	  secrete	  IL-­‐17	  and	  other	  cytokines	  and	  chemokines	  that	  promote	  tissue	  inflammation	  and	  recruit	  neutrophils	  and	  other	  immune	  cells	  (Bettelli	  et	  al.	  2006;	  Zou	  and	  Restifo	  2010).	  TH17	  cells	  are	  believed	  to	  be	  important	  in	  responses	  directed	  at	  extracellular	  bacteria	  and	  fungi	  and	  to	  play	  a	  major	  role	  in	  some	  auto-­‐immunes	  diseases	  such	  as	  rheumatoid	  arthritis	  and	  the	  mouse	  model	  of	  multiple	  sclerosis,	  experimental	  autoimmune	  encephalitis	  (EAE)	  (A.	  Kimura	  and	  Kishimoto	  2010;	  Zou	  and	  Restifo	  2010).	  Exposure	  to	  TGF-­‐β	  alone,	  or	  to	  TGF-­‐β	  and	  retinoic	  acic,	  drives	  expression	  of	  the	  transcription	  factor	  FoxP3	  and	  can	  induce	  naïve	  CD4	  T	  cells	  to	  convert	  to	  a	  regulatory	  phenotype	  (induced	  regulatory	  T	  cell	  or	  iTreg)	  that	  suppresses	  T	  cell	  responses	  (W.	  Chen	  et	  al.	  2003;	  C.-­‐M.	  Sun	  et	  al.	  2007).	  It	  is	  generally	  believed	  that	  the	  aim	  of	  cancer	  vaccines	  should	  be	  to	  elicit	  a	  CD8	  CTL	  response	  supported	  by	  a	  TH1-­‐dominated	  CD4	  T	  cell	  response.	  Because	  TH2	  cytokines	  inhibit	  TH1	  differentiation	  and	  antagonise	  TH1	  cytokines,	  it	  follows	  that	  TH2	  responses	  are	  generally	  considered	  to	  be	  undesirable	  in	  this	  context	  (M.	  Kobayashi	  et	  al.	  1998;	  Shimato	  et	  al.	  2012).	  Furthermore,	  TH2	  cells	  secrete	  IL-­‐13,	  that	  induces	  macrophages	  and	  other	  myeloid	  cells	  to	  secrete	  the	  immunosuppressive	  cytokine	  TGF-­‐β	  (Berzofsky	  and	  Terabe	  2008),	  and	  IL-­‐10,	  that	  suppresses	  macrophage	  and	  DC	  function	  and	  induces	  IL-­‐10-­‐producing	  suppressive	  T	  cells	  (Groux	  et	  al.	  1997;	  Yamaguchi	  et	  al.	  2011).	  It	  is	  therefore	  interesting	  that	  several	  studies	  have	  found	  an	  inverse	  correlation	  between	  the	  incidence	  of	  GBM	  and	  atopic	  asthma,	  a	  disease	  characterised	  by	  TH2	  responses	  (reviewed	  in	  C.	  S.	  Curran	  and	  Bertics	  2012;	  Schwartzbaum	  et	  al.	  2006).	  Together	  with	  studies	  in	  animal	  models	  showing	  that	  IL-­‐4	  at	  the	  tumour	  site	  can	  have	  anti-­‐tumour	  effects	  that	  are	  dependent	  on	  a	  local	  accumulation	  of	  IL-­‐12-­‐producing	  dendritic	  cells	  (Eguchi	  et	  al.	  2005)	  or	  an	  influx	  of	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eosinophils	  (Tepper	  et	  al.	  1992),	  this	  raises	  the	  intriguing	  possibility	  that	  TH2	  responses	  might	  be	  protective	  against	  GBM.	  	  In	  addition	  to	  the	  helper	  functions	  described	  above,	  there	  is	  some	  evidence	  that	  activated	  CD4	  T	  cells	  can	  also	  directly	  lyse	  tumour	  cells	  using	  the	  Fas-­‐FasL	  pathway	  to	  directly	  kill	  Fas-­‐expressing	  tumour	  cells	  (D.	  M.	  Brown	  2010;	  Stalder	  et	  al.	  1994).	  However,	  many	  human	  tumour	  cells	  downregulate	  Fas	  or	  even	  subvert	  signalling	  via	  Fas	  to	  promote	  tumour	  cell	  growth	  (L.	  Chen	  et	  al.	  2010).	  Recently,	  “cytotoxic”	  CD4	  T	  cells	  were	  demonstrated	  in	  a	  mouse	  model	  of	  melanoma	  (Quezada	  et	  al.	  2010).	  In	  this	  model,	  CD4	  T	  cells	  induced	  upregulation	  of	  MHC	  class	  II	  expression	  on	  the	  target	  cells	  by	  secreting	  IFN-­‐γ	  before	  directly	  killing	  tumour	  cells	  in	  an	  MHC	  class	  II-­‐	  and	  granzyme	  B-­‐dependent	  manner.	  	  
1.2.3	  Dendritic	  Cells	  and	  the	  control	  of	  T	  cell	  responses	  1.2.3.1	  Overview	  of	  DC	  biology	  T	  cell	  responses	  are	  controlled	  by	  APC	  that	  are	  equipped	  to	  take	  up,	  process,	  and	  present	  antigen	  in	  the	  form	  of	  peptide-­‐MHC	  complexes	  along	  with	  co-­‐stimulatory	  molecules	  and	  cytokines.	  Although	  macrophages	  and	  B	  cells	  also	  have	  this	  capacity,	  DC	  are	  the	  most	  potent	  APC	  and	  are	  specialised	  for	  this	  purpose	  (leading	  to	  the	  term	  “professional”	  APC).	  DC	  are	  named	  for	  their	  characteristic	  dendritic	  morphology,	  the	  purpose	  of	  which	  is	  to	  encourage	  DC-­‐T	  cell	  interactions,	  and	  are	  part	  of	  the	  mononuclear	  phagocyte	  system	  that	  also	  includes	  monocytes	  and	  macrophages	  (Collin	  et	  al.	  2013).	  In	  the	  steady	  state,	  DC	  develop	  from	  a	  common	  DC	  precursor	  that	  travels	  from	  the	  bone	  marrow	  via	  the	  circulation	  to	  peripheral	  tissues	  and	  secondary	  lymphoid	  organs,	  where	  development	  into	  DC	  is	  completed.	  Migratory	  DC	  take	  up	  antigen	  in	  the	  periphery	  and	  travel	  via	  the	  lymphatic	  system	  to	  draining	  lymph	  nodes	  (LNs)	  to	  present	  antigen	  to	  T	  cells.	  Migratory	  DC	  make	  up	  approximately	  half	  of	  the	  DC	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population	  in	  LNs	  in	  the	  steady	  state	  (Randolph	  et	  al.	  2005).	  Lymphoid	  organ-­‐resident	  DC	  in	  the	  LN	  and	  spleen	  take	  up	  and	  present	  antigens	  arriving	  in	  lymph	  and	  blood	  respectively.	  In	  disease	  states,	  “inflammatory”	  DC	  may	  also	  develop	  from	  circulating	  monocytes	  (Collin	  et	  al.	  2013).	  	  	  1.2.3.2	  Plasmacytoid	  DC	  DC	  can	  be	  classified	  at	  a	  high	  level	  into	  “conventional”	  DC	  and	  plasmacytoid	  DC	  (pDC).	  	  Although	  they	  develop	  from	  the	  same	  precursor	  cell,	  the	  precise	  role	  of	  pDC	  is	  still	  unclear	  (Reizis	  et	  al.	  2011).	  In	  contrast	  to	  conventional	  DC,	  pDC	  are	  found	  predominantly	  in	  the	  circulation	  in	  the	  steady	  state	  and	  are	  named	  for	  their	  plasma	  cell-­‐like	  appearance.	  Plasmacytoid	  DC	  express	  receptors	  that	  recognise	  pathogen-­‐associated	  molecules	  and,	  in	  inflammatory	  situations,	  migrate	  to	  lymph	  nodes	  where	  they	  produce	  large	  quantities	  of	  Type	  1	  interferons	  that	  are	  pro-­‐inflammatory	  and	  inhibit	  viral	  replication	  (Cella	  et	  al.	  1999).	  Once	  activated,	  pDC	  adopt	  a	  dendritic	  morphology	  but	  they	  are	  unable	  to	  take	  up	  exogenous	  antigen	  by	  phagocytosis	  or	  macropinocytosis,	  and	  their	  capacity	  to	  prime	  naïve	  T	  cells	  in	  vivo	  is	  controversial	  (Young	  et	  al.	  2008).	  Pertinent	  to	  the	  subject	  of	  this	  thesis,	  there	  is	  evidence	  that	  pDC	  can	  be	  immunosuppressive	  in	  a	  tumour	  context.	  In	  a	  study	  of	  patients	  with	  breast	  cancer,	  the	  presence	  of	  tumour-­‐infiltrating	  pDC	  strongly	  correlated	  with	  shorter	  survival	  (Treilleux	  et	  al.	  2004).	  Subsequent	  studies	  have	  shown	  an	  ability	  of	  pDC	  to	  promote	  regulatory	  T	  cell	  (Treg)-­‐mediated	  immunosuppression	  (M.	  D.	  Sharma	  et	  al.	  2007;	  Sisirak	  et	  al.	  2013).	  In	  apparent	  contradiction,	  activated	  pDC	  were	  recently	  reported	  to	  be	  capable	  of	  exerting	  direct	  TRAIL-­‐	  and	  Granzyme	  B-­‐mediated	  tumour	  cytolysis	  in	  a	  mouse	  model	  of	  melanoma	  (Drobits	  et	  al.	  2012).	  In	  summary,	  the	  effect	  of	  pDC	  in	  the	  context	  of	  cancer	  is	  complex.	  The	  remainder	  of	  this	  discussion	  will	  focus	  on	  conventional	  DC.	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1.2.3.3	  Antigen	  Processing	  and	  Presentation	  	  Steady	  state	  DC	  continuously	  sample	  their	  surrounding	  environment	  by	  macropinocytosis.	  DC	  also	  express	  a	  large	  number	  of	  receptors	  that	  mediate	  endocytosis	  of	  a	  wide	  range	  of	  potential	  sources	  of	  antigen	  including	  microbes,	  dead	  or	  dying	  cells,	  exosomes,	  cellular	  debris,	  and	  soluble	  antigens	  (reviewed	  in	  Heath	  et	  al.	  2004;	  Petersen	  et	  al.	  2010a;	  Trombetta	  and	  Mellman	  2005).	  Acquisition	  of	  antigen	  from	  living	  cells	  has	  also	  been	  described	  (Heath	  et	  al.	  2004).	  Once	  inside	  the	  cell,	  soluble	  proteins	  and	  cellular	  debris	  are	  enzymatically	  digested	  within	  endosomes	  into	  peptides	  (Watts	  2004).	  The	  endosomic	  pH	  progressively	  falls	  as	  early	  endosomes	  evolve	  into	  late	  endosomes,	  favouring	  increased	  protease	  activity.	  MHC	  class	  II	  molecules,	  synthesized	  in	  the	  endoplasmic	  reticulum	  (ER),	  are	  transported	  to	  late	  endosomes	  where	  they	  are	  loaded	  with	  12-­‐16	  mer	  peptides.	  The	  peptide-­‐MHC	  complexes	  are	  then	  transported	  to	  the	  cell	  surface.	  This	  process	  is	  known	  as	  the	  “exogenous	  pathway”	  of	  antigen	  presentation.	  An	  “endogenous	  pathway”	  is	  used	  to	  present	  peptides	  from	  proteins	  synthesized	  within	  the	  DC	  itself,	  whether	  these	  are	  normal	  “self”	  proteins	  or,	  in	  virally-­‐infected	  DC,	  the	  translated	  products	  of	  viral	  nucleic	  acid	  (Trombetta	  and	  Mellman	  2005).	  Endogenous	  proteins	  in	  the	  cytosol	  and	  nucleus	  are	  continuously	  cleaved	  into	  peptides	  by	  large	  tubular	  protease	  complexes	  called	  proteasomes.	  Most	  of	  the	  resulting	  peptides	  are	  rapidly	  destroyed	  by	  cytosolic	  peptidases	  but	  some	  are	  transported	  into	  the	  ER	  by	  Transporter	  associated	  with	  Antigen	  Presentation	  (TAP)	  molecules	  where	  8-­‐10	  mer	  peptides	  are	  loaded	  on	  to	  MHC	  class	  I	  molecules.	  The	  peptide-­‐MHC	  complexes	  are	  then	  transported	  to	  the	  surface	  for	  presentation.	  	  	  There	  are	  exceptions	  to	  these	  general	  arrangements.	  Exogenous	  proteins,	  usually	  presented	  on	  MHC	  class	  II	  to	  CD4	  T	  cells,	  can	  be	  diverted	  to	  be	  presented	  on	  MHC	  class	  I	  to	  CD8	  T	  cells,	  a	  process	  known	  as	  “cross-­‐presentation”	  (Trombetta	  and	  Mellman	  2005).	  Cross-­‐presentation	  is	  required	  for	  CD8	  T	  cell	  mediated	  immunity	  against	  viruses	  that	  do	  not	  infect	  APCs	  directly	  or	  against	  tumour	  antigens	  that	  are	  not	  endogenously	  expressed	  by	  DCs	  (Burgdorf	  et	  al.	  2007).	  A	  number	  of	  different	  
 38 
pathways	  for	  cross-­‐presentation	  have	  been	  described	  but	  the	  relative	  importance	  of	  each	  of	  these	  pathways	  in	  vivo	  is	  controversial	  (reviewed	  in	  Petersen	  et	  al.	  2010a).	  	  Common	  to	  most	  of	  these	  pathways	  is	  a	  mechanism	  by	  which	  exogenous	  protein	  is	  transferred	  from	  endosomes	  to	  the	  cytosol	  where	  it	  can	  enter	  the	  endogenous	  processing	  pathway	  (Norbury	  et	  al.	  1995;	  Ackerman	  et	  al.	  2005;	  Rodriguez	  et	  al.	  1999).	  	  Similarly,	  endogenous	  proteins	  that	  access	  endosomal	  compartments	  (for	  example	  as	  a	  result	  of	  autophagy,	  or	  endosomal	  recycling	  of	  membrane	  proteins)	  can	  be	  loaded	  onto	  MHC	  class	  II,	  thereby	  allowing	  the	  presentation	  of	  endogenous	  antigens	  to	  CD4	  T	  cells	  (Crotzer	  and	  Blum	  2010;	  Strawbridge	  and	  Blum	  2007;	  Villadangos	  and	  Schnorrer	  2007;	  N.	  S.	  Wilson	  et	  al.	  2004).	  	  1.2.3.4	  DC	  activation,	  CTL	  priming	  and	  CD4	  T	  cell	  help	  Naïve	  T	  cells	  express	  the	  integrin	  CD62L	  (also	  known	  as	  L-­‐selectin)	  and	  the	  chemokine	  receptor	  CCR7.	  These	  surface	  molecules	  allow	  naïve	  T	  cells	  arriving	  at	  lymph	  nodes	  via	  the	  circulation	  to	  migrate	  across	  the	  endothelium	  of	  high	  endothelial	  venules	  and	  reach	  the	  T	  cell	  areas	  of	  the	  lymph	  node.	  Intravital	  imaging	  studies	  show	  that	  in	  the	  first	  8	  hours	  after	  entering	  the	  lymph	  node	  T	  cells	  form	  brief	  contacts	  with	  multiple	  DC	  (Mempel	  et	  al.	  2004).	  If	  cognate	  antigen	  is	  present,	  a	  second	  phase	  occurs	  in	  which	  T	  cells	  form	  long-­‐lasting	  contacts	  with	  DC	  over	  the	  next	  12	  hours	  followed	  by	  a	  third	  phase	  of	  proliferation	  and	  high	  motility.	  It	  has	  been	  proposed	  that,	  in	  the	  first	  phase,	  T	  cells	  integrate	  signals	  from	  multiple	  DC	  contacts	  before	  reaching	  a	  threshold	  for	  the	  prolonged	  immunological	  synapse	  formation	  necessary	  for	  full	  activation.	  Antigen	  dose	  has	  been	  shown	  to	  be	  a	  crucial	  factor	  in	  determining	  whether	  the	  threshold	  for	  long-­‐lasting	  DC-­‐T	  cell	  contacts	  is	  reached	  (Henrickson	  et	  al.	  2008).	  The	  third	  phase	  of	  “frantic”	  migration	  is	  believed	  to	  represent	  a	  search	  for	  an	  exit	  into	  efferent	  lymphatics.	  	  The	  outcome	  of	  DC-­‐T	  cell	  interactions	  in	  secondary	  lymphoid	  organs	  is	  crucially	  dependent	  on	  the	  activation	  state	  of	  DC	  (Behrens	  et	  al.	  2004;	  Bevan	  2004;	  Curtsinger	  et	  al.	  2003).	  Fully	  activated	  DC	  are	  licensed	  to	  deliver	  all	  the	  necessary	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signals	  to	  prime	  a	  fully-­‐competent	  CD8	  T	  cell	  response	  (Curtsinger	  et	  al.	  2003).	  Antigen	  presentation	  by	  DC	  that	  are	  not	  activated	  can	  induce	  T	  cell	  anergy	  (Schwartz	  2003)	  or	  conversion	  to	  FoxP3+	  Treg	  (Yamazaki	  et	  al.	  2008).	  In	  the	  steady	  state,	  where	  the	  stimuli	  for	  DC	  activation	  are	  not	  present,	  migratory	  DC	  play	  an	  important	  role	  in	  maintaining	  peripheral	  tolerance	  (R	  M	  Steinman	  et	  al.	  2000;	  Ralph	  M	  Steinman	  et	  al.	  2003).	  Tolerising	  DC	  may	  also	  play	  an	  important	  role	  during	  infections	  by	  counteracting	  potential	  auto-­‐reactivity	  caused	  by	  fully	  activated	  DC	  presenting	  both	  foreign	  and	  self-­‐antigens	  in	  an	  immunogenic	  manner	  (Joffre	  et	  al.	  2009).	  Activating	  stimuli	  for	  DC	  include	  “pathogen-­‐associated	  molecular	  patterns”	  (PAMPs),	  “danger-­‐associated	  molecular	  patterns”	  (DAMPs),	  pro-­‐inflammatory	  cytokines	  (released	  by	  stromal	  or	  immune	  cells),	  and	  help	  from	  CD4	  T	  cells.	  	  PAMPs	  are	  molecular	  motifs	  conserved	  across	  a	  wide	  range	  of	  bacterial	  and	  viral	  pathogens.	  PAMPs	  are	  detected	  by	  surface	  receptors	  termed	  pattern	  recognition	  receptors	  (PRRs).	  The	  best	  studied	  class	  of	  PRR	  are	  the	  Toll-­‐like	  receptors	  (TLRs)	  of	  which	  there	  are	  currently	  ten	  known	  members	  (reviewed	  in	  Iwasaki	  and	  Medzhitov	  2004).	  	  Resting	  or	  “immature”	  DC	  stimulated	  by	  TLRs	  undergo	  changes	  rendering	  them	  competent	  to	  prime	  naïve	  T	  cells.	  These	  changes	  include	  reduced	  uptake	  of	  further	  antigen,	  translocation	  of	  peptide-­‐MHC	  class	  II	  complexes	  from	  endosomes	  to	  the	  cell	  surface,	  increased	  expression	  of	  T	  cell	  co-­‐stimulatory	  molecules,	  secretion	  of	  pro-­‐inflammatory	  cytokines,	  upregulation	  of	  the	  DC	  activating	  receptor	  CD40,	  increased	  expression	  of	  NK	  activating	  ligands,	  secretion	  of	  chemokines	  to	  attract	  T	  cells,	  and,	  in	  the	  case	  of	  migratory	  DC,	  expression	  of	  chemokine	  receptors	  (notably	  CCR7)	  to	  promote	  trafficking	  to	  LNs	  (R	  M	  Steinman	  et	  al.	  2000).	  TLR	  agonists	  are	  already	  in	  clinical	  use	  for	  certain	  skin	  cancers	  (Drobits	  et	  al.	  2012)	  and	  are	  attracting	  attention	  as	  adjuvants	  in	  vaccines,	  including	  therapeutic	  vaccines	  for	  glioma	  (Prins	  et	  al.	  2011;	  Xiong	  and	  Ohlfest	  2011).	  	  DC	  can	  also	  be	  activated	  in	  the	  absence	  of	  pathogen-­‐derived	  molecules	  by	  endogenous	  “danger	  signals”	  (Gallucci	  et	  al.	  1999;	  Matzinger	  2002).	  DAMPs	  consist	  mainly	  of	  molecules	  released	  or	  exposed	  by	  necrotic	  cells	  that	  provide	  a	  signal	  to	  the	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immune	  system	  that	  pathological	  death	  of	  host	  cells	  is	  underway	  (as	  opposed	  to	  orderly	  programmed	  cell	  death	  that	  is	  efficiently	  cleared	  by	  phagocytic	  cells).	  	  DAMP-­‐mediated	  DC	  activation	  is	  believed	  to	  explain	  spontaneous	  endogenous	  anti-­‐tumour	  immune	  responses	  and	  is	  probably	  also	  responsible	  for	  autoimmune	  conditions	  that	  arise	  in	  situations	  of	  tissue	  damage	  or	  inflammation	  (Gallucci	  et	  al.	  1999).	  A	  variety	  of	  DAMPs	  with	  diverse	  actions	  have	  been	  described.	  	  Calreticulin	  translocates	  from	  the	  ER	  to	  the	  surface	  of	  dying	  cells	  where	  it	  has	  a	  role	  in	  enhancing	  phagocytosis	  of	  the	  dying	  cell	  by	  DC	  (Obeid	  et	  al.	  2007).	  High	  Mobility	  Group	  Box	  Protein1	  (HMGB1)	  is	  a	  nuclear	  chromatin-­‐binding	  protein	  that,	  when	  released	  by	  post-­‐apoptotic	  cells,	  becomes	  a	  soluble	  “alarmin”	  that	  signals	  through	  TLR4	  to	  promote	  cross-­‐presentation	  (Apetoh	  et	  al.	  2007).	  Other	  DAMPs	  include	  uric	  acid	  (Hu	  et	  al.	  2004),	  heat	  shock	  proteins	  (Binder	  and	  Srivastava	  2005)	  and	  adenosine	  triphosphate	  (ATP),	  which	  binds	  to	  purinergic	  receptors	  on	  DC	  to	  activate	  the	  NLR3P	  inflammasome	  and	  induce	  secretion	  of	  pro-­‐inflammatory	  IL-­‐1β	  (Ghiringhelli	  et	  al.	  2009).	  	  DC	  can	  also	  be	  activated	  by	  pro-­‐inflammatory	  cytokines	  such	  as	  TNF-­‐α	  and	  Type	  1	  interferons	  released	  by	  other	  immune	  cells	  or	  stromal	  cells.	  This	  “indirect”	  activation	  is	  exploited	  in	  DC-­‐based	  immunotherapies	  to	  activate	  antigen-­‐loaded	  DC	  prior	  to	  adoptive	  transfer.	  However,	  it	  is	  controversial	  whether	  this	  kind	  of	  activation	  alone	  is	  sufficient	  for	  DC	  to	  prime	  fully	  competent	  T	  cell	  responses	  (Joffre	  et	  al.	  2009).	  This	  is	  discussed	  further	  below.	  CD4	  T	  cells	  that	  encounter	  cognate	  antigen	  presented	  by	  DC	  upregulate	  CD40L	  surface	  expression.	  CD40L	  binding	  to	  CD40	  on	  the	  surface	  of	  DC	  provides	  a	  strong	  activation	  signal	  that	  licenses	  DC	  and	  stimulates	  the	  release	  of	  chemokines	  such	  as	  CCR5	  ligands	  that	  attract	  naïve	  CD8	  T	  cells	  (Bennett	  et	  al.	  1998;	  Ridge	  et	  al.	  1998;	  Schoenberger	  et	  al.	  1998).	  CD4	  T	  cell	  help	  has	  been	  described	  as	  a	  form	  of	  immunological	  “second	  opinion”	  because	  licensing	  to	  prime	  CTL	  responses	  against	  MHC	  class	  I-­‐restricted	  epitopes	  requires	  recognition	  by	  CD4	  T	  cells	  of	  MHC	  class	  II-­‐restricted	  epitopes	  (Kurts	  et	  al.	  2010).	  This	  form	  of	  help	  to	  CTL	  responses	  requires	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CD4	  and	  CD8	  T	  cells	  to	  both	  interact	  with	  the	  same	  DC	  (Bevan	  2004),	  a	  point	  of	  critical	  importance	  to	  vaccine	  design.	  It	  is	  possible	  that	  CD4	  T	  cells	  also	  provide	  help	  directly	  to	  CD8	  T	  cells	  by	  paracrine	  release	  of	  cytokines	  or	  via	  CD40	  expressed	  on	  CD8	  T	  cells	  but	  this	  remains	  controversial	  (Bevan	  2004).	  Naïve	  CD8	  T	  cells	  require	  three	  signals	  from	  DC	  to	  differentiate	  into	  competent	  cytolytic	  cells:	  cognate	  antigen	  bound	  to	  MHC	  class	  I	  (signal	  1),	  costimulation	  (signal	  2),	  and	  a	  third	  signal	  (Curtsinger	  et	  al.	  2003;	  Clint	  S	  Schmidt	  and	  Mescher	  2002).	  Signals	  1	  and	  2	  can	  be	  sufficient	  to	  initiate	  weak	  expansion	  but	  T	  cells	  lack	  cytolytic	  function	  and	  fail	  to	  proliferate	  on	  restimulation	  (Curtsinger	  et	  al.	  2003;	  C	  S	  Schmidt	  and	  Mescher	  1999).	  IL-­‐12	  released	  by	  activated	  DC	  can	  provide	  the	  necessary	  third	  signal	  for	  CTL	  differentiation	  (Clint	  S	  Schmidt	  and	  Mescher	  2002)	  but	  is	  not	  the	  only	  possible	  signal	  because	  competent	  CTL	  responses	  can	  be	  primed	  in	  IL-­‐12-­‐deficient	  mice	  (C	  S	  Schmidt	  and	  Mescher	  1999).	  	  	  CD40-­‐CD40L	  interactions,	  provided	  by	  CD4	  T	  cells,	  are	  capable	  of	  licensing	  DC	  to	  provide	  the	  third	  signal	  (Bennett	  et	  al.	  1998;	  Ridge	  et	  al.	  1998;	  Schoenberger	  et	  al.	  1998).	  However,	  PAMPs	  signalling	  through	  TLRs	  can	  also	  be	  sufficient	  to	  license	  DC,	  independent	  of	  CD4	  T	  cell	  help	  (Buller	  et	  al.	  1987;	  Rahemtulla	  et	  al.	  1991).	  	  Thus	  the	  importance	  of	  T	  cell	  help	  to	  CTL	  responses	  depends	  on	  the	  strength	  of	  other	  danger	  signals	  (Bevan	  2004).	  There	  is,	  however,	  strong	  evidence	  that	  all	  CTL	  responses	  require	  at	  least	  some	  CD4	  T	  cell	  help	  for	  the	  formation	  of	  long-­‐lived	  competent	  memory	  cells	  (discussed	  below).	  	  The	  induction	  of	  fully	  activated,	  licensed	  DC	  is	  fundamental	  to	  the	  success	  of	  any	  immunotherapy	  aiming	  to	  elicit	  a	  fully	  competent	  and	  long-­‐lasting	  adaptive	  immune	  response.	  In	  active	  specific	  immunotherapies	  this	  is	  commonly	  achieved	  by	  providing	  antigen	  in	  association	  with	  a	  PAMP	  in	  the	  form	  of	  a	  live	  attenuated	  organism,	  microbial	  fragments,	  or	  synthetic	  TLR	  ligands	  (reviewed	  in	  Olive	  2012;	  Steinhagen	  et	  al.	  2011).	  Alternatively,	  or	  in	  addition,	  DC	  licensing	  by	  CD4	  T	  cells	  can	  be	  encouraged	  by	  providing	  MHC	  class	  II	  as	  well	  as	  MHC	  class	  I	  epitopes	  in	  the	  vaccine.	  In	  DC-­‐based	  therapies,	  a	  commonly	  used	  approach	  is	  to	  induce	  DC	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maturation	  by	  exposure	  to	  a	  cytokine	  “cocktail”	  (Feuerstein	  et	  al.	  2000).	  The	  term	  “DC	  maturation”	  describes	  the	  increased	  expression	  of	  MHC	  class	  II	  and	  co-­‐stimulatory	  molecules	  in	  response	  to	  an	  activating	  stimulus.	  However,	  as	  discussed	  above,	  the	  ability	  to	  provide	  signals	  1	  and	  2	  is	  necessary	  but	  not	  sufficient	  to	  prime	  a	  fully	  competent	  effector	  T	  cell	  response	  (Joffre	  et	  al.	  2009;	  Reis	  e	  Sousa	  2006;	  Spörri	  and	  Reis	  e	  Sousa	  2005).	  In	  fact,	  migratory	  DC	  naturally	  undergo	  maturation	  as	  they	  traffic	  to	  lymph	  nodes	  where,	  in	  the	  steady	  state,	  they	  serve	  a	  tolerising	  function	  (Albert	  et	  al.	  2001).	  The	  common	  practice	  of	  using	  surface	  marker	  expression	  as	  a	  surrogate	  for	  DC	  immunogenicity	  may	  therefore	  be	  misleading	  and	  the	  optimum	  method	  of	  activating	  DC	  for	  adoptive	  transfer	  remains	  controversial	  (Joffre	  et	  al.	  2009).	  	  1.2.3.5	  T	  cell	  memory	  In	  a	  primary	  adaptive	  immune	  response,	  the	  activated	  T	  cell	  population	  rapidly	  expands,	  reaching	  a	  peak	  in	  about	  7	  days.	  Then,	  providing	  the	  antigen	  is	  efficiently	  cleared,	  90-­‐95	  %	  of	  these	  cells	  die	  over	  the	  next	  few	  weeks,	  leaving	  a	  small	  pool	  of	  long-­‐lived	  antigen-­‐experienced	  cells	  (Harty	  and	  Badovinac	  2008).	  These	  long-­‐lived	  cells	  are	  responsible	  for	  the	  phenomenon	  of	  immunological	  memory,	  in	  which	  subsequent	  exposure	  to	  the	  same	  antigen	  elicits	  a	  stronger	  and	  more	  rapid	  response.	  	  T	  cells	  that	  survive	  beyond	  the	  contraction	  phase	  are	  termed	  memory	  cells.	  	  Whereas	  naïve	  lymphocytes	  have	  a	  finite	  lifespan	  and	  require	  constant	  replacement,	  memory	  T	  cells	  are	  long-­‐lived,	  with	  T	  cells	  activated	  in	  the	  first	  year	  of	  life	  capable	  of	  surviving	  for	  the	  lifetime	  of	  the	  host	  organism	  (Bevan	  2011).	  Activated	  naïve	  T	  cells	  downregulate	  receptors	  for	  the	  cytokines	  IL-­‐7	  (CD127)	  and	  IL-­‐15	  (CD122),	  required	  for	  survival	  and	  homeostatic	  proliferation	  respectively.	  A	  distinguishing	  feature	  of	  memory	  T	  cells	  is	  the	  early	  re-­‐expression	  of	  these	  receptors,	  in	  turn	  leading	  to	  increased	  expression	  of	  anti-­‐apoptotic	  molecules	  (Kaech	  et	  al.	  2003;	  van	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Leeuwen	  et	  al.	  2009).	  This	  permits	  the	  survival	  of	  an	  expanded	  population	  of	  antigen-­‐specific	  cells	  without	  a	  need	  for	  TCR	  stimulation.	  Two	  distinct	  memory	  cell	  phenotypes	  have	  been	  described	  (Sallusto	  et	  al.	  1999).	  Effector	  memory	  T	  cells	  (TEM)	  patrol	  the	  tissues,	  particularly	  at	  barrier	  sites	  such	  as	  the	  skin,	  lung	  and	  gut,	  but	  also	  blood	  and	  spleen.	  They	  are	  equipped	  to	  rapidly	  exhibit	  effector	  functions	  (such	  as	  the	  ability	  to	  secrete	  IFN-­‐γ)	  as	  soon	  as	  they	  encounter	  cognate	  antigen,	  without	  needing	  co-­‐stimulation	  from	  APC.	  Central	  memory	  T	  cells	  (TCM)	  express	  the	  lymph	  node-­‐homing	  molecules	  CCR7	  and	  CD62L	  and	  circulate	  through	  secondary	  lymphoid	  organs.	  TCM	  do	  not	  have	  the	  ability	  to	  immediately	  perform	  effector	  functions.	  Instead,	  cognate	  antigen	  recognition	  by	  TCM	  triggers	  IL-­‐2	  secretion	  and	  proliferation,	  with	  differentiation	  to	  an	  effector	  phenotype	  occurring	  later	  (Pepper	  and	  Jenkins	  2011).	  Thus	  TCM	  provide	  a	  second	  line	  of	  defence	  that	  can	  expand	  the	  ranks	  of	  effector	  cells	  at	  the	  infected	  site	  or	  deal	  with	  a	  systemic	  infection	  that	  has	  managed	  to	  breach	  barrier	  defences	  (Sallusto	  et	  al.	  1999).	  Which	  memory	  subset	  is	  most	  important	  for	  protection	  thus	  depends	  on	  the	  location	  of	  the	  rechallenge	  and	  the	  nature	  of	  the	  pathogen	  (Obar	  and	  Lefrançois	  2010).	  The	  timing	  of	  the	  rechallenge	  may	  also	  be	  relevant	  in	  this	  respect.	  In	  one	  study,	  the	  relative	  importance	  of	  TCM	  in	  mediating	  protection	  after	  an	  acute	  infection	  increased	  over	  time	  due	  to	  a	  progressive	  decrease	  in	  the	  proportion	  of	  TEM	  to	  TCM	  and	  a	  decrease	  in	  the	  proliferative	  potential	  of	  TEM	  cells	  (Roberts	  et	  al.	  2005).	  	  	  How	  memory	  cells	  develop	  from	  naïve	  cells	  is	  uncertain	  and	  a	  full	  discussion	  is	  beyond	  the	  scope	  of	  this	  introduction.	  Briefly,	  the	  “linear	  differentiation”	  model	  (Wherry	  et	  al.	  2003)	  proposes	  that	  naïve	  CD8	  T	  cells	  develop	  into	  effector	  cells	  which	  then	  either	  die	  or	  differentiate	  into	  memory	  cells	  as	  the	  antigen	  is	  cleared.	  According	  to	  this	  model	  TEM	  are	  an	  intermediate	  phenotype	  in	  the	  transition	  from	  effector	  to	  memory	  cell	  i.e.	  Naive	  →	  Effector	  →	  TEM	  →	  TCM.	  The	  alternative	  “divergent”	  model	  holds	  that	  the	  fate	  of	  a	  naïve	  cell	  is	  determined	  from	  the	  outset,	  with	  some	  cells	  programmed	  to	  become	  effector	  cells	  and	  others	  to	  become	  long-­‐lived	  memory	  cells	  at	  the	  time	  of	  priming.	  	  In	  fact,	  both	  models	  may	  be	  correct.	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Experiments	  in	  which	  the	  fate	  of	  naïve	  CD8	  T	  cells	  was	  tracked	  in	  vivo	  using	  a	  granzyme	  B	  reporter	  system	  have	  shown	  that	  cells	  that	  have	  acquired	  at	  least	  some	  effector	  function	  can	  still	  retain	  the	  capacity	  to	  differentiate	  into	  memory	  cells	  (Bannard	  et	  al.	  2009).	  On	  the	  other	  hand,	  although	  it	  seems	  likely	  that	  all	  activated	  CD8	  T	  cells	  pass	  through	  an	  early	  effector	  phase,	  there	  is	  now	  strong	  evidence	  that	  two	  distinct	  phenotypes	  emerge	  early	  in	  the	  course	  of	  a	  primary	  response.	  Short-­‐lived	  effector	  cells	  (SLEC)	  and	  Memory	  precursor	  effector	  cells	  (MPEC)	  can	  be	  distinguished	  by	  the	  early	  re-­‐expression	  by	  MPEC	  of	  the	  alpha	  chain	  of	  the	  IL-­‐7	  receptor	  (CD127)	  (Kaech	  et	  al.	  2003).	  The	  relative	  proportion	  of	  these	  subsets	  is	  determined	  by	  the	  prevailing	  conditions	  at	  the	  time	  of	  priming	  (Lees	  and	  Farber	  2010).	  IL-­‐12,	  for	  example,	  drives	  expression	  of	  the	  transcription	  factor	  T-­‐bet	  (the	  same	  “master	  transcription	  factor”	  of	  TH1	  CD4	  T	  cell	  responses)	  and	  promotes	  SLEC	  differentiation	  (Joshi	  et	  al.	  2007).	  	  A	  third	  “hierarchical”	  model	  was	  recently	  proposed	  in	  which	  stimulation	  of	  a	  naïve	  T	  cell	  leads	  to	  expansion	  of	  a	  stem	  cell-­‐like	  population,	  that	  can	  then	  progressively	  differentiate	  into	  TCM,	  TEM	  or	  terminally-­‐differentiated	  effectors	  as	  needed,	  i.e.	  Naive	  	  TCM	  	  TEM	  	  Effector	  cell	  (Gattinoni	  et	  al.	  2011).	  	  Lineage	  controversy	  aside,	  a	  consistent	  observation	  is	  that	  terminally-­‐differentiated	  CD8	  T	  cells	  have	  a	  reduced	  capacity	  for	  survival	  and	  proliferation	  than	  memory	  cells.	  This	  is	  important	  in	  designing	  immunotherapies	  for	  cancer,	  particularly	  in	  regard	  to	  the	  adoptive	  cell	  transfer	  (ACT)	  of	  T	  cells.	  Clinical	  responses	  in	  melanoma	  patients	  receiving	  in	  vitro-­‐activated	  CD8	  T	  cells	  are	  strongly	  correlated	  with	  survival	  and	  persistence	  of	  the	  transferred	  cells	  (Perret	  and	  Ronchese	  2008).	  The	  optimal	  conditions	  for	  generating	  long-­‐lived	  functional	  T	  cells	  for	  ACT	  are	  still	  contentious	  but	  evidence	  from	  mouse	  models	  has	  shown	  that	  repeated	  antigen	  exposure	  and	  extended	  culture	  in	  IL-­‐2	  in	  vitro	  drives	  T	  cells	  towards	  a	  terminally-­‐differentiated	  senescent	  effector	  phenotype	  that	  survives	  poorly	  and	  is	  suboptimal	  for	  treatment	  (Gattinoni	  et	  al.	  2005a).	  The	  data	  regarding	  the	  relative	  efficacy	  of	  TCM	  compared	  with	  TEM	  in	  adoptive	  T	  cell	  transfer	  for	  tumour	  immunotherapy	  is	  conflicting	  although,	  in	  most	  models,	  TCM	  appear	  to	  be	  superior	  (reviewed	  in	  Perret	  and	  
 45 
Ronchese	  2008).	  	  Reasons	  for	  this	  may	  be	  superior	  survival	  and	  proliferation	  potential,	  and	  the	  ability	  to	  home	  to	  secondary	  lymph	  nodes	  for	  restimulation	  by	  resident	  APC	  (Klebanoff	  et	  al.	  2005b).	  Our	  understanding	  of	  CD4	  T	  cell	  memory	  is	  less	  advanced	  than	  for	  CD8	  T	  cells.	  With	  respect	  to	  origin,	  there	  is	  evidence	  for	  both	  linear	  and	  divergent	  models,	  with	  a	  degree	  of	  plasticity	  between	  CD4	  memory	  cell	  subsets.	  For	  example,	  TEM	  derived	  from	  TH1	  effector	  cells	  can	  produce	  TH2	  cytokines	  depending	  on	  conditions	  at	  the	  time	  of	  restimulation	  and	  vice	  versa	  (Pepper	  and	  Jenkins	  2011).	  CD4	  T	  cell	  memory	  decays	  more	  quickly	  than	  CD8	  over	  time,	  possibly	  related	  to	  lower	  IL-­‐15R	  expression	  (Pepper	  and	  Jenkins	  2011;	  van	  Leeuwen	  et	  al.	  2009).	  	  	  States	  of	  persistent	  antigen	  (such	  as	  some	  chronic	  viral	  infections	  and	  cancer)	  are	  associated	  with	  defective	  memory	  formation	  (Klebanoff	  et	  al.	  2006).	  Conversely,	  early	  pathogen	  clearance	  accelerates	  memory	  formation	  (Badovinac	  and	  Harty	  2007).	  In	  chronic	  infection	  in	  mice,	  effector	  CD8	  T	  cells	  fail	  to	  upregulate	  the	  receptors	  for	  IL-­‐7	  and	  IL-­‐15,	  leaving	  them	  dependent	  (or	  “addicted”)	  on	  TCR	  stimulation	  for	  survival,	  and	  unable	  to	  survive	  even	  when	  transferred	  into	  naïve	  mice	  (Shin	  and	  Wherry	  2007).	  This	  process	  is	  closely	  linked	  to	  the	  phenomenon	  of	  T	  cell	  exhaustion	  (discussed	  further	  below)	  (Shin	  and	  Wherry	  2007;	  Wherry	  2011).	  	  Importantly,	  there	  is	  evidence	  that	  CD4	  T	  cell	  help	  at	  the	  time	  of	  priming	  is	  required	  to	  “program”	  CD8	  T	  cells	  with	  the	  capacity	  to	  develop	  into	  memory	  cells	  (reviewed	  in	  Bevan	  2004).	  The	  exact	  mechanism	  is	  uncertain.	  There	  is	  also	  evidence	  that	  CD4	  T	  cells	  supports	  CD8	  memory	  in	  a	  way	  that	  is	  not	  antigen-­‐specific,	  possibly	  by	  providing	  cytokines	  that	  support	  the	  survival	  of	  memory	  cells	  (J.	  C.	  Sun	  et	  al.	  2004).	  This	  fact	  has	  important	  implications	  for	  active	  vaccination	  strategies	  for	  established	  cancer,	  where	  the	  goal	  is	  to	  generate	  not	  only	  a	  potent	  effector	  response	  but	  also	  long-­‐lived	  memory	  cells	  capable	  of	  preventing	  relapse	  (Palucka	  et	  al.	  2011).	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1.2.3.6	  DC	  subsets	  Surface	  markers	  and	  gene	  profiling	  have	  identified	  distinct	  DC	  subsets	  that	  differ	  in	  anatomical	  location,	  migratory	  behaviour,	  the	  nature	  of	  the	  antigens	  they	  take	  up	  and	  the	  T	  cell	  populations	  they	  stimulate.	  DC	  can	  be	  broadly	  separated	  into	  migratory	  DC	  that	  reside	  in	  tissues	  and	  have	  the	  capacity	  to	  migrate	  to	  lymph	  nodes,	  and	  lymphoid	  organ	  resident	  DC	  that	  develop	  from	  blood	  precursors	  without	  trafficking	  through	  tissues	  (Collin	  et	  al.	  2013).	  DC	  of	  both	  kinds	  can	  be	  further	  resolved	  into	  subsets	  based	  on	  function	  and	  surface	  markers.	  Whereas	  all	  DC	  can	  present	  exogenous	  antigen	  to	  CD4	  T	  cells	  (Bedoui	  et	  al.	  2009),	  some	  DC	  are	  also	  capable	  of	  cross-­‐priming	  CD8	  T	  cells.	  In	  the	  secondary	  lymphoid	  organs	  of	  mice	  these	  cross-­‐presenting	  DC	  reside	  in	  a	  CD8α+	  fraction	  (Heath	  et	  al.	  2004)	  (although	  the	  function	  of	  this	  T	  cell	  co-­‐receptor	  molecule	  on	  DC	  is	  unknown).	  CD8α+	  DCs	  are	  more	  efficient	  at	  phagocytosing	  dead	  cells	  than	  CD8α-­‐	  DC	  (den	  Haan	  et	  al.	  2000;	  Iyoda	  et	  al.	  2002;	  Schulz	  and	  Reis	  e	  Sousa	  2002).	  	  This	  is	  thought	  to	  be	  mainly	  due	  to	  the	  differential	  expression	  of	  receptors	  that	  recognise	  ligands	  on	  dead	  cells,	  because	  all	  DC	  subsets	  are	  able	  to	  phagocytose	  latex	  beads	  and	  bacteria	  (Iyoda	  et	  al.	  2002;	  Schulz	  and	  Reis	  e	  Sousa	  2002;	  Valdez	  et	  al.	  2002).	  One	  such	  receptor	  is	  DEC205,	  a	  plasma	  membrane-­‐bound	  molecule	  with	  an	  external	  C-­‐type	  lectin	  domain	  that	  is	  differentially	  expressed	  on	  CD8α+	  DC	  relative	  to	  CD8α-­‐	  DC	  (Idoyaga	  et	  al.	  2011).	  	  Although	  the	  ligand	  for	  DEC205	  is	  still	  unknown,	  it	  has	  been	  shown	  to	  be	  involved	  in	  the	  uptake	  of	  dying	  cells	  (Shrimpton	  et	  al.	  2009).	  	  There	  are	  also	  differences	  downstream	  of	  antigen	  uptake.	  CD8α+	  DC	  are	  much	  more	  efficient	  at	  cross-­‐presenting	  exogenous	  antigen	  on	  MHC	  class	  I	  than	  CD8α-­‐	  DC,	  even	  when	  antigen	  uptake	  is	  equivalent	  (Schnorrer	  et	  al.	  2006).	  This	  can	  be	  partly	  explained	  by	  the	  finding	  that	  CD8α+	  DC	  express	  higher	  levels	  of	  molecules	  involved	  in	  MHC	  class	  I	  presentation	  and	  lower	  levels	  of	  molecules	  involved	  in	  MHC	  class	  II	  presentation	  when	  compared	  with	  CD8α-­‐	  DC	  (Dudziak	  et	  al.	  2007).	  In	  addition,	  the	  processing	  pathway	  into	  which	  an	  antigen	  is	  directed	  can	  depend	  on	  the	  way	  in	  which	  it	  enters	  the	  DC,	  which	  can	  differ	  because	  of	  different	  endocytic	  receptor	  expression	  by	  the	  two	  subsets.	  For	  example,	  the	  mannose	  receptor	  (MR)	  is	  a	  C-­‐type	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lectin	  receptor	  that	  mediates	  the	  endocytosis	  of	  chicken	  ovalbumin	  (OVA)	  (Burgdorf	  et	  al.	  2006).	  OVA	  taken	  up	  by	  this	  mechanism	  is	  directed	  from	  early	  endosomes	  into	  a	  cross-­‐presentation	  pathway	  (Burgdorf	  et	  al.	  2007).	  	  OVA	  taken	  up	  by	  pinocytosis	  follows	  the	  normal	  exogenous	  pathway	  to	  be	  presented	  on	  MHC	  class	  II.	  Whereas	  all	  DC	  subsets	  are	  capable	  of	  pinocytosis,	  only	  the	  CD8α+	  DC	  subset	  express	  MR.	  Thus	  CD8α+	  DC	  can	  present	  peptides	  from	  soluble	  OVA	  on	  MHC	  class	  I	  and	  class	  II,	  whereas	  CD8α-­‐	  DC	  can	  present	  only	  on	  MHC	  class	  II	  (Burgdorf	  et	  al.	  2007).	  Recently	  it	  has	  been	  shown	  that	  CD8α+	  DC	  differentially	  express	  Clec9A,	  a	  C-­‐type	  lectin	  that	  is	  required	  for	  the	  cross-­‐presentation	  of	  dead	  cell-­‐associated	  antigens	  (Sancho	  et	  al.	  2008;	  Sancho	  et	  al.	  2009).	  	  Clec9A	  recognises	  an	  undefined	  ligand	  in	  normal	  host	  cells	  that	  becomes	  exposed	  when	  plasma	  membrane	  integrity	  is	  lost.	  It	  is	  not	  required	  for	  the	  uptake	  of	  necrotic	  cell	  fragments	  but	  appears	  to	  act	  as	  a	  sensor	  for	  diverting	  the	  ingested	  necrotic	  cell-­‐associated	  material	  to	  the	  cross-­‐presentation	  pathway.	  	  In	  summary,	  in	  the	  lymphoid	  organs	  of	  mice,	  whereas	  CD8α-­‐	  DC	  are	  capable	  of	  presenting	  exogenous	  antigen	  to	  CD4	  T	  cells,	  CD8α+	  DC	  are	  equipped	  to	  present	  antigen	  to	  both	  CD4	  and	  CD8	  T	  cells,	  and	  are	  particularly	  specialised	  at	  presenting	  antigen	  associated	  with	  dead	  or	  dying	  cells.	  Because	  the	  aim	  of	  most	  anti-­‐cancer	  vaccines	  is	  to	  elicit	  strong	  CTL	  responses,	  there	  is	  considerable	  interest	  in	  trying	  to	  target	  antigens	  to	  cross-­‐presenting	  DC	  (Kreutz	  et	  al.	  2013).	  	  CD8α+	  DC	  are	  not	  all	  equally	  efficient	  at	  cross-­‐priming	  CD8	  T	  cells.	  It	  has	  recently	  been	  shown	  in	  mice	  that	  a	  subset	  of	  CD8α+	  DC	  express	  the	  C-­‐type	  lectin	  langerin	  (CD207)	  and	  that	  depletion	  of	  langerin+	  cells	  severely	  impairs	  the	  cross-­‐priming	  of	  CD8	  T	  cells	  in	  response	  to	  soluble	  OVA	  co-­‐administered	  with	  adjuvant	  in	  vivo	  (Farrand	  et	  al.	  2009).	  The	  reasons	  for	  this	  are	  still	  under	  investigation.	  Langerin	  binds	  to	  carbohydrate	  molecules	  found	  on	  the	  surface	  of	  certain	  fungi	  and	  viruses	  and	  has	  recently	  been	  shown	  to	  mediate	  the	  uptake	  of	  the	  measles	  virus	  by	  DC	  (Stoitzner	  and	  Romani	  2011)	  so	  that	  in	  some	  circumstances	  langerin	  acts	  as	  a	  pathogen/antigen	  endocytosis	  receptor.	  Langerin+	  CD8α+	  DC	  are	  more	  efficient	  than	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langerin-­‐	  DC	  at	  cross-­‐presenting	  soluble	  OVA	  in	  vitro	  (Farrand	  et	  al.	  2009)	  but	  cross-­‐presentation	  of	  soluble	  OVA	  by	  CD8α+	  DC	  is	  not	  impaired	  in	  langerin-­‐deficient	  mice	  (Kissenpfennig	  et	  al.	  2005),	  suggesting	  that	  langerin	  itself	  is	  not	  required	  for	  antigen	  uptake	  or	  cross-­‐presentation	  in	  this	  model.	  Other	  possible	  explanations	  for	  the	  superior	  cross-­‐priming	  ability	  of	  langerin+	  DC	  include	  the	  anatomical	  location	  of	  these	  cells	  (in	  the	  marginal	  zone	  of	  the	  spleen,	  so	  that	  langerin+	  DC	  are	  optimally	  situated	  to	  take	  up	  blood-­‐borne	  antigens)	  (Idoyaga	  et	  al.	  2009)	  or	  some	  other	  intrinsic	  property	  such	  as	  increased	  IL-­‐12	  or	  chemokine	  production	  (Farrand	  et	  al.	  2009).	  	  Interestingly,	  a	  recent	  study	  in	  which	  antigen	  was	  targeted	  to	  DC	  in	  vivo	  by	  conjugation	  to	  antibodies	  to	  DEC205,	  Clec9A	  or	  langerin	  found	  no	  difference	  between	  groups	  in	  the	  magnitude	  of	  antigen-­‐specific	  CD8	  T	  cell	  responses	  (Idoyaga	  et	  al.	  2011).	  	  A	  similar	  arrangement	  of	  DC	  subsets	  exists	  in	  tissues.	  In	  murine	  skin,	  for	  example,	  two	  main	  populations	  of	  migratory	  DC	  are	  present	  in	  the	  deep	  dermis	  in	  the	  resting	  state:	  a	  CD103+	  minority	  and	  a	  CD11b+	  majority	  (CD103	  is	  integrin	  alpha	  E,	  the	  main	  ligand	  for	  which	  is	  E-­‐cadherin	  expressed	  on	  epithelial	  cells).	  CD103+	  DC	  are	  efficient	  at	  cross-­‐presenting	  skin-­‐derived	  antigens	  in	  draining	  LNs	  and	  support	  TH1	  responses	  (Henri	  et	  al.	  2010;	  Igyártó	  et	  al.	  2011).	  In	  addition	  to	  a	  shared	  capacity	  for	  efficient	  cross-­‐presentation,	  migratory	  CD103+	  DC	  and	  lymphoid	  organ-­‐resident	  cross-­‐presenting	  CD8α+	  DC	  also	  share	  expression	  of	  the	  surface	  receptors	  DEC205,	  Clec9A	  and	  langerin,	  and	  are	  absent	  in	  mice	  deficient	  in	  the	  transcription	  factor	  Batf3,	  suggesting	  a	  close	  developmental	  relationship	  between	  these	  two	  subsets	  (Edelson	  et	  al.	  2010).	  The	  larger	  CD11b+	  fraction	  of	  migratory	  DC	  is	  more	  heterogeneous	  and	  less	  well	  studied.	  Proposed	  roles	  for	  this	  DC	  subset	  include	  specialisation	  in	  CD4	  T	  cell	  activation,	  humoral	  immunity	  and	  responses	  to	  extracellular	  parasites	  (Guilliams	  et	  al.	  2010).	  A	  role	  for	  CD11b+	  DC	  in	  maintaining	  peripheral	  tolerance	  has	  been	  proposed	  based	  on	  their	  ability	  to	  produce	  retinoic	  acid	  (that	  promotes	  conversion	  of	  naïve	  T	  cells	  to	  iTreg)	  and	  to	  induce	  Treg	  in	  vitro	  (Guilliams	  et	  al.	  2010;	  Vitali	  et	  al.	  2012).	  However,	  a	  recent	  study	  using	  an	  in	  vivo	  model	  found	  that	  Treg	  induction	  in	  the	  resting	  state	  was	  restricted	  to	  migratory	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langerin+	  Langerhans	  cells	  (LC)	  and	  CD103+	  langerin+	  dermal	  DC,	  leading	  to	  the	  suggestion	  that	  the	  retinoic	  acid	  produced	  by	  CD11b+	  DC	  might	  act	  in	  paracrine	  fashion	  to	  boost	  Treg	  induction	  by	  other	  migratory	  DC	  subsets	  (Idoyaga	  et	  al.	  2013).	  	  	  Other	  DC	  subsets	  found	  in	  tissues	  include	  tissue-­‐specific	  DC	  such	  as	  LC	  and	  “inflammatory”	  DC.	  LC	  uniquely	  reside	  in	  the	  epidermis.	  Although	  long	  thought	  to	  be	  important	  sentinels	  of	  pathogen	  invasion	  in	  the	  epidermis,	  the	  physiological	  role	  of	  LC	  is	  controversial.	  	  Recent	  evidence	  suggests	  LC	  do	  not	  cross-­‐present	  antigen	  in	  
vivo	  (Igyártó	  et	  al.	  2011).	  It	  has	  been	  proposed	  that	  LC	  may	  therefore	  act	  primarily	  as	  antigen	  transporters	  and/or	  have	  a	  major	  role	  in	  maintaining	  tolerance	  to	  commensal	  skin	  flora.	  “Inflammatory”	  DC,	  found	  in	  tissues	  and	  lymphoid	  organs,	  are	  believed	  to	  differentiate	  from	  circulating	  monocytes	  in	  response	  to	  PAMPs	  and/or	  cytokines	  and	  may	  act	  to	  locally	  amplify	  or	  tune	  down	  T	  cell	  responses	  depending	  on	  the	  time	  point	  of	  the	  immune	  response	  (Alonso	  et	  al.	  2011;	  Karman	  et	  al.	  2006;	  Ziegler-­‐Heitbrock	  et	  al.	  2010).	  Tumour-­‐infiltrating	  DC	  (TIDC)	  are	  present	  in	  murine	  (Norian	  et	  al.	  2009)	  and	  human	  (Karthaus	  et	  al.	  2012)	  tumours	  but	  the	  presence	  of	  these	  cells	  is	  not	  necessarily	  conducive	  to	  tumour	  immunity.	  In	  mouse	  tumour	  models,	  TIDC	  have	  been	  found	  to	  lack	  efficient	  antigen-­‐presentation	  capacity	  (Stoitzner	  et	  al.	  2008)	  or	  even	  to	  suppress	  T	  cell	  function	  (Norian	  et	  al.	  2009).	  However,	  these	  TIDC	  can	  regain	  the	  capacity	  to	  prime	  naïve	  T	  cells	  if	  removed	  from	  the	  tumour	  environment	  (Preynat-­‐Seauve	  et	  al.	  2006)	  and,	  in	  animal	  models	  of	  glioma,	  intra-­‐tumoural	  administration	  of	  DC	  (Pellegatta	  et	  al.	  2010;	  Tsugawa	  et	  al.	  2004)	  or	  activation	  of	  TIDC	  in	  situ	  (Mineharu	  et	  al.	  2011)	  can	  promote	  tumour	  immunity.	  	  Human	  and	  murine	  DC	  subsets	  share	  a	  considerable	  degree	  of	  functional	  homology.	  Three	  main	  DC	  subsets	  are	  currently	  recognised	  in	  human	  blood:	  pDC	  and	  two	  classical	  DC	  subsets	  identified	  by	  expression	  of	  CD1c	  (recognised	  by	  the	  blood	  DC	  antibody	  BDCA-­‐1)	  and	  CD141	  (recognised	  by	  BDCA-­‐3),	  being	  the	  functional	  equivalents	  of	  the	  CD11b+	  and	  CD103+	  /	  CD8α+	  murine	  subsets	  respectively	  (Collin	  et	  al.	  2013).	  Although	  blood	  DC	  are	  developmentally	  less	  mature,	  corresponding	  DC	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subsets	  have	  also	  been	  described	  in	  human	  lymphoid	  organs	  and	  tissues	  (Ziegler-­‐Heitbrock	  et	  al.	  2010)	  with	  an	  additional	  CD14+	  DC	  subset	  also	  found	  in	  tissues	  (Collin	  et	  al.	  2013;	  Haniffa	  et	  al.	  2012).	  Importantly,	  CD141+	  human	  DC	  are	  superior	  at	  cross-­‐presenting	  soluble	  antigen	  compared	  with	  CD1c+	  or	  CD14+	  DC	  and	  share	  similar	  expression	  of	  PRRs	  (particularly	  TLR3),	  chemokine	  receptors	  (XCR1)	  and	  endocytosis	  receptors	  	  (Clec9A)	  with	  their	  CD8α+	  /	  CD103+	  murine	  counterparts	  (Guilliams	  et	  al.	  2010;	  Haniffa	  et	  al.	  2012).	  	  	  	  DC	  subsets	  differ	  in	  their	  expression	  of	  PRRs	  consistent	  with	  their	  specialised	  roles.	  Plasmacytoid	  DC	  are	  activated	  by	  single-­‐stranded	  RNA	  and	  CpG-­‐containing	  DNA	  	  through	  TLR7	  and	  TLR9	  respectively,	  consistent	  with	  their	  proposed	  role	  in	  innate	  responses	  to	  extracellular	  viral	  material	  through	  release	  of	  type	  1	  Interferon	  (Kaisho	  2012).	  With	  respect	  to	  classical	  DC,	  whereas	  CD11b+	  migratory	  DC	  and	  CD8α-­‐	  lymphoid	  organ-­‐resident	  DC	  express	  a	  wide	  range	  of	  TLRs,	  subsets	  that	  specialise	  in	  cross-­‐presentation	  of	  exogenous	  antigen	  to	  CD8	  T	  cells	  and	  driving	  TH1	  differentiation	  (and	  hence	  are	  equipped	  to	  mount	  effective	  responses	  against	  intracellular	  viral	  infections)	  express	  a	  more	  restricted	  range	  of	  TLRs	  incuding	  TLR3	  that	  recognises	  double-­‐stranded	  RNA	  (Schreibelt	  et	  al.	  2010).	  Ex	  vivo	  generated	  monocyte-­‐derived	  DC	  uniquely	  express	  high	  levels	  of	  TLR4	  (Schreibelt	  et	  al.	  2010).	  These	  differences	  have	  clear	  implications	  for	  the	  design	  of	  immunotherapies.	  	  
1.2.4	  Innate-­‐like	  T	  cells	  	  1.2.4.1	  Natural	  Killer	  T	  cells	  	  	  Natural	  Killer	  T	  (NKT)	  cells	  are	  a	  T	  cell	  subset	  that	  also	  express	  NK	  markers	  and	  differ	  from	  conventional	  T	  cells	  in	  a	  number	  of	  ways.	  The	  defining	  characteristic	  of	  NKT	  cells	  is	  the	  expression	  of	  a	  T	  cell	  receptor	  of	  limited	  diversity	  that	  recognises	  antigens	  presented	  on	  the	  non-­‐classical	  MHC	  class	  I-­‐like	  molecule	  CD1d.	  The	  α-­‐	  and	  β-­‐chains	  that	  together	  form	  the	  TCR	  are	  specified	  by	  VDJ	  gene	  regions.	  Because	  of	  genetic	  recombination	  during	  T	  cell	  development	  in	  the	  thymus,	  TCR	  diversity	  in	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conventional	  T	  cells	  is	  highly	  diverse.	  In	  contrast	  the	  Type	  1	  NKT	  cell	  TCR	  α-­‐chain	  is	  invariably	  specified	  in	  mice	  by	  Vα14-­‐Jα18	  and	  the	  β-­‐chain	  semi-­‐invariably	  by	  one	  of	  Vβ2,	  Vβ7	  or	  Vβ8	  (Cerundolo	  et	  al.	  2009).	  Cells	  bearing	  this	  TCR	  are	  accordingly	  termed	  “invariant”	  NKT	  cells	  (iNKT).	  In	  human	  iNKT	  cells,	  gene	  usage	  is	  limited	  to	  Vα24-­‐Jα18	  and	  Vβ11	  (Cerundolo	  et	  al.	  2009).	  Type	  2	  NKT	  cells	  are	  also	  CD1d-­‐restricted	  but	  have	  different	  VDJ	  gene	  usage	  and	  different	  properties	  and	  will	  be	  discussed	  separately	  later.	  	  The	  proportion	  of	  αβ	  T	  cells	  that	  are	  iNKT	  cells	  varies	  according	  to	  tissue.	  In	  mice,	  iNKT	  cells	  account	  for	  2-­‐3	  %	  of	  T	  cells	  in	  the	  spleen,	  1	  %	  in	  blood,	  0.5	  %	  in	  lymph	  nodes,	  and	  30	  %	  in	  the	  liver	  (Albert	  Bendelac	  et	  al.	  2007).	  The	  tissue	  distribution	  in	  humans	  is	  less	  studied.	  In	  peripheral	  blood,	  the	  proportion	  of	  T	  cells	  that	  are	  iNKT	  cells	  is	  highly	  variable	  and	  age-­‐dependent	  (Weinkove	  et	  al.	  2013),	  with	  a	  mean	  of	  0.3	  %	  in	  young	  adults	  falling	  to	  0.1	  %	  in	  the	  elderly	  (DelaRosa	  et	  al.	  2002).	  Although	  NKT	  cells	  were	  named	  for	  the	  fact	  that	  they	  also	  express	  markers	  associated	  with	  NK	  cells,	  this	  is	  not	  true	  of	  all	  iNKT	  cells.	  In	  C57BL/6	  mice,	  iNKT	  cells	  acquire	  the	  NK	  marker	  NK1.1	  as	  they	  mature.	  However,	  some	  mature	  iNKT	  cells	  remain	  NK1.1-­‐	  (Benlagha	  et	  al.	  2005).	  In	  mice,	  iNKT	  cells	  are	  CD8-­‐	  but	  may	  be	  CD4+	  or	  CD4-­‐.	  In	  humans	  there	  is	  an	  additional	  subset	  that	  is	  CD8+	  CD4-­‐.	  Like	  all	  T	  cells,	  iNKT	  cells	  undergo	  selection	  in	  the	  thymus	  with	  the	  important	  difference	  that	  positive	  selection	  is	  dependent	  on	  CD1d	  rather	  than	  the	  classical	  MHC	  molecules	  (A	  Bendelac	  1995).	  Thus	  CD1d-­‐deficient	  mice	  lack	  iNKT	  cells.	  	  1.2.4.2	  Antigen	  recognition	  by	  iNKT	  cells	  	  CD1	  molecules	  are	  transmembrane	  proteins	  that	  share	  significant	  homology	  with	  MHC	  molecules	  and,	  like	  MHC	  class	  I,	  associate	  non-­‐covalently	  with	  β2-­‐microglobulin	  (Porcelli	  et	  al.	  1989).	  CD1	  molecules	  perform	  a	  similar	  function	  to	  MHC	  in	  that	  they	  are	  expressed	  at	  high	  levels	  on	  APC	  and	  present	  antigen	  to	  T	  cells	  but	  present	  lipid	  antigens	  instead	  of	  peptides.	  Five	  CD1	  isoforms	  have	  been	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described	  in	  humans	  (CD1a-­‐e)	  but	  only	  CD1d	  is	  expressed	  in	  mice.	  CD1b-­‐d	  present	  a	  range	  of	  foreign	  and	  self-­‐lipid	  molecules.	  CD1e	  is	  not	  expressed	  on	  the	  cell	  surface	  but	  is	  located	  in	  soluble	  form	  in	  phagolysosomes	  where	  it	  appears	  to	  act	  as	  a	  lipid	  transfer	  molecule,	  facilitating	  the	  loading	  of	  ingested	  lipid	  antigens	  onto	  other	  members	  of	  the	  CD1	  family	  (reviewed	  in	  D.	  C.	  Barral	  and	  Brenner	  2007).	  	  	  	  The	  existence	  of	  a	  CD1-­‐restricted	  subset	  of	  human	  αβ	  T	  cells	  was	  first	  reported	  by	  Porcelli	  and	  colleagues	  in	  1989	  (Porcelli	  et	  al.	  1989).	  The	  existence	  of	  a	  subset	  of	  NK1.1+	  T	  cells	  that	  express	  a	  semi-­‐invariant	  αβ	  TCR	  was	  reported	  in	  1994	  (Lantz	  and	  Bendelac	  1994).	  In	  1995,	  a	  screening	  exercise	  for	  bioactive	  substances	  identified	  a	  novel	  compound	  in	  a	  marine	  sponge,	  alpha-­‐galactosylceramide	  (α-­‐GalCer)	  that	  had	  potent	  anti-­‐tumour	  effects	  in	  mouse	  models	  (E.	  Kobayashi	  et	  al.	  1995).	  A	  synthetic	  version	  of	  α-­‐GalCer	  was	  subsequently	  shown	  to	  be	  a	  CD1d-­‐restricted	  ligand	  for	  the	  iNKT	  cell	  TCR	  (Kawano	  et	  al.	  1997).	  Several	  analogues	  of	  α-­‐GalCer	  have	  been	  synthesized	  in	  an	  effort	  to	  maximise	  and	  direct	  iNKT	  responses	  (reviewed	  in	  Cerundolo	  et	  al.	  2009)	  but	  α-­‐GalCer	  remains	  one	  of	  the	  most	  potent	  known	  iNKT	  cell	  antigens.	  	  The	  natural	  ligands	  for	  the	  iNKT	  TCR	  (and	  hence	  the	  physiological	  role	  of	  iNKT	  cells)	  remains	  uncertain.	  Alpha-­‐galactosylceramide	  is	  a	  glycosphingolipid	  consisting	  of	  a	  sugar	  “head”	  and	  a	  bifid	  “tail”	  that	  has	  lipid	  and	  sphingosine	  components.	  The	  alpha	  link	  between	  the	  head	  and	  tail	  regions	  does	  not	  occur	  naturally	  in	  mammals	  and	  is	  crucial	  to	  the	  immunogenicity	  of	  the	  molecule	  as	  β-­‐GalCer	  is	  much	  less	  potent	  (Kawano	  et	  al.	  1997).	  Alpha-­‐linked	  glycolipid	  antigens	  derived	  from	  Borrelia	  
burgdorferi	  (the	  microbe	  responsible	  for	  the	  CNS	  infection	  Lyme	  Disease)	  (Kinjo	  et	  al.	  2006)	  and	  from	  Sphingomonas	  (a	  bacterium	  of	  low	  virulence	  in	  humans)	  (Kinjo	  et	  al.	  2005;	  Mattner	  et	  al.	  2005)	  are	  recognised	  by	  iNKT	  cells,	  which	  raises	  the	  possibility	  that	  iNKT	  cells	  may	  serve	  a	  general	  purpose	  in	  responding	  to	  foreign	  α-­‐linked	  glycolipids.	  	  However,	  because	  iNKT	  cell	  activation	  occurs	  in	  many	  situations	  where	  microbial	  lipid	  antigens	  do	  not	  appear	  to	  be	  present,	  it	  is	  widely	  believed	  that	  naturally-­‐occurring	  endogenous	  iNKT	  cell	  ligands	  must	  exist.	  A	  recent	  study	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(Brennan	  et	  al.	  2011)	  screened	  a	  panel	  of	  naturally-­‐occurring	  glycosphingolipids	  eluted	  from	  CD1d	  molecules	  and	  found	  that	  β-­‐D-­‐glucopyranosylceramide	  (β-­‐GlcCer)	  potently	  activates	  iNKT	  cells	  in	  mice	  and	  humans.	  Because	  this	  molecule	  accumulates	  during	  infection,	  the	  authors	  propose	  that	  β-­‐GlcCer	  serves	  as	  an	  endogenously-­‐generated	  	  “danger”	  signal	  that	  recruits	  iNKT	  cells	  to	  immune	  responses	  during	  infections.	  	  Several	  TCR-­‐independent	  mechanisms	  of	  iNKT	  cell	  activation	  have	  also	  been	  described	  including	  exposure	  to	  cytokines	  such	  as	  IL-­‐12	  (Nagarajan	  and	  Kronenberg	  2007)	  and	  engagement	  of	  iNKT	  cell	  costimulatory	  molecule	  receptors,	  Fc	  receptors,	  NK	  cell	  activating	  receptors,	  and	  PRRs	  (Luc	  Van	  Kaer	  et	  al.	  2013).	  	  	  	  1.2.4.3	  iNKT	  cell	  effector	  functions	  In	  disease	  states,	  iNKT	  cells	  may	  stimulate	  or	  inhibit	  immunity	  depending	  on	  the	  context.	  Mice	  lacking	  iNKT	  cells	  experience	  more	  severe	  pathology	  after	  infection	  with	  Borellia	  burgdorferi,	  a	  known	  source	  of	  ligands	  for	  the	  iNKT	  cell	  TCR	  (Kinjo	  et	  al.	  2006).	  Infections	  with	  Streptococcus	  pneumoniae	  (Kawakami	  et	  al.	  2003)	  and	  Influenza	  virus	  (De	  Santo	  et	  al.	  2008),	  organisms	  that	  do	  not	  furnish	  ligands	  for	  iNKT	  cells,	  are	  also	  prolonged	  or	  more	  severe	  in	  these	  mice.	  iNKT	  cells	  also	  appear	  to	  have	  a	  role	  in	  cancer	  immunosurveillance.	  Carcinogen-­‐induced	  cancers	  occur	  earlier	  in	  iNKT	  cell-­‐deficient	  mice	  than	  in	  wild	  type	  (WT)	  mice	  (Crowe	  et	  al.	  2005;	  M	  J	  Smyth	  et	  al.	  2000).	  	  iNKT	  cells	  are	  also	  implicated	  in	  dysfunctional	  immune	  states.	  Although	  the	  role	  of	  iNKT	  cells	  in	  human	  asthma	  is	  highly	  controversial,	  they	  are	  important	  mediators	  in	  a	  mouse	  model	  of	  asthma,	  allergic	  airway	  hyperresponsiveness,	  in	  an	  IL-­‐4	  and	  IL-­‐13	  –dependent	  manner	  (Akbari	  et	  al.	  2003).	  	  Whereas	  production	  of	  these	  TH2	  cytokines	  by	  iNKT	  cells	  is	  harmful	  in	  some	  contexts,	  it	  may	  be	  protective	  in	  others.	  Nude	  Obese	  Diabetic	  (NOD)	  mice	  spontaneously	  develop	  diabetes	  due	  to	  autoimmune	  pancreatic	  islet	  destruction.	  NOD	  mice	  mice	  lack	  T-­‐	  and	  B-­‐cells	  but	  retain	  some	  iNKT	  cells.	  Diabetes	  develops	  more	  quickly	  in	  these	  mice	  if	  iNKT	  cells	  are	  depleted	  (B.	  Wang	  et	  al.	  2001)	  suggesting	  a	  protective	  role	  for	  iNKT	  cells.	  	  In	  undepleted	  NOD	  mice,	  the	  protective	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function	  of	  iNKT	  cells	  is	  enhanced	  by	  administering	  α-­‐GalCer	  (S.	  Hong	  et	  al.	  2001;	  Sharif	  et	  al.	  2001;	  B.	  Wang	  et	  al.	  2001)	  and	  even	  more	  enhanced	  by	  ligands	  that	  skew	  iNKT	  cells	  towards	  secretion	  of	  TH2	  cytokines	  (Mizuno	  et	  al.	  2004).	  A	  protective	  effect	  of	  TH2-­‐biased	  iNKT	  cell	  cytokine	  secretion	  has	  also	  been	  observed	  in	  EAE,	  a	  murine	  model	  of	  multiple	  sclerosis	  that	  is	  mediated	  by	  TH1	  and	  TH17	  cells	  (Miyamoto	  et	  al.	  2001;	  Oki	  et	  al.	  2004).	  The	  complex	  and	  seemingly	  contradictory	  behaviour	  of	  iNKT	  cells	  in	  disease	  states	  is	  mirrored	  by	  diverse	  and	  complex	  effector	  functions.	  Firstly,	  several	  studies	  have	  shown	  that	  mouse	  and	  human	  iNKT	  cells	  are	  capable	  of	  directly	  inducing	  apoptosis	  in	  tumour	  cell	  lines	  and	  DC	  in	  vitro	  (Fais	  et	  al.	  2004;	  Kawano	  et	  al.	  1998;	  Nicol	  et	  al.	  2000a;	  Takahashi	  et	  al.	  2000).	  Some	  of	  these	  studies	  showed	  that	  blocking	  perforin	  secretion	  abrogated	  cytoxicity,	  and	  that	  CD1d-­‐expression	  by	  the	  target	  cell	  was	  not	  necessarily	  required.	  However,	  it	  has	  subsequently	  been	  suggested	  that	  these	  observations	  were	  due	  to	  contamination	  of	  the	  cell	  cultures	  by	  NK	  cells	  (Wingender	  et	  al.	  2010).	  More	  recently	  it	  has	  been	  shown	  that	  α-­‐GalCer-­‐pulsed	  splenocytes	  and	  B16	  melanoma	  cells	  are	  lysed	  in	  vivo	  in	  a	  way	  that	  requires	  iNKT	  cells	  and	  CD1d	  expression	  by	  the	  target	  cells,	  and	  that	  this	  was	  abrogated	  by	  blocking	  the	  Fas-­‐FasL	  pathway	  (Wingender	  et	  al.	  2010).	  This	  study	  would	  therefore	  suggest	  that	  direct	  iNKT	  cell	  killing	  in	  the	  setting	  of	  cancer	  would	  require	  the	  target	  cells	  to	  express	  both	  Fas	  and	  CD1d.	  At	  the	  present	  time,	  the	  relevance	  of	  iNKT	  cytoxicity	  is	  unclear	  and	  other	  iNKT	  cell	  properties	  to	  be	  described	  below	  are	  probably	  more	  important.	  Direct	  iNKT	  cell	  killing	  of	  CD1d-­‐expressing	  dendritic	  cells	  may	  be	  an	  important	  regulatory	  mechanism	  for	  limiting	  immune	  responses	  (Nicol	  et	  al.	  2000b).	  	  A	  hallmark	  of	  iNKT	  cells	  is	  the	  capacity	  of	  naïve	  cells	  to	  rapidly	  secrete	  large	  amounts	  of	  cytokine	  upon	  antigen	  encounter.	  Similar	  to	  innate	  cells	  such	  as	  NK	  cells,	  this	  property	  is	  due	  to	  the	  presence	  of	  preformed	  mRNA,	  and	  iNKT	  cells	  are	  often	  referred	  to	  as	  “innate-­‐like”.	  Activated	  iNKT	  cells	  secrete	  a	  broad	  range	  of	  cytokines	  including	  IFN-­‐γ,	  IL-­‐2,	  IL-­‐4,	  IL-­‐5,	  IL-­‐6,	  IL-­‐10,	  IL-­‐13,	  IL-­‐17,	  IL-­‐21,	  granulocyte	  macrophage	  colony	  stimulating	  factor	  (GM-­‐CSF),	  TNF-­‐α	  and	  TGF-­‐β	  (Coquet	  et	  al.	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2008).	  Thus,	  confusingly,	  iNKT	  cells	  secrete	  both	  TH1	  and	  TH2	  cytokines	  that	  have	  very	  different	  effects	  and	  counter-­‐regulate	  each	  other,	  as	  well	  as	  both	  pro-­‐inflammatory	  and	  immunosuppressive	  cytokines.	  Cytokine	  secretion	  by	  iNKT	  cells	  depends	  to	  an	  extent	  on	  the	  ligand,	  with	  some	  synthetic	  analogues	  of	  α-­‐GalCer	  eliciting	  a	  more	  TH1-­‐	  or	  TH2-­‐skewed	  cytokine	  profile	  than	  α-­‐GalCer	  itself	  (reviewed	  in	  Cerundolo	  et	  al.	  2009).	  The	  dominant	  effect	  of	  the	  cytokines	  secreted	  by	  iNKT	  cells	  probably	  depends	  on	  multiple	  factors	  including	  the	  ligand,	  the	  anatomical	  site,	  and	  the	  context	  in	  which	  activation	  is	  occurring.	  Further	  complexity	  is	  introduced	  by	  the	  fact	  that	  iNKT	  responses	  are	  sensitive	  to	  the	  time	  course	  of	  α-­‐GalCer	  exposure.	  Thus	  iNKT	  cell	  cytokine	  secretion	  profile	  differs	  after	  single	  exposure	  to	  α-­‐GalCer	  compared	  with	  repeated	  exposure	  (TH1-­‐	  and	  TH2-­‐skewed	  respectively)	  (Parekh	  et	  al.	  2005).	  	  A	  third	  important	  action	  of	  iNKT	  cells	  is	  the	  activation	  of	  other	  cells	  of	  the	  innate	  and	  adaptive	  immune	  systems.	  Interaction	  between	  iNKT	  cells	  and	  APC	  presenting	  α-­‐GalCer	  on	  CD1d	  leads	  to	  iNKT	  activation	  and	  cytokine	  release	  but	  also	  causes	  iNKT	  cells	  to	  upregulate	  CD40L	  expression	  and	  provide	  an	  activation	  signal	  to	  DC	  (Fujii	  et	  al.	  2003;	  Hermans	  et	  al.	  2003b).	  In	  this	  way,	  iNKT	  cells	  are	  able	  to	  licence	  DC	  to	  initiate	  T	  cell	  responses,	  and	  provide	  help	  to	  B	  cells,	  in	  a	  manner	  similar	  to	  conventional	  CD4	  T	  cells.	  DC	  activated	  by	  α-­‐GalCer	  /	  iNKT	  cells	  are	  also	  induced	  to	  secrete	  significant	  quantities	  of	  IL-­‐12	  (Kitamura	  et	  al.	  1999;	  Tomura	  et	  al.	  1999).	  As	  discussed	  above,	  IL-­‐12	  provides	  a	  third	  signal	  to	  CD8	  T	  cells	  during	  priming	  and	  promotes	  TH1	  polarisation	  of	  CD4	  T	  cells.	  In	  addition,	  IL-­‐12	  enhances	  NK	  cytotoxicity	  and	  induces	  NK	  cells	  to	  release	  large	  quantities	  of	  IFN-­‐γ	  (Carnaud	  et	  al.	  1999;	  Mark	  J	  Smyth	  et	  al.	  2002).	  Thus	  the	  iNKT	  cell–DC	  interactions	  induced	  by	  α-­‐GalCer	  lead	  to	  a	  number	  of	  downstream	  effects	  that	  are	  conducive	  to	  anti-­‐tumour	  immunity.	  For	  this	  reason,	  there	  is	  considerable	  interest	  in	  using	  iNKT	  cell	  agonists	  as	  adjuvants	  in	  vaccines.	  Vaccines	  that	  deliver	  antigen	  with	  α-­‐GalCer	  (as	  coadministered	  free	  α-­‐GalCer,	  pulsed	  on	  to	  DC,	  or	  pulsed	  on	  to	  tumour	  cells)	  are	  capable	  of	  inducing	  effective	  tumour-­‐specific	  adaptive	  immune	  responses	  in	  mice	  (discussed	  in	  greater	  detail	  in	  Chapter	  3)	  but	  this	  approach	  has	  not	  yet	  been	  tested	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in	  humans.	  Adding	  to	  the	  interest	  in	  exploiting	  iNKT	  cells	  in	  cancer	  vaccines,	  iNKT	  cells	  have	  also	  been	  shown	  to	  be	  capable	  of	  negatively	  regulating	  several	  immunosuppressive	  cell	  types	  including	  tumour-­‐associated	  macrophages	  (TAM)	  (Song	  et	  al.	  2009),	  myeloid-­‐derived	  suppressor	  cells	  (MDSC)	  (De	  Santo	  et	  al.	  2008)	  and	  Type	  II	  NKT	  cells	  (Ambrosino	  et	  al.	  2007).	  	  	  Several	  studies	  have	  shown	  that	  DC	  in	  the	  spleen	  and	  Kupffer	  cells	  in	  the	  liver	  play	  major	  roles	  in	  presenting	  blood-­‐borne	  lipid	  antigens	  to	  iNKT	  cells	  (Fujii	  et	  al.	  2003;	  Schmieg	  et	  al.	  2005).	  Less	  attention	  has	  been	  given	  to	  events	  in	  LN	  because	  of	  the	  lower	  number	  of	  iNKT	  cells	  in	  this	  location.	  However,	  it	  has	  now	  been	  shown	  that	  α-­‐GalCer	  delivered	  intradermally	  (i.d.)	  with	  antigen	  is	  capable	  of	  inducing	  antigen-­‐specific	  T	  cell	  responses	  in	  the	  draining	  LN	  (Bontkes	  et	  al.	  2010;	  Dondji	  et	  al.	  2008;	  Tripp	  et	  al.	  2009).	  Vaccination	  via	  this	  route	  is	  particularly	  effective	  against	  skin	  tumours,	  possibly	  because	  priming	  in	  cutaneous	  LNs	  imprints	  responding	  T	  cells	  with	  a	  skin-­‐homing	  phenotype	  (Mullins	  et	  al.	  2003).	  Alpha-­‐galactosylceramide	  has	  also	  been	  used	  successfully	  as	  an	  adjuvant	  in	  mouse	  models	  when	  administered	  orally,	  intraperitoneally	  (i.p.),	  or	  intranasally	  (Courtney	  et	  al.	  2009;	  Courtney	  et	  al.	  2011).	  When	  administered	  intranasally,	  α-­‐GalCer-­‐induced	  T	  cell	  priming	  has	  been	  shown	  to	  take	  place	  in	  the	  mediastinal	  LN	  (Courtney	  et	  al.	  2011).	  Although	  some	  systemic	  activation	  of	  iNKT	  cells	  occurs	  when	  α-­‐GalCer	  is	  given	  via	  these	  routes	  (presumably	  because	  some	  α-­‐GalCer	  finds	  its	  way	  into	  the	  circulation),	  antigen-­‐specific	  T	  cell	  responses	  are	  largely	  restricted	  to	  the	  draining	  LNs,	  consistent	  with	  the	  idea	  that	  efficient	  T	  cell	  priming	  requires	  presentation	  of	  α-­‐GalCer	  and	  antigen	  by	  the	  same	  APC.	  When	  α-­‐GalCer	  is	  administered	  systemically	  with	  soluble	  antigen,	  T	  cell	  priming	  in	  peripheral	  LNs	  has	  been	  reported	  to	  be	  either	  absent	  (Tripp	  et	  al.	  2009)	  or	  modest	  (Bontkes	  et	  al.	  2010).	  	  A	  study	  of	  iNKT	  cell	  behaviour	  in	  intact	  lymph	  nodes	  showed	  that	  iNKT	  cells	  randomly	  patrol	  the	  paracortical	  region	  searching	  for	  cognate	  antigen	  in	  the	  same	  manner	  as	  conventional	  CD4+	  T	  cells	  (P.	  Barral	  et	  al.	  2010).	  When	  particulate	  α-­‐GalCer	  is	  administered	  subcutaneously	  (s.c.)	  it	  quickly	  reaches	  the	  subcapsular	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sinus	  of	  the	  draining	  LN	  where	  it	  is	  taken	  up	  by	  CD169+	  macrophages.	  Within	  6	  hours	  of	  α-­‐GalCer	  administration	  iNKT	  cells	  are	  observed	  to	  form	  long-­‐lasting	  contacts	  with	  these	  CD169+	  macrophages,	  which	  is	  dependent	  on	  CD1d	  (P.	  Barral	  et	  al.	  2010).	  This	  suggests	  that,	  at	  least	  in	  the	  very	  early	  stages	  of	  an	  immune	  response,	  macrophages	  in	  draining	  lymph	  nodes	  may	  play	  an	  important	  role	  in	  taking	  up	  and	  presenting	  glycolipid	  antigen	  to	  induce	  early	  activation	  of	  iNKT	  cells.	  The	  authors	  of	  this	  study	  speculate	  that	  these	  macrophage-­‐activated	  iNKT	  cells	  are	  then	  available	  to	  enhance	  adaptive	  immune	  responses	  by	  interacting	  with	  DC	  and	  B	  cells	  in	  the	  same	  lymph	  node.	  Consistent	  with	  this,	  others	  have	  shown	  that,	  although	  both	  skin-­‐resident	  migratory	  DC	  and	  LN-­‐resident	  DC	  express	  CD1d	  and	  are	  capable	  of	  presenting	  α-­‐GalCer	  to	  iNKT	  cells	  in	  vitro,	  skin-­‐resident	  DC	  are	  dispensable	  for	  the	  adjuvant	  effects	  of	  i.d.	  α-­‐GalCer	  in	  vivo	  (Tripp	  et	  al.	  2009).	  	  	  1.2.4.4	  iNKT	  cell	  anergy	  After	  systemic	  administration	  of	  α-­‐GalCer	  in	  mice,	  iNKT	  cells	  become	  undetectable	  in	  spleen,	  liver	  and	  blood	  within	  a	  few	  hours	  leading	  to	  the	  proposal	  that	  strong	  stimulation	  of	  iNKT	  cells	  causes	  antigen-­‐induced	  cell	  death.	  Subsequently,	  it	  has	  been	  shown	  that	  this	  phenomenon	  is	  due	  to	  transient	  downregulation	  of	  NK1.1	  and	  of	  the	  invariant	  TCR	  (Crowe	  et	  al.	  2003;	  M.	  T.	  Wilson	  et	  al.	  2003).	  In	  fact,	  surface	  expression	  of	  the	  TCR	  begins	  to	  return	  after	  48	  hours	  and	  the	  surviving	  cells	  proliferate,	  with	  peak	  expansion	  occurring	  at	  around	  Day	  3	  (greater	  than	  10	  fold	  in	  spleen)	  before	  contraction	  to	  baseline	  levels	  occurs	  (Parekh	  et	  al.	  2005).	  However,	  iNKT	  cells	  typically	  exhibit	  a	  suppressed	  response	  to	  a	  second	  exposure	  to	  α-­‐GalCer	  for	  at	  least	  4-­‐6	  weeks,	  with	  a	  reduction	  in	  iNKT	  cell	  capacity	  to	  secrete	  cytokines,	  proliferate,	  activate	  DC,	  and	  provide	  tumour	  protection	  (Cerundolo	  et	  al.	  2009;	  Parekh	  et	  al.	  2005).	  The	  phenomenon	  of	  iNKT	  cell	  anergy	  is	  of	  vital	  importance	  to	  the	  design	  of	  vaccination	  strategies	  incorporating	  α-­‐GalCer	  as	  an	  adjuvant.	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Suppression	  of	  cytokine	  secretion	  is	  dose-­‐dependent	  (Parekh	  et	  al.	  2005)	  and	  does	  not	  affect	  all	  cytokines	  equally,	  with	  IFN-­‐γ	  secretion	  being	  more	  profoundly	  suppressed	  than	  IL-­‐4	  (Parekh	  et	  al.	  2005;	  N.	  Singh	  et	  al.	  1999).	  At	  doses	  that	  induce	  a	  similar	  level	  of	  DC	  activation	  (as	  measured	  by	  IL-­‐12	  production),	  free	  α-­‐GalCer	  is	  more	  suppressive	  than	  α-­‐GalCer	  pulsed	  onto	  DC	  (Fujii	  et	  al.	  2002),	  an	  effect	  that	  has	  been	  attributed	  to	  presentation	  of	  α-­‐GalCer	  by	  non-­‐professional	  APC	  (Fujii	  et	  al.	  2002)	  such	  as	  B	  cells	  that	  do	  not	  provide	  equivalent	  co-­‐stimulation	  to	  iNKT	  cells	  (Courtney	  et	  al.	  2011;	  Parekh	  et	  al.	  2005;	  Thapa	  et	  al.	  2009).	  However,	  the	  idea	  that	  iNKT	  cell	  anergy	  is	  due	  to	  a	  lack	  of	  co-­‐stimulation	  is	  not	  universally	  supported	  (Iyoda	  et	  al.	  2010).	  Anergy	  may	  also	  depend	  on	  the	  route	  of	  adminstration,	  with	  lower	  levels	  of	  anergy	  reported	  after	  i.d.	  (Bontkes	  et	  al.	  2010)	  and	  intranasal	  (Courtney	  et	  al.	  2011)	  delivery	  of	  α-­‐GalCer	  compared	  with	  intravenous	  (i.v.).	  The	  molecular	  events	  underlying	  iNKT	  cell	  anergy	  are	  not	  well	  understood.	  Upregulation	  of	  the	  co-­‐inhibitory	  molecule	  programmed	  cell	  death	  protein	  1	  (PD-­‐1)	  on	  the	  surface	  of	  activated	  iNKT	  cells	  may	  be	  at	  least	  partially	  responsible	  but,	  again,	  the	  evidence	  for	  this	  is	  inconsistent	  (Iyoda	  et	  al.	  2010;	  Parekh	  et	  al.	  2009).	  Chronic	  α-­‐GalCer	  administration	  leads	  to	  a	  different	  form	  of	  tolerance	  in	  which	  there	  is	  depletion	  of	  existing	  iNKT	  cells	  and	  repopulation	  from	  thymus	  with	  iNKT	  cells	  expressing	  high	  levels	  of	  inhibitory	  receptors	  (Hayakawa	  et	  al.	  2004).	  In	  an	  early	  study	  in	  human	  cancer	  patients,	  free	  α-­‐GalCer	  administered	  i.v.	  led	  to	  a	  sustained	  fall	  in	  iNKT	  cell	  numbers	  to	  undetectable	  levels,	  as	  measured	  using	  flow	  cytometry	  and	  antibodies	  to	  CD3	  and	  the	  invariant	  TCR	  (Giaccone	  et	  al.	  2002).	  Several	  subsequent	  studies	  using	  α-­‐GalCer–pulsed	  DC	  administered	  i.v.	  have	  reported	  rises	  in	  iNKT	  cell	  numbers	  (D.	  H.	  Chang	  et	  al.	  2005;	  A.	  Ishikawa	  et	  al.	  2005;	  T.	  Uchida	  et	  al.	  2008)	  or	  falls	  that	  were	  only	  transient	  (Nieda	  et	  al.	  2004).	  In	  some	  patients,	  IFN-­‐γ	  secretion	  (Nieda	  et	  al.	  2004;	  T.	  Uchida	  et	  al.	  2008)	  or	  iNKT	  cell	  proliferation	  (D.	  H.	  Chang	  et	  al.	  2005;	  A.	  Ishikawa	  et	  al.	  2005)	  was	  observed	  only	  after	  the	  second	  vaccine	  or	  was	  boosted	  by	  the	  second	  vaccine.	  Although	  it	  is	  difficult	  to	  reach	  firm	  conclusions	  from	  these	  studies,	  the	  data	  appear	  to	  suggest	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that,	  in	  humans,	  α-­‐GalCer	  pulsed-­‐DC	  can	  be	  administered	  repeatedly	  at	  1-­‐4	  week	  intervals	  without	  necessarily	  inducing	  systemic	  iNKT	  cell	  anergy.	  	  	  1.2.4.5	  iNKT	  cell	  subsets	  Recently,	  evidence	  has	  been	  accumulating	  to	  support	  the	  existence	  of	  distinct	  iNKT	  cell	  subsets	  that	  diverge	  during	  thymic	  development.	  NKT1,	  NKT2,	  and	  NKT17	  subsets	  are	  characterised	  by	  the	  secretion	  of	  TH1	  cytokines,	  TH2	  cytokines	  and	  IL-­‐17	  respectively	  (reviewed	  in	  Buechel	  et	  al.	  2015).	  Two	  other	  putative	  subsets	  have	  been	  described	  but	  it	  is	  less	  clear	  whether	  these	  are	  distinct	  lineages	  or	  develop	  from	  other	  iNKT	  cell	  subsets.	  NKTFH	  (follicular	  helper)	  cells	  appear	  to	  play	  an	  important	  role	  in	  supporting	  humoral	  responses	  to	  infections	  (P.-­‐P.	  Chang	  et	  al.	  2011b;	  King	  et	  al.	  2012).	  NKT10	  cells	  secrete	  the	  immunosuppressive	  cytokine	  IL-­‐10	  and	  can	  be	  detected	  in	  mice	  after	  strong	  stimulation	  with	  α-­‐GalCer	  (Sag	  et	  al.	  2014).	  The	  existence	  of	  distinct	  subsets	  with	  different	  effector	  functions	  would	  provide	  a	  plausible	  explanation	  for	  the	  apparently	  diverse	  effects	  of	  iNKT	  cells	  in	  different	  contexts	  and	  disease	  states.	  	  	  1.2.4.6	  Type	  2	  NKT	  cells	  Type	  2	  NKT	  cells	  are	  also	  CD1d-­‐restricted	  but	  have	  diverse	  αβ	  TCRs	  and	  do	  not	  recognise	  α-­‐GalCer	  (Masaki	  Terabe	  et	  al.	  2005).	  	  Among	  the	  identified	  ligands	  for	  Type	  2	  NKT	  cell	  TCRs	  are	  phospholipid	  antigens	  derived	  from	  Mycobacterium	  
tuberculosis	  and	  other	  bacteria	  suggesting	  a	  protective	  role	  for	  Type	  II	  NKT	  cells	  against	  some	  infections	  (Tatituri	  et	  al.	  2013).	  Another	  well-­‐known	  Type	  2	  NKT	  cell	  ligand	  is	  sulfatide,	  a	  major	  constituent	  of	  myelin,	  prompting	  speculation	  that	  these	  cells	  might	  have	  a	  natural	  regulatory	  role	  in	  the	  CNS	  (Blomqvist	  et	  al.	  2009).	  In	  tumour	  models	  these	  cells	  act	  in	  an	  immunosuppressive	  manner	  by	  secreting	  IL-­‐13	  that,	  in	  turn,	  induces	  myeloid	  cells	  to	  produce	  TGF-­‐β	  (M	  Terabe	  et	  al.	  2000;	  Masaki	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Terabe	  et	  al.	  2003).	  Activated	  Type	  2	  cells	  also	  inhibit	  the	  tumour	  protective	  effect	  of	  Type	  1	  NKT	  cells	  (Ambrosino	  et	  al.	  2007).	  Interestingly,	  one	  study	  reported	  that	  nearly	  half	  of	  all	  T	  cells	  infiltrating	  GBM	  tumours	  were	  also	  positive	  for	  the	  NK	  marker	  CD56	  but	  were	  not	  iNKT	  cells	  (Waziri	  et	  al.	  2008).	  	  
1.2.5	  Anti-­‐tumour	  responses	  mediated	  by	  innate	  cells	  	  1.2.5.1	  NK	  cells	  Natural	  Killer	  cells	  are	  lymphocytes	  whose	  main	  purpose	  is	  to	  detect	  and	  kill	  tumour	  cells	  and	  host	  cells	  infected	  with	  pathogens	  (Hayakawa	  and	  Smyth	  2006;	  J.	  C.	  Sun	  and	  Lanier	  2011)	  but	  use	  a	  very	  different	  recognition	  system	  to	  T	  and	  B	  cells.	  NK	  cells	  develop	  in	  the	  bone	  marrow	  and	  reside	  principally	  in	  the	  blood,	  spleen,	  liver	  and	  lung.	  Although	  the	  majority	  of	  resting	  NK	  cells	  express	  the	  LN	  homing	  integrin	  L-­‐selectin	  (CD62L),	  they	  are	  present	  at	  low	  frequency	  in	  LN	  in	  the	  steady	  state	  (J.	  C.	  Sun	  and	  Lanier	  2011).	  When	  activated,	  NK	  cells	  proliferate,	  secrete	  cytokines	  such	  as	  IFN-­‐γ	  and	  TNF-­‐α,	  and	  induce	  apoptosis	  in	  target	  cells	  by	  releasing	  perforin	  and	  granzymes	  (J.	  C.	  Sun	  and	  Lanier	  2011).	  	  NK	  cell	  activation	  is	  determined	  by	  the	  integration	  of	  signals	  received	  from	  multiple	  activating	  and	  inhibitory	  receptors	  on	  the	  cell	  surface	  (Bryceson	  and	  Ljunggren	  2008).	  The	  inhibitory	  receptors	  recognise	  host	  MHC	  class	  I	  molecules,	  so	  that	  cells	  expressing	  MHC	  class	  I	  are	  protected	  from	  NK	  cell	  attack	  (Karlhofer	  et	  al.	  1992).	  	  All	  nucleated	  cells	  continuously	  cleave	  cytosolic	  proteins	  into	  peptides	  and	  display	  these	  on	  the	  cell	  surface.	  In	  this	  way	  the	  adaptive	  immune	  system	  is	  alerted	  to	  the	  presence	  of	  foreign,	  mutant	  or	  overexpressed	  proteins	  inside	  the	  cell.	  As	  previously	  described,	  these	  peptides	  must	  be	  presented	  in	  a	  complex	  with	  MHC	  class	  I	  molecules	  in	  order	  to	  be	  recognised	  by	  the	  T	  cell	  receptor.	  Downregulation	  of	  MHC	  class	  I	  is	  a	  common	  immune	  evasion	  mechanism	  employed	  by	  many	  viruses	  and	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tumours	  to	  evade	  the	  adaptive	  immune	  system.	  One	  of	  the	  main	  roles	  of	  NK	  cells	  is	  therefore	  to	  eliminate	  potentially	  dangerous	  cells	  that	  lack	  MHC	  class	  I	  expression.	  The	  best	  characterised	  activating	  NK	  receptor	  is	  NKG2D.	  The	  ligands	  for	  this	  receptor	  are	  induced	  by	  cellular	  stress	  and/or	  DNA	  damage	  and	  are	  frequently	  expressed	  by	  tumours	  and	  infected	  cells	  (Hayakawa	  and	  Smyth	  2006;	  Ljunggren	  2008).	  Blocking	  the	  NKG2D	  activating	  receptor	  in	  mice	  increases	  susceptibility	  to	  chemically-­‐induced	  tumours	  (Mark	  J	  Smyth	  et	  al.	  2005).	  NK	  cells	  can	  also	  be	  activated	  by	  DC	  by	  direct	  cell-­‐to-­‐cell	  contact	  through	  activating	  receptors	  or	  by	  soluble	  cytokines	  such	  as	  IL-­‐12	  and	  type	  1	  interferon	  (J.	  C.	  Sun	  and	  Lanier	  2011).	  Although	  NK	  cells	  do	  not	  undergo	  gene	  rearrangement	  during	  development	  (and	  therefore	  do	  not	  have	  the	  degree	  of	  receptor	  diversity	  exhibited	  by	  T	  cells),	  it	  has	  been	  shown	  in	  mice	  that	  after	  a	  primary	  challenge	  with	  certain	  antigens	  or	  viruses,	  NK	  cells	  transferred	  to	  naïve	  hosts	  are	  able	  to	  protect	  against	  challenge,	  and	  that	  this	  protection	  is	  antigen-­‐specific	  and	  persists	  for	  at	  least	  several	  months	  (Paust	  and	  Andrian	  2011).	  	  Thus,	  although	  considered	  to	  be	  innate	  cells,	  NK	  cells	  are	  capable	  of	  exhibiting	  a	  form	  of	  antigen-­‐specific	  immunological	  memory,	  at	  least	  in	  mice.	  The	  mechanisms	  underlying	  antigen-­‐specific	  “NK	  memory”	  are	  unclear	  (Paust	  and	  Andrian	  2011).	  NK	  cells	  activated	  by	  cytokines	  alone	  can	  also	  exhibit	  memory-­‐like	  properties	  in	  that,	  for	  at	  least	  3	  weeks,	  they	  produce	  significantly	  more	  IFN-­‐γ	  when	  restimulated	  (Cooper	  et	  al.	  2009).	  NK	  cells	  are	  able	  to	  lyse	  a	  wide	  range	  of	  tumour	  cells	  in	  vitro	  and	  many	  independent	  studies	  demonstrate	  a	  role	  for	  NK	  cells	  in	  tumour	  immune	  surveillance	  in	  mouse	  models	  in	  vivo	  (Hayakawa	  and	  Smyth	  2006;	  Mark	  J	  Smyth	  et	  al.	  2005;	  Vivier	  et	  al.	  2008).	  In	  the	  clinic,	  allogeneic	  haematopoietic	  stem	  cell	  transplantation	  for	  acute	  and	  chronic	  myeloid	  leukaemia	  results	  in	  a	  graft-­‐versus-­‐leukaemia	  effect	  that	  is	  often	  curative.	  There	  is	  strong	  evidence	  in	  human	  patients	  and	  in	  mice	  that	  the	  graft-­‐versus-­‐leukaemia	  effect	  is	  at	  least	  partly	  due	  to	  lysis	  of	  HLA-­‐mismatched	  leukaemic	  cells	  by	  donor	  NK	  (Barrett	  2008;	  Ruggeri	  et	  al.	  1999).	  	  However,	  whether	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this	  phenomenon	  can	  be	  successfully	  extended	  to	  non-­‐haematopoietic	  solid	  tumours	  is	  not	  yet	  clear	  (Vivier	  et	  al.	  2008).	  	  	  1.2.5.2	  Macrophages	  Macrophages	  are	  phagocytic	  cells	  of	  myeloid	  lineage	  found	  in	  almost	  all	  tissues	  and	  in	  secondary	  lymphoid	  organs	  (Murray	  and	  Wynn	  2011).	  In	  the	  steady	  state,	  when	  danger	  signals	  are	  absent,	  macrophages	  play	  a	  central	  role	  in	  normal	  tissue	  homeostasis	  by	  removing	  apoptotic	  cells	  and	  cellular	  debris.	  The	  recognition	  of	  apoptotic	  cells	  via	  “scavenger”	  receptors	  (such	  as	  for	  phosphatidyl	  serine)	  does	  not	  trigger	  cytokine	  gene	  transduction	  (Mosser	  and	  Edwards	  2008)	  but	  does	  stimulate	  release	  of	  TGF-­‐β	  (Mosser	  and	  Edwards	  2008)	  and	  IL-­‐10	  (Murray	  and	  Wynn	  2011).	  Thus,	  the	  default	  setting	  of	  macrophages	  in	  the	  steady	  state	  is	  to	  suppress	  inflammation	  (Mosser	  and	  Edwards	  2008;	  Murray	  and	  Wynn	  2011).	  	  Macrophages	  are	  important	  players	  in	  the	  innate	  response	  to	  invading	  pathogens.	  Invading	  bacteria	  are	  recognised	  by	  cell	  surface	  receptors,	  taken	  up	  by	  phagocytosis	  and	  then	  killed	  within	  phagosomes	  by	  several	  mechanisms	  including	  acidification,	  fusion	  with	  lysosomes,	  and	  exposure	  to	  nitric	  oxide	  (NO)	  and	  reactive	  oxygen	  species	  (ROS).	  Ligation	  of	  PRRs	  also	  causes	  activated	  macrophages	  to	  release	  cytokines	  and	  chemokines	  that	  recruit	  other	  immune	  cells	  to	  the	  site	  of	  infection	  (Murray	  and	  Wynn	  2011).	  	  Macrophages	  also	  play	  important	  roles	  in	  adaptive	  immune	  responses,	  including	  anti-­‐tumoural	  responses.	  “Classically-­‐activated	  macrophages”	  (CAM,	  also	  known	  as	  M1	  macrophages)	  develop	  in	  response	  to	  PAMPs	  and/or	  pro-­‐inflammatory	  cytokines	  IFN-­‐γ	  and	  TNF-­‐α.	  	  CAM	  themselves	  promote	  inflammation	  by	  secreting	  cytokines	  (such	  as	  TNF-­‐α,	  IL-­‐1,	  IL-­‐6,	  and	  IL-­‐23),	  chemokines	  and	  proteases,	  and	  by	  increasing	  production	  of	  toxic	  NO	  and	  ROS	  (Mosser	  and	  Edwards	  2008).	  CAM	  also	  upregulate	  expression	  of	  MHC	  class	  II	  and	  co-­‐stimulatory	  molecules	  and	  secrete	  IL-­‐12,	  thereby	  restimulating	  arriving	  T	  cells	  and	  reinforcing	  TH1	  differentiation.	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Although	  the	  initial	  source	  of	  IFN-­‐γ	  required	  to	  generate	  CAMs	  can	  come	  from	  innate	  cells	  such	  as	  NK	  cells,	  sustained	  generation	  of	  CAMs	  requires	  IFN-­‐γ	  from	  TH1	  or	  CTL.	  IFN-­‐γ	  and	  TNF-­‐α	  released	  by	  the	  arriving	  T	  cells	  in	  turn	  promotes	  phagocytic	  function	  and	  a	  “respiratory	  burst”	  in	  M1	  macrophages	  that	  enhances	  the	  cells	  ability	  to	  kill	  intracellular	  pathogens	  and	  release	  tumouricidal	  free	  radicals	  (Miguel	  et	  al.	  2010).	  Macrophages	  also	  elicit	  help	  from	  CD4	  T	  cells	  by	  displaying	  antigen-­‐MHC	  class	  II	  complexes	  and	  CD40	  on	  their	  surface.	  Thus	  M1	  macrophages	  and	  T	  cells	  are	  interdependent.	  Macrophages,	  that	  kill	  indiscriminantly,	  are	  dependent	  for	  sustained	  activation	  on	  antigen-­‐specific	  T	  cells.	  Conversely,	  the	  tumouricidal	  properties	  of	  T	  cells	  may	  be	  mediated	  indirectly	  by	  boosting	  the	  effector	  functions	  of	  macrophages	  (Hicks	  et	  al.	  2006;	  Mace	  et	  al.	  1988).	  Contact-­‐dependent	  mechanisms	  of	  tumour	  cell	  killing	  by	  macrophages	  have	  also	  been	  described	  (Hicks	  et	  al.	  2006;	  Tsung	  et	  al.	  2002).	  In	  keeping	  with	  this,	  depletion	  of	  macrophages	  has	  been	  shown	  to	  promote	  tumour	  growth	  in	  a	  murine	  glioma	  model	  (Galarneau	  et	  al.	  2007).	  However,	  these	  tumouricidal	  functions	  of	  macrophages	  become	  subverted	  as	  tumours	  progress	  and	  immunosuppressive	  phenotypes	  predominate	  by	  the	  time	  patients	  present	  with	  symptomatic	  tumours	  (Mosser	  and	  Edwards	  2008).	  This	  probably	  explains	  why	  the	  presence	  of	  TAM	  has	  been	  associated	  with	  a	  poorer	  prognosis	  in	  breast	  cancer	  (X.	  Tang	  2013)	  and	  GBM	  (Nagai	  et	  al.	  2009).	  This	  will	  be	  discussed	  in	  greater	  detail	  below.	  	  
1.3	  IMMUNOTHERAPY	  FOR	  GBM	  	  
1.3.1	  Spontaneous	  anti-­‐tumour	  immune	  responses	  The	  immunosurveillance	  hypothesis,	  according	  to	  which	  the	  immune	  system	  destroys	  tumour	  cells	  as	  they	  arise,	  is	  supported	  by	  animal	  models	  in	  which	  immunodeficent	  mice	  are	  more	  susceptible	  to	  tumour	  development	  than	  WT	  mice	  (Shankaran	  et	  al.	  2001;	  Street	  et	  al.	  2001;	  van	  den	  Broek	  et	  al.	  1996).	  In	  human	  patients,	  all	  detectable	  tumours	  have,	  by	  definition,	  evaded	  elimination.	  However,	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there	  is	  abundant	  evidence	  that	  anti-­‐tumour	  immune	  responses	  exist	  in	  cancer-­‐bearing	  patients	  and	  have	  useful	  anti-­‐tumour	  effects	  (Apetoh	  et	  al.	  2007;	  DuPage	  et	  al.	  2011;	  reviewed	  in	  Fridman	  et	  al.	  2012).	  In	  glioma	  patients,	  several	  studies	  have	  reported	  finding	  spontaneous	  antibody	  responses	  to	  tumour-­‐associated	  antigens	  (Pallasch	  et	  al.	  2005;	  Ueda	  et	  al.	  2004)	  (Schmits	  et	  al.	  2002)	  that,	  at	  least	  in	  one	  report,	  correlated	  with	  improved	  outcome	  (Pallasch	  et	  al.	  2005).	  Reports	  of	  spontaneous	  cellular	  immunity	  to	  specific	  antigens	  also	  exist	  (Yajima	  et	  al.	  2005)	  but	  are	  less	  common	  (Dunn	  et	  al.	  2012).	  Tumour-­‐infiltrating	  lymphocytes	  (TIL)	  extracted	  from	  glioma	  tumours	  and	  expanded	  ex	  vivo	  in	  IL-­‐2	  are	  capable	  of	  lysing	  autologous	  tumour	  cells	  in	  vitro	  (Sawamura	  et	  al.	  1989)	  and,	  in	  one	  study,	  PBMC	  from	  four	  of	  four	  GBM	  patients	  released	  IFN-­‐γ	  after	  stimulation	  with	  autologous	  tumour	  (J.	  Tang	  et	  al.	  2005).	  In	  many	  other	  cancer	  types,	  the	  presence	  of	  TIL	  is	  a	  good	  prognostic	  factor	  (Mihm	  et	  al.	  1996;	  Ohtani	  2007;	  Sato	  et	  al.	  2005;	  Fridman	  et	  al.	  2012).	  In	  glioma,	  studies	  on	  the	  effect	  of	  the	  presence	  of	  TIL	  on	  prognosis	  have	  yielded	  conflicting	  results.	  Most	  studies	  have	  reported	  a	  beneficial	  impact	  (Böker	  et	  al.	  1984;	  Kmiecik	  et	  al.	  2013;	  Lohr	  et	  al.	  2011;	  Palma	  et	  al.	  1978;	  I.	  Yang	  et	  al.	  2010).	  Two	  studies	  have	  reported	  no	  association	  between	  survival	  and	  infiltration	  with	  small	  round	  cells	  (Rutledge	  et	  al.	  2013)	  or	  with	  CD4+	  or	  CD8+	  T	  cells	  (Rossi	  et	  al.	  1989)	  and	  one	  found	  the	  presence	  of	  small	  round	  cells	  had	  a	  negative	  impact	  on	  survival	  but	  did	  not	  further	  phenotype	  these	  cells	  (Safdari	  et	  al.	  1985).	  Recent	  studies	  that	  have,	  at	  least	  to	  some	  extent,	  characterised	  the	  infiltrating	  cells	  have	  reported	  positive	  correlations	  between	  survival	  and	  tumour	  infiltration	  by	  CD8+	  T	  cells	  (I.	  Yang	  et	  al.	  2010),	  by	  CD8+	  or	  CD8-­‐	  effector	  T	  cells	  (Lohr	  et	  al.	  2011),	  and	  by	  CD3+	  or	  CD8+	  cells	  (Kmiecik	  et	  al.	  2013).	  	  A	  notable	  feature	  of	  GBM	  is	  the	  fact	  that,	  although	  extensive	  local	  invasion	  is	  invariable,	  metastasis	  outside	  the	  CNS	  is	  extremely	  rare,	  with	  approximately	  ten	  reported	  cases	  of	  spontaneous	  metastasis	  of	  unresected	  GBM	  over	  50	  years	  (Volovitz	  et	  al.	  2011).	  Strong	  evidence	  that	  this	  is	  due	  to	  immunological	  factors	  rather	  than	  to	  a	  barrier	  to	  tumour	  cells	  entering	  the	  circulation	  is	  provided	  by	  the	  observation	  that	  immunosuppressed	  patients	  receiving	  organ	  transplants	  from	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donors	  with	  high	  grade	  glioma	  have	  a	  31	  %	  chance	  of	  developing	  a	  GBM	  metastasis	  in	  the	  transplanted	  organ	  (Buell	  et	  al.	  2003).	  This	  suggests	  that,	  in	  many	  patients	  at	  least,	  spontaneous	  endogenous	  immune	  responses	  exist	  and	  are	  able	  to	  keep	  systemic	  metastases	  in	  check	  while	  failing	  to	  control	  the	  primary	  tumour.	  	  Taken	  together,	  these	  data	  show	  that	  tumour-­‐specific	  immune	  responses	  can	  develop	  spontaneously	  in	  glioma-­‐bearing	  patients	  and	  that	  these	  responses	  are	  capable	  of	  exerting	  meaningful	  anti-­‐tumour	  activity.	  	  In	  the	  next	  section,	  progress	  in	  the	  field	  of	  immunotherapy	  for	  cancer	  is	  briefly	  reviewed.	  Although	  the	  focus	  is	  on	  glioma,	  reference	  is	  also	  made	  to	  landmark	  studies	  in	  other	  cancer	  types.	  	  	  
1.3.2	  Immunotherapy	  for	  cancer	  1.3.2.1	  Cytokine	  therapy	  	  Some	  of	  the	  earliest	  cancer	  immunotherapies	  have	  consisted	  of	  attempts	  to	  non-­‐specifically	  stimulate	  or	  boost	  endogenous	  anti-­‐tumoural	  immune	  responses.	  Based	  on	  the	  observation	  of	  spontaneous	  remissions	  of	  soft	  tissue	  sarcoma	  after	  streptococcal	  skin	  infection,	  a	  New	  York	  surgeon	  William	  Coley	  administered	  heat-­‐killed	  bacteria,	  repeatedly	  eliciting	  high	  fever	  and	  rigors	  over	  a	  period	  of	  weeks	  or	  months.	  Remarkably,	  durable	  remissions	  occurred	  in	  approximately	  one	  half	  of	  patients	  with	  soft	  tissue	  sarcoma	  (Starnes	  1992).	  The	  mechanism	  of	  action	  of	  “Coley’s	  toxins”	  is	  not	  known	  with	  certainty	  but	  is	  likely	  to	  involve	  release	  of	  pro-­‐inflammatory	  cytokines	  such	  as	  TNF	  (Brouckaert	  et	  al.	  1992).	  The	  advent	  of	  recombination	  technology	  has	  allowed	  more	  precise	  approaches.	  Systemic	  or	  intra-­‐tumoural	  administration	  of	  pro-­‐inflammatory	  cytokines	  has	  been	  highly	  effective	  in	  animal	  models	  but	  toxicity	  has	  hampered	  this	  approach	  in	  patients.	  	  	  IL-­‐2	  stimulates	  NK	  cells	  and	  promotes	  T	  cell	  proliferation.	  In	  metastatic	  melanoma	  patients,	  the	  systemic	  administration	  of	  IL-­‐2	  achieved	  a	  16	  %	  objective	  response	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rate	  in	  8	  clinical	  trials,	  including	  some	  durable	  complete	  responses	  (Atkins	  et	  al.	  1999).	  Systemic	  treatment	  was	  associated	  with	  a	  high	  incidence	  of	  serious	  toxicity	  consisting	  mainly	  of	  transient	  hypotension	  and	  a	  2.2	  %	  incidence	  of	  death	  due	  to	  sepsis,	  thought	  to	  be	  due	  to	  an	  effect	  of	  IL-­‐2	  on	  neutrophil	  chemotaxis.	  In	  a	  recent	  report,	  repeated	  injections	  of	  IL-­‐2	  directly	  into	  metastatic	  melanoma	  lesions	  resulted	  in	  complete	  response	  lasting	  at	  least	  6	  months	  in	  70	  %	  of	  injected	  lesions	  with	  no	  serious	  toxicity	  (Weide	  et	  al.	  2010).	  No	  effect	  on	  uninjected	  lesions	  was	  observed	  in	  these	  studies.	  In	  glioma,	  IL-­‐2	  has	  most	  notably	  been	  used	  as	  an	  adjunct	  to	  adoptive	  cell	  transfer	  as	  described	  below.	  	  	  	  IL-­‐12	  stimulates	  NK	  cells	  to	  release	  cytokines,	  notably	  IFN-­‐γ,	  and	  promotes	  TH1	  CD4	  T	  cell	  differentiation.	  Systemic	  IL-­‐12	  administration	  has	  also	  been	  associated	  with	  severe	  toxicity,	  including	  death	  in	  some	  patients	  (Leonard	  et	  al.	  1997).	  Local	  intracranial	  delivery	  of	  IL-­‐12	  by	  various	  means	  is	  highly	  effective	  in	  rodent	  models	  of	  glioma	  both	  as	  single	  agent	  (Dimeco	  et	  al.	  2000;	  Ehtesham	  et	  al.	  2002;	  Y.	  Liu	  et	  al.	  2002)	  or	  in	  combination	  with	  systemic	  CTLA-­‐4	  blockade	  (Johannes	  Vom	  Berg,	  oral	  presentation,	  Keystone	  Symposium,	  Vancouver	  2013)	  but	  has	  yet	  to	  be	  tested	  in	  patients.	  	  	  A	  number	  of	  other	  cytokines	  (reviewed	  in	  Butowski	  2010;	  Kane	  and	  Yang	  2010)	  and	  PAMPs	  (Butowski	  2010;	  Carpentier	  et	  al.	  2010;	  Rosenfeld	  et	  al.	  2010;	  Apostolis	  Stathopoulos	  et	  al.	  2012)	  have	  also	  been	  tested	  in	  glioma	  models	  and	  early	  phase	  clinical	  trials	  but	  appear	  more	  likely	  to	  find	  a	  role	  as	  adjuvants	  or	  in	  combination	  with	  other	  immunomodulators	  than	  as	  single	  agents.	  	  	  1.3.2.2	  Monoclonal	  antibodies	  targeting	  tumour	  cells	  	  Monoclonal	  antibodies	  are	  now	  firmly	  incorporated	  into	  the	  standard	  treatment	  for	  a	  number	  of	  haematological	  and	  solid	  cancers.	  Retuximab,	  a	  humanised	  monoclonal	  antibody	  (mAb)	  specific	  for	  the	  B	  cell	  marker	  CD20,	  has	  become	  a	  backbone	  of	  the	  treatment	  for	  chronic	  lymphocytic	  leukaemia	  and	  other	  B	  cell	  malignancies	  (Jain	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and	  O'Brien	  2013).	  Other	  FDA-­‐approved	  mAbs	  that	  directly	  target	  tumour	  cells	  include	  transtuzumab	  for	  Her	  2-­‐positive	  breast	  cancer	  and	  EGFR-­‐specific	  mAbs	  for	  colon	  and	  head	  and	  neck	  cancer	  (reviewed	  in	  Bhutani	  and	  Vaishampayan	  2013).	  These	  mAbs	  are	  believed	  to	  act	  by	  blocking	  pathways	  that	  promote	  tumour	  cell	  survival	  and	  proliferation,	  and	  by	  mediating	  antibody-­‐dependent	  and	  complement-­‐mediated	  cytotoxicity	  (Bhutani	  and	  Vaishampayan	  2013).	  Although	  EGFR	  is	  overexpressed	  in	  40-­‐50	  %	  of	  GBM,	  early	  phase	  trials	  of	  the	  anti-­‐EGFR	  mAbs	  cetuximab	  and	  nimotuzumab	  suggest	  modest	  efficacy	  (Bode	  et	  al.	  2012;	  and	  reviewed	  in	  Mitra	  et	  al.	  2010).	  	  The	  anti-­‐VEGF	  antibody	  bevacizumab	  targets	  tumour	  vasculature	  by	  binding	  and	  neutralising	  circulating	  VEGF.	  Early	  phase	  trials	  in	  patients	  with	  recurrent	  GBM	  revealed	  striking	  radiological	  response	  rates	  but	  modest	  or	  no	  effect	  on	  overall	  survival	  relative	  to	  historical	  controls	  (Friedman	  et	  al.	  2009;	  Morris	  2012;	  Norden	  et	  al.	  2009;	  Vredenburgh	  et	  al.	  2007b;	  Vredenburgh	  et	  al.	  2007a).	  This	  phenomenon	  has	  led	  some	  to	  question	  whether	  the	  radiological	  response	  in	  these	  patients	  is	  due	  to	  an	  effect	  on	  the	  permeability	  of	  blood	  vessels	  to	  gadolinium	  rather	  than	  a	  real	  anti-­‐tumour	  effect	  and	  has	  prompted	  the	  development	  of	  new	  methods	  for	  assessing	  clinical	  response	  in	  clinical	  trials	  in	  glioma	  patients	  (Quant	  and	  Wen	  2011).	  An	  international	  Phase	  III	  multicentre	  trial	  of	  bevacizumab	  in	  combination	  with	  standard	  therapy	  for	  newly	  presenting	  GBM	  is	  currently	  underway.	  Antibodies	  can	  also	  be	  used	  to	  deliver	  cytotoxic	  agents.	  An	  antibody	  to	  the	  extracellular	  matrix	  protein	  tenascin-­‐C,	  expressed	  in	  most	  gliomas	  but	  not	  in	  normal	  brain,	  has	  been	  used	  to	  deliver	  a	  radioactive	  isotope	  to	  the	  tumour	  resection	  cavity	  in	  GBM	  patients	  (Reardon	  et	  al.	  2008).	  Promising	  results	  in	  early	  phase	  trials	  have	  led	  to	  a	  randomised	  Phase	  III	  trial	  that	  is	  currently	  in	  progress	  (Mitra	  et	  al.	  2010).	  	  Bi-­‐specific	  antibodies	  are	  a	  promising	  new	  approach.	  These	  bivalent	  antibodies	  typically	  bind	  both	  a	  defined	  tumour	  cell	  surface	  molecule	  and	  CD3,	  thereby	  combining	  high	  affinity	  binding	  of	  the	  target	  molecule	  with	  the	  cytotoxic	  machinery	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of	  T	  cells	  irrespective	  of	  their	  TCR	  specificity	  (Withoff	  et	  al.	  2001).	  As	  for	  anti-­‐EGFR	  mAbs,	  this	  approach	  requires	  stable	  surface	  expression	  of	  the	  target	  molecule.	  	  	  1.3.2.3	  Adoptive	  cell	  transfer	  (ACT)	  In	  ACT,	  autologous	  T	  lymphocytes	  with	  anti-­‐tumour	  activity	  are	  expanded	  ex	  vivo	  and	  reinfused	  into	  the	  patient.	  Considerable	  success	  has	  been	  achieved	  with	  this	  approach	  in	  patients	  with	  melanoma.	  	  Using	  TIL	  expanded	  in	  vitro	  with	  IL-­‐2,	  Rosenberg	  and	  colleagues	  reported	  objective	  tumour	  responses	  in	  50	  %	  of	  patients	  with	  metastatic	  melanoma,	  providing	  patients	  were	  lymphodepleted	  prior	  to	  adoptive	  transfer	  (summarised	  in	  Steven	  A	  Rosenberg	  et	  al.	  2008).	  Although	  extraction	  of	  TIL	  from	  GBM	  tumours	  is	  feasible	  (Quattrocchi	  et	  al.	  1999),	  most	  clinical	  studies	  of	  adoptive	  immunotherapy	  for	  glioma	  have	  involved	  “lymphokine-­‐activated	  killer	  (LAK)	  cells”,	  a	  mixture	  of	  T	  lymphocytes	  and	  NK	  cells	  expanded	  from	  autologous	  peripheral	  blood	  mononuclear	  cells	  (PBMC)	  in	  the	  presence	  of	  IL-­‐2.	  Systemic	  administration	  of	  LAK	  cells	  was	  pioneered	  in	  cancer	  patients	  by	  Rosenberg	  and	  colleagues	  (S	  A	  Rosenberg	  et	  al.	  1985)	  but,	  in	  most	  glioma	  studies,	  LAK	  cells	  have	  been	  co-­‐administered	  with	  IL-­‐2	  directly	  into	  the	  tumour	  resection	  cavity.	  Initial	  clinical	  trials	  in	  patients	  with	  recurrent	  GBM	  were	  disappointing	  and	  associated	  with	  local	  IL-­‐2-­‐related	  toxicity	  (Barba	  et	  al.	  1989;	  Merchant	  et	  al.	  1988).	  In	  several	  subsequent	  studies,	  long-­‐lasting	  objective	  responses	  have	  been	  observed	  but	  the	  effect	  on	  overall	  survival	  relative	  to	  historical	  or	  contemporaneous	  controls	  has	  been	  variable	  (Boiardi	  et	  al.	  1994;	  Robert	  O	  Dillman	  et	  al.	  2004;	  Hayes	  et	  al.	  1995;	  Hayes	  et	  al.	  2001;	  Lillehei	  et	  al.	  1991;	  Sankhla	  et	  al.	  1996).	  Most	  recently,	  Dillman	  and	  colleagues	  (Robert	  Owen	  Dillman	  et	  al.	  2009)	  tested	  this	  approach	  in	  the	  setting	  of	  newly	  presenting	  GBM,	  with	  direct	  surgical	  administration	  of	  LAK	  cells	  and	  IL-­‐2	  into	  the	  resection	  cavity	  following	  standard	  treatment.	  Considering	  that	  patients	  who	  progressed	  during	  standard	  treatment	  were	  excluded,	  the	  observed	  median	  survival	  of	  20	  months	  indicates	  a	  modest	  clinical	  benefit	  at	  best.	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Allogeneic	  Haematopoietic	  Stem	  Cell	  Transplantation,	  a	  highly	  successful	  form	  of	  ACT	  for	  haematopoietic	  cancers	  that	  exploits	  a	  graft	  versus	  tumour	  effect,	  has	  also	  been	  used	  for	  solid	  cancers	  with	  some	  durable	  objective	  responses	  observed	  in	  patients	  with	  renal	  cell	  cancer	  (Childs	  et	  al.	  2000)	  and	  metastatic	  breast	  cancer	  (Ueno	  et	  al.	  2008)	  but	  is	  associated	  with	  a	  treatment-­‐related	  mortality	  of	  up	  to	  29	  %	  (Ueno	  et	  al.	  2008)	  and	  has	  not	  found	  a	  place	  in	  the	  standard	  treatment	  of	  solid	  cancers	  to	  date.	  Recently,	  autologous	  T	  cells	  engineered	  to	  express	  a	  TCR	  specific	  for	  a	  selected	  epitope	  or	  a	  chimeric	  antigen	  receptor	  (CAR)	  that	  combines	  the	  specificity	  of	  an	  antibody	  with	  the	  intracellular	  machinery	  of	  a	  T	  cell	  receptor	  are	  attracting	  considerable	  attention	  and	  early	  studies	  are	  showing	  particular	  promise	  in	  B	  cell	  lymphomas	  that	  express	  CD19	  or	  CD20	  (T.	  S.	  Park	  et	  al.	  2011;	  Till	  et	  al.	  2012).	  However,	  like	  antibody-­‐based	  immunotherapies,	  this	  monovalent	  approach	  requires	  stable	  and	  ubiquitous	  expression	  of	  the	  target	  antigen	  by	  tumour	  cells.	  	  	  1.3.2.4	  Antigens	  for	  cancer	  vaccines	  	  Active	  specific	  immunotherapy,	  or	  vaccination,	  can	  be	  defined	  as	  the	  administration	  of	  antigen	  along	  with	  a	  “danger”	  signal,	  or	  adjuvant,	  with	  the	  aim	  of	  eliciting	  a	  long-­‐lasting	  antigen-­‐specific	  adaptive	  immune	  response.	  While	  the	  efficacy	  of	  prophylactic	  vaccination	  against	  pathogenic	  microorganisms	  is	  firmly	  established,	  therapeutic	  vaccination	  against	  established	  cancer	  has	  proven	  to	  be	  much	  more	  difficult	  proposition.	  The	  nature	  of	  the	  target	  antigens	  is	  a	  major	  factor.	  Pathogen-­‐derived	  “foreign”	  proteins	  furnish	  epitopes	  that	  bind	  T	  cell	  receptors	  with	  high	  affinity	  and	  provide	  strong	  T	  cell	  stimulation.	  Theoretically,	  the	  ideal	  antigens	  for	  cancer	  immunotherapy	  are	  also	  tumour-­‐specific	  mutant	  proteins	  not	  previously	  encountered	  by	  the	  host	  immune	  system	  (Gilboa	  1999;	  Neller	  et	  al.	  2008).	  In	  practice,	  the	  targets	  in	  cancer	  vaccines	  are	  often	  “self”	  antigens	  that	  are	  over-­‐expressed,	  termed	  “tumour-­‐associated	  antigens”	  (TAA)	  or	  “shared”	  antigens.	  	  Thymic	  selection	  ensures	  that	  T	  cells	  recognising	  these	  antigens	  are	  of	  low	  avidity.	  In	  addition,	  peripheral	  tolerance	  mechanisms	  act	  in	  the	  steady	  state	  to	  continuously	  anergise	  self-­‐reactive	  T	  cells.	  Despite	  this,	  tolerance	  to	  self-­‐antigens	  can	  be	  “broken”	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if	  the	  vaccine	  incorporates	  an	  adjuvant	  capable	  of	  stimulating	  APC	  to	  deliver	  the	  signals	  required	  to	  fully	  prime	  naïve	  T	  cells	  (Cordaro	  et	  al.	  2002;	  Daniels	  et	  al.	  2004;	  Kottke	  et	  al.	  2011;	  Morgan	  et	  al.	  1998).	  The	  quantity	  of	  antigen	  delivered	  to	  APC	  (and	  hence	  the	  density	  of	  peptide-­‐MHC	  complexes	  on	  the	  APC	  surface)	  and	  the	  duration	  of	  antigen	  presentation	  are	  also	  important	  in	  determining	  whether	  T	  cells	  reach	  a	  threshold	  for	  priming	  (Henrickson	  et	  al.	  2008).	  Assuming	  tolerance	  can	  be	  broken,	  a	  constant	  concern	  is	  the	  threat	  of	  “on-­‐target”	  auto-­‐immunity.	  In	  certain	  situations,	  an	  absence	  of	  inflammation	  in	  tissues	  expressing	  the	  target	  antigen	  protects	  them	  from	  immune	  attack	  (Kottke	  et	  al.	  2011).	  In	  others,	  expression	  of	  the	  target	  antigen	  is	  restricted	  to	  expendable	  tissues	  such	  as	  melanocytes	  or	  prostate	  gland,	  so	  that	  auto-­‐immunity,	  when	  it	  occurs,	  is	  clinically	  acceptable.	  These	  are	  special	  cases	  that	  do	  not	  apply	  to	  the	  GBM	  setting.	  However,	  auto-­‐immunity	  does	  not	  inevitably	  accompany	  effective	  anti-­‐tumour	  immunity	  even	  if	  the	  targeted	  TAA	  are	  also	  expressed	  by	  normal	  cells	  within	  the	  inflamed	  organ	  harbouring	  the	  tumour.	  How	  this	  occurs	  is	  not	  clear.	  One	  possibility	  is	  that	  degranulation	  of	  CTL	  requires	  a	  threshold	  density	  of	  peptide-­‐MHC	  complexes	  on	  the	  target	  cell	  surface	  that	  is	  reached	  by	  tumour	  cells	  but	  not	  normal	  cells	  (Morgan	  et	  al.	  1998;	  Weijtens	  et	  al.	  2000).	  	  The	  antigen	  component	  of	  a	  cancer	  vaccine	  may	  take	  many	  forms.	  Autologous	  tumour	  cells	  constitute	  a	  simple	  antigen	  source	  that	  is	  personalised	  and	  can	  therefore	  be	  applied	  to	  all	  patients	  regardless	  of	  HLA	  type.	  The	  provision	  of	  a	  wide	  range	  of	  protein	  antigens	  has	  the	  theoretical	  potential	  to	  provide	  epitopes	  for	  both	  CD4	  and	  CD8	  T	  cells	  and	  to	  induce	  a	  polyclonal	  response	  that	  reduces	  the	  risk	  of	  immune	  escape.	  Because	  the	  targeted	  antigens	  are	  personalised	  and	  not	  pre-­‐determined,	  the	  possibility	  exists	  of	  targeting	  novel	  immunogenic	  mutant	  proteins	  particular	  to	  that	  patient’s	  tumour.	  The	  most	  commonly	  used	  vaccination	  platforms	  used	  to	  deliver	  whole	  tumour	  antigens	  in	  patients	  have	  been	  whole	  tumour	  cells	  or	  their	  lysates,	  and	  antigen-­‐pulsed	  DC.	  DC	  vaccines	  in	  particular	  have	  been	  a	  workhorse	  in	  the	  field	  for	  several	  years	  due	  to	  excellent	  safety	  and	  applicability	  to	  a	  whole	  tumour	  antigen	  approach.	  The	  development	  of	  DC	  vaccines	  was	  in	  part	  driven	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by	  the	  idea	  that	  APC	  activation	  could	  be	  enhanced	  by	  removing	  the	  APC	  from	  the	  immunosuppressive	  environment	  of	  the	  tumour-­‐bearing	  patient	  (D.	  Gabrilovich	  2004;	  Ralph	  M	  Steinman	  and	  Banchereau	  2007).	  Recently,	  a	  landmark	  series	  of	  Phase	  III	  trials	  demonstrated	  a	  four	  month	  increase	  in	  median	  survival	  in	  patients	  with	  advanced	  prostate	  cancer	  who	  received	  Sipuleucel-­‐T,	  a	  product	  consisting	  of	  autologous	  PBMC	  pulsed	  with	  a	  fusion	  protein	  combining	  Prostate	  Specific	  Antigen	  and	  GM-­‐CSF	  (Higano	  et	  al.	  2009;	  Kantoff	  et	  al.	  2010).	  Most	  clinical	  trials	  of	  DC	  vaccines	  have	  used	  DC	  that	  are	  first	  differentiated	  from	  PBMC	  in	  the	  presence	  of	  GM-­‐CSF	  or	  a	  combination	  of	  GM-­‐CSF	  and	  IL-­‐4,	  followed	  by	  antigen	  loading.	  Most	  protocols	  also	  include	  a	  maturation	  step	  using	  various	  combinations	  of	  pro-­‐inflammatory	  cytokines	  although,	  as	  discussed	  above,	  the	  optimum	  phenotype	  for	  the	  infused	  DC	  remains	  uncertain.	  DC	  vaccines	  have	  most	  commonly	  been	  administered	  i.d.	  on	  the	  assumption	  that	  the	  injected	  DC	  will	  migrate	  and	  present	  antigen	  in	  draining	  LNs,	  although	  in	  some	  trials	  DC	  have	  been	  injected	  directly	  into	  LN	  or	  into	  the	  tumour	  site.	  Recently,	  it	  has	  even	  been	  questioned	  whether	  the	  infused	  DC	  actually	  present	  antigen	  or	  act	  mainly	  as	  couriers	  that	  transfer	  their	  antigen	  cargo	  to	  endogenous	  DC	  (Kleindienst	  and	  Brocker	  2003;	  Petersen	  et	  al.	  2011;	  Yewdall	  et	  al.	  2010).	  	  A	  disadvantage	  of	  any	  approach	  using	  whole	  tumour	  antigens	  is	  the	  inclusion	  of	  many	  irrelevant	  normal	  tissue	  proteins,	  raising	  concerns	  about	  auto-­‐immunity	  and	  diluting	  the	  concentration	  of	  TAA.	  In	  addition,	  personalised	  cell-­‐based	  vaccines	  introduce	  practical	  issues	  such	  as	  consistency	  of	  product,	  safety,	  expense,	  and	  the	  need	  to	  satisfy	  stringent	  regulations.	  	  Peptide-­‐based	  vaccines	  therefore	  appeal	  as	  “off-­‐the-­‐shelf”	  platforms.	  Because	  the	  target	  is	  known,	  responses	  can	  be	  more	  readily	  assessed	  in	  vitro.	  On-­‐target	  toxicity	  is	  theoretically	  more	  predictable.	  	  A	  drawback	  of	  short	  peptide	  vaccines	  is	  that	  they	  are	  limited	  to	  patients	  of	  the	  appropriate	  Human	  Leucocyte	  Antigen	  (HLA)	  type.	  Also,	  since	  the	  epitope	  in	  single	  peptide	  vaccines	  is	  usually	  MHC	  Class	  I-­‐restricted,	  CD4	  T	  cell	  help	  is	  not	  recruited.	  Furthermore,	  a	  short	  peptide	  can	  be	  loaded	  directly	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onto	  MHC	  molecules	  of	  non-­‐APC,	  including	  cells	  with	  access	  to	  secondary	  lymphoid	  organs	  such	  as	  T	  cells.	  Thus	  so-­‐called	  “exact”	  peptide	  vaccines	  can	  be	  weak	  or	  even	  tolerogenic	  (Melief	  and	  van	  der	  Burg	  2008).	  To	  address	  some	  of	  these	  problems,	  Melief	  and	  colleagues	  developed	  synthetic	  long	  peptides	  (SLP)	  that	  require	  processing	  before	  presentation	  and	  provide	  epitopes	  for	  both	  CD4	  and	  CD8	  T	  cells	  (Melief	  and	  van	  der	  Burg	  2008).	  Peptides	  and	  SLPs	  have	  been	  used	  in	  vaccines	  as	  free	  molecules,	  loaded	  onto	  DC,	  and	  in	  a	  wide	  variety	  of	  other	  delivery	  systems.	  Free	  nucleic	  acid	  as	  a	  source	  of	  antigen	  is	  poorly	  immunogenic	  but	  has	  been	  successfully	  used	  in	  DC-­‐based	  vaccines.	  Viruses	  can	  also	  be	  manipulated	  to	  encode	  cancer	  antigens	  but	  prime-­‐boost	  regimens	  are	  hampered	  by	  the	  development	  of	  neutralising	  humoral	  responses	  to	  the	  viral	  vector.	  	  Another	  potential	  drawback	  of	  using	  peptide	  vaccines	  to	  treat	  heterogeneous	  cancer	  cell	  populations	  is	  that	  a	  narrow	  target	  can	  lead	  to	  immune	  escape.	  In	  a	  recently	  reported	  Phase	  III	  trial	  of	  systemic	  IL-­‐2	  versus	  systemic	  IL-­‐2	  plus	  a	  gp100	  peptide	  vaccine	  in	  patients	  with	  advanced	  melanoma,	  the	  objective	  response	  rate	  was	  higher	  in	  patients	  who	  received	  the	  peptide	  vaccine	  but	  long	  term	  survival	  was	  no	  different	  (Schwartzentruber	  et	  al.	  2011).	  Prins	  and	  colleagues	  (Prins	  et	  al.	  2013)	  recently	  compared	  the	  results	  of	  two	  separate	  but	  concurrent	  trials	  of	  DC	  vaccination	  in	  patients	  with	  newly-­‐diagnosed	  GBM	  in	  which	  DC	  were	  loaded	  with	  autologous	  tumour	  lysate	  or	  with	  a	  panel	  of	  four	  synthetic	  glioma-­‐associated	  antigen	  (GAA)	  peptides.	  Median	  survival	  was	  34	  months	  in	  the	  autologous	  tumour	  group	  compared	  with	  14	  months	  in	  the	  GAA	  group.	  These	  findings	  need	  to	  be	  treated	  with	  caution	  because	  of	  small	  patient	  numbers	  and	  differences	  in	  the	  DC	  maturation	  protocols	  in	  the	  two	  trials.	  Nevertheless,	  the	  authors	  speculated	  that	  a	  diverse	  immune	  response	  may	  yield	  better	  long	  term	  results	  than	  targeting	  one	  or	  a	  few	  antigens.	  In	  support	  of	  this,	  Schmidt	  and	  colleagues	  (Neller	  et	  al.	  2008)	  have	  analysed	  the	  results	  of	  75	  published	  trials	  of	  various	  cancer	  vaccines	  involving	  1601	  patients	  with	  metastatic	  melanoma	  and	  found	  an	  objective	  response	  rate	  of	  12.7	  %	  to	  immunotherapies	  directed	  at	  undefined	  antigens	  derived	  from	  whole	  tumour	  or	  tumour	  extracts	  
versus	  6.7	  %	  to	  those	  directed	  at	  molecularly	  defined	  antigens	  (P<0.001).	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Interestingly,	  they	  found	  no	  significant	  difference	  in	  the	  response	  rates	  to	  antigens	  derived	  from	  autologous	  and	  allogeneic	  tumour.	  	  	  	  1.3.2.5	  Immunomodulatory	  antibodies	  Cytotoxic	  Lymphocyte	  Antigen	  4	  (CTLA-­‐4)	  is	  a	  receptor	  for	  the	  costimulatory	  molecules	  CD80	  and	  CD86	  but,	  unlike	  CD28,	  delivers	  an	  inhibitory	  signal	  that	  downregulates	  T	  cell	  function	  and	  proliferation	  (Krummel	  and	  Allison	  1995).	  CTLA-­‐4	  is	  not	  expressed	  by	  resting	  T	  cells	  but	  is	  progressively	  upregulated	  after	  activation	  and	  is	  constitutively	  expressed	  by	  FoxP3+	  Treg.	  Binding	  of	  the	  CTLA-­‐4	  receptor	  to	  its	  ligand	  not	  only	  delivers	  an	  inhibitory	  signal	  to	  T	  cells	  but	  also	  results	  in	  “capture”	  of	  the	  ligand	  by	  the	  CTLA-­‐4-­‐expressing	  cell,	  thereby	  reducing	  the	  number	  of	  CD80/86	  molecules	  present	  on	  the	  surface	  of	  APC	  (Qureshi	  et	  al.	  2011).	  This	  system	  represents	  an	  important	  “checkpoint”	  that	  prevents	  tissue	  damage	  due	  to	  excessive	  T	  cell	  overactivity	  (Sharpe	  and	  Freeman	  2002).	  Antibodies	  to	  CTLA-­‐4	  can	  augment	  anti-­‐tumour	  T	  cell	  responses	  both	  by	  blocking	  this	  CTLA-­‐4-­‐mediated	  “checkpoint”	  and	  by	  reducing	  the	  number	  of	  intra-­‐tumoural	  Treg	  via	  a	  mechanism	  that	  depends	  on	  the	  Fc	  portion	  of	  the	  antibody	  (Selby	  et	  al.	  2013).	  In	  a	  randomised	  Phase	  III	  trial,	  the	  humanised	  anti-­‐CTLA-­‐4	  antibody	  ipilimumab	  resulted	  in	  objective	  responses	  in	  11	  %	  of	  patients	  with	  advanced	  melanoma,	  with	  stable	  disease	  in	  a	  further	  17	  %	  and	  improved	  overall	  survival	  compared	  with	  a	  peptide	  vaccine	  (median	  survival	  10	  months	  and	  6	  months	  respectively)	  (Hodi	  et	  al.	  2010).	  A	  clinical	  trial	  of	  a	  CTLA-­‐4	  antibody	  in	  patients	  with	  GBM	  is	  currently	  in	  development	  (S.	  Tanaka	  et	  al.	  2013).	  Another	  “checkpoint”	  for	  T	  cell	  responses	  is	  mediated	  by	  the	  progressive	  upregulation	  of	  the	  PD-­‐1	  receptor	  on	  activated	  T	  cells.	  PD-­‐L1	  is	  a	  ligand	  for	  PD-­‐1	  and	  is	  expressed	  on	  activated	  immune	  cells	  and	  on	  stromal	  cells	  in	  response	  to	  IFN-­‐γ	  (Zou	  and	  Chen	  2008).	  PD-­‐L1	  is	  also	  expressed	  by	  tumour	  cells	  in	  a	  range	  of	  cancers	  (reviewed	  in	  Zou	  and	  Chen	  2008)	  including	  glioma	  (Parsa	  et	  al.	  2007;	  Wintterle	  et	  al.	  2003).	  Engagement	  of	  PD-­‐1	  inhibits	  T	  cell	  function	  and	  promotes	  apoptosis	  
 74 
(Dong	  et	  al.	  2002;	  Freeman	  et	  al.	  2000).	  Tumour-­‐infiltrating	  CD8	  T	  cells	  in	  established	  human	  tumours	  are	  often	  found	  to	  lack	  effector	  functions	  and	  express	  high	  levels	  of	  PD-­‐1	  and	  other	  inhibitory	  receptors	  (Haymaker	  et	  al.	  2012).	  A	  similar	  phenomenon	  in	  chronic	  viral	  infections,	  termed	  T	  cell	  “exhaustion”,	  has	  been	  attributed	  to	  chronic	  stimulation	  (Wherry	  et	  al.	  2011).	  In	  the	  tumour	  setting	  it	  has	  been	  proposed	  that	  T	  cell	  dysfunction	  is	  due	  predominantly	  to	  the	  susceptibility	  of	  activated	  PD-­‐1+	  T	  cells	  to	  regulation	  by	  PD-­‐1	  ligands	  rather	  than	  “exhaustion”	  (Haymaker	  et	  al.	  2012).	  In	  animal	  tumour	  models	  this	  dysfunctional	  state	  can	  be	  reversed	  by	  antibodies	  that	  block	  PD-­‐1	  and	  other	  “exhaustion”	  markers	  (Duraiswamy	  et	  al.	  2013;	  Sakuishi	  et	  al.	  2010).	  	  In	  a	  recent	  study,	  a	  PD-­‐1	  antibody	  combined	  with	  focussed	  irradiation	  was	  effective	  in	  a	  murine	  glioma	  model,	  whereas	  neither	  treatment	  alone	  was	  effective	  (Zeng	  et	  al.	  2013).	  Antibodies	  that	  block	  the	  PD-­‐1	  system	  have	  been	  tested	  in	  phase	  I	  trials	  in	  patients	  with	  melanoma	  and	  other	  solid	  cancers	  and	  are	  showing	  promising	  results	  (Brahmer	  et	  al.	  2012;	  Topalian	  et	  al.	  2012).	  Recently,	  it	  was	  reported	  that	  concomitant	  administration	  of	  anti-­‐CTLA-­‐4	  and	  anti-­‐PD-­‐1	  antibodies	  achieved	  tumour	  regression	  of	  more	  than	  80	  %	  in	  53	  %	  of	  patients	  with	  advanced	  melanoma	  (Wolchok	  et	  al.	  2013).	  	  	  	  
1.3.3.	  Therapeutic	  vaccination	  for	  GBM	  1.3.3.1	  DC-­‐based	  vaccines	  The	  first	  case	  report	  of	  DC	  vaccination	  in	  a	  patient	  with	  high	  grade	  glioma	  was	  published	  in	  2000	  (L	  M	  Liau	  et	  al.	  2000).	  Since	  then,	  at	  least	  29	  clinical	  trials	  of	  DC-­‐based	  immunotherapy	  have	  been	  reported	  in	  this	  patient	  group	  (Ardon	  et	  al.	  2010a;	  Ardon	  et	  al.	  2010b;	  Ardon	  et	  al.	  2012;	  Caruso	  et	  al.	  2004;	  C.-­‐N.	  Chang	  et	  al.	  2011a;	  De	  Vleeschouwer	  et	  al.	  2008;	  Camilo	  E	  Fadul	  et	  al.	  2011b;	  Jie	  et	  al.	  2012;	  T	  Kikuchi	  et	  al.	  2001;	  Tetsuro	  Kikuchi	  et	  al.	  2004;	  T.	  Kobayashi	  et	  al.	  2003;	  Linda	  M	  Liau	  et	  al.	  2005;	  Mitchell	  et	  al.	  2015a;	  H	  Okada	  et	  al.	  2001;	  Hideho	  Okada	  et	  al.	  2011;	  Pellegatta	  et	  al.	  2013;	  Phuphanich	  et	  al.	  2012;	  Prins	  et	  al.	  2011;	  Prins	  et	  al.	  2013;	  Rutkowski	  et	  al.	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2004;	  Sampson	  et	  al.	  2009;	  Vik-­‐Mo	  et	  al.	  2013;	  D.	  G.	  Walker	  et	  al.	  2008;	  Wheeler	  et	  al.	  2008;	  R	  Yamanaka	  et	  al.	  2003;	  Ryuya	  Yamanaka	  et	  al.	  2005b;	  Ryuya	  Yamanaka	  et	  al.	  2005a;	  J	  S	  Yu	  et	  al.	  2001;	  John	  S	  Yu	  et	  al.	  2004).	  Almost	  all	  of	  these	  trials	  have	  used	  monocyte-­‐derived	  DC	  differentiated	  from	  autologous	  PBMC	  in	  IL-­‐4	  and	  GM-­‐CSF	  and	  pulsed	  in	  vitro	  with	  unselected	  autologous	  tumour	  antigens	  in	  various	  forms	  including	  irradiated	  tumour	  cells	  (D.	  G.	  Walker	  et	  al.	  2008),	  tumour	  lysates	  (De	  Vleeschouwer	  et	  al.	  2008;	  Rutkowski	  et	  al.	  2004;	  Wheeler	  et	  al.	  2008;	  R	  Yamanaka	  et	  al.	  2003;	  Ryuya	  Yamanaka	  et	  al.	  2005b;	  John	  S	  Yu	  et	  al.	  2004),	  peptides	  acid-­‐eluted	  from	  tumour	  cells	  (Linda	  M	  Liau	  et	  al.	  2005;	  J	  S	  Yu	  et	  al.	  2001),	  whole	  tumour	  cell	  RNA	  (Caruso	  et	  al.	  2004;	  T.	  Kobayashi	  et	  al.	  2003;	  Vik-­‐Mo	  et	  al.	  2013),	  and	  defined	  antigen	  RNA	  (Mitchell	  et	  al.	  2015a).	  Kikuchi	  and	  colleagues	  have	  uniquely	  reported	  the	  use	  of	  cellular	  fusions	  of	  tumour	  cells	  and	  DC	  (T	  Kikuchi	  et	  al.	  2001;	  Tetsuro	  Kikuchi	  et	  al.	  2004).	  In	  several	  trials	  DC	  were	  loaded	  with	  defined	  peptides,	  targeting	  either	  epidermal	  growth	  factor	  receptor,	  variant	  III	  (EGFRvIII)	  (Sampson	  et	  al.	  2009)	  or	  a	  panel	  of	  selected	  GAA	  (Hideho	  Okada	  et	  al.	  2011;	  Phuphanich	  et	  al.	  2012;	  Prins	  et	  al.	  2013).	  DC	  vaccines	  have	  been	  administered	  i.d.	  or	  s.c.	  in	  almost	  all	  of	  these	  trials	  although	  direct	  intratumoural	  injection	  (R	  Yamanaka	  et	  al.	  2003),	  intranodal	  injection	  (Camilo	  E	  Fadul	  et	  al.	  2011b)	  and	  i.v.	  infusion	  (Caruso	  et	  al.	  2004)	  have	  also	  been	  reported.	  Vaccine	  design	  has	  evolved	  over	  time	  to	  include	  the	  incorporation	  of	  a	  dedicated	  DC	  maturation	  step	  using	  various	  cytokine	  combinations	  (De	  Vleeschouwer	  et	  al.	  2008;	  Prins	  et	  al.	  2013;	  Rutkowski	  et	  al.	  2004)	  or	  TLR	  ligands	  (Hideho	  Okada	  et	  al.	  2011;	  Ryuya	  Yamanaka	  et	  al.	  2005b)	  and	  the	  integration	  of	  immunotherapy	  with	  standard	  chemo-­‐radiotherapy	  in	  patients	  with	  newly	  presenting	  disease	  (Ardon	  et	  al.	  2012;	  Phuphanich	  et	  al.	  2012;	  Prins	  et	  al.	  2013).	  Efforts	  to	  further	  enhance	  adjuvanticity	  have	  included	  the	  local	  application	  of	  a	  TLR	  ligand	  (Prins	  et	  al.	  2011)	  or	  tetanus	  toxoid	  (Mitchell	  et	  al.	  2015a)	  at	  the	  vaccination	  site	  and	  systemic	  administration	  of	  IL-­‐12	  (Tetsuro	  Kikuchi	  et	  al.	  2004).	  One	  early	  trial	  uniquely	  co-­‐administered	  tumour-­‐lysate	  pulsed	  DC	  with	  fibroblasts	  engineered	  to	  secrete	  IL-­‐4	  but	  encountered	  major	  problems	  with	  feasibility	  (H	  Okada	  et	  al.	  2001).	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The	  results	  of	  most	  of	  these	  trials	  have	  been	  comprehensively	  reviewed	  (W.	  Kim	  and	  Liau	  2010;	  Vauleon	  et	  al.	  2010;	  X.	  Xu	  et	  al.	  2012).	  Feasibility	  and	  safety	  have	  been	  conclusively	  demonstrated	  in	  patients	  with	  newly	  presenting	  and	  recurrent	  GBM.	  One	  trial	  reported	  NCI	  CTC	  Grade	  IV	  toxicity	  in	  one	  participant	  consisting	  of	  cerebral	  oedema	  in	  a	  patient	  with	  significant	  residual	  tumour	  bulk	  (De	  Vleeschouwer	  et	  al.	  2008).	  Otherwise	  toxicity	  has	  typically	  been	  limited	  to	  Grade	  I	  and	  II	  toxicity	  such	  as	  flu-­‐like	  symptoms,	  injection	  site	  reactions,	  lymphadenopathy	  and	  rashes	  24-­‐48	  hours	  after	  vaccination	  (Prins	  et	  al.	  2013).	  Seizures	  (Grade	  III)	  are	  also	  not	  uncommonly	  reported	  but,	  very	  reasonably,	  are	  usually	  attributed	  to	  disease	  progression	  (Prins	  et	  al.	  2013).	  Auto-­‐immune	  disease	  has	  not	  been	  reported	  in	  any	  of	  these	  trials.	  	  	  With	  respect	  to	  outcome,	  many	  trials	  involved	  very	  small	  numbers	  of	  patients	  and/or	  included	  heterogeneous	  patient	  groups,	  and	  there	  has	  been	  no	  standardised	  approach	  in	  assessing	  vaccine-­‐induced	  responses,	  making	  comparisons	  of	  efficacy	  difficult.	  Briefly,	  the	  larger	  and	  more	  recent	  trials	  have	  all	  reported	  objective	  radiological	  responses	  and/or	  improved	  survival	  relative	  to	  historical	  or	  contemporaneous	  controls	  and	  all	  have	  shown	  some	  evidence	  of	  vaccine	  bioactivity.	  To	  illustrate	  this,	  three	  recent	  studies	  conducted	  by	  groups	  with	  a	  longstanding	  interest	  in	  this	  field	  are	  described	  in	  more	  detail	  below.	  	  	  Liau	  and	  colleagues	  reported	  a	  Phase	  I	  trial	  of	  autologous	  tumour	  lysate-­‐pulsed	  DC	  vaccination	  in	  28	  patients	  with	  either	  newly	  diagnosed	  or	  recurrent	  GBM	  (Prins	  et	  al.	  2011).	  In	  the	  newly	  diagnosed	  patients	  median	  overall	  survival	  (OS)	  was	  35.9	  months.	  The	  authors	  compared	  this	  with	  median	  OS	  of	  15	  months	  in	  patients	  undergoing	  standard	  treatment	  in	  the	  landmark	  study	  by	  Stupp	  and	  colleagues	  (Stupp	  et	  al.	  2005).	  	  The	  main	  assessment	  of	  immune	  response	  in	  this	  study	  was	  measurement	  of	  serum	  cytokine	  levels	  14	  days	  after	  vaccination.	  Rises	  in	  TNF-­‐α	  and	  IL-­‐6	  were	  observed	  in	  some	  patients	  but	  this	  did	  not	  correlate	  with	  clinical	  outcome.	  This	  study	  has	  provoked	  considerable	  interest	  by	  finding	  a	  significantly	  better	  OS	  in	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patients	  with	  tumours	  with	  a	  mesenchymal	  gene	  expression	  profile,	  suggesting	  that	  gene	  expression	  profiling	  might	  be	  useful	  in	  predicting	  response	  to	  immunotherapy.	  	  De	  Vleeschouwer	  and	  colleagues	  (De	  Vleeschouwer	  et	  al.	  2008)	  treated	  56	  patients	  with	  recurrent	  GBM	  with	  3	  different	  vaccination	  dosing	  schedules	  using	  DC	  pulsed	  with	  autologous	  tumour	  lysate.	  Improved	  progression-­‐free	  survival	  (PFS)	  and	  OS	  relative	  to	  historical	  controls	  was	  observed	  in	  some	  subgroups.	  Post-­‐vaccine	  delayed-­‐type	  hypersensitivity	  (DTH)	  tests	  were	  positive	  in	  nine	  of	  22	  patients	  tested	  but	  were	  known	  to	  be	  negative	  prior	  to	  vaccination	  in	  only	  two	  of	  these	  nine,	  making	  interpretation	  difficult.	  There	  was	  no	  correlation	  between	  clinical	  outcome	  and	  the	  DTH	  test	  results.	  	  This	  group	  subsequently	  undertook	  a	  pilot	  study	  (Ardon	  et	  al.	  2010b)	  in	  which	  DC	  vaccinations	  were	  integrated	  into	  standard	  radiation	  and	  chemotherapy	  of	  eight	  newly	  diagnosed	  GBM	  patients.	  Median	  OS	  was	  24	  months.	  ELISpot	  was	  used	  to	  enumerate	  the	  proportion	  of	  PBMC	  secreting	  IFN-­‐γ	  after	  stimulation	  with	  autologous	  tumour	  lysate.	  A	  two-­‐fold	  increase	  in	  IFN-­‐γ-­‐secreting	  cells	  was	  seen	  in	  five	  of	  the	  eight	  patients.	  DTH	  tests	  were	  also	  performed.	  Only	  one	  became	  positive	  after	  vaccination.	  A	  further	  two	  were	  positive	  at	  baseline.	  The	  proportion	  of	  circulating	  CD8	  T	  cells	  that	  were	  activated	  (defined	  as	  CD25+)	  increased	  in	  six	  of	  seven	  tested	  patients.	  In	  this	  small	  study,	  the	  authors	  found	  no	  correlation	  between	  the	  immunological	  assessments	  and	  clinical	  outcome.	  Recently,	  the	  same	  group	  reported	  the	  results	  of	  a	  Phase	  II	  study	  in	  77	  patients	  using	  a	  similar	  protocol	  (Ardon	  et	  al.	  2012).	  Median	  OS	  in	  a	  subgroup	  of	  patients	  with	  better	  prognostic	  factors	  was	  39	  months	  compared	  with	  18.7	  months	  in	  the	  equivalent	  subgroup	  from	  the	  Stupp	  trial	  (Stupp	  et	  al.	  2009).	  The	  authors	  concluded	  that	  the	  treatment	  was	  possibly	  beneficial	  and	  a	  randomised	  Phase	  IIb	  trial	  is	  currently	  underway.	  No	  immune	  monitoring	  was	  undertaken	  in	  this	  study.	  Finally,	  Phuphanich	  and	  colleagues	  (Phuphanich	  et	  al.	  2012)	  conducted	  a	  Phase	  I	  trial	  in	  which	  HLA-­‐A1	  or	  HLA–A2	  glioma	  patients	  were	  vaccinated	  with	  DC	  pulsed	  with	  six	  synthetic	  peptide	  epitopes	  from	  known	  GAA	  (HER2,	  TRP-­‐2,	  gp100,	  MAGE-­‐1,	  IL13Rα2,	  and	  AIM-­‐2).	  In	  the	  17	  newly	  diagnosed	  GBM	  patients,	  median	  OS	  was	  38.4	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months.	  Vaccine-­‐induced	  responses	  were	  assessed	  by	  intracellular	  cytokine	  staining.	  A	  1.5	  fold	  increase	  in	  the	  proportion	  of	  CD8	  T	  cells	  staining	  for	  IFN-­‐γ	  after	  
in	  vitro	  stimulation	  with	  the	  peptide	  pool	  occurred	  in	  33	  %.	  The	  authors	  found	  a	  trend	  toward	  increased	  progression-­‐free	  survival	  in	  the	  responders	  but	  this	  was	  not	  significant	  and	  there	  was	  no	  correlation	  with	  overall	  survival.	  	  1.3.3.2	  	  Peptide	  and	  protein	  vaccines	  EGFRvIII	  is	  a	  constitutively-­‐active	  mutant	  form	  of	  EGFR	  expressed	  in	  approximately	  one	  third	  of	  GBM	  tumours	  (Heimberger	  et	  al.	  2005).	  The	  in-­‐frame	  deletion	  creates	  a	  novel	  amino	  acid	  sequence	  in	  the	  extracellular	  portion	  of	  the	  EGFR	  protein.	  	  Because	  the	  genetic	  mutation	  is	  not	  present	  in	  normal	  cells,	  EGFRvIII	  has	  the	  potential	  to	  be	  exploited	  as	  a	  tumour-­‐specific	  antigen.	  	  Moscatello	  and	  colleagues	  (Moscatello	  et	  al.	  1997)	  conjugated	  a	  short	  peptide	  spanning	  the	  novel	  region	  of	  EGFRvIII	  to	  keyhole	  limpet	  haemocyanin,	  (KLH)	  a	  carrier	  protein	  known	  to	  elicit	  CD4	  T	  cell	  responses	  (J.	  R.	  Harris	  and	  Markl	  1999)	  and	  showed	  efficacy	  of	  the	  conjugate	  as	  a	  vaccine	  in	  rodents	  against	  EGFRvIII-­‐expressing	  tumours.	  	  	  After	  initially	  testing	  the	  peptide	  conjugate	  in	  a	  DC-­‐based	  vaccine,	  Sampson,	  Heimberger	  and	  colleagues	  moved	  to	  vaccinating	  directly	  with	  peptide	  (coadministered	  i.d.	  with	  GM-­‐CSF)	  to	  reduce	  cost	  and	  variability	  (Kanaly	  et	  al.	  2010)	  and	  have	  completed	  two	  Phase	  II	  trials.	  In	  the	  first	  trial	  (Sampson	  et	  al.	  2010),	  which	  preceded	  the	  advent	  of	  the	  Stupp	  protocol	  as	  standard	  treatment,	  21	  patients	  with	  newly	  diagnosed	  EGFRvIII+	  GBM	  underwent	  >	  95	  %	  debulking	  and	  concomitant	  radiation/TMZ	  followed	  by	  a	  priming	  course	  of	  three	  vaccinations.	  Monthly	  vaccinations	  continued	  indefinitely	  until	  progression.	  Three	  patients	  were	  retrospectively	  excluded	  from	  analysis	  because	  debulking	  was	  less	  than	  95	  %	  and	  progression	  during	  concomitant	  treatment	  was	  an	  exclusion	  criterion.	  	  Median	  OS	  was	  26.0	  months.	  At	  relapse,	  11	  tumours	  were	  resampled	  and	  82	  %	  were	  found	  to	  have	  lost	  expression	  of	  EGFRvIII.	  Perhaps	  surprisingly,	  no	  spontaneous	  immune	  responses	  to	  EGFRvIII	  were	  detected	  prior	  to	  vaccination.	  Post-­‐vaccination,	  43	  %	  of	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patients	  developed	  a	  humoral	  response	  and	  three	  of	  17	  assessed	  patients	  developed	  a	  positive	  DTH	  test.	  Median	  OS	  in	  immunological	  responders	  was	  markedly	  better	  than	  non-­‐responders.	  	  	  The	  second	  trial	  (Sampson	  et	  al.	  2011)	  used	  the	  same	  vaccination	  schedule	  but	  the	  monthly	  booster	  vaccinations	  alternated	  with	  adjuvant	  cycles	  of	  TMZ.	  Two	  different	  TMZ	  dosing	  schedules	  were	  assessed	  with	  12	  patients	  receiving	  adjuvant	  TMZ	  according	  to	  the	  standard	  Stupp	  protocol	  and	  10	  patients	  treated	  according	  to	  a	  “dose-­‐intensified”	  protocol	  of	  100	  mg/m2	  for	  21	  days	  every	  28	  days.	  The	  median	  OS	  for	  all	  patients	  combined	  was	  23.6	  months.	  11	  of	  12	  resampled	  tumours	  were	  found	  to	  be	  EGFRvIII	  negative.	  All	  22	  patients	  developed	  a	  de	  novo	  humoral	  response	  to	  EGFRvIII	  and	  seven	  of	  13	  tested	  patients	  developed	  a	  positive	  DTH	  test.	  Interestingly,	  antibody	  titres	  were	  higher	  in	  the	  dose-­‐intensified	  group,	  and	  all	  seven	  positive	  DTH	  tests	  were	  in	  this	  group,	  even	  though	  TMZ-­‐induced	  lymphopaenia	  was	  more	  severe.	  	  These	  trials	  clearly	  demonstrated	  the	  feasibility	  of	  inducing	  an	  adaptive	  immune	  response	  to	  a	  tumour-­‐specific	  antigen	  in	  GBM	  patients.	  These	  findings	  also	  strongly	  suggest	  that	  the	  effector	  arms	  of	  this	  response	  were	  capable	  of	  gaining	  access	  to	  the	  tumour	  site	  and	  killing	  EGFRvIII+	  cells.	  However,	  the	  fact	  that	  most	  patients	  had	  relapsed	  at	  the	  time	  of	  publication	  suggests	  that	  a	  potent	  response	  against	  a	  single	  epitope	  may	  not	  be	  sufficient	  to	  achieve	  longterm	  remission.	  An	  international	  multicentre	  randomised	  Phase	  III	  trial	  of	  this	  peptide	  conjugate	  vaccine	  is	  currently	  underway.	  Included	  in	  this	  discussion	  of	  peptide	  vaccines	  is	  the	  approach	  taken	  by	  Parsa	  and	  colleagues	  in	  which	  unselected	  peptides	  complexed	  to	  the	  “chaperone”	  heat	  shock	  protein	  gp-­‐96	  are	  extracted	  from	  GBM	  tumours	  and	  administered	  s.c.	  as	  a	  personalised	  vaccine	  without	  additional	  adjuvant	  (Crane	  et	  al.	  2013).	  This	  design	  is	  based	  on	  the	  finding	  that	  DC	  take	  up	  heat	  shock	  protein-­‐peptide	  complexes	  via	  the	  surface	  receptor	  CD91	  (Binder	  and	  Srivastava	  2004).	  	  This	  phase	  I	  trial	  in	  12	  patients	  reported	  encouraging	  efficacy	  data	  and	  evidence	  of	  a	  systemic	  immune	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response	  to	  the	  vaccine	  in	  11	  of	  the	  12	  patients	  as	  assessed	  by	  IFN-­‐γ	  gene	  expression	  in	  PBMC	  stimulated	  in	  vitro	  with	  the	  vaccine.	  Taking	  a	  different	  approach,	  Yajima	  and	  colleagues	  (Yajima	  et	  al.	  2005)	  selected	  patients	  for	  peptide	  vaccination	  based	  on	  the	  existence	  of	  spontaneous	  immune	  responses.	  25	  HLA-­‐A24	  or	  HLA–A2	  patients	  with	  high	  grade	  glioma	  were	  screened	  for	  cell-­‐mediated	  or	  humoral	  responses	  to	  a	  panel	  of	  peptides	  derived	  from	  16	  previously-­‐described	  cancer-­‐associated	  antigens.	  Patients	  were	  then	  vaccinated	  s.c.	  with	  up	  to	  four	  peptides	  emulsified	  in	  Montanide.	  In	  the	  21	  patients	  who	  completed	  the	  planned	  initial	  course	  of	  six	  vaccinations,	  15	  exhibited	  an	  augmented	  antigen-­‐specific	  cell-­‐mediated	  or	  humoral	  response	  to	  at	  least	  one	  of	  the	  peptides.	  Peptide-­‐specific	  antibodies	  were	  also	  detected	  in	  CSF	  or	  the	  tumour	  cavity	  in	  three	  of	  three	  tested	  patients	  who	  had	  objective	  responses.	  Median	  OS	  in	  patients	  with	  recurrent	  GBM	  was	  622	  days,	  with	  a	  trend	  to	  improved	  survival	  in	  immunologically-­‐responding	  patients	  that	  was	  not	  statistically	  significant.	  	  Izumoto	  and	  colleagues	  (Izumoto	  et	  al.	  2008)	  used	  a	  peptide	  vaccine	  to	  target	  the	  product	  of	  the	  WT1	  Wilms’	  tumour	  oncogene	  with	  a	  peptide	  vaccine.	  37	  patients	  with	  recurrent	  GBM	  were	  all	  found	  to	  have	  tumours	  expressing	  WT1.	  The	  21	  HLA-­‐A2402+	  patients	  then	  received	  at	  least	  12	  s.c.	  vaccinations	  with	  a	  9-­‐mer	  peptide	  derived	  from	  WT1	  protein	  emulsified	  in	  Montanide.	  There	  were	  two	  partial	  responses	  (PR)	  and	  10	  patients	  with	  stable	  disease	  (SD),	  with	  a	  PFS	  at	  six	  months	  (PFS6MO)	  of	  33.3	  %.	  Using	  tetramer	  staining,	  the	  frequency	  of	  WT1-­‐specific	  CTL	  was	  higher	  in	  pre-­‐vaccination	  GBM	  patients	  than	  normal	  controls	  but	  did	  not	  increase	  after	  vaccination,	  leading	  the	  authors	  to	  speculate	  that	  the	  vaccine	  may	  have	  acted	  by	  inducing	  a	  qualitative	  change	  in	  antigen-­‐specific	  CTL.	  The	  important	  observation	  was	  also	  made	  that	  the	  longest	  survivors	  did	  not	  respond	  clinically	  until	  near	  the	  end	  of	  the	  12	  week	  vaccination	  regimen	  and	  never	  met	  the	  objective	  criteria	  for	  PR.	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1.3.3.3	  Autologous	  tumour	  cell	  (ATC)	  vaccines	  	  Nine	  clinical	  trials	  and	  two	  case	  reports	  of	  vaccination	  with	  ATC	  in	  101	  patients	  with	  high	  grade	  glioma	  have	  been	  reported	  to	  date	  (Andrews	  et	  al.	  2001;	  Clavreul	  et	  al.	  2010;	  Fakhrai	  et	  al.	  2006;	  E.	  Ishikawa	  et	  al.	  2007;	  Muragaki	  et	  al.	  2011;	  Hideho	  Okada	  et	  al.	  2003;	  Hideho	  Okada	  et	  al.	  2007;	  Parney	  et	  al.	  2006;	  Schneider	  et	  al.	  2001;	  Sobol	  et	  al.	  1995;	  Steiner	  et	  al.	  2004).	  In	  most	  studies	  tumour	  cells	  were	  irradiated	  prior	  to	  administration.	  In	  some,	  tumour	  cells	  were	  inactivated	  by	  exposure	  to	  chemotherapy	  or	  formalin-­‐fixation	  (Muragaki	  et	  al.	  2011).	  The	  ATC	  vaccines	  were	  administered	  s.c	  or	  i.d.	  with	  one	  exception	  in	  which	  irradiated	  ATC	  were	  enclosed	  in	  semi-­‐permeable	  diffusion	  chambers	  implanted	  temporarily	  in	  the	  rectus	  sheath	  (Andrews	  et	  al.	  2001).	  Immunogenicity	  of	  the	  injected	  tumour	  cells	  has	  been	  enhanced	  in	  a	  variety	  of	  ways	  including	  admixture	  with	  fibroblasts	  engineered	  to	  release	  IL-­‐2	  (Sobol	  et	  al.	  1995)	  or	  IL-­‐4	  (Hideho	  Okada	  et	  al.	  2007),	  continuous	  infusion	  of	  GM-­‐CSF	  at	  the	  vaccination	  site	  (Clavreul	  et	  al.	  2010),	  co-­‐administration	  with	  BCG	  (Muragaki	  et	  al.	  2011),	  infection	  of	  the	  tumour	  cells	  with	  Newcastle	  virus	  (Schneider	  et	  al.	  2001;	  Steiner	  et	  al.	  2004)	  and	  engineering	  of	  tumour	  cells	  to	  express	  pro-­‐inflammatory	  cytokines	  and	  co-­‐stimulatory	  molecules	  (Parney	  et	  al.	  2006),	  downregulate	  expression	  of	  the	  immunosuppressant	  cytokine	  TGF-­‐β2	  (Fakhrai	  et	  al.	  2006)	  or	  downregulate	  expression	  of	  Insulin-­‐like	  Growth	  Receptor-­‐1	  which	  in	  turn	  induces	  tumour	  cell	  apoptosis	  (Andrews	  et	  al.	  2001).	  The	  vaccines	  were	  well	  tolerated	  and	  the	  results	  of	  these	  studies	  have	  been	  broadly	  similar	  to	  DC	  studies	  with	  most	  reporting	  objective	  responses	  in	  a	  minority	  of	  patients	  and/or	  a	  survival	  benefit	  in	  comparison	  to	  historical	  controls.	  Vaccine-­‐induced	  immune	  responses	  were	  observed	  in	  many	  of	  these	  studies	  using	  a	  variety	  of	  assessment	  methods.	  Lethal	  allergic	  encephalomyelitis	  has	  been	  reported	  in	  rats	  vaccinated	  with	  human	  GBM	  tumour	  cells	  (Bigner	  et	  al.	  1981).	  However,	  no	  adverse	  events	  attributable	  to	  auto-­‐immunity	  were	  reported	  in	  these	  studies,	  including	  one	  study	  that	  specifically	  assessed	  for	  humoral	  responses	  to	  myelin	  basic	  protein	  or	  evidence	  of	  demyelination	  on	  MRI	  (Clavreul	  et	  al.	  2010).	  Importantly,	  significant	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feasibility	  issues	  were	  encountered	  in	  some	  of	  these	  studies	  (Clavreul	  et	  al.	  2010;	  Hideho	  Okada	  et	  al.	  2007).	  	  In	  the	  largest	  and	  most	  recently	  reported	  study	  of	  an	  ATC	  vaccine	  (Muragaki	  et	  al.	  2011),	  22	  patients	  with	  newly	  diagnosed	  GBM	  undergoing	  post-­‐operative	  radiation	  were	  vaccinated	  concomitantly	  with	  formalin-­‐fixed	  ATC	  mixed	  with	  BCG	  and	  tuberculin	  administered	  i.d.	  	  Most	  patients	  received	  TMZ	  at	  relapse	  (the	  study	  was	  conducted	  in	  2005-­‐2007	  before	  TMZ	  became	  standard	  treatment	  for	  newly-­‐diagnosed	  disease).	  Median	  OS	  was	  21	  months	  compared	  with	  12	  months	  in	  comparable	  historical	  controls.	  DTH	  tests,	  all	  negative	  at	  baseline,	  ranged	  from	  1	  mm	  to	  47	  mm	  post-­‐vaccination.	  A	  DTH	  test	  >/=	  12mm	  was	  strongly	  associated	  with	  prolonged	  PFS	  but	  not	  OS.	  In	  a	  very	  early	  study	  in	  1983,	  Mahaley	  and	  colleagues	  (Mahaley	  et	  al.	  1983b;	  Mahaley	  et	  al.	  1983a)	  vaccinated	  20	  patients	  with	  allogeneic	  glioma	  cells	  mixed	  with	  BCG	  cell	  wall.	  The	  vaccine	  was	  well	  tolerated	  and	  OS	  was	  improved	  relative	  to	  historical	  controls.	  Proof	  of	  principle	  for	  this	  interesting	  approach	  has	  subsequently	  been	  provided	  in	  a	  rodent	  model	  (Apostolos	  Stathopoulos	  et	  al.	  2008).	  	  	  
1.3.4	  Barriers	  to	  effective	  glioma	  immunotherapy	  	  1.3.4.1	  CNS	  immunology	  and	  Immunoprivilege	  The	  concept	  of	  immunoprivilege	  arose	  from	  early	  studies	  showing	  that	  allogeneic	  and	  xenogeneic	  tissues	  were	  rejected	  after	  s.c.	  implantation	  but	  not	  when	  implanted	  in	  the	  anterior	  chamber	  of	  the	  eye	  or	  in	  the	  brain	  (Medawar	  1948;	  J.	  B.	  Murphy	  and	  Sturm	  1923).	  Factors	  contributing	  to	  relative	  immunoprivilege	  in	  the	  CNS	  are	  the	  lack	  of	  a	  conventional	  lymphatic	  system,	  the	  lack	  of	  conventional	  tissue-­‐resident	  APC,	  the	  blood-­‐brain	  barrier	  (BBB),	  and	  a	  low	  level	  of	  MHC	  expression	  by	  normal	  cells	  in	  the	  CNS	  (Kanaly	  et	  al.	  2010;	  Lampson	  and	  Hickey	  1986).	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Despite	  the	  lack	  of	  a	  conventional	  lymphatic	  system,	  the	  outflow	  of	  antigen	  and	  immune	  cells	  from	  the	  steady	  state	  CNS	  has	  been	  demonstrated	  in	  animal	  models.	  Cserr	  and	  colleagues	  showed	  that	  14	  –	  47	  %	  of	  radiolabelled	  albumin	  injected	  into	  the	  brain	  parenchyma	  or	  cerebrospinal	  fluid	  (CSF)	  eventually	  entered	  the	  lymphatic	  system	  (Cserr	  et	  al.	  1992).	  	  In	  a	  rat	  model,	  indian	  ink	  injected	  into	  CSF	  was	  shown	  to	  drain	  directly	  through	  the	  cribriform	  plate	  into	  the	  nasal	  submucosa	  and	  reached	  the	  deep	  cervical	  LNs	  within	  30	  minutes	  (Kida	  et	  al.	  1993).	  Lumbar	  para-­‐aortic	  LN	  were	  stained	  within	  six	  hours,	  presumably	  by	  draining	  along	  spinal	  nerve	  roots.	  Drainage	  from	  CSF	  to	  blood	  through	  arachnoid	  villi	  has	  also	  been	  proposed	  (Cserr	  et	  al.	  1992).	  Lymphocytes	  and	  DC	  injected	  into	  CSF	  are	  able	  to	  reach	  secondary	  lymphoid	  organs	  (Hatterer	  et	  al.	  2006;	  Seabrook	  et	  al.	  1998).	  In	  disease	  states,	  T	  cell-­‐mediated	  responses	  appear	  to	  be	  initiated	  in	  a	  manner	  similar	  to	  other	  tissues.	  Karman	  and	  colleagues	  injected	  Green	  Fluoresence	  Protein	  (GFP)-­‐labelled	  DC	  pulsed	  with	  OVA	  into	  the	  brain	  parenchyma	  and	  detected	  these	  cells	  in	  cervical	  LN	  (Karman	  et	  al.	  2004).	  OVA-­‐specific	  CD8	  T	  cells	  subsequently	  accumulated	  in	  the	  brain,	  a	  process	  that	  required	  the	  injected	  DC	  to	  be	  alive.	  The	  importance	  of	  the	  deep	  cervical	  LN	  as	  a	  major	  site	  of	  priming	  in	  responses	  to	  CNS-­‐derived	  antigens	  has	  been	  supported	  by	  several	  other	  studies	  (de	  Vos	  et	  al.	  2002;	  M.	  J.	  Phillips	  et	  al.	  1997).	  However,	  this	  is	  not	  the	  only	  site	  where	  priming	  occurs.	  Exploiting	  the	  phenomenon	  of	  epitope	  spreading	  in	  an	  animal	  model	  of	  multiple	  sclerosis,	  de	  Vos	  and	  colleagues	  showed	  that,	  in	  an	  inflammatory	  state,	  priming	  of	  responses	  to	  CNS	  self-­‐antigens	  could	  be	  observed	  in	  deep	  cervical	  LN	  and	  also	  in	  spleen	  (but	  not	  axillary	  or	  inguinal	  LN)	  (de	  Vos	  et	  al.	  2002).	  	  Whether	  the	  site	  of	  priming	  determines	  the	  capacity	  of	  activated	  T	  cells	  to	  home	  to	  the	  tumour	  site	  is	  clearly	  a	  point	  of	  vital	  interest	  to	  vaccine	  design.	  In	  the	  study	  by	  Karman	  et	  al	  referred	  to	  above	  (Karman	  et	  al.	  2004),	  the	  OVA-­‐pulsed	  DC	  failed	  to	  induce	  trafficking	  of	  antigen-­‐specific	  T	  cells	  to	  the	  brain	  when	  injected	  i.v.	  even	  when	  the	  brain	  was	  physically	  disrupted	  with	  an	  injection	  of	  media.	  The	  authors	  pointed	  out	  that	  inflammation	  caused	  by	  injection	  into	  parenchyma	  may	  have	  altered	  the	  activation	  state	  of	  the	  brain-­‐injected	  DC.	  However,	  the	  other	  possibility	  is	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that	  brain-­‐emigrant	  DC	  “imprint”	  primed	  T	  cells	  to	  specifically	  home	  to	  the	  CNS.	  Several	  studies	  have	  shown	  that	  the	  majority	  of	  T	  cells	  primed	  in	  secondary	  lymphoid	  organs	  in	  the	  skin	  and	  gut	  are	  induced	  to	  express	  adhesion	  molecules	  that	  encourage	  trafficking	  to	  skin	  and	  gut	  respectively	  (Ferguson	  and	  Engelhard	  2010;	  Mora	  et	  al.	  2003).	  There	  is	  no	  evidence	  of	  a	  phenotype	  that	  homes	  specifically	  to	  the	  CNS	  (Hickey	  2001).	  T	  cells	  primed	  in	  the	  spleen	  and	  mediastinal	  LNs	  dominantly	  express	  integrin	  α4β1,	  a	  phenotype	  associated	  with	  homing	  to	  multiple	  inflamed	  sites	  (Ferguson	  and	  Engelhard	  2010).	  In	  a	  brain	  tumour	  model,	  expression	  of	  α4β1	  integrin	  (also	  known	  as	  Very	  Late	  Antigen-­‐4,	  VLA-­‐4),	  which	  binds	  Vascular	  Cell	  Adhesion	  Molecule	  1	  (VCAM-­‐1),	  was	  shown	  to	  be	  critical	  for	  CTL	  homing	  to	  the	  tumour	  site	  (Sasaki	  et	  al.	  2007).	  Expression	  of	  the	  chemokine	  CXCL10	  at	  the	  brain	  tumour	  site	  has	  also	  been	  found	  to	  be	  critical	  (X.	  Zhu	  et	  al.	  2010).	  CXCR3,	  the	  receptor	  for	  CXCL10,	  is	  expressed	  by	  a	  subset	  of	  activated	  T	  cells	  regardless	  of	  priming	  site	  (Ferguson	  and	  Engelhard	  2010).	  Recently	  the	  lung	  was	  shown	  to	  be	  a	  site	  where	  adoptively	  transferred	  T	  cells	  can	  become	  competent	  to	  enter	  the	  CNS,	  a	  property	  dependent	  on	  the	  expression	  of	  CXCR3,	  VLA-­‐4,	  and,	  in	  the	  EAE	  model	  employed	  in	  that	  study,	  the	  adhesion	  molecule	  Ninjurin-­‐1	  (Odoardi	  et	  al.	  2012).	  	  Together	  these	  data	  suggest	  that	  glioma	  vaccines	  might	  be	  more	  effective	  if	  designed	  to	  induce	  priming	  in	  lymphoid	  organs	  that	  filter	  blood	  or	  in	  deep	  cervical	  lymph	  nodes	  rather	  than	  in	  skin	  draining	  lymph	  nodes.	  Inefficient	  homing	  to	  the	  tumour	  site	  may	  also	  help	  explain	  the	  poor	  correlation	  between	  systemic	  immune	  responses	  and	  clinical	  outcomes	  in	  many	  glioma	  vaccine	  trials,	  most	  of	  which	  have	  been	  administered	  i.d.	  or	  s.c.	  To	  add	  further	  complexity,	  a	  recent	  study	  used	  an	  orthotopic	  OVA-­‐transfected	  glioma	  model	  to	  compare	  the	  outcome	  of	  cutaneous	  vaccination	  in	  the	  hindlimb,	  forelimb	  and	  neck	  and	  found	  that	  the	  magnitude	  of	  the	  OVA-­‐specific	  CTL	  response	  at	  the	  tumour	  site	  increased	  as	  the	  distance	  from	  the	  tumour	  site	  increased	  (Ohlfest	  et	  al.	  2013).	  	  Formed	  by	  a	  combination	  of	  tight	  junctions	  between	  endothelial	  cells	  and	  active	  transport	  mechanisms,	  the	  BBB	  (along	  with	  the	  Blood-­‐CSF	  barrier	  in	  the	  choroid	  plexus)	  regulates	  the	  entry	  of	  macromolecules	  and	  immune	  cells	  into	  the	  CNS.	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Resting	  lymphocytes	  do	  enter	  the	  steady	  state	  CNS	  but	  to	  an	  extent	  that	  is	  quantitatively	  greatly	  reduced	  in	  comparison	  with	  other	  tissues	  (Pachter	  et	  al.	  2003).	  Beyond	  the	  BBB,	  T	  cells	  encounter	  a	  hostile	  environment	  in	  which	  proliferation	  is	  inhibited	  by	  TGF-­‐β	  and	  apoptosis	  promoted	  by	  an	  uncertain	  mechanism	  (J.	  Bauer	  et	  al.	  1998;	  Hickey	  2001).	  However,	  as	  described	  above,	  activated	  lymphocytes	  are	  more	  readily	  able	  to	  cross	  the	  BBB	  and	  local	  inflammation	  also	  encourages	  T	  cell	  entry.	  Pro-­‐inflammatory	  cytokines	  increase	  BBB	  permeability	  and	  upregulate	  expression	  of	  intercellular	  adhesion	  molecules	  (Hickey	  2001;	  Pachter	  et	  al.	  2003).	  	  The	  BBB	  presents	  a	  significant	  barrier	  to	  antibody-­‐based	  treatments.	  In	  the	  steady	  state,	  IgG	  (but	  not	  IgA	  or	  IgM)	  is	  detectable	  in	  CSF	  at	  much	  lower	  concentrations	  than	  in	  serum	  (Mitchell	  et	  al.	  2008a).	  In	  breast	  cancer	  patients	  treated	  with	  the	  anti-­‐herceptin	  mAb	  transtuzumab,	  the	  ratio	  of	  antibody	  in	  CSF	  compared	  to	  serum	  was	  1:420	  (Stemmler	  et	  al.	  2007),	  improving	  to	  1:76	  after	  whole	  brain	  radiotherapy.	  	  Accordingly,	  transtuzumab	  does	  not	  delay	  CNS	  metastases	  in	  these	  patients	  (Burstein	  et	  al.	  2005).	  However,	  clinically	  useful	  concentrations	  of	  antibody	  may	  be	  achievable	  when	  the	  BBB	  is	  perturbed	  by	  the	  presence	  of	  a	  glioma	  and/or	  when	  the	  antibody	  is	  tumour-­‐specific,	  encouraging	  gradual	  accumulation	  at	  the	  tumour	  site	  (Scott	  et	  al.	  2007).	  	  Alternatively,	  convection-­‐enhanced	  delivery	  has	  been	  used	  to	  deliver	  large	  molecules	  to	  the	  brain	  parenchyma	  (Bobo	  et	  al.	  1994).	  	  	  A	  lack	  of	  resident	  DC	  has	  also	  long	  been	  thought	  to	  contribute	  to	  CNS	  immunoprivilege.	  However,	  microglial	  cells,	  the	  resident	  macrophages	  of	  the	  brain	  parenchyma,	  appear	  to	  be	  capable	  of	  serving	  as	  APC	  (Kaur	  et	  al.	  2010).	  Microglial	  cells	  arise	  from	  myeloid	  precursors	  in	  the	  yolk	  sac	  and	  populate	  the	  brain	  during	  early	  CNS	  development	  (Kierdorf	  et	  al.	  2013).	  They	  are	  maintained	  in	  adult	  life	  predominantly	  by	  self-­‐renewal	  (Ajami	  et	  al.	  2007)	  although	  bone	  marrow	  precursors	  may	  contribute	  in	  inflammatory	  states	  (Soulet	  and	  Rivest	  2008).	  Like	  conventional	  DC,	  microglia	  continuously	  sample	  their	  surroundings	  (Nimmerjahn	  et	  al.	  2005)	  and	  a	  subset	  of	  microglia	  express	  the	  DC	  marker	  CD11c	  (Bulloch	  et	  al.	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2008).	  Microglia	  are	  poor	  APC	  under	  resting	  conditions	  but	  readily	  upregulate	  MHC	  class	  II	  and	  co-­‐stimulatory	  molecules	  (Aloisi	  et	  al.	  1998;	  Gottfried-­‐Blackmore	  et	  al.	  2009)	  and	  are	  capable	  of	  processing	  and	  presenting	  exogenous	  antigen	  to	  CD4	  and	  CD8	  T	  cells	  (Aloisi	  et	  al.	  1998;	  Beauvillain	  et	  al.	  2008).	  Aloisi	  and	  colleagues	  (Aloisi	  et	  al.	  1999)	  showed	  that	  IFN-­‐γ-­‐activated	  microglia	  were	  able	  to	  prime	  naïve	  CD4	  T	  cells	  with	  an	  efficiency	  that	  was	  intermediate	  between	  DC	  and	  B	  cells.	  The	  ability	  of	  microglia	  to	  traffic	  to	  regional	  lymph	  nodes	  has	  yet	  to	  be	  definitively	  demonstrated	  (D'Agostino	  et	  al.	  2012).	  In	  addition	  to	  parenchymal	  microglia,	  antigen	  presentation	  is	  likely	  to	  be	  performed	  also	  by	  perivascular	  macrophages	  (Fabriek	  et	  al.	  2005)	  and	  myeloid	  cells	  in	  the	  choroid	  plexus	  (Nataf	  et	  al.	  2006).	  Astrocytes	  can	  also	  serve	  as	  weak	  APC,	  being	  unable	  to	  prime	  naïve	  T	  cells	  but	  capable	  of	  reactivating	  primed	  T	  cells	  (Aloisi	  et	  al.	  1999).	  	  1.3.4.2	  Immunoevasion	  and	  immunosuppression	  According	  to	  the	  cancer	  immunoediting	  hypothesis,	  the	  relationship	  between	  tumours	  and	  the	  immune	  system	  evolves	  from	  a	  phase	  of	  immunosurveillance	  to	  one	  of	  immunoequilibrium	  and	  finally	  to	  immunoescape	  (Dunn	  et	  al.	  2002).	  Glioma	  immunotherapy	  faces	  the	  formidable	  opponent	  of	  an	  established	  tumour	  that	  has	  already	  overwhelmed	  the	  immune	  system’s	  defences.	  The	  underlying	  mechanisms	  are	  many	  and	  varied.	  One	  strategy,	  shared	  with	  some	  viral	  infections,	  is	  to	  escape	  detection	  downregulating	  MHC	  class	  I	  expression	  (Zagzag	  et	  al.	  2005).	  GBM	  tumour	  cells	  also	  elaborate	  a	  range	  of	  surface,	  intracellular	  and	  secreted	  molecules	  that	  directly	  inhibit	  the	  immune	  system.	  For	  example,	  GBM	  tumour	  cells	  have	  been	  reported	  to	  express	  high	  surface	  levels	  of	  programmed	  death	  receptor	  ligand	  -­‐1	  (PD-­‐L1,	  also	  known	  as	  B7-­‐H1)	  (Parsa	  et	  al.	  2007;	  Wintterle	  et	  al.	  2003).	  Interaction	  of	  PD-­‐L1	  with	  PD-­‐1	  expressed	  by	  activated	  T	  cells	  can	  induce	  anergy	  or	  apoptosis	  (Tsushima	  et	  al.	  2007).	  	  Indoleamine	  2,3-­‐dioxygenase	  1	  (IDO)	  is	  an	  intracellular	  enzyme	  that	  catabolises	  the	  essential	  amino	  acid	  tryptophan.	  Local	  depletion	  of	  tryptophan	  directly	  inhibits	  effector	  T	  cell	  function	  (Choi	  et	  al.	  2012).	  Other	  effects	  of	  IDO	  are	  discussed	  below.	  Soluble	  factors	  with	  immunosuppressive	  properties	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reported	  to	  be	  secreted	  by	  GBM	  tumour	  cells	  include	  prostaglandin	  E2	  (PGE2)	  (Fujita	  et	  al.	  2011),	  TGF-­‐β	  (Crane	  et	  al.	  2012;	  B.	  Qiu	  et	  al.	  2011),	  IL-­‐10	  (both	  human	  and	  CMV-­‐derived	  forms)	  (Dziurzynski	  et	  al.	  2011),	  and	  a	  range	  of	  chemokines.	  Many	  of	  these	  act	  indirectly	  by	  inducing	  the	  accumulation	  of	  suppressive	  immune	  cells,	  some	  of	  which	  are	  now	  described	  in	  more	  detail.	  	  	  1.3.4.3	  Regulatory	  T	  cells	  Treg	  are	  a	  distinct	  and	  functionally	  mature	  CD4	  T	  cell	  subset	  that	  act	  to	  maintain	  self	  tolerance	  and	  to	  limit	  tissue	  damage	  in	  inflammatory	  conditions	  by	  suppressing	  immune	  responses	  (Yamaguchi	  et	  al.	  2011).	  A	  hallmark	  of	  Treg	  is	  expression	  of	  the	  transcription	  factor	  FoxP3	  (Yamaguchi	  et	  al.	  2011).	  The	  importance	  of	  Treg	  in	  maintaining	  self-­‐tolerance	  is	  demonstrated	  by	  the	  fact	  that	  FoxP3	  deficiency	  leads	  to	  severe	  autoimmune	  disease	  in	  mice	  and	  humans.	  	  Under	  normal	  conditions,	  Treg	  account	  for	  approximately	  10	  %	  of	  CD4	  T	  cells	  in	  mice	  and	  5-­‐10	  %	  in	  humans	  (Sakaguchi	  2005;	  Yamaguchi	  et	  al.	  2011).	  	  The	  majority	  of	  Treg	  are	  “natural”	  Treg	  (nTreg)	  that	  develop	  in	  the	  thymus	  but	  conventional	  CD4	  T	  cells	  may	  also	  be	  converted	  into	  “induced”	  Treg	  (iTreg)	  in	  the	  periphery	  by	  antigen	  recognition	  in	  the	  presence	  of	  TGF-­‐β	  (Nishikawa	  and	  Sakaguchi	  2010;	  Yamagiwa	  et	  al.	  2001;	  Yamaguchi	  et	  al.	  2011).	  In	  the	  steady	  state,	  Treg	  induction	  occurs	  notably	  in	  the	  gut	  (where	  tolerisation	  to	  abundant	  foreign	  microbial	  antigens	  is	  necessary	  to	  prevent	  excessive	  inflammation),	  a	  process	  that	  here	  requires	  the	  production	  of	  TGF-­‐β	  and	  retinoic	  acid	  by	  DC	  (del	  Rio	  et	  al.	  2010).	  Expression	  of	  Helios	  protein	  (Thornton	  et	  al.	  2010)	  and	  the	  surface	  receptor	  neuropilin-­‐1	  (Weiss	  et	  al.	  2012;	  Yadav	  et	  al.	  2012)	  have	  been	  identified	  as	  markers	  that	  can	  be	  used	  to	  distinguish	  nTreg	  from	  iTreg.	  In	  the	  steady	  state,	  70	  %	  of	  FoxP3+	  CD4	  Tcells	  are	  nTreg	  (Thornton	  et	  al.	  2010).	  Treg	  constitutively	  express	  CTLA-­‐4	  and	  most	  also	  express	  the	  IL-­‐2Rα	  chain	  CD25.	  	  	  Immunosuppressive	  FoxP3+	  CD8	  T	  cells	  (Chaput	  et	  al.	  2009),	  FoxP3+	  iNKT	  cells	  (Monteiro	  et	  al.	  2010)	  and	  other	  regulatory	  T	  cell	  populations	  (Nishikawa	  and	  Sakaguchi	  2010)	  have	  been	  described	  but	  the	  importance	  of	  these	  populations	  in	  the	  context	  of	  cancer	  is	  unclear	  at	  present.	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Treg	  have	  been	  described	  as	  “anergic”	  because	  they	  do	  not	  proliferate	  in	  response	  to	  cognate	  self-­‐antigen	  alone	  in	  vitro.	  However,	  expansion	  in	  response	  to	  cognate	  antigen	  readily	  occurs	  in	  vivo.	  This	  may	  be	  explained	  by	  the	  finding	  that	  TGF-­‐β	  effectively	  acts	  as	  a	  co-­‐stimulator	  for	  Treg	  (Ghiringhelli	  et	  al.	  2005).	  Although	  TCR-­‐independent	  mechanisms	  of	  Treg	  activation	  have	  been	  described,	  it	  is	  generally	  believed	  that	  activation	  of	  Treg	  in	  vivo	  is	  antigen-­‐specific	  (Sakaguchi	  et	  al.	  2010).	  	  Once	  activated,	  Treg	  may	  act	  directly	  on	  conventional	  T	  cells	  or	  indirectly	  by	  suppressing	  the	  function	  of	  APC,	  and,	  in	  the	  context	  of	  tumour	  immunology,	  may	  act	  both	  at	  the	  tumour	  site	  and	  in	  secondary	  lymphoid	  organs	  (Nishikawa	  and	  Sakaguchi	  2010;	  Yamaguchi	  et	  al.	  2011).	  A	  large	  number	  of	  Treg	  suppressive	  mechanisms	  have	  been	  described	  in	  vitro	  but	  the	  relative	  importance	  of	  these	  mechanisms	  in	  vivo	  remains	  unclear	  and	  may	  depend	  on	  location	  and	  context	  (reviewed	  in	  Shevach	  2009;	  D.	  Vignali	  2008;	  D.	  A.	  A.	  Vignali	  et	  al.	  2008;	  Yamaguchi	  et	  al.	  2011).	  A	  consistent	  observation	  from	  in	  vitro	  studies	  is	  that	  Treg	  are	  unable	  to	  exert	  suppressive	  effects	  when	  separated	  from	  their	  target	  cells	  by	  a	  semi-­‐permeable	  membrane	  (Shevach	  2009).	  This	  has	  been	  interpreted	  as	  evidence	  that	  direct	  cell-­‐to-­‐cell	  contact	  is	  required.	  However,	  an	  alternative	  explanation	  is	  that	  close	  proximity	  is	  required	  to	  achieve	  sufficiently	  high	  local	  concentrations	  of	  soluble	  factors	  (D.	  A.	  A.	  Vignali	  et	  al.	  2008).	  	  Sakaguchi	  has	  proposed	  that	  the	  predominant	  mode	  of	  action	  by	  which	  Treg	  maintain	  self-­‐tolerance	  in	  the	  steady	  state	  is	  via	  CTLA-­‐4	  expression	  leading	  to	  a	  denial	  of	  co-­‐stimulation	  for	  conventional	  T	  cells	  but	  that	  in	  inflammatory	  states,	  where	  more	  potent	  suppression	  is	  required,	  other	  mechanisms	  are	  also	  recruited,	  such	  as	  the	  secretion	  of	  soluble	  factors	  including	  TGF-­‐β,	  that	  are	  not	  only	  directly	  suppressive	  but	  act	  in	  a	  positive	  feedback	  loop	  to	  expand	  and	  enhance	  Treg	  function	  (Yamaguchi	  et	  al.	  2011).	  Sharma	  and	  colleagues	  (M.	  D.	  Sharma	  et	  al.	  2007)	  found	  that	  the	  main	  mechanism	  of	  Treg-­‐mediated	  immunosuppression	  in	  an	  animal	  cancer	  model	  was	  by	  upregulating	  DC	  expression	  of	  ligands	  for	  PD-­‐1.	  	  There	  is	  abundant	  evidence	  that	  Treg	  expand	  in	  tumour-­‐bearing	  mice	  and	  humans	  and	  exert	  immunosuppressive	  effects	  that	  impair	  endogenous	  anti-­‐tumour	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immunity	  and	  constitute	  a	  major	  impediment	  to	  therapeutic	  immunotherapies.	  	  Studies	  in	  murine	  models	  of	  glioma	  (Cantini	  et	  al.	  2011;	  Grauer	  et	  al.	  2007;	  Wainwright	  et	  al.	  2011)	  show	  that	  Tregs	  progressively	  accumulate	  at	  the	  tumour	  site	  after	  implantation,	  eventually	  accounting	  for	  40	  %	  of	  tumour-­‐infiltrating	  CD4	  T	  cells	  in	  one	  study	  (Grauer	  et	  al.	  2007).	  The	  importance	  of	  Treg	  in	  suppressing	  endogenous	  immune	  responses	  is	  supported	  by	  the	  consistent	  observation	  that	  depletion	  of	  Treg	  alone	  is	  sufficient	  to	  confer	  protection	  or	  improve	  survival	  in	  many	  animal	  tumour	  models	  (Onizuka	  et	  al.	  1999)	  including	  glioma	  (Curtin	  et	  al.	  2008;	  El	  Andaloussi	  et	  al.	  2006;	  Fecci	  et	  al.	  2006b;	  Grauer	  et	  al.	  2008;	  Wim	  Maes	  et	  al.	  2009b).	  	  Tumour-­‐infiltrating	  CD4+	  FoxP3+	  T	  cells	  and	  expansion	  of	  circulating	  Treg	  have	  been	  described	  in	  many	  human	  cancers	  (Wolf	  et	  al.	  2003).	  In	  glioma,	  several	  studies	  have	  reported	  a	  correlation	  between	  tumour	  FoxP3	  expression	  (El	  Andaloussi	  and	  Lesniak	  2007)	  or	  the	  presence	  of	  glioma-­‐infiltrating	  FoxP3+	  cells	  (Heimberger	  et	  al.	  2008;	  Jacobs	  et	  al.	  2010;	  Lohr	  et	  al.	  2011)	  and	  tumour	  grade.	  Crane	  and	  colleagues	  (Crane	  et	  al.	  2012)	  	  found	  that	  FoxP3+	  CD25+	  Treg	  were	  present	  disproportionately	  in	  the	  tumour	  tissue	  of	  20	  GBM	  patients,	  constituting	  38.5	  %	  of	  tumour-­‐infiltrating	  CD4+	  T	  cells	  compared	  with	  12	  %	  in	  peripheral	  blood.	  Findings	  with	  respect	  to	  the	  impact	  of	  tumour-­‐infiltrating	  Treg	  on	  prognosis	  have	  been	  discordant	  (Heimberger	  et	  al.	  2008;	  Jacobs	  et	  al.	  2010;	  Lohr	  et	  al.	  2011).	  	  In	  the	  peripheral	  blood	  of	  glioma-­‐bearing	  patients	  Fecci	  and	  colleagues	  (Fecci	  et	  al.	  2006a)	  found	  a	  reduction	  in	  the	  absolute	  number	  of	  both	  conventional	  and	  regulatory	  CD4	  T	  cells	  but	  in	  five	  of	  eight	  GBM	  patients	  there	  was	  a	  2-­‐2.5	  fold	  increase	  in	  the	  proportion	  that	  were	  Treg.	  In	  these	  five	  there	  was	  a	  marked	  reduction	  in	  CD4	  T	  cell	  proliferation	  in	  vitro	  which	  returned	  to	  normal	  when	  Treg	  were	  depleted.	  Crane	  and	  colleagues	  (Crane	  et	  al.	  2012)	  found	  a	  modest	  increase	  in	  the	  proportion	  of	  Treg	  in	  peripheral	  blood	  (12	  %	  of	  CD4	  T	  cells	  compared	  with	  5-­‐10	  %	  in	  control	  patients).	  This	  group	  also	  found	  that	  the	  proportion	  of	  Treg	  in	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peripheral	  blood	  fell	  to	  normal	  levels	  after	  GBM	  resection	  in	  seven	  patients,	  but	  returned	  to	  pre-­‐surgery	  levels	  at	  time	  of	  recurrence.	  	  Human	  GBM-­‐conditioned	  medium	  can	  induce	  conversion	  of	  conventional	  T	  cells	  to	  suppressive	  FoxP3+	  T	  cells	  in	  vitro	  (Crane	  et	  al.	  2012).	  However,	  a	  recent	  study	  showed	  that	  the	  great	  majority	  (90	  %)	  of	  tumour-­‐infiltrating	  Treg	  in	  murine	  glioma	  models	  and	  in	  human	  GBM	  tumour	  tissue	  samples	  are	  Helios+	  nTreg	  (Wainwright	  et	  al.	  2011).	  The	  origin	  of	  tumour-­‐infiltrating	  Treg	  has	  important	  implications	  for	  immunotherapy	  because	  if	  they	  are	  recruited	  from	  the	  periphery	  then	  systemic	  Treg	  depletion	  should	  also	  reduce	  Treg	  at	  the	  tumour	  site.	  In	  support	  of	  this,	  in	  an	  orthotopic	  murine	  glioma	  model,	  a	  single	  i.p.	  dose	  of	  an	  anti-­‐CD25	  antibody	  reduced	  tumour-­‐infiltrating	  Treg	  to	  the	  same	  level	  as	  tumours	  in	  thymectomised	  mice	  (Wainwright	  et	  al.	  2011).	  	  Several	  mechanisms	  have	  been	  proposed	  to	  explain	  the	  presence	  of	  Treg	  in	  glioma	  tumours.	  Circulating	  CCR4+	  Treg	  may	  be	  recruited	  by	  chemokines	  CCL2	  and/or	  CCL22	  secreted	  by	  tumour	  cells	  (Crane	  et	  al.	  2012;	  Jacobs	  et	  al.	  2010;	  Jordan	  et	  al.	  2008).	  TGF-­‐β	  secreted	  by	  tumour	  cells	  and/or	  tumour-­‐infiltrating	  immune	  cells	  may	  promote	  Treg	  survival	  and	  expansion	  (Ueda	  et	  al.	  2009).	  IDO	  is	  attracting	  considerable	  interest	  as	  a	  potential	  “master	  controller”	  of	  Treg	  tumour-­‐infiltration.	  IDO	  is	  expressed	  by	  glioma	  tumour	  cells,	  particularly	  after	  exposure	  to	  IFN-­‐γ,	  and	  IDO	  expression	  correlates	  inversely	  with	  survival	  (Wainwright	  et	  al.	  2012).	  As	  described	  above,	  depletion	  of	  tryptophan	  from	  the	  tumour	  microenvironment	  directly	  supresses	  effector	  T	  cell	  function.	  The	  degradation	  of	  tryptophan	  also	  produces	  metabolites	  that	  lead	  to	  the	  accumulation	  of	  Treg	  at	  the	  tumour	  site.	  The	  precise	  mechanism	  remains	  unclear	  but	  one	  possibility	  is	  that	  a	  tryptophan	  catabolite	  induces	  CCL22	  secretion	  by	  tumour	  cells	  or	  immune	  cells	  (Wainwright	  et	  al.	  2013).	  Although	  a	  study	  in	  an	  implantable	  glioma	  model	  found	  that	  IDO	  expression	  by	  tumour	  cells,	  rather	  than	  host	  cells,	  was	  primarily	  responsible	  for	  Treg	  accumulation,	  it	  is	  possible	  that	  IDO	  expressed	  in	  immune	  cells	  is	  also	  relevant.	  	  Sharma	  and	  colleagues	  (M.	  D.	  Sharma	  et	  al.	  2007)	  showed	  that	  pDC	  in	  the	  tumour-­‐
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draining	  LNs	  in	  mice	  bearing	  melanoma	  tumours	  promoted	  Treg	  suppressor	  function	  in	  an	  IDO-­‐dependent	  manner.	  Clinical	  trials	  of	  IDO	  inhibitors	  in	  patients	  with	  a	  range	  of	  solid	  tumours	  are	  currently	  underway	  (reviewed	  in	  Wainwright	  et	  al.	  2013).	  	  Attenuation	  of	  Treg-­‐mediated	  immunosuppression	  is	  likely	  to	  be	  a	  cornerstone	  of	  successful	  therapeutic	  immunotherapy	  for	  glioma	  and	  many	  strategies	  have	  been	  proposed	  or	  are	  already	  in	  use	  (reviewed	  in	  Byrne	  et	  al.	  2011).	  Evidence	  is	  emerging	  that	  the	  success	  of	  anti-­‐CTLA-­‐4	  treatment	  for	  melanoma	  may	  be	  partly	  due	  to	  a	  reduction	  in	  the	  number	  of	  tumour-­‐infiltrating	  Treg,	  a	  process	  that	  is	  dependent	  on	  the	  Fc	  portion	  of	  the	  antibody	  (James	  Allison,	  oral	  presentation,	  Keystone	  Symposium,	  Vancouver	  2012).	  Depletion	  of	  Treg	  is	  also	  one	  of	  the	  main	  mechanisms	  underlying	  the	  immunopotentiating	  effects	  of	  lymphodepleting	  chemotherapy	  prior	  to	  adoptive	  cell	  transfer	  (discussed	  in	  detail	  in	  Chapter	  7).	  	  In	  animal	  models,	  including	  models	  of	  glioma	  (Fecci	  et	  al.	  2006b;	  Grauer	  et	  al.	  2008;	  Wim	  Maes	  et	  al.	  2009b;	  Mitchell	  et	  al.	  2011)	  depletion	  of	  Treg	  using	  anti-­‐CD25	  antibodies	  or	  using	  transgenic	  mice	  that	  permit	  the	  conditional	  depletion	  of	  FoxP3+	  cells	  (Klages	  et	  al.	  2010)	  has	  been	  shown	  to	  enhance	  the	  efficacy	  of	  active	  specific	  immunotherapies	  without	  inducing	  overt	  auto-­‐immunity.	  One	  of	  the	  limitations	  of	  using	  CD25	  to	  target	  Treg	  is	  that	  activated	  T	  cells	  also	  upregulate	  CD25	  so	  that	  timing	  is	  crucial	  to	  avoid	  compromising	  the	  effector	  response	  (Curtin	  et	  al.	  2008).	  In	  human	  trials,	  an	  anti-­‐CD25	  antibody	  conjugated	  to	  Diphtheria	  toxin	  induced	  a	  transient	  depletion	  of	  Treg	  at	  best,	  lasting	  less	  than	  three	  weeks	  (reviewed	  in	  Rech	  et	  al.	  2012).	  A	  humanised	  anti-­‐CD25	  monoclonal	  antibody,	  daclizumab,	  looks	  more	  promising.	  A	  single	  dose	  of	  daclizumab	  in	  patients	  with	  metastatic	  breast	  cancer,	  co-­‐administered	  with	  a	  peptide	  vaccine,	  resulted	  in	  a	  marked	  and	  prolonged	  (>5	  weeks)	  decrease	  in	  the	  number	  of	  circulating	  Treg	  and	  was	  associated	  with	  successful	  induction	  of	  peptide-­‐specific	  T	  cell	  responses	  without	  auto-­‐immunity	  (Rech	  and	  Vonderheide	  2009).	  Similar	  findings	  were	  reported	  in	  a	  pilot	  study	  of	  six	  patients	  with	  newly	  diagnosed	  GBM	  undergoing	  Stupp	  protocol	  treatment.	  Administration	  of	  a	  single	  dose	  of	  daclizumab	  resulted	  in	  34	  %	  mean	  fall	  in	  the	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absolute	  number	  of	  circulating	  FoxP3+	  CD4+	  cells	  that	  was	  sustained	  for	  at	  least	  50	  days	  and	  did	  not	  prevent	  the	  expansion	  of	  antigen-­‐specific	  T	  cells	  in	  response	  to	  a	  co-­‐adminstered	  DC-­‐based	  vaccine	  (Mitchell	  et	  al.	  2011).	  In	  vitro	  studies	  suggest	  that	  the	  antibody	  works	  not	  just	  by	  reducing	  Treg	  numbers	  but	  also	  by	  inducing	  a	  downregulation	  in	  Treg	  suppressor	  function	  (Rech	  et	  al.	  2012).	  	  	  1.3.4.4	  	  Tumour-­‐associated	  macrophages	  and	  myeloid	  derived	  suppressor	  cells.	  Several	  studies	  have	  reported	  that	  high	  grade	  glioma	  tumours	  are	  often	  infiltrated	  by	  large	  numbers	  of	  cells	  of	  the	  monocyte/macrophage	  lineage	  (Morantz	  et	  al.	  1979;	  	  Dziurzynski	  et	  al.	  2011;	  Hussain	  2006;	  Parney	  et	  al.	  2009;	  Shinonaga	  et	  al.	  1988).	  Precise	  characterisation	  of	  these	  cells	  has	  been	  hampered	  by	  a	  lack	  of	  markers	  that	  clearly	  distinguish	  brain-­‐resident	  microglia	  from	  cells	  derived	  from	  circulating	  monocytes.	  Recent	  studies	  in	  mice	  have	  used	  flow	  cytometry	  to	  distinguish	  CD11b+	  CD45hi	  and	  CD11b+	  CD45dim	  populations	  that	  are	  considered	  to	  represent	  tumour-­‐infiltrating	  monocytes/macrophages	  and	  microglia	  respectively	  (Ford	  et	  al.	  1995).	  Applying	  the	  same	  technique	  to	  human	  tissues	  Parney	  and	  colleagues	  assessed	  single	  cell	  suspensions	  from	  nine	  newly	  diagnosed	  high	  grade	  gliomas	  and	  found	  microglial	  cells	  and	  monocytes/macrophages	  to	  make	  up	  1.6	  %	  and	  6	  %	  (range	  1-­‐15	  %)	  of	  cells	  respectively	  (Parney	  et	  al.	  2009).	  Dziurzynski	  and	  colleagues	  reported	  equivalent	  figures	  of	  3	  %	  and	  24	  %	  albeit	  in	  a	  single	  patient	  (Dziurzynski	  et	  al.	  2011).	  In	  rodent	  models	  of	  glioma,	  studies	  of	  the	  kinetics	  of	  immune	  cell	  infiltrates	  have	  shown	  that,	  whereas	  microglia	  account	  for	  almost	  all	  CD45+	  cells	  in	  normal	  brain,	  macrophages	  come	  to	  dominate	  the	  immune	  cell	  infiltrate	  in	  the	  brains	  of	  terminally-­‐ill	  glioma-­‐bearing	  mice	  (Kennedy	  et	  al.	  2009;	  Tran	  Thang	  et	  al.	  2010).	  Interestingly,	  both	  these	  studies	  showed	  that	  peripheral	  expansion	  and	  tumour-­‐infiltration	  by	  regulatory	  T	  cells	  preceded	  the	  final	  expansion	  of	  TAM.	  	  Whereas	  M1-­‐polarised	  macrophages	  are	  pro-­‐inflammatory,	  antimicrobial,	  tumouricidal,	  and	  drive	  TH1	  responses,	  the	  role	  of	  	  “alternatively-­‐activated”	  (or	  M2)	  macrophages	  is	  to	  promote	  tissue	  healing	  by	  releasing	  growth	  factors	  (Biswas	  and	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Mantovani	  2010;	  Murray	  and	  Wynn	  2011).	  M2	  macrophages	  also	  release	  TGF-­‐β,	  IL-­‐10	  and	  arginase-­‐1	  that	  dampen	  T	  cell-­‐mediated	  immune	  responses	  (Riccadonna	  2012).	  Thus	  M2	  polarisation,	  a	  normal	  event	  in	  the	  transition	  from	  inflammation	  to	  healing,	  can	  be	  a	  disadvantage	  in	  the	  context	  of	  cancer,	  both	  suppressing	  anti-­‐tumour	  immunity	  and	  directly	  driving	  tumour	  growth.	  In	  GBM	  tumours,	  as	  in	  most	  established	  human	  tumours	  (Mantovani	  et	  al.	  2011)	  the	  majority	  of	  TAM	  have	  an	  M2	  phenotype	  (Komohara	  et	  al.	  2008).	  The	  mechanisms	  responsible	  for	  M2	  polarisation	  are	  diverse	  and	  context-­‐specific	  (Mantovani	  et	  al.	  2011).	  In	  glioma,	  tumour	  cell-­‐derived	  IL-­‐10	  (Dziurzynski	  et	  al.	  2011)	  and	  M-­‐CSF	  (Komohara	  et	  al.	  2008)	  have	  been	  implicated	  in	  this	  process.	  M2	  macrophages	  in	  turn	  secrete	  IL-­‐10	  and	  TGF-­‐β	  that	  promote	  Treg	  differentiation	  and	  sustain	  M2	  differentiation	  in	  a	  positive	  feedback	  loop.	  	  However,	  the	  plasticity	  of	  macrophage	  phenotypes	  opens	  the	  door	  to	  possible	  therapeutic	  intervention.	  Conversion	  of	  TAM	  from	  an	  M2-­‐	  to	  an	  M1-­‐phenotype	  in	  vivo	  has	  been	  demonstrated	  in	  animal	  cancer	  models	  in	  response	  to	  IFN-­‐γ	  (Duluc	  et	  al.	  2009)	  and	  an	  agonistic	  anti-­‐CD40	  antibody	  (Beatty	  et	  al.	  2011).	  The	  extent	  to	  which	  TAM	  are	  recruited	  from	  circulating	  monocytes	  or	  derived	  from	  the	  expansion	  and	  differentiation	  of	  tissue-­‐resident	  microglial	  cells	  remains	  clear	  (Mantovani	  et	  al.	  2011)	  but	  there	  is	  evidence	  for	  a	  scenario	  in	  which	  growth	  factors	  and	  chemokines	  (notably	  CCL2)	  released	  by	  tumour	  cells	  act	  systemically	  to	  expand	  and	  release	  monocytes	  and	  immature	  myeloid	  cells	  from	  the	  bone	  marrow	  that	  are	  then	  recruited	  to	  the	  tumour	  site	  (Mantovani	  et	  al.	  2011;	  Qian	  et	  al.	  2011;	  Serbina	  and	  Pamer	  2006).	  Amongst	  these	  are	  MDSC,	  a	  phenotypically	  heterogeneous	  mixture	  of	  cells	  with	  granulocytic	  or	  monocytic	  morphology	  but	  lacking	  the	  surface	  markers	  of	  fully	  differentiated	  cells	  (D.	  I.	  Gabrilovich	  and	  Nagaraj	  2009).	  	  Immature	  myeloid	  cells	  normally	  account	  for	  20-­‐30	  %	  of	  bone	  marrow	  cells,	  2-­‐4	  %	  of	  splenocytes	  and	  0.5	  %	  of	  PBMC	  (D.	  I.	  Gabrilovich	  and	  Nagaraj	  2009).	  These	  immature	  myeloid	  cells	  become	  expanded	  by	  a	  factor	  of	  up	  to	  ten	  in	  the	  spleen	  of	  tumour-­‐bearing	  mice	  and	  the	  peripheral	  blood	  of	  cancer	  patients	  and	  acquire	  immunosuppressive	  properties	  (D.	  I.	  Gabrilovich	  and	  Nagaraj	  2009).	  Similar	  to	  Treg,	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MDSC	  exert	  their	  effects	  both	  at	  the	  tumour	  site	  and	  in	  secondary	  lymphoid	  organs	  and	  multiple	  immunosuppressive	  mechanisms	  have	  been	  described.	  These	  include	  expression	  of	  high	  levels	  of	  arginase	  (which	  depletes	  L-­‐arginine,	  in	  turn	  inhibiting	  T	  cell	  proliferation),	  iNOS	  (which	  also	  catabolises	  arginine	  and	  generates	  NO	  which	  in	  turn	  directly	  suppresses	  T	  cell	  function),	  ROS,	  and	  peroxynitrite	  (which	  results	  in	  the	  nitration	  of	  the	  TCR	  and	  renders	  T	  cells	  unresponsive	  to	  antigen)	  (Nagaraj	  et	  al.	  2007).	  MDSC	  require	  close	  cell	  proximity	  to	  exert	  their	  suppressive	  effects	  on	  T	  cells	  (D.	  I.	  Gabrilovich	  and	  Nagaraj	  2009).	  Although	  MDSC	  can	  suppress	  T	  cells	  non-­‐specifically	  in	  vitro,	  in	  vivo	  suppression	  in	  one	  study	  appeared	  to	  be	  mainly	  antigen-­‐specific,	  with	  suppression	  requiring	  MDSC	  to	  present	  TAA	  to	  CD8	  T	  cells	  in	  an	  MHC	  class	  I-­‐restricted	  manner	  (Kusmartsev	  and	  Gabrilovich	  2002).	  	  In	  murine	  studies,	  MDSC	  have	  been	  defined	  by	  the	  co-­‐expression	  of	  the	  myeloid	  lineage	  marker	  Gr1	  and	  CD11b,	  with	  further	  subclassification	  into	  monocytic	  and	  granulocytic	  subsets	  (D.	  I.	  Gabrilovich	  and	  Nagaraj	  2009).	  Although	  both	  subsets	  are	  expanded	  in	  tumour	  models	  in	  mice,	  granulocytic	  MDSC	  are	  expanded	  to	  a	  greater	  extent	  (D.	  I.	  Gabrilovich	  and	  Nagaraj	  2009).	  Functional	  differences	  in	  the	  suppressive	  mechanisms	  used	  by	  the	  two	  subsets	  have	  been	  described	  (Youn	  et	  al.	  2008).	  In	  the	  presence	  of	  appropriate	  cytokines,	  up	  to	  30	  %	  of	  MDSC	  have	  the	  ability	  to	  differentiate	  in	  vitro	  into	  mature	  macrophages	  or	  DC,	  this	  ability	  being	  restricted	  to	  the	  monocytic	  subset	  (D.	  I.	  Gabrilovich	  and	  Nagaraj	  2009).	  Thus	  MDSC	  are	  closely	  related	  to	  immunosuppressive	  TAM	  and	  may	  be	  their	  precursors	  (Mosser	  and	  Edwards	  2008;	  Movahedi	  et	  al.	  2008).	  The	  relationship	  between	  Treg,	  TAM	  and	  MDSC	  in	  glioma	  is	  unclear.	  	  Some	  studies	  have	  shown	  that	  MDSC	  can	  participate	  in	  the	  expansion	  of	  Treg	  (Ghiringhelli	  et	  al.	  2005;	  Ostrand-­‐Rosenberg	  and	  Sinha	  2009).	  However,	  Kennedy	  and	  colleagues	  studied	  the	  kinetics	  of	  immune	  cell	  populations	  in	  an	  implantable	  PDGF-­‐driven	  murine	  glioma	  model	  and	  found	  an	  increase	  in	  the	  proportion	  of	  Tregs	  in	  the	  spleen	  preceded	  the	  expansion	  of	  CD11b+	  CD45+	  cells	  at	  the	  tumour	  site	  (Kennedy	  et	  al.	  2009).	  Tran	  Thang	  and	  colleagues	  (Tran	  Thang	  et	  al.	  2010)	  also	  studied	  the	  kinetics	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of	  TIL	  in	  a	  transgenic	  mouse	  model	  of	  spontaneous	  glioma	  and	  found	  a	  progressive	  local	  expansion	  of	  Treg	  and	  TAM	  with	  expansion	  of	  CD11b+	  Gr1+	  MDSC	  occurring	  later.	  	  	  Strategies	  to	  target	  MDSC	  that	  have	  been	  explored	  or	  proposed	  include	  differentiating	  MDSC	  into	  mature	  non-­‐suppressive	  myeloid	  cells	  (Shirota	  et	  al.	  2012),	  blocking	  tumour-­‐derived	  growth	  factors	  that	  drive	  peripheral	  expansion	  of	  MDSC	  (Kao	  et	  al.	  2011),	  inhibiting	  trafficking	  of	  MDSC	  to	  the	  tumour	  site	  (X.	  Zhu	  et	  al.	  2011),	  inhibiting	  MDSC	  suppressive	  functions	  (Meyer	  et	  al.	  2011),	  and	  direct	  elimination	  of	  MDSC	  (Ko	  et	  al.	  2007).	  Of	  concern,	  some	  standard	  chemotherapy	  regimes	  may	  actually	  promote	  MDSC	  expansion	  (Diaz-­‐Montero	  et	  al.	  2009).	  Tempering	  this	  discussion	  is	  the	  fact	  that,	  while	  MDSC	  have	  been	  described	  in	  several	  rodent	  models	  of	  glioma	  (Fujita	  et	  al.	  2011;	  Kennedy	  et	  al.	  2009;	  Tran	  Thang	  et	  al.	  2010)	  and	  circulating	  MDSC	  have	  been	  described	  in	  the	  PBMC	  of	  GBM	  patients	  (Raychaudhuri	  et	  al.	  2011;	  Rodrigues	  et	  al.	  2010),	  MDSC	  have	  not	  been	  conclusively	  demonstrated	  in	  human	  GBM	  tumour	  tissue	  to	  date	  (Riccadonna	  2012).	  STAT-­‐3,	  a	  member	  of	  the	  Signal	  Tranducer	  and	  Activation	  of	  Transcription	  family	  of	  signalling	  proteins,	  appears	  to	  play	  a	  role	  in	  the	  control	  of	  many	  immunosuppressive	  mechanisms	  operating	  in	  the	  tumour	  setting.	  STAT-­‐3	  phosphorylation	  downstream	  of	  IL-­‐6	  and	  IL-­‐10	  signalling	  inhibits	  the	  function	  of	  macrophages,	  DC	  and	  T	  cells	  (Kubo	  et	  al.	  2003)	  and	  STAT-­‐3	  activation	  is	  required	  for	  MDSC	  to	  inhibit	  effector	  T	  cells	  (Mao	  et	  al.	  2013).	  STAT-­‐3	  is	  also	  activated	  in	  GBM	  tumour	  cells	  and	  has	  been	  shown	  to	  control	  the	  release	  by	  tumour	  cells	  of	  soluble	  factors	  that	  induce	  M2	  differentiation	  (A	  Wu	  et	  al.	  2010).	  Accordingly,	  systemic	  treatment	  of	  glioma-­‐bearing	  mice	  with	  a	  STAT-­‐3	  inhibitor	  improved	  survival	  in	  WT	  but	  not	  athymic	  mice,	  and	  synergized	  with	  adoptive	  CTL	  transfer	  (Fujita	  et	  al.	  2008).	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1.4	  AIMS	  OF	  THE	  THESIS	  	  This	  thesis	  starts	  by	  reporting	  the	  results	  of	  a	  recently	  completed	  clinical	  trial	  in	  which	  patients	  with	  recurrent	  GBM	  were	  treated	  with	  a	  DC-­‐based	  vaccine	  combined	  with	  chemotherapy.	  As	  will	  be	  seen,	  a	  major	  conclusion	  of	  this	  Phase	  I	  trial	  was	  that	  the	  feasibility	  of	  making	  vaccines	  from	  autologous	  monocyte-­‐derived	  DC	  in	  this	  patient	  group	  is	  marginal.	  An	  alternative	  immunotherapeutic	  strategy	  that	  could	  improve	  feasibility	  in	  the	  clinical	  arena	  would	  be	  to	  deliver	  antigen	  to	  endogenous	  DC	  along	  with	  an	  effective	  adjuvant.	  Accordingly,	  in	  the	  next	  chapter	  a	  novel	  a	  vaccine	  consisting	  of	  irradiated	  tumour	  cells	  pulsed	  with	  an	  adjuvant	  that	  potently	  stimulates	  iNKT	  cells	  is	  tested	  in	  a	  murine	  model	  of	  glioma.	  When	  coupled	  with	  attenuation	  of	  regulatory	  T	  cell-­‐mediated	  immunosuppression,	  the	  vaccine	  is	  shown	  to	  be	  capable	  of	  eradicating	  established	  intracranial	  glioma	  tumours	  in	  43	  %	  of	  mice.	  To	  try	  and	  improve	  therapeutic	  outcome	  even	  further,	  the	  subsequent	  chapters	  explore	  the	  idea	  of	  modifying	  the	  whole	  tumour	  cell-­‐based	  vaccine	  to	  target	  particular	  tumour	  cell	  subsets	  or	  phenotypes.	  The	  aims	  of	  the	  thesis	  are	  therefore:	  
	  
Clinical	  study:	  
• Contribute	  to	  the	  conduct	  of	  a	  Phase	  1	  clinical	  trial	  of	  dendritic	  cell	  vaccination	  combined	  with	  temozolomide	  retreatment	  in	  patients	  with	  recurrent	  GBM.	  
• Establish	  methodology	  and	  undertake	  assessment	  of	  vaccine-­‐induced	  immune	  responses	  in	  trial	  participants.	  
• Analyse	  and	  report	  the	  trial	  findings.	  
	  
Pre-­‐clinical	  studies:	  
• Establish	  a	  murine	  model	  of	  glioma	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• Assess	  the	  feasibility,	  efficacy	  and	  mechanism	  of	  action	  of	  a	  vaccine	  consisting	  of	  irradiated	  tumour	  cells	  combined	  with	  an	  adjuvant	  that	  stimulates	  iNKT	  cells.	  	  



















CHAPTER	  TWO:	  MATERIALS	  AND	  METHODS	  
 
Explanatory	  note	  Chapter	  3	  describes	  a	  clinical	  trial	  performed	  in	  collaboration	  with	  several	  colleagues.	  For	  ease	  of	  reading,	  the	  methods	  used	  in	  the	  trial	  are	  included	  in	  the	  body	  of	  that	  chapter.	  This	  chapter	  describes	  the	  materials	  and	  methods	  used	  in	  the	  rest	  of	  the	  thesis.	  In	  all	  chapters,	  the	  contributions	  of	  others	  are	  clearly	  acknowledged	  in	  the	  text	  and/or	  figure	  legends.	  
 
2.1	  	   MICE	  
The	  inbred	  strain	  C57BL/6	  was	  obtained	  from	  the	  Animal	  Resource	  Centre,	  Canning	  Vale,	  Western	  Australia.	  Also	  used	  were	  CD1d-­‐/-­‐	  mice	  (Y.	  H.	  Chen	  et	  al.	  1997),	  MHC	  class	  II-­‐deficient	  B6Aa0/Aa0	  mice	  (Köntgen	  et	  al.	  1993),	  TAP1-­‐deficient	  mice	  (L	  Van	  Kaer	  et	  al.	  1992),	  langerin-­‐DTREGFP	  mice	  that	  express	  the	  human	  Diptheria	  toxin	  receptor	  under	  control	  of	  the	  langerin	  gene	  (Kissenpfennig	  et	  al.	  2005),	  and	  FoxP3-­‐GFP	  reporter	  mice	  that	  have	  the	  enhanced	  GFP	  coding	  sequence	  inserted	  in-­‐frame	  into	  the	  first	  coding	  exon	  of	  the	  FoxP3	  gene	  (Fontenot	  et	  al.	  2005).	  For	  one	  experiment,	  cells	  from	  OT-­‐I	  x	  B6.SJL-­‐PtprcaPepcb/BoyJ	  mice	  were	  transferred	  into	  C57BL/6	  recipients.	  OT-­‐1	  mice	  are	  transgenic	  for	  a	  TCR	  recognising	  an	  MHC	  class	  I-­‐restricted	  epitope	  from	  OVA	  (Hogquist	  et	  al.	  1994).	  B6.SJL-­‐Ptprca	  Pepcb/BoyJ	  mice	  express	  the	  congenic	  marker	  CD45.1	  so	  that	  crossing	  these	  two	  strains	  allows	  discrimination	  of	  cells	  adoptively	  transferred	  into	  CD45.2+	  WT	  recipients.	  	  All	  mice	  were	  maintained	  by	  the	  Biomedical	  Research	  Unit,	  Malaghan	  Institute	  of	  Medical	  Research,	  Wellington,	  New	  Zealand.	  	  Experimental	  protocols	  were	  approved	  by	  Victoria	  University	  Animal	  Ethics	  Committee	  and	  performed	  according	  to	  their	  guidelines.	  Mice	  were	  6-­‐10	  weeks	  of	  age	  and	  matched	  for	  age	  and	  gender.	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2.2	   CELL	  CULTURE	  
2.2.1	  	   Plasticware	  	  
Falcon	  and	  Nunc	  tissue	  culture	  flasks	  and	  plates	  were	  from	  BD	  Biosciences	  (San	  Jose,	  CA)	  and	  Thermo	  Fisher	  Scientific	  (Auckland,	  NZ)	  respectively.	  	  
	  
2.2.2	  	   Cell	  lines	  The	  murine	  glioma	  cell	  line	  GL261	  was	  obtained	  from	  the	  DCTD	  Tumour	  Repository	  (National	  Cancer	  Institute,	  Frederick,	  MD)	  and,	  unless	  stated,	  was	  cultured	  in	  Dulbecco’s	  Modified	  Eagle	  Medium	  (DMEM)	  (Life	  Technologies,	  Auckland,	  NZ)	  supplemented	  with	  20	  %	  Foetal	  Calf	  Serum	  (FCS)	  (Sigma-­‐Aldrich,	  St	  Louis,	  MO),	  2	  mM	  glutamax,	  100	  U/mL	  penicillin	  and	  100	  µg/mL	  streptomycin	  (all	  Life	  Technologies).	  Cultures	  were	  incubated	  at	  37	  0C	  in	  5	  %	  CO2	  until	  80-­‐90	  %	  confluent	  then	  harvested	  with	  TrypLE	  (Life	  Technologies)	  and	  passaged.	  Cultures	  were	  discarded	  after	  approximately	  8	  weeks.	  The	  B16-­‐F10	  melanoma	  cell	  line	  (Fidler	  1975)	  was	  obtained	  from	  the	  American	  Type	  Culture	  Collection	  (Manassas,	  VA).	  The	  Lewis	  Lung	  Carcinoma	  cell	  line	  (LLC)	  (Finlay	  et	  al.	  1987)	  was	  kindly	  provided	  by	  Dr.	  Graeme	  Finlay	  (Cancer	  Research	  Laboratories,	  Auckland,	  NZ).	  B16	  and	  LLC	  were	  cultured	  in	  Iscove’s	  Modified	  Dulbecco’s	  Medium	  (IMDM)	  (Life	  Technologies)	  supplemented	  with	  5	  %	  FCS	  (Sigma-­‐Aldrich),	  2	  mM	  glutamax,	  100	  U/mL	  penicillin,	  100	  μg/mL	  streptomycin	  and	  50	  μM	  2-­‐mercaptoethanol	  (all	  Life	  Technologies)	  at	  37	  0C	  in	  5	  %	  CO2.	  A	  methylcholanthrene-­‐induced	  fibrosarcoma	  cell	  line	  raised	  in	  a	  CD1d-­‐/-­‐	  mouse,	  and	  a	  CD1d-­‐transfected	  C1R	  cell	  line,	  both	  used	  as	  controls	  in	  flow	  cytometry	  experiments,	  were	  gifts	  from	  Prof.	  Mark	  Smyth	  (Peter	  MacCallum	  Cancer	  Institute,	  University	  of	  Melbourne,	  Melbourne,	  Australia)	  and	  Prof.	  Vincenzo	  Cerundolo	  (Weatherall	  Institute	  of	  Molecular	  Medicine,	  University	  of	  Oxford,	  Oxford,	  UK)	  respectively.	  The	  DC2114	  murine	  dendritic	  cell	  line	  (Fuertes	  Marraco	  et	  al.	  2012)	  was	  kindly	  provided	  by	  Hans	  Acha-­‐Orbea	  (Department	  of	  Biochemistry,	  University	  of	  Lausanne,	  Switzerland)	  and	  was	  cultured	  in	  IMDM	  supplemented	  with	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10%	  FCS,	  2	  mM	  glutamax,	  100	  U/mL	  penicillin,	  100	  μg/mL	  streptomycin	  and	  50	  μM	  2-­‐mercaptoethanol	  at	  37	  0C	  in	  5	  %	  CO2.	  DC2114	  cultures	  were	  harvested	  with	  Trypsin-­‐EDTA	  (Life	  Technologies).	  	  
 
2.2.3	  	   Culture	  in	  Stem	  Cell	  Medium	  
To	  induce	  stem	  cell-­‐like	  tumour	  cells,	  GL261	  was	  cultured	  in	  serum-­‐free	  “stem	  cell	  	  medium”	  (SC	  medium)	  consisting	  of	  DMEM/F12	  with	  B27	  supplement	  (Life	  Technologies),	  heparin	  2	  μg/mL,	  recombinant	  human	  epidermal	  growth	  factor	  (EGF)	  20	  ng/mL,	  and	  basic	  fibroblast	  growth	  factor	  (bFGF)	  10	  ng/mL	  (all	  Stem	  Cell	  Technologies,	  Victoria,	  Australia).	  When	  non-­‐adherent	  spheroidal	  cell	  aggregations	  (spheres)	  reached	  approximately	  100-­‐150	  μm	  in	  diameter,	  the	  spheres	  were	  harvested	  by	  collecting	  the	  culture	  supernatant,	  washed,	  mechanically	  dissociated	  by	  trituration	  10	  times	  through	  a	  26	  gauge	  needle,	  counted,	  and	  used	  to	  reseed	  new	  cultures	  in	  fresh	  SC	  medium.	  
	  	  	  	  
2.2.4	  	   Culture	  under	  hypoxic	  conditions	  	  
GL261	  cultures	  were	  seeded	  in	  complete	  media	  and	  incubated	  in	  an	  hypoxic	  chamber	  (Pro-­‐ox	  Model	  C21,	  Biospherix,	  Lacone,	  NY)	  placed	  inside	  a	  standard	  incubator	  at	  37	  0C	  with	  a	  CO2	  level	  of	  5	  %.	  O2	  concentration	  was	  lowered	  to	  0.5	  %	  by	  adjusting	  the	  level	  of	  N2.	  	  
	  
2.2.5	  	   Testing	  for	  mycoplasma	  contamination	  	  
Contamination	  of	  the	  GL261	  cell	  line	  by	  mycoplasma	  infection	  was	  excluded	  by	  polymerase	  chain	  reaction	  (PCR)	  using	  a	  commercially	  available	  kit	  (e-­‐Myco,	  Intron	  BioTechnology,	  Seoul,	  South	  Korea)	  according	  to	  the	  manufacturer’s	  instructions.	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2.3	  	   IN	  VIVO	  TUMOUR	  MODELS	  
2.3.1	  	   Subcutaneous	  implantation	  	  
GL261	  cells	  were	  harvested,	  washed,	  and	  resuspended	  in	  DMEM.	  5	  x	  105	  cells	  in	  100	  µL	  of	  DMEM	  were	  injected	  subcutaneously	  in	  the	  left	  flank.	  Mice	  were	  considered	  to	  harbour	  tumours	  when	  any	  two	  perpendicular	  diameters	  were	  both	  at	  least	  2	  mm.	  	  
	  
2.3.2	  	   Intracranial	  implantation	  
GL261	  cells	  were	  harvested,	  washed,	  resuspended	  in	  phosphate-­‐buffered	  saline	  (PBS)	  (Life	  Technologies),	  and	  kept	  on	  ice	  until	  injection.	  General	  anaesthesia	  was	  induced	  by	  i.p.	  injection	  of	  100	  mg/kg	  ketamine	  and	  10	  mg/kg	  xylazine	  (both	  Phoenix	  Pharm,	  Auckland,	  New	  Zealand)	  and	  buprenorphine	  (Renckitt	  Benckiser	  Pharmaceuticals,	  Richmond,	  VA)	  0.1	  mg/kg	  was	  administered	  s.c.	  for	  analgesia.	  Mice	  were	  positioned	  within	  a	  small	  animal	  stereotactic	  frame	  (Harvard	  Apparatus,	  Holliston,	  MA)	  using	  ear	  bars	  to	  stabilise	  the	  head.	  Lacrilube	  ointment	  (Allergan,	  Irvine,	  CA)	  was	  applied	  to	  the	  cornea	  to	  prevent	  dessication.	  After	  preparing	  the	  skin	  with	  povidone-­‐iodine	  (Betadine,	  Purdue	  Products,	  Stamford,	  CT),	  a	  burrhole	  was	  made	  2.1	  mm	  lateral	  to	  the	  bregma	  on	  the	  right	  side	  using	  the	  tip	  of	  a	  22	  gauge	  needle.	  The	  single	  cell	  suspension	  was	  drawn	  up	  into	  a	  10	  µL	  Hamilton	  syringe	  (Hamilton	  Company,	  Reno,	  NV)	  and	  5	  x	  103	  cells	  in	  2	  µL	  PBS	  were	  injected	  via	  a	  32	  gauge	  needle	  into	  the	  right	  striatum	  at	  a	  depth	  of	  3	  mm.	  The	  needle	  was	  left	  in	  position	  for	  1	  minute	  before	  withdrawal.	  The	  burrhole	  was	  sealed	  with	  bone	  wax	  (Ethicon,	  Amtech	  Medical,	  Auckland,	  NZ)	  and	  the	  skin	  closed	  with	  interrupted	  7-­‐0	  nylon	  sutures	  (Ethicon,	  Amtech	  Medical).	  Carprofen	  (Norbrook,	  Auckland,	  NZ)	  5	  mg/kg	  was	  administered	  s.c.	  on	  days	  1	  and	  2	  post-­‐surgery.	  Time	  to	  symptom	  appearance	  was	  defined	  as	  time	  to	  weight	  loss	  ≥	  10	  %	  or	  overt	  behavioural	  symptoms	  (reduced	  activity,	  hunching).	  The	  presence	  of	  brain	  tumours	  in	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symptomatic	  mice	  was	  confirmed	  by	  necropsy,	  including	  histological	  examination	  in	  some	  experiments.	  
	  
2.4	   MANUFACTURE	  AND	  ADMINISTRATION	  OF	  VACCINES	  
2.4.1	  	   Whole	  tumour	  vaccine	  (Glioma-­‐Gal)	  	  
The	  iNKT	  cell	  ligand	  α-­‐galactosylceramide	  (α-­‐GalCer)	  was	  manufactured	  by	  Industrial	  Research	  Laboratories	  (Lower	  Hutt,	  New	  Zealand)	  as	  previously	  described	  (A.	  Lee	  et	  al.	  2006a).	  To	  generate	  Glioma-­‐Gal	  vaccines,	  GL261	  cells	  were	  incubated	  in	  complete	  media	  supplemented	  with	  200	  ng/mL	  α-­‐GalCer	  for	  24	  h,	  gamma-­‐irradiated	  (Gammacell	  3000	  Elan	  irradiator,	  Best	  Theratronics,	  Ottawa,	  Canada)	  to	  150	  Gy	  on	  ice,	  washed	  three	  times	  in	  PBS,	  and	  resuspended	  in	  PBS	  for	  injection.	  The	  method	  for	  Glioma-­‐Gal-­‐Dox	  vaccines	  was	  identical	  except	  that	  0.05	  µM	  doxorubicin	  (Ebewe	  Pharm,	  Unterach,	  Austria)	  was	  also	  added	  to	  the	  final	  24	  hours	  of	  culture.	  Unless	  otherwise	  stated,	  mice	  received	  1	  x	  105	  cells	  in	  200	  µL	  PBS,	  injected	  i.v.	  into	  a	  lateral	  tail	  vein.	  To	  mitigate	  toxicity	  when	  more	  than	  105	  cells	  were	  injected,	  mice	  were	  pre-­‐treated	  10	  minutes	  before	  vaccination	  with	  2	  IU	  heparin	  i.v.	  (Pfizer,	  NY,	  NY).	  To	  deplete	  regulatory	  T	  cells,	  mice	  received	  125	  µg	  of	  anti-­‐CD25	  antibody	  i.p.	  (clone	  PC61,	  prepared	  in-­‐house	  from	  hybridoma	  supernatant),	  a	  dose	  that	  was	  shown	  to	  deplete	  approximately	  50	  %	  of	  FoxP3+	  CD4+	  T	  cells	  in	  naïve	  mice	  (Appendix	  B,	  Fig	  B2.1),	  consistent	  with	  a	  previous	  study	  in	  this	  laboratory	  (Ataera	  et	  al.	  2011).	  
 
2.4.2	   Lysate	  vaccine	  (Lysate-­‐Gal)	  
Tumour	  cells	  were	  harvested	  with	  TrypLE,	  washed	  three	  times	  in	  PBS,	  and	  resuspended	  in	  PBS	  in	  a	  cryovial	  at	  10	  x	  106	  live	  cells/mL.	  Tumour	  cell	  lysis	  was	  achieved	  by	  6	  cycles	  of	  freezing	  by	  immersion	  in	  liquid	  N2	  alternating	  with	  thawing	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in	  a	  waterbath	  at	  37	  0C.	  100	  %	  cell	  death	  was	  confirmed	  by	  staining	  with	  Trypan	  Blue	  (Life	  Technologies).	  The	  lysate	  was	  triturated	  ten	  times	  through	  a	  26	  gauge	  needle	  to	  disrupt	  dead	  and	  dying	  cells.	  Particulate	  matter	  was	  removed	  by	  centrifugation	  at	  1000	  g	  for	  10	  min.	  The	  supernatant	  was	  passed	  through	  0.8	  and	  0.2	  µm	  filters.	  The	  protein	  concentration	  of	  each	  lysate	  was	  measured	  using	  a	  colourimetric	  protein	  assay	  (Bio-­‐Rad	  DC	  Protein	  Assay,	  Bio-­‐Rad	  Laboratories,	  Auckland,	  NZ).	  Absorbance	  at	  wavelength	  750	  nm	  was	  read	  on	  a	  Versamax	  microplate	  reader	  (Molecular	  Devices,	  Sunnyvale,	  CA).	  	  Lysates	  were	  stored	  at	  -­‐80	  0C	  until	  required.	  To	  prepare	  vaccines,	  lysates	  were	  diluted	  with	  PBS	  to	  achieve	  the	  desired	  concentration	  and	  then	  α-­‐GalCer	  was	  added	  to	  the	  lysate	  to	  achieve	  a	  dose	  of	  200	  ng	  per	  animal.	  The	  lysate	  +	  α-­‐GalCer	  mixture	  was	  injected	  into	  a	  lateral	  tail	  vein,	  typically	  at	  a	  volume	  of	  200	  μL.	  	  
	  
2.5	   IN	  VIVO	  OT-­‐1	  CROSS-­‐PRIMING	  ASSAY	  
Spleens	  and	  lymph	  nodes	  from	  OT-­‐I	  x	  B6.SJL-­‐	  Ptprca	  Pepcb/BoyJ	  mice	  (CD45.1+)	  were	  strained	  through	  a	  70	  μm	  filter,	  then	  CD8	  cells	  positively	  selected	  using	  magnetic	  beads	  (Dynabead	  FlowComp,	  Life	  Technologies)	  and	  analyzed	  by	  flow	  cytometry	  to	  check	  purity.	  OT-­‐1	  cells	  (104)	  were	  transferred	  into	  C57BL/6	  mice	  by	  i.v.	  injection	  and	  1	  day	  later	  recipient	  mice	  were	  injected	  i.v.	  with	  200	  µg	  endotoxin-­‐free	  OVA	  (Profos	  AG,	  Regensburg,	  Germany)	  and	  200	  ng	  α-­‐GalCer.	  Seven	  days	  later	  mice	  were	  bled	  from	  a	  lateral	  tail	  vein	  and	  leukocytes	  stained	  directly	  ex	  vivo	  with	  antibodies	  for	  TCR	  Vα2,	  CD8,	  and	  CD45.1.	  Flow	  cytometry	  was	  used	  to	  enumerate	  OT-­‐1	  cells	  as	  a	  proportion	  of	  total	  CD8+	  lymphocytes.	  
	  
2.6	  	   IN	  VIVO	  DEPLETION	  STUDIES	  
CD8α+	  cells	  were	  depleted	  with	  antibody	  from	  clone	  2.43,	  CD4+	  cells	  with	  clone	  GK1.5,	  and	  NK1.1+	  cells	  with	  clone	  PK136,	  all	  prepared	  in-­‐house	  from	  hybridoma	  
 105 
supernatants.	  Appropriate	  i.p.	  dosing	  schedules	  were	  developed	  to	  achieve	  >	  95	  %	  depletion	  over	  the	  course	  of	  a	  given	  experiment	  (Appendix	  B,	  Figs	  B2.2,	  2.3,	  2.4).	  Depletion	  of	  langerin+	  cells	  in	  langerin-­‐DTREGFP	  recipients	  was	  achieved	  with	  350	  ng	  of	  Diphtheria	  toxin	  (Sigma-­‐Aldrich)	  given	  48	  and	  24	  hours	  before	  vaccination,	  and	  one	  and	  two	  days	  after	  vaccination.	  	  In	  some	  experiments,	  antigen-­‐presentation	  in	  spleen	  was	  prevented	  entirely	  by	  splenectomy	  performed	  7	  days	  before	  vaccination.	  Splenectomies	  were	  conducted	  under	  general	  anaesthesia	  using	  the	  method	  described	  by	  Reeves	  and	  colleagues	  (Reeves	  et	  al.	  2001).	  Mice	  were	  allowed	  to	  recover	  for	  7	  days	  before	  experiments.	  
	  
2.7	   IN-­‐HOUSE	  PREPARATION	  OF	  DEPLETING	  ANTIBODIES	  FROM	  
HYBRIDOMA	  SUPERNATANTS	  Hybridomas	  stored	  in	  the	  vapour	  phase	  of	  liquid	  N2	  were	  thawed	  and	  briefly	  cultured	  in	  IMDM	  supplemented	  with	  5%	  FCS.	  The	  cell	  compartment	  of	  a	  double	  chamber	  cell	  culture	  flask	  (CELLine	  CL-­‐1000,	  Integra	  Biosciences	  AG,	  Zizers,	  Switzerland)	  was	  seeded	  with	  30	  x	  106	  cells	  at	  2	  x	  106	  cells/mL	  in	  IMDM	  supplemented	  with	  20	  %	  FCS.	  The	  nutrient	  chamber	  was	  filled	  with	  500	  ml	  of	  IMDM	  supplemented	  with	  1	  %	  FCS.	  Cells	  were	  cultured	  at	  37	  0C,	  5	  %	  CO2.	  Every	  few	  days,	  the	  cell	  culture	  chamber	  was	  emptied	  and	  reseeded	  with	  150	  x	  106	  cells	  at	  10	  x	  106	  cells/mL.	  Supernatant	  from	  the	  cell	  compartment	  was	  sterilised	  with	  0.01%	  NaN3	  (Sigma-­‐Aldrich)	  and	  stored	  at	  4	  0C	  until	  purification.	  
To	  purify	  IgG,	  supernatants	  were	  passed	  through	  a	  0.2	  μm	  filter	  and	  then	  run	  through	  a	  Protein	  G	  column	  (HiTrap	  Protein	  G	  HP,	  GE	  Healthcare,	  Auckland,	  NZ)	  on	  a	  low	  pressure	  liquid	  chromatography	  system	  (BioLogic	  LP,	  Bio-­‐Rad	  Laboratories).	  Bound	  IgG	  was	  eluted	  at	  pH	  2.7	  while	  monitoring	  absorbance	  at	  a	  wavelength	  of	  280	  nm.	  Eluted	  fractions	  were	  collected	  using	  a	  BioLogic	  Biofrac	  Fraction	  Collector	  (Bio-­‐Rad	  Laboratories).	  IgG	  content	  of	  collected	  fractions	  was	  quantified	  by	  spectrophotometry	  (Nanodrop	  ND-­‐1000	  with	  software	  V3.5.2,	  Thermo	  Fisher	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Scientific).	  Fractions	  containing	  IgG	  were	  pooled	  and	  dialysed	  to	  exchange	  the	  buffer	  solution	  using	  a	  dialysis	  cassette	  (Slide-­‐A-­‐Lyzer	  Cassette	  with	  3500	  Da	  cut-­‐off,	  Pierce,	  Thermo	  Fisher	  Scientific)	  placed	  overnight	  in	  1.5	  L	  PBS	  at	  4	  0C.	  The	  final	  product	  was	  passed	  through	  a	  0.2	  μm	  filter,	  aliquoted	  and	  stored	  at	  -­‐80	  0C	  until	  use.	  	  
Elution	  buffer	  (0.1	  M	  glycine-­‐HCl,	  pH	  2.7):	  	  dH2O	  500	  mL,	  glycine	  3.75	  g,	  HCl	  to	  bring	  pH	  to	  2.7	  	  
	  
2.8	  	   SAMPLE	  COLLECTION	  
2.8.1	   Collection	  and	  preparation	  of	  murine	  leucocytes	  
Blood	  was	  obtained	  by	  nicking	  a	  lateral	  tail	  vein	  with	  a	  scalpel	  blade	  and	  collecting	  5-­‐8	  drops	  in	  1.7	  mL	  tubes	  containing	  200	  μL	  PBS	  and	  10	  mM	  Ethylenediaminetetraacetic	  acid	  (EDTA)	  (Sigma-­‐Aldrich).	  Red	  blood	  cells	  (RBC)	  were	  removed	  by	  adding	  1	  mL	  RBC	  lysis	  buffer	  (Qiagen,	  Germantown,	  MA)	  and	  incubating	  for	  30	  min	  at	  37	  0C.	  After	  centrifugation	  at	  664	  g	  for	  5	  min,	  the	  supernatant	  was	  discarded	  and	  the	  pellet	  resuspended	  in	  appropriate	  medium	  or	  buffer.	  
Spleens	  and	  lymph	  nodes	  were	  harvested	  and	  placed	  into	  IMDM	  on	  ice.	  Tissue	  was	  mechanically	  dissociated	  by	  passage	  through	  a	  70	  μm	  filter.	  RBC	  were	  removed	  from	  spleen	  samples	  with	  RBC	  lysis	  buffer	  as	  above.	  Cells	  were	  washed	  twice	  in	  IMDM	  and	  resuspended	  in	  appropriate	  medium	  or	  buffer.	  
For	  liver	  lymphocytes,	  mice	  were	  sacrificed	  by	  cervical	  dislocation	  and	  the	  livers	  perfused	  with	  ice	  cold	  PBS	  via	  the	  portal	  vein	  before	  harvesting.	  Livers	  were	  cut	  into	  small	  pieces,	  incubated	  in	  IMDM	  containing	  2.4	  mg/mL	  collagenase	  II	  (Life	  Technologies)	  and	  0.2	  mg/mL	  DNase	  I	  (Roche,	  Mannheim,	  Germany)	  for	  60	  min	  at	  37	  0C	  then	  passed	  through	  a	  70	  μm	  filter.	  Cells	  were	  washed	  and	  resuspended	  in	  IMDM.	  To	  enrich	  for	  lymphocytes,	  7	  mL	  of	  the	  single	  cell	  suspension	  was	  underlaid	  with	  3	  mL	  of	  Lymphoprep	  (Axis-­‐Shield	  PoC	  AS,	  Oslo,	  Norway).	  After	  centrifugation	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at	  840	  g	  for	  20	  min	  at	  room	  temperature,	  cells	  at	  the	  sample-­‐medium	  interface	  were	  collected.	  Cells	  were	  washed	  in	  IMDM	  and	  resuspended.	  	  
	  
2.8.2	   Patient	  sample	  collection	  
Peripheral	  blood	  and	  tumour	  tissue	  had	  previously	  been	  collected	  from	  GBM	  patients	  with	  their	  informed	  consent	  under	  a	  Central	  Regional	  Ethics	  Committee	  of	  New	  Zealand-­‐approved	  protocol	  that	  allowed	  for	  future	  unspecified	  research.	  Venous	  blood	  was	  drawn	  into	  CPT	  cell	  preparation	  tubes	  (BD	  Biosciences)	  and	  the	  buffy	  coat	  collected	  after	  centrifugation	  at	  room	  temperature	  according	  to	  the	  manufacturer’s	  instructions.	  PBMC	  were	  washed	  and	  cryopreserved	  in	  the	  vapour	  phase	  of	  liquid	  N2	  in	  70	  %	  RPMI	  (Life	  Technologies),	  20	  %	  FCS	  and	  10	  %	  Dimethyl	  sulfoxide	  (DMSO)	  (Sigma-­‐Aldrich)	  until	  use.	  Patient	  blood	  samples	  were	  predominantly	  processed	  by	  Malaghan	  Institute	  research	  officers	  although	  the	  author	  also	  processed	  some	  samples.	  Absolute	  differential	  blood	  counts	  were	  determined	  by	  separate	  venesection	  within	  24	  hours	  of	  PBMC	  collection	  by	  Wellington	  Hospital	  laboratory	  staff	  using	  a	  Sysmex	  XE	  2100	  analyser	  (Roche	  Diagnostics,	  Auckland,	  New	  Zealand).	  PBMC	  from	  35	  healthy	  age-­‐matched	  controls	  were	  collected	  and	  stored	  by	  Dr	  R.	  Weinkove	  according	  to	  a	  similar	  protocol.	  	  




2.9	   FLOW	  CYTOMETRY	  






























67%-/3/-/.8& 9$+,%& :$2+4+7;+4%& 6277$/%4&
B220 67859:;! <(%=<! :>!:&./0&(+0(/!
B220 67859:;! <(%=<=?@A@! (:&./0&(+0(!
CD1d B:B! <C! D+E&,%.2(+!
CD3! BF@5;=BB! GDH=! D+E&,%.2(+!
CD3! BF@5;=BB! <(=?I! (:&./0&(+0(!
CD4 JKBA@! <C! D+E&,%.2(+!
CD4 JKBA@! 7<=! D+E&,%.2(+!
CD4 6LF5@! <*0!:3$(! (:&./0&(+0(!
CD8" @859AI! GDH=! D+E&,%.2(+!
CD8" @859AI! :M9@N! :&.3(2(+)!
CD11b LBOIN! 7<==?I! :>!<4*%P&+2(+!
CD11c QR8! 7<=! :>!:&./0&(+0(/!
CD11c SFBT! 7<=! :&.3(2(+)!
CD15 (SSEA-1) L=FTN! <C! :>!<4*%P&+2(+!
CD25 <=9B! <C! :&.3(2(+)!
CD40 8O;8! <C! :>!:&./0&(+0(/!
CD44 DLI! <C! :>!<4*%P&+2(+!
CD44 DLI! 7<=! :>!:&./0&(+0(/!
CD45.1 7;N! <C! D+E&,%.2(+!
CD45.2 BNF! 73(U*!FTT! D+E&,%.2(+"!
CD69 QBA;G8! GDH=! :>!:&./0&(+0(/!
CD86 JRB! <C! (:&./0&(+0(!
CD133 (Prominin 1) L:V58JT! 7<=! L&3,(+?&!:&.,(0!
CD200 WXVN! 73(U*!FTT! (:&./0&(+0("!
Fas Y.;! GDH=! :>!<4*%P&+2(+!
Gr-1 6:95T=@! 7<=! :>!<4*%P&+2(+!
MHC class I (H-2Kb) 7G95TTA@A@A8! 7<=! (:&./0&(+0(!
MHC class II (I-A/I-E) L@OBBFAB@A;! <C! (:&./0&(+0(!
MHC class II (I-A/I-E) L@OBBFAB@A;! 73(U*!FTT! (:&./0&(+0("!
MHC class II (I-Ab) 7G95B;NAB! <C! :>!<4*%P&+2(+!
NK1.1 <KB89! 73(U*!FTT! :>!:&./0&(+0(/"!
TCR V"2 :;NAB! 73(U*!9FI! (:&./0&(+0("!
TCR# Q@I5@VI! GDH=! :>!:&./0&(+0(/!
TCR# Q@I5@VI! <C! :>!:&./0&(+0(/!
 ! ! !
Isotype controls: ! ! !
Mouse IgG2a,$ LW<=5BI8! GDH=! :&.3(2(+)!
Mouse IgG2a,$ (:L;*! <C! (:&./0&(+0(!
Mouse IgG2a,$ (:L;*! 73(U*!7FTT! (:&./0&(+0("!
Mouse IgG2a,$ (:L;*! 7<=! (:&./0&(+0(!
Mouse IgG2b,$ BFVOBNQ@! <C! (:&./0&(+0(!
Mouse IgM,$ JB@@5;;T! <C! :>!<4*%P&+2(+!
Rat IgG1,$ 6858F! 7<=! :>!:&./0&(+0(/!
Rat IgG2a 68@5V@! <C! :>!:&./0&(+0(/!
Rat IgG2b (:BFVOBNQ@! <C! (:&./0&(+0(!
Hamster IgG QHKTTT! GDH=! :&.3(2(+)!
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All	  antibody	  staining	  of	  murine	  cells	  was	  performed	  for	  10	  minutes	  at	  4	  °C	  in	  PBS	  supplemented	  with	  1	  %	  FCS,	  0.05	  %	  sodium	  azide,	  and	  2	  mM	  EDTA.	  Non-­‐specific	  Fc	  receptor-­‐mediated	  binding	  was	  blocked	  by	  incubation	  for	  10	  min	  with	  anti-­‐CD16/32	  (clone	  24G2,	  prepared	  in-­‐house	  from	  hybridoma	  supernatant).	  Propidium	  iodide	  (Sigma-­‐Aldrich)	  was	  used	  to	  exclude	  dead	  cells.	  Flow	  cytometry	  was	  performed	  on	  a	  FACSCalibur	  (BD	  Biosciences)	  with	  data	  analysis	  using	  FlowJo	  software	  (TreeStar	  Inc,	  Ashland,	  OR).	  Compensation	  was	  performed	  with	  single-­‐stained	  positive	  control	  cells	  or	  with	  fluorophore-­‐labeled	  antibodies	  bound	  to	  beads	  coated	  with	  anti-­‐rat	  Ig	  (BD	  Compbeads,	  BD	  Biosciences).	  Monoclonal	  antibodies	  were	  purchased	  from	  eBioscience	  (San	  Diego,	  CA),	  BD	  Biosciences,	  Miltenyi	  Biotec	  (Bergisch	  Gladbach,	  Germany)	  or	  Biolegend	  (San	  Diego,	  CA)	  and	  are	  listed	  in	  Table	  2.1.	  Some	  purified	  antibodies	  were	  conjugated	  in-­‐house	  to	  Alexa-­‐A488	  or	  Alexa-­‐A647	  (Life	  Technologies).	  A	  PE-­‐labelled	  CD1d	  tetramer	  (Proimmune,	  Oxford,	  UK)	  loaded	  with	  α-­‐GalCer	  according	  to	  the	  manufacturer’s	  instructions	  was	  used	  to	  discriminate	  iNKT	  cells.	  All	  antibodies	  were	  used	  at	  the	  lowest	  concentration	  at	  which	  binding	  site	  saturation	  occurred.	  This	  concentration	  was	  determined	  by	  performing	  a	  titration	  study	  using	  splenocytes	  or	  a	  tumour	  cell	  line.	  A	  titration	  study	  was	  performed	  for	  each	  newly	  acquired	  antibody	  by	  a	  member	  of	  the	  author’s	  research	  group,	  including	  some	  by	  the	  author.	  
	  
2.9.2	  	  	  Flow	  cytometric	  analysis	  of	  human	  PBMC	  samples	  	  
PBMC	  were	  thawed,	  washed,	  and	  resuspended	  in	  PBS.	  Antibody	  staining	  was	  conducted	  at	  4	  °C	  for	  20	  min	  in	  PBS.	  Fc	  receptors	  were	  blocked	  by	  incubation	  with	  2	  mg/mL	  polyclonal	  human	  IgG	  (Intragam	  P,	  CSL	  Limited,	  Australia)	  for	  15	  min.	  Dead	  cells	  were	  excluded	  using	  LIVE/DEAD	  Fixable	  Blue	  (Molecular	  Probes,	  Eugene,	  OR),	  4',6-­‐diamidino-­‐1	  2-­‐phenylindole	  (DAPI)	  (Molecular	  Probes),	  or	  propidium	  iodide.	  Data	  were	  acquired	  on	  an	  LSRII	  flow	  cytometer	  or	  FACS	  Calibur	  apparatus	  (both	  BD	  Biosciences)	  and	  analyzed	  using	  FlowJo	  software.	  Compensation	  was	  performed	  using	  fluorophore-­‐labeled	  antibodies	  bound	  to	  anti-­‐mouse	  Ig-­‐coated	  particles	  (BD	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Compbeads,	  BD	  Biosciences).	  For	  non-­‐antibody	  stains,	  compensation	  was	  performed	  using	  stained	  and	  unstained	  populations	  of	  positive	  control	  cells.	  The	  fluorescent	  monoclonal	  antibodies	  used	  in	  these	  studies	  are	  listed	  in	  Table	  2.2.	  Human	  iNKT	  cells	  were	  detected	  using	  CD1d	  monomers	  (National	  Institutes	  of	  Health	  Tetramer	  Core	  Facility,	  Emory	  University,	  Atlanta,	  GA)	  that	  had	  been	  loaded	  with	  α-­‐GalCer	  and	  tetramerized	  with	  streptavidin-­‐PE	  (BD	  Biosciences).	  The	  antibody	  panels	  for	  FC	  of	  human	  PBMC	  samples	  described	  in	  Chapter	  4	  were	  designed	  and	  optimised	  by	  Dr	  R.	  Weinkove.	  
	  
2.10	   ANALYSIS	  OF	  CYTOKINE	  RELEASE	  
Blood	  was	  collected	  from	  the	  lateral	  tail	  vein	  and	  allowed	  to	  clot	  at	  room	  temperature.	  Serum	  was	  collected	  after	  centrifugation.	  Levels	  of	  the	  cytokines	  IL-­‐4,	  IL-­‐12p70	  and	  IFN-­‐γ	  were	  assessed	  by	  cytokine	  bead	  arrays	  analysed	  on	  a	  Bio-­‐Plex	  analyzer	  (Bio-­‐Rad	  Laboratories)	  according	  to	  the	  manufacturer’s	  instructions.	  For	  analysis	  of	  cytokine	  release	  in	  spleen,	  liver	  and	  lymph	  node	  post-­‐vaccination,	  tissue	  was	  removed	  from	  euthanized	  animals	  and	  mechanically	  dissociated.	  Enrichment	  for	  liver	  lymphocytes	  was	  performed	  using	  a	  Lymphoprep	  gradient	  as	  described	  












*CD3, CD14, CD16, CD19, CD20, CD56 
 
Specificity Clone Fluorophore Supplier 
CD1d CD1d42 PE BD Biosciences 
CD3 SK7 APC-H7 Biolegend 
CD11c Bul5 APC Biolegend 
CD14 MφP9 APC BD Biosciences 
CD16 3G8 FITC Biolegend 
CD19 SJ25C1 APC BD Biosciences 
HLA-DR L243 PerCP Biolegend 
Lineage-1*  FITC BD Biosciences 
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above.	  	  Cells	  were	  washed	  and	  incubated	  at	  37	  °C	  in	  IMDM	  with	  5	  %	  FBS,	  2	  mM	  glutamax,	  100	  U/mL	  penicillin,	  100	  µg/mL	  streptomycin,	  and	  50	  µM	  2-­‐mercaptoethanol.	  Culture	  supernatants	  were	  collected	  after	  48	  hours	  for	  analysis.	  	  
	  
2.11	   MAGNETIC	  RESONANCE	  IMAGING	  (MRI)	  
MRI	  was	  performed	  on	  anesthetized	  animals	  using	  a	  clinical	  1.5	  Tesla	  MR	  scanner	  (Philips	  Medical	  Systems,	  Eindhoven,	  The	  Netherlands)	  equipped	  with	  a	  wrist	  solenoid	  coil.	  	  T1-­‐weighted	  images	  were	  acquired	  with	  the	  following	  parameters:	  TE=	  21.4	  ms,	  TR	  =	  800	  ms,	  pixel	  size	  =	  300	  mm	  x	  300	  mm,	  thickness	  =	  1	  mm,	  3	  averages.	  	  Contrast	  was	  enhanced	  by	  i.v.	  administration	  of	  100	  µL	  gadolinium-­‐DTPA	  (Magnevist,	  Bayer	  Schering	  Pharma,	  Berlin,	  Germany).	  T2-­‐weighted	  spin-­‐echo	  images	  were	  acquired	  with	  the	  parameters:	  TE	  =	  54	  ms,	  TR	  =	  2000	  ms.	  	  
	  
2.12	   IN	  VITRO	  iNKT	  CELL	  PROLIFERATION	  ASSAY	  
PBMCs	  were	  thawed,	  washed,	  and	  plated	  (5	  x	  105	  PBMCs	  per	  well	  in	  a	  96-­‐well	  plate)	  in	  IMDM	  supplemented	  with	  5	  %	  human	  AB	  serum	  (Life	  Technologies),	  and	  either	  100	  ng/mL	  α-­‐GalCer	  or	  vehicle.	  After	  24	  hours,	  50	  U/mL	  recombinant	  human	  IL-­‐2	  (Chiron	  Corporation,	  Emeryville,	  CA)	  was	  added	  to	  each	  well.	  After	  7	  days,	  live	  cells	  were	  counted	  with	  Trypan	  Blue	  exclusion,	  and	  iNKT	  cells	  enumerated	  by	  flow	  cytometry.	  	  	  
	  
2.13	   IMPACT	  OF	  α-­‐GALCER-­‐LOADED	  TUMOUR	  CELLS	  ON	  iNKT	  CELL	  
PROLIFERATION	  AND	  ALLORESPONSE	  	  
Primary	  GBM	  cell	  cultures	  from	  five	  patients	  were	  either	  pulsed	  overnight	  with	  200	  ng/mL	  α-­‐GalCer	  or	  left	  untreated,	  and	  then	  γ-­‐irradiated	  on	  ice	  (150	  Gy).	  After	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washing	  three	  times	  to	  remove	  any	  free	  α-­‐GalCer,	  105	  irradiated	  tumour	  cells	  were	  co-­‐cultured	  with	  5	  x	  105	  carboxyfluorescein	  succinimidyl	  ester	  (CFSE)-­‐labelled	  allogeneic	  PBMC	  in	  96-­‐well	  plates.	  After	  5	  days,	  CFSE	  dilution	  was	  assessed	  by	  flow	  cytometry.	  CFSE	  was	  from	  Sigma-­‐Aldrich.	  
	  
2.14	   ASSESSMENT	  OF	  MHC	  CLASS	  II	  EXPRESSION	  BY	  GBM	  TUMOUR	  CELLS	  	  
Primary	  GBM	  cell	  lines	  were	  cultured	  as	  above	  for	  48	  hours	  with	  and	  without	  100	  U/mL	  recombinant	  human	  IFN-­‐γ	  (PeproTech,	  Rocky	  Hill,	  NJ).	  Cells	  were	  assessed	  for	  HLA-­‐DR	  expression	  by	  flow	  cytometry	  as	  described	  above.	  	  
	  
2.15	   HARVEST	  AND	  ENRICHMENT	  OF	  FOETAL	  NEURAL	  STEM	  CELLS	  (FNSC)	  	  
Mating	  of	  C57BL6	  mice	  was	  timed	  and	  E14	  pregnant	  dams	  were	  sacrificed	  by	  cervical	  dislocation.	  Under	  sterile	  conditions,	  foetuses	  were	  harvested,	  decapitated,	  and	  heads	  placed	  in	  ice	  cold	  PBS.	  Under	  a	  laminar	  flow	  hood	  with	  HEPA	  filter,	  and	  using	  10X	  magnification,	  skin	  and	  dura	  were	  removed	  as	  previously	  described	  (Chojnacki	  and	  Weiss	  2008).	  Foetal	  brains	  were	  mechanically	  dissociated	  by	  straining	  through	  70	  and	  40	  μm	  filters	  followed,	  if	  necessary,	  by	  gentle	  trituration	  to	  create	  a	  single	  cell	  suspension.	  	  Cells	  were	  washed,	  counted	  and	  used	  to	  seed	  cultures	  at	  a	  concentration	  of	  5	  x	  104/mL	  in	  NeuroCult	  Mouse	  Basal	  Medium	  supplemented	  with	  10	  %	  Neurocult	  Mouse	  Supplement,	  10	  ng/mL	  bFGF,	  20	  ng/mL	  EGF,	  2	  μg/mL	  heparin	  (all	  Stem	  Cell	  Technologies),	  a	  medium	  shown	  to	  support	  and	  enrich	  for	  normal	  neural	  stem	  cells	  (Galli	  et	  al.	  2008;	  S.	  A.	  Louis	  et	  al.	  2008).	  Because	  settling	  debris	  was	  likely	  to	  prevent	  adherence	  of	  cells	  of	  interest	  (Chojnacki	  and	  Weiss	  2008),	  only	  non-­‐adherent	  cells	  were	  harvested	  at	  the	  first	  passage	  .	  Thereafter	  both	  floating	  cells	  and	  the	  adherent	  layer	  of	  “attached	  spheres”	  were	  serially	  passaged.	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2.16	   SIDE	  POPULATION	  ASSAY	  AND	  FLUORESCENCE-­‐ACTIVATED	  CELL	  	  
SORTING	  (FACS)	  	  
Tumour	  cells	  at	  70–80	  %	  confluency	  were	  harvested	  with	  TrypLE	  and	  washed	  twice	  in	  Hanks	  Buffered	  Salt	  Solution	  (HBSS)	  (Life	  Technologies)	  with	  2	  %	  FCS.	  Cells	  were	  resuspended	  at	  1	  x	  106	  cells/mL	  in	  HBSS	  supplemented	  with	  2	  %	  FCS	  warmed	  to	  37	  0C,	  then	  incubated	  at	  37	  0C	  with	  5	  μg/mL	  Hoechst	  33342	  (Life	  Technologies)	  and	  15	  mM	  sodium	  azide.	  2-­‐deoxyglucose	  (2-­‐DOG)	  (Sigma-­‐Aldrich)	  which	  inhibits	  ATP-­‐binding	  cassette	  transporters,	  was	  added	  to	  some	  cells	  prior	  to	  Hoechst	  33342	  as	  a	  negative	  control.	  Cells	  were	  shielded	  from	  ambient	  light	  and	  incubated	  for	  90	  min,	  with	  mixing	  every	  30	  min.	  Staining	  was	  halted	  by	  rinsing	  in	  ice-­‐cold	  HBSS/2%	  FCS.	  Propidium	  iodide	  was	  added	  at	  4	  μM	  for	  viability	  assessment.	  Cells	  were	  resuspended	  at	  2–4	  x	  106	  cells/mL	  in	  HBSS/2%	  FCS	  and	  sorted	  on	  a	  BD	  FACS	  Vantage	  DiVa	  (BD	  Biosciences)	  by	  Ms	  Kylie	  Price.	  Cells	  were	  excited	  with	  a	  UV	  laser	  (150	  mW	  on	  the	  FACS	  Vantage	  DiVa).	  The	  emission	  was	  detected	  through	  250/50	  nm	  (‘‘Hoechst	  Blue’’)	  and	  620	  LP	  (‘‘Hoechst	  Red’’)	  filters	  with	  signal	  separated	  by	  a	  610-­‐nm	  short	  pass	  dichroic	  mirror.	  	  Live	  cells	  were	  displayed	  on	  a	  Hoechst	  Blue	  
versus	  Hoechst	  Red	  dot	  plot	  to	  visualize	  the	  SP.	  SP	  cells	  were	  sorted	  at	  20	  psi	  sheath	  pressure,	  with	  a	  100-­‐	  Xm	  nozzle	  and	  approximately	  37,500	  Hz	  drop	  drive	  frequency,	  at	  a	  rate	  of	  approximately	  2,000	  cells	  per	  second.	  All	  data	  were	  collected	  in	  linear	  mode	  and	  analyzed	  using	  FlowJo.	  	  
	  
2.17	   ASSESSMENT	  OF	  GENE	  EXPRESSION	  BY	  QUANTITATIVE	  REVERSE	  
TRANSCRIPTION	  POLYMERASE	  CHAIN	  REACTION	  (RT-­‐PCR)	  
Cells	  were	  washed	  in	  PBS	  and	  frozen	  at	  -­‐80	  0C	  until	  required.	  	  Cells	  were	  lysed	  and	  total	  RNA	  extracted	  using	  the	  Mini	  RNA	  Isolation	  II	  kit	  (Zymo	  Research,	  Irvine,	  CA,	  http://www.zymoresearch.com)	  according	  to	  the	  manufacturer’s	  instructions.	  Care	  was	  taken	  to	  prevent	  contamination	  with	  extraneous	  nucleic	  acid	  throughout	  the	  process.	  RNA	  concentration	  was	  measured	  by	  spectrophotometry	  (Nanodrop	  ND-­‐
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1000,	  Software	  V3.5.2,	  Thermo	  Fisher	  Scientific).	  	  cDNA	  was	  synthesized	  using	  commercially-­‐available	  reverse	  transcriptase	  and	  reagents	  (iScript,	  Bio-­‐Rad	  Laboratories)	  and	  an	  automated	  thermal	  cycler	  (Biorad	  iCycler,	  Bio-­‐Rad	  Laboratories)	  programmed	  to	  heat	  to	  25	  0C	  for	  5	  min,	  42	  0C	  for	  30	  min,	  85	  0C	  degrees	  for	  5	  min.	  The	  resulting	  cDNA	  was	  pipetted	  into	  96	  well	  plates	  and	  mixed	  with	  pre-­‐designed	  commercially-­‐available	  forward	  and	  reverse	  primers	  for	  murine	  genes	  of	  interest	  (CD133,	  Musashi-­‐1,	  SOX2,	  SOX6,	  IL-­‐13Rα2,	  gp100,	  TRP-­‐2,	  survivin,	  
nestin,	  Oct4,	  ABCB1,	  ABCC1,	  ABCG2)	  or	  18s	  ribosomal	  RNA	  (QuantiTect	  primer	  assays,	  Qiagen)	  and	  a	  commercially-­‐available	  RT-­‐PCR	  mixture	  that	  includes	  a	  DNA	  polymerase,	  deoxynucleotide	  triphosphates,	  a	  green	  dye	  that	  binds	  to	  dsDNA,	  and	  buffer	  components	  (SYBR	  green-­‐based	  RT-­‐PCR	  kit,	  Qiagen).	  RT-­‐PCR	  was	  performed	  on	  the	  ABI	  7500	  RT-­‐PCR	  platform	  (Applied	  Biosystems,	  Life	  Technologies)	  using	  40	  cycles	  of:	  94	  0C	  for	  15	  seconds,	  55	  0	  C	  for	  30	  seconds,	  72	  0C	  for	  35	  seconds.	  The	  exponential	  phase	  of	  the	  amplification	  curve	  was	  used	  to	  determine	  the	  cycle	  threshold	  (Ct)	  for	  each	  gene	  and	  Ct	  values	  were	  normalized	  to	  the	  Ct	  value	  for	  18S	  rRNA	  (∆Ct).	  Amplification	  efficiency	  of	  QuantiTect	  primer	  assays	  is	  equivalent	  (http://www.qiagen.com/Products/PCR/QuantiTect/PrimerAssays)	  so	  the	  ∆∆Ct	  method	  was	  used	  to	  determine	  fold	  change	  from	  parental	  cells.	  	  
	  
2.18	   GENERATION	  OF	  DOXORUBICIN-­‐RESISTANT	  TUMOUR	  CELLS	  
	  GL261	  cultures	  were	  set	  up	  as	  normal	  in	  complete	  media.	  After	  1-­‐2	  days	  doxorubicin	  was	  added	  directly	  to	  the	  media	  to	  achieve	  a	  final	  concentration	  of	  0.01	  μM.	  Extensive	  cell	  death	  was	  observed	  but	  a	  small	  fraction	  of	  cells	  remained	  viable	  (termed	  “drug-­‐tolerant	  persisters”).	  After	  several	  days	  of	  growth	  arrest	  surviving	  cells	  eventually	  began	  to	  proliferate	  (termed	  “drug-­‐tolerant	  expanding	  persisters”	  or	  DTEP).	  On	  reaching	  80	  -­‐90	  %	  confluency	  cells	  were	  harvested	  and	  reseeded	  in	  media	  containing	  0.1	  μM	  doxorubicin.	  After	  several	  passages	  the	  doubling	  time	  of	  these	  cells	  stabilised	  at	  level	  close	  to	  parental	  culture.	  These	  cells	  were	  thereafter	  termed	  “DTEP	  0.01”.	  	  Some	  DTEP	  0.01	  cells	  were	  reseeded	  in	  media	  containing	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progressively	  increasing	  concentrations	  of	  doxorubicin.	  In	  this	  way	  stable	  DTEP	  cultures	  were	  established	  at	  a	  range	  of	  different	  doxorubicin	  concentrations	  although	  the	  doubling	  time	  of	  stable	  cultures	  progressively	  increased	  with	  increasing	  drug	  concentration.	  	  
	  
2.19	   ASSESSMENT	  OF	  TUMOUR	  CELL	  PROLIFERATION	  BY	  MEASUREMENT	  OF	  
3H-­‐THYMIDINE	  INCORPORATION	  	  GL261	  parental	  and	  DTEP	  cultures	  were	  harvested	  and	  resuspended	  in	  complete	  media.	  1	  x	  104	  cells	  in	  100	  μL	  media	  were	  added	  to	  wells	  of	  a	  round-­‐bottomed	  96	  well	  plate.	  A	  further	  100	  μL	  of	  media	  containing	  doxorubicin	  at	  different	  concentrations	  was	  added	  to	  each	  well	  to	  achieve	  final	  concentrations	  ranging	  from	  0.001	  –	  100	  μM.	  	  Each	  cell	  line	  was	  assessed	  at	  each	  concentration	  in	  triplicate.	  Cells	  were	  incubated	  overnight	  at	  37	  0C,	  5	  %	  CO2.	  The	  following	  day	  0.25	  µCi	  3H-­‐thymidine	  (MP	  Biomedicals,	  Santa	  Ana,	  CA)	  were	  added	  to	  each	  well.	  	  The	  plate	  was	  incubated	  at	  37	  0C	  for	  a	  further	  16	  hours	  and	  then	  thymidine	  uptake	  assessed	  by	  liquid	  scintillation	  counting.	  	  Briefly,	  the	  contents	  of	  the	  wells	  were	  transferred	  to	  a	  glassfibre	  filtermat	  (Wallac,	  PerkinElmer,	  Waltham,	  MA)	  using	  a	  cell	  harvester	  (TomTec,	  Unterschleisheim,	  Germany)	  and	  beta-­‐emission	  read	  on	  a	  liquid	  scintillation	  counter	  (Wallac	  1450	  microbeta	  PLUS,	  PerkinElmer).	  	  	  
2.20	   DOXORUBICIN	  TREATMENT	  OF	  MICE	  IN	  VIVO	  
Doxorubicin	  supplied	  by	  the	  manufacturer	  in	  soluble	  form	  at	  2	  mg/mL	  (Ebewe	  Pharm)	  was	  diluted	  in	  PBS	  shortly	  before	  use	  and	  administered	  to	  mice	  by	  slow	  injection	  into	  a	  lateral	  tail	  vein	  in	  a	  volume	  of	  200	  μL.	  No	  obvious	  toxicity	  was	  observed	  in	  C57BL/6	  mice	  at	  any	  of	  the	  doses	  tested,	  i.e.	  up	  to	  8	  mg/kg.	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2.21	   ASSESSMENT	  OF	  DC	  MATURATION	  IN	  RESPONSE	  TO	  PULSING	  WITH	  
TUMOUR	  LYSATE	  OR	  TO	  DOXORUBICIN	  EXPOSURE	  IN	  VITRO	  	  	  Cells	  of	  the	  DC2114	  cell	  line	  were	  harvested,	  resuspended	  in	  complete	  IMDM	  with	  10%	  FCS	  and	  each	  well	  of	  a	  24	  well	  flat	  bottom	  plate	  seeded	  with	  2.5	  x	  105	  cells	  in	  1	  mL	  medium.	  Plates	  were	  incubated	  for	  4	  hours	  at	  37	  0C	  to	  allow	  cells	  to	  adhere.	  In	  doxorubicin	  experiments,	  doxorubicin	  was	  then	  added	  at	  concentrations	  ranging	  from	  1	  μM	  to	  0.001	  μM.	  In	  some	  experiments,	  GL261	  tumour	  cell	  lysates	  created	  by	  the	  freeze/thaw	  method	  described	  in	  Section	  1.4.2	  were	  added	  to	  wells	  at	  concentrations	  of	  10	  μg/mL	  or	  100	  μg/mL.	  In	  one	  experiment,	  GL261	  tumour	  cells	  were	  harvested,	  washed,	  and	  resuspended	  in	  complete	  media	  at	  2.5	  x	  105	  /mL	  in	  cryovials.	  Cryovials	  were	  sonicated	  in	  a	  benchtop	  ultrasonic	  cleaner	  (Unisonics	  Model	  FXP8M,	  Unisonics	  Australia,	  Brookvale,	  NSW,	  Australia)	  until	  all	  cells	  were	  Trypan	  Blue	  positive	  (typically	  90	  min).	  Sonicate	  was	  then	  added	  to	  wells	  at	  a	  ratio	  of	  1	  DC	  :	  1	  sonicated	  tumour	  cell.	  Poly	  I:C	  (Invivogen,	  San	  Diego,	  CA)	  was	  added	  to	  some	  wells	  at	  100	  μg/mL	  as	  a	  positive	  control	  and	  all	  experimental	  conditions	  were	  assessed	  in	  triplicate	  wells.	  After	  incubation	  for	  16	  hours	  at	  37	  0C,	  5	  %	  CO2	  cells	  were	  harvested	  and	  expression	  of	  CD40	  and	  CD86	  assessed	  by	  antibody	  staining	  and	  flow	  cytometry,	  gating	  on	  live	  GFP+	  cells.	  	  
	  
2.22	   WESTERN	  BLOT	  ANALYSIS	  OF	  TRP-­‐2	  PROTEIN	  IN	  CELL	  LYSATES	  	  
Cells	  were	  lysed	  by	  freeze/thaw	  and	  mechanical	  disruption	  as	  described	  for	  production	  of	  lysate	  vaccines.	  A	  protease	  inhibitor	  was	  not	  used	  during	  lysate	  preparation.	  	  	  Insoluble	  debris	  was	  removed	  by	  centrifugation	  with	  collection	  of	  supernatant.	  Protein	  concentration	  was	  quantified	  using	  the	  Lowry	  method	  (Bio-­‐Rad	  DC	  Protein	  Assay,	  Bio-­‐Rad	  Laboratories).	  Absorbance	  at	  wavelength	  750	  nm	  was	  measured	  on	  a	  Versamax	  microplate	  reader	  (Molecular	  Devices,	  Sunnyvale,	  CA).	  Protein	  was	  diluted	  in	  sodium	  dodecyl	  sulfate	  (SDS)-­‐loading	  buffer	  and	  denatured	  at	  96	  0C	  for	  5	  min.	  A	  10	  %	  acrylamide	  resolving	  gel	  was	  prepared,	  cast	  between	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parallel	  glass	  plates	  (Miniprotean	  III	  system,	  Bio-­‐Rad	  Laboratories),	  overlaid	  with	  a	  stacking	  gel,	  left	  to	  set,	  and	  stored	  overnight	  4	  0C.	  The	  gel	  was	  loaded	  with	  10	  μg	  of	  sample	  proteins,	  immersed	  in	  running	  buffer	  and	  electrophoresis	  applied	  at	  a	  constant	  voltage	  of	  190	  V	  for	  1	  hour	  (Bio-­‐Rad	  PowerPack	  3000,	  Bio-­‐Rad	  Laboratories).	  To	  estimate	  protein	  size,	  side	  lanes	  were	  loaded	  with	  protein	  standards	  (Precision	  Plus	  All	  Blue	  Protein	  Standards,	  Bio-­‐Rad	  Laboratories).	  Protein	  was	  transferred	  to	  a	  polyvinyl	  difluoride	  (PVDF)	  membrane	  by	  electrophoresis	  at	  a	  constant	  current	  of	  300	  mA	  for	  2	  hours	  in	  transfer	  buffer.	  Non-­‐specific	  protein	  binding	  was	  blocked	  with	  3	  %	  weight/volume	  non-­‐fat	  milk	  in	  PBS	  with	  0.01	  %	  Tween	  20	  (Sigma-­‐Aldrich)	  then	  the	  membrane	  was	  probed	  overnight	  at	  4	  0C	  with	  rabbit	  anti-­‐mouse	  TRP-­‐2	  antibody	  (Santa	  Cruz	  Biotechnology,	  Dallas,	  TX)	  at	  1:600.	  	  The	  following	  day	  the	  membrane	  was	  washed	  in	  PBS	  with	  0.01	  %	  Tween20,	  blocked,	  and	  secondary	  labeling	  performed	  using	  goat	  anti-­‐rabbit	  antibody	  conjugated	  to	  peroxidase	  (Santa	  Cruz	  Biotechnology)	  at	  1:2000.	  Signal	  was	  detected	  with	  SuperSignal	  West	  Pico	  Chemiluminescent	  Substrate	  (Thermo	  Fisher	  Scientific).	  	  Detection	  of	  β-­‐actin	  loading	  control	  was	  performed	  the	  following	  day	  using	  mouse	  anti-­‐mouse	  β-­‐actin	  antibody	  (Sigma-­‐Aldrich)	  at	  1:200,000	  and	  goat	  anti-­‐mouse	  antibody	  conjugated	  to	  peroxidase	  (Santa	  Cruz	  Biotechnology).	  The	  fully	  developed	  membrane	  was	  imaged	  by	  autoradiography	  (X-­‐Omat,	  Kodak,	  Los	  Angeles,	  CA).	  Loading	  Buffer:	  1	  M	  Tris.HCl	  (pH	  6.8),	  20	  %	  glycerol,	  40	  mg/mL	  SDS,	  2	  %	  2-­‐mercaptoethanol,	  0.01	  mg/mL	  bromophenol	  blue.	  	  	  Resolving	  Gel:	  dH20,	  10	  %	  Acrylamide,	  10	  %	  SDS,	  10	  %	  APS,	  TEMED	  (5	  μL	  per	  10	  mL).	  Stacking	  Gel:	  dH20,	  5	  %	  Acrylamide,	  0.5	  M	  Tris.HCl	  (pH	  6.8),	  10	  %	  SDS,	  10	  %	  APS,	  TEMED	  (5	  μL	  per	  4	  mL).	  Running	  Buffer	  (1	  L):	  dH20,	  Tris	  base	  3	  g,	  Glycine	  14.4	  g,	  SDS	  1	  g,	  pH	  adjusted	  to	  8.3	  Transfer	  Buffer	  (1	  L):	  dH20,	  pure	  methanol	  100	  mL	  (20	  %	  v/v),	  Glycine	  14.4	  g,	  Tris	  base	  3.02	  g,	  pH	  adjusted	  to	  8.3	  	  
	  
2.23	   HISTOLOGY	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After	  cervical	  dislocation,	  mouse	  brains	  were	  removed	  whole,	  fixed	  overnight	  in	  10	  %	  formalin	  (Sigma-­‐Aldrich)	  and	  then	  cut	  into	  2	  mm	  coronal	  sections.	  Selected	  sections	  were	  sent	  in	  formalin	  to	  the	  Department	  of	  Pathology	  and	  Molecular	  Medicine,	  University	  of	  Otago,	  Wellington.	  Under	  the	  supervision	  of	  Dr	  Rose	  Miller	  or	  Dr	  Peter	  Ferguson,	  the	  tissue	  provided	  was	  embedded	  in	  paraffin,	  cut	  into	  4	  μm	  sections	  mounted	  on	  glass	  slides,	  and	  stained	  with	  Harris’	  haematoxylin	  and	  eosin	  stain.	  Slides	  were	  photographed	  at	  20X	  magnification.	  	  	  
	  
2.24	   STATISTICAL	  ANALYSES	  
Unless	  stated	  otherwise,	  bars	  and	  error	  bars	  depict	  means	  and	  standard	  error	  of	  the	  mean	  except	  in	  graphs	  of	  observational	  patient	  data	  where	  they	  depict	  medians	  and	  quartiles.	  Non-­‐parametric	  tests	  were	  used	  to	  assess	  statistical	  significance.	  For	  comparisons	  of	  one	  variable,	  the	  Mann	  Whitney	  test	  was	  used	  for	  unpaired	  data,	  the	  Wilcoxon	  matched	  pairs	  test	  for	  paired	  data,	  and	  the	  Kruskal	  Wallis	  one-­‐way	  analysis	  of	  variance	  (ANOVA)	  for	  experiments	  comparing	  more	  than	  two	  groups,	  with	  Dunn’s	  post-­‐test	  to	  determine	  statistical	  significance	  between	  two	  individual	  groups.	  For	  comparing	  group	  means	  over	  time	  in	  animal	  experiments,	  non-­‐parametric	  anaylsis	  was	  performed	  at	  each	  time	  point	  using	  a	  Mann	  Whitney	  test	  (for	  2	  groups)	  or	  Kruskal	  Wallis	  test	  with	  Dunn’s	  post-­‐test	  (for	  more	  than	  2	  groups).	  A	  log-­‐rank	  test	  was	  used	  to	  determine	  statistical	  significance	  between	  Kaplan-­‐Meier	  survival	  curves.	  In	  some	  experiments,	  comparisons	  of	  two	  variables	  was	  performed	  using	  a	  two	  way	  ANOVA	  test	  with	  Bonferroni’s	  post-­‐test.	  All	  statistical	  analyses	  were	  done	  with	  Prism	  5.0	  software	  (GraphPad	  Software,	  Inc.,	  La	  Jolla,	  CA),	  with	  P	  values	  of	  <	  0.05	  considered	  significant	  (*	  =	  p	  <	  0.05,	  **	  =	  p	  <	  	  0.01,	  ***	  =	  p	  <	  0.001).	  	  In	  studies	  comparing	  patient	  groups,	  all	  subjects	  with	  complete	  data	  for	  that	  particular	  study	  were	  included.	  Age	  matching	  was	  performed	  by	  alternately	  removing	  the	  oldest	  or	  youngest	  subject	  from	  each	  group	  until	  the	  difference	  between	  the	  mean	  ages	  of	  the	  two	  groups	  was	  no	  more	  than	  2.5	  years.	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CHAPTER	  THREE:	  ASSESSING	  VACCINE-­‐INDUCED	  IMMUNE	  
RESPONSES	  IN	  A	  CLINICAL	  TRIAL	  OF	  DENDRITIC	  CELL	  
VACCINATION	  COMBINED	  WITH	  TEMOZOLOMIDE	  FOR	  








3.1	   INTRODUCTION	  	  GBM	  is	  a	  highly	  malignant	  primary	  brain	  tumour	  that	  almost	  invariably	  recurs	  after	  standard	  therapy.	  TMZ	  is	  a	  firmly	  established	  component	  of	  standard	  treatment	  for	  newly-­‐presenting	  disease	  (Stupp	  et	  al.	  2005).	  The	  relative	  tolerability	  of	  TMZ	  makes	  it	  an	  attractive	  option	  for	  use	  in	  the	  recurrent	  setting	  as	  well	  (C.	  Chen	  et	  al.	  2013;	  Perry	  et	  al.	  2010).	  However,	  there	  are	  few	  reports	  of	  retreating	  GBM	  patients	  with	  TMZ	  using	  the	  same	  maximally	  tolerated	  dose	  (MTD)	  regimen	  that	  is	  currently	  used	  in	  the	  adjuvant	  phase	  of	  standard	  treatment	  (Franceschi	  et	  al.	  2005;	  A.	  Wick	  et	  al.	  2009).	  While	  retreatment	  with	  MTD	  TMZ	  is	  clearly	  capable	  of	  achieving	  objective	  responses,	  the	  overall	  results	  are	  modest,	  with	  a	  PFS6mo	  of	  28.6	  %	  in	  the	  largest	  series	  of	  15	  patients	  (A.	  Wick	  et	  al.	  2009).	  The	  disappointing	  results	  of	  salvage	  chemotherapies	  in	  general	  have	  driven	  interest	  in	  novel	  treatments	  for	  GBM	  such	  as	  immunotherapies.	  DC	  are	  potent	  antigen-­‐presenting	  cells	  and	  can	  be	  differentiated	  
in	  vitro	  from	  patients’	  own	  PBMC.	  Vaccination	  with	  autologous	  monocyte-­‐derived	  DC	  pulsed	  with	  unselected	  antigens	  derived	  from	  whole	  tumour	  cells	  has	  been	  the	  most	  widely	  tested	  active	  immunotherapy	  in	  GBM	  patients	  to	  date.	  Although	  well	  tolerated,	  the	  clinical	  benefit	  of	  DC-­‐based	  vaccination	  in	  the	  recurrent	  setting	  has	  generally	  been	  modest	  (reviewed	  in	  Vauleon	  et	  al.	  2010;	  X.	  Xu	  et	  al.	  2012).	  	  	  Interestingly,	  GBM	  patients	  who	  had	  previously	  participated	  in	  clinical	  trials	  of	  autologous	  tumour	  lysate-­‐pulsed	  DC-­‐based	  vaccines	  were	  observed	  anecdotally	  to	  respond	  unusually	  well	  to	  subsequent	  salvage	  chemotherapy	  (Wheeler	  et	  al.	  2004)	  and	  similar	  observations	  have	  been	  reported	  in	  other	  cancers	  (reviewed	  in	  Ramakrishnan	  et	  al.	  2008).	  To	  potentially	  explain	  this,	  there	  is	  evidence	  that	  cytokines	  released	  by	  T	  cells	  can	  enhance	  the	  tumouricidal	  activity	  of	  chemotherapeutic	  agents	  in	  vitro	  (Natsume	  et	  al.	  2005)	  and	  in	  vivo	  (Radfar	  et	  al.	  2009),	  including	  TMZ.	  	  Antigen-­‐specific	  mechanisms	  have	  also	  been	  proposed.	  Tyrosinase-­‐related	  protein-­‐2	  (TRP-­‐2)	  is	  a	  melanoma-­‐associated	  protein	  upregulated	  in	  many	  GBM	  tumours	  (Chi	  et	  al.	  1997;	  G.	  Liu	  et	  al.	  2003)	  that	  provides	  protection	  against	  apoptosis	  (Chu	  et	  al.	  2000;	  Nishioka	  et	  al.	  1999;	  Pak	  et	  al.	  2001).	  TRP-­‐2-­‐
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specific	  CTL	  responses	  have	  been	  detected	  in	  GBM	  patients	  vaccinated	  with	  autologous	  tumour	  lysate-­‐pulsed	  DC,	  an	  event	  associated	  with	  editing	  of	  TRP2hi	  tumour	  cells	  and	  a	  heightened	  sensitivity	  of	  resampled	  tumours	  to	  chemotherapy	  agents	  in	  vitro	  including	  TMZ	  (G.	  Liu	  et	  al.	  2005).	  Survivin	  (Chakravarti	  et	  al.	  2002;	  Ciesielski	  et	  al.	  2010;	  Preusser	  et	  al.	  2005)	  and	  the	  mutant	  epidermal	  growth	  factor	  receptor	  EGFRvIII	  (Choi	  et	  al.	  2009)	  are	  two	  other	  glioma-­‐associated	  antigens	  also	  implicated	  in	  mediating	  resistance	  of	  GBM	  to	  standard	  treatments.	  Thus,	  while	  relative	  overexpression	  of	  certain	  proteins	  confers	  chemoresistance,	  this	  may	  also	  render	  cells	  more	  susceptible	  to	  antigen-­‐specific	  immune	  attack.	  We	  hypothesised	  that	  immunotherapy	  could	  be	  used	  to	  overcome	  resistance	  to	  a	  given	  chemotherapeutic	  agent	  after	  failure	  of	  primary	  treatment.	  In	  GBM,	  one	  way	  of	  achieving	  this	  could	  be	  to	  manufacture	  DC	  vaccines	  pulsed	  with	  tumour	  tissue	  from	  recurrent	  lesions;	  this	  tissue	  would	  already	  have	  been	  exposed	  to	  TMZ,	  and	  therefore	  likely	  to	  be	  enriched	  in	  proteins	  mediating	  resistance	  to	  that	  agent,	  potentially	  skewing	  the	  vaccine-­‐induced	  response	  towards	  chemoresistant	  cells.	  Prior	  to	  assessing	  this	  possibility	  directly,	  we	  conducted	  a	  phase	  I	  study	  to	  determine	  whether	  manufacturing	  such	  DC	  vaccines	  is	  feasible	  in	  GBM	  patients	  recurring	  after	  standard	  treatment,	  and	  the	  overall	  safety	  of	  combining	  DC	  vaccination	  with	  TMZ	  retreatment.	  	  	  	  	  
3.2	   MATERIALS	  AND	  METHODS	  
	  3.2.1	   Patient	  population	  	  Participants	  in	  this	  trial	  had	  MRI	  scans	  consistent	  with	  relapsing	  tumour	  following	  previous	  treatment	  with	  radiotherapy	  and	  TMZ	  for	  histologically-­‐proven	  WHO	  grade	  4	  diffuse	  astrocytoma.	  	  There	  was	  a	  two-­‐stage	  enrolment	  process,	  with	  final	  confirmation	  of	  eligibility	  after	  histological	  confirmation	  of	  recurrent	  GBM.	  	  Other	  inclusion	  criteria	  were:	  age	  ≥18,	  ECOG	  performance	  status	  ≤2;	  prior	  completion	  of	  at	  least	  three	  cycles	  of	  adjuvant	  TMZ	  according	  to	  the	  Stupp	  protocol	  (Stupp	  et	  al.	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2005);	  at	  least	  1	  cm3	  of	  surgically-­‐accessible	  tumour	  tissue;	  and	  ability	  to	  give	  informed	  consent.	  	  Exclusion	  criteria	  were:	  pregnancy	  or	  breastfeeding;	  diagnosis	  of	  another	  malignancy	  within	  5	  years	  or	  presence	  of	  other	  serious	  unstable	  medical	  conditions;	  serology	  indicating	  active	  infection	  with	  hepatitis	  B	  or	  C,	  or	  HIV;	  uncontrolled	  or	  unstable	  auto-­‐immune	  disease;	  recent	  immunosuppressive	  therapy	  other	  than	  dexamethasone	  for	  management	  of	  GBM;	  previous	  treatment	  with	  a	  chemotherapeutic	  agent	  other	  than	  TMZ	  since	  first	  diagnosis	  with	  GBM;	  haemoglobin	  <	  100	  g/L;	  platelet	  count	  <	  100	  x	  109/L;	  neutrophil	  count	  	  <	  1.5x109/L;	  liver	  function	  tests	  or	  creatinine	  >	  2	  x	  upper	  limit	  normal;	  unfit	  for	  general	  anaesthesia;	  significant	  dysphasia	  or	  other	  neurological	  deficit	  precluding	  reliable	  communication.	  All	  participants	  gave	  written	  informed	  consent.	  The	  study	  was	  approved	  by	  the	  Central	  Regional	  Ethics	  Committee	  of	  New	  Zealand	  (CEN/07/12/086)	  and	  registered	  with	  the	  Australian	  and	  New	  Zealand	  Clinical	  Trials	  Registry	  (ACTRN12611000029998).	  	  
3.2.2	   Treatment	  plan	  Patients	  underwent	  leukapheresis	  to	  harvest	  PBMC	  followed	  a	  few	  days	  later	  by	  craniotomy	  for	  maximum	  safe	  tumour	  resection.	  Three	  weeks	  after	  surgery	  patients	  received	  a	  priming	  course	  of	  three	  rounds	  of	  DC-­‐based	  vaccination	  administered	  i.d.	  at	  2	  week	  intervals.	  The	  intended	  dose	  for	  priming	  vaccinations	  was	  4	  x	  106	  DC.	  	  One	  week	  after	  the	  third	  vaccine,	  patients	  began	  treatment	  with	  TMZ	  150-­‐200	  mg/m2	  orally	  for	  5	  consecutive	  days,	  every	  28	  days,	  for	  up	  to	  6	  cycles.	  Dose	  reductions	  and	  treatment	  delays	  of	  up	  to	  two	  weeks	  were	  allowed	  for	  recovery	  of	  haematological	  parameters.	  A	  booster	  vaccination	  of	  1	  x	  106	  DC	  was	  administered	  2	  weeks	  after	  each	  cycle	  of	  TMZ.	  	  Corticosteroid	  was	  reduced	  to	  the	  lowest	  possible	  dose	  tolerated	  by	  the	  patient.	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3.2.3	   Vaccine	  production	  	  Vaccine	  production	  was	  carried	  out	  in	  a	  dedicated	  Good	  Manufacturing	  Practice	  facility.	  Fresh	  tumour	  tissue	  was	  disaggregated	  to	  create	  a	  single	  cell	  suspension	  and	  γ-­‐irradiated	  to	  a	  dose	  of	  200	  Gy.	  PBMC	  were	  obtained	  by	  leukapheresis	  and	  the	  plastic-­‐adherent	  fraction	  cultured	  for	  5	  days	  in	  RPMI-­‐1640	  (Invitrogen,	  Life	  Technologies,	  Auckland,	  NZ)	  supplemented	  with	  1	  %	  autologous	  serum,	  1000	  U/ml	  rhGM-­‐CSF	  (Bayer	  Health	  Care,	  Lynnwood,	  WA)	  and	  1000	  U/ml	  rhIL-­‐4	  (CellGenix,	  Freiburg,	  Germany)	  to	  induce	  DC	  differentiation	  as	  previously	  described	  (O'Rourke	  et	  al.	  2003;	  Romani	  et	  al.	  1996).	  Non-­‐adherent	  cells	  were	  harvested	  and	  pulsed	  for	  two	  days	  with	  autologous	  irradiated	  tumour	  cells.	  DC	  were	  matured	  in	  monocyte-­‐conditioned	  medium	  obtained	  by	  culturing	  autologous	  monocytes	  on	  petri	  dishes	  pre-­‐coated	  with	  human	  immunoglobulin	  (O'Rourke	  et	  al.	  2003).	  The	  final	  product	  was	  cryopreserved	  until	  required	  in	  RPMI-­‐1640	  supplemented	  with	  10	  %	  DMSO	  (OriGen	  Biomedical,	  TX,	  USA)	  and	  20	  %	  autologous	  serum.	  Sterility	  was	  confirmed	  by	  negative	  cultures	  and	  endotoxin	  <	  0.5	  EU/ml	  in	  the	  final	  supernatant	  of	  DC	  culture.	  The	  phenotype	  of	  thawed	  cells	  was	  determined	  by	  flow	  cytometery,	  using	  FITC-­‐labeled	  and	  PE-­‐labeled	  monoclonal	  antibodies	  (Miltenyi	  Biotec,	  Bergisch	  Gladbach,	  Germany).	  Vaccine	  production	  and	  assessment	  of	  products	  was	  performed	  by	  trained	  GMP	  technicians	  (Evelyn	  Bauer,	  Brigitta	  Mester	  and	  Olivier	  Gasser).	  	  	  
3.2.4	   Monitoring	  	  Clinical	  examination	  and	  assessment	  of	  full	  blood	  count	  (FBC),	  serum	  biochemistry,	  and	  autoantibodies	  was	  undertaken	  before	  the	  first	  vaccination,	  one	  week	  after	  the	  third	  priming	  vaccination,	  and	  then	  every	  8	  weeks.	  MRI	  scans	  were	  performed	  at	  the	  same	  time	  points	  and	  within	  48	  hours	  of	  surgery.	  An	  additional	  FBC	  was	  performed	  prior	  to	  each	  cycle	  of	  TMZ.	  Adverse	  events	  (AE)	  were	  defined	  and	  graded	  according	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to	  the	  National	  Cancer	  Institute	  Common	  Terminology	  Criteria	  Version	  3	  (http://ctep.cancer.gov/).	  	  	  
3.2.5	   Endpoints	  Primary	  endpoints	  were:	  (1)	  feasibility	  of	  using	  resected	  tumour	  tissue	  from	  recurrent	  TMZ-­‐treated	  GBM	  patients	  to	  generate	  sufficient	  DC-­‐based	  vaccines	  to	  complete	  immunotherapy	  (measured	  as	  the	  percentage	  of	  patients	  providing	  3	  ‘priming’	  doses	  of	  vaccine	  and	  6	  ‘booster’	  doses);	  (2)	  feasibility	  of	  completing	  a	  minimum	  course	  of	  combined	  treatment	  (measured	  as	  the	  percentage	  of	  patients	  completing	  the	  second	  cycle	  of	  TMZ);	  and	  (3)	  safety	  (measured	  as	  the	  percentage	  of	  patients	  undergoing	  therapy	  without	  serious	  adverse	  events	  requiring	  withdrawal).	  Secondary	  endpoints	  were:	  (1)	  radiological	  response	  rate	  and	  PFS6mo	  relative	  to	  retreatment	  with	  TMZ	  alone	  in	  historical	  controls;	  (2)	  rate	  of	  vaccine-­‐induced	  immune	  responses;	  and	  (3)	  tolerability	  of	  treatment.	  	  
3.2.6	   Clinical	  assessment	  Tumour	  size	  was	  determined	  by	  an	  independent	  neuroradiologist	  and	  defined	  as	  the	  largest	  product	  of	  two	  perpendicular	  diameters	  on	  axial	  or	  coronal	  gadolinium-­‐enhanced	  T1-­‐weighted	  views	  (Shah	  et	  al.	  2006).	  Classification	  of	  responses	  was	  based	  on	  the	  WHO	  UICC	  system	  (Miller	  et	  al.	  1981)	  i.e.	  complete	  response	  (CR),	  complete	  disappearance	  of	  all	  lesions	  for	  ≥	  4	  weeks;	  partial	  response	  (PR),	  reduction	  in	  tumour	  size	  ≥	  50	  %	  for	  ≥	  4	  weeks;	  progressive	  disease	  (PD),	  increase	  in	  tumour	  size	  ≥	  25	  %	  or	  appearance	  of	  new	  lesions;	  stable	  disease	  (SD),	  not	  PD,	  PR	  or	  CR	  in	  comparison	  with	  the	  preceding	  scan.	  	  For	  CR	  and	  PR,	  scans	  were	  compared	  with	  maximum	  tumour	  size	  at	  any	  point.	  For	  PD,	  scans	  were	  compared	  with	  the	  post-­‐operative	  scan.	  If	  patients	  experienced	  a	  CR,	  PR	  or	  SD,	  subsequent	  disease	  progression	  was	  determined	  by	  comparison	  with	  minimum	  tumour	  size	  reached	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during	  the	  period	  of	  CR/PR/SD.	  New	  enhancement	  at	  the	  pre-­‐vaccination	  time	  point	  (3	  weeks	  following	  surgery)	  was	  interpreted	  as	  reactive	  change.	  Otherwise,	  new	  enhancement	  was	  considered	  to	  represent	  tumour	  growth.	  Some	  patients	  progressed	  during	  the	  priming	  vaccination	  phase	  but	  subsequently	  stabilised	  or	  responded	  after	  commencing	  TMZ.	  	  Since	  the	  aim	  of	  the	  trial	  was	  to	  assess	  the	  combined	  effect	  of	  both	  treatments,	  time	  to	  progression	  in	  these	  patients	  was	  defined	  as	  the	  day	  on	  which	  progression	  next	  occurred.	  Treatment	  was	  discontinued	  at	  time	  of	  progression.	  Tolerability	  was	  assessed	  with	  a	  validated	  quality	  of	  life	  assessment	  questionnaire	  (EORTC	  QLQ-­‐C30	  version	  3,	  Aaronson	  et	  al.	  1993).	  	  	  
3.2.7	   Immunological	  assessment	  Vaccine	  induced	  immune	  responses	  were	  assessed	  by	  DTH	  responses	  and	  by	  an	  IFN-­‐γ	  Enzyme-­‐Linked	  ImmunoSpot	  (ELISpot)	  assay.	  For	  DTH	  tests,	  3	  x	  105	  DC	  loaded	  with	  irradiated	  tumour	  tissue	  (i.e.	  an	  aliquot	  of	  the	  DC	  vaccine)	  were	  injected	  i.d.	  5	  days	  after	  the	  initial	  priming	  course	  of	  three	  vaccinations,	  just	  before	  the	  administration	  of	  the	  first	  cycle	  of	  TMZ.	  Unloaded	  DC	  were	  also	  injected	  as	  a	  negative	  control.	  Tests	  were	  read	  24	  and	  48	  h	  later.	  A	  positive	  test	  was	  defined	  as	  a	  diameter	  of	  induration	  or	  erythema	  >	  5mm.	  	   	  	  For	  IFN-­‐γ	  ELISpot	  tests,	  whole	  blood	  samples	  were	  collected	  at	  enrolment,	  after	  the	  first	  and	  third	  vaccinations,	  and	  then	  every	  four	  weeks.	  PBMC	  were	  isolated	  by	  density	  gradient	  centrifugation	  using	  Lymphoprep	  (Axis-­‐Shield,	  Oslo,	  Norway),	  and	  cryopreserved	  in	  RPMI	  1640,	  supplemented	  with	  20	  %	  foetal	  calf	  serum	  (Sigma-­‐Aldrich,	  St	  Louis,	  MO)	  and	  10	  %	  DMSO	  until	  required.	  All	  time	  points	  from	  an	  individual	  patient	  were	  tested	  on	  the	  same	  day.	  The	  PBMC	  were	  thawed	  and	  rested	  overnight	  at	  37	  0C	  in	  RPMI	  1640	  supplemented	  with	  5	  %	  foetal	  calf	  serum,	  100	  U/ml	  penicillin	  and	  100	  µg/ml	  streptomycin	  (both	  Invitrogen),	  and	  then	  counted	  manually	  using	  Trypan	  Blue	  (Invitrogen)	  exclusion.	  Stimulation	  was	  with	  one	  of	  the	  following:	  autologous	  tumour	  cell-­‐pulsed	  DC;	  autologous	  tumour	  lysate;	  or	  pools	  of	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15-­‐mer	  long	  peptides	  covering	  the	  full	  length	  of	  TRP-­‐2,	  gp100,	  survivin,	  tyrosinase,	  and	  SOX2	  proteins	  (peptides&elephants	  GmbH,	  Potsdam,	  Germany).	  Earlier	  studies	  had	  found	  that	  each	  of	  these	  antigens	  was	  expressed	  in	  at	  least	  one	  of	  a	  panel	  of	  five	  primary	  GBM	  cell	  lines	  (data	  not	  shown).	  	  Tests	  were	  conducted	  using	  either	  pre-­‐coated	  IFN-­‐γ	  ELISpot	  96	  well	  plates	  (Mabtech,	  Nacka	  Strand,	  Sweden)	  or	  PVDF	  96	  well	  plates	  (Merk	  Ltd.,	  Palmerston	  North,	  New	  Zealand)	  coated	  with	  anti-­‐human	  IFN-­‐γ	  (Mabtech)	  according	  to	  the	  manufacturer’s	  instructions.	  Blocking	  was	  performed	  with	  RPMI	  supplemented	  with	  10	  %	  foetal	  calf	  serum,	  and	  wells	  were	  seeded	  with	  0.5	  -­‐	  2	  x	  105	  viable	  PBMC.	  For	  stimulation	  with	  tumour	  cell-­‐pulsed	  DC,	  aliquots	  of	  vaccine	  were	  thawed,	  rested	  for	  2	  hours,	  and	  added	  to	  wells	  at	  different	  responder	  cell	  to	  stimulator	  cell	  ratios.	  Unloaded	  DCs	  were	  used	  as	  controls	  for	  non-­‐specific	  IFN-­‐γ	  release.	  For	  tumour	  lysate-­‐stimulated	  wells,	  irradiated	  single	  cell	  tumour	  suspensions	  were	  washed	  in	  PBS	  and	  subjected	  to	  six	  freeze-­‐thaw	  cycles.	  Lysates	  equivalent	  to	  1.5	  x	  105	  tumour	  cells	  were	  added	  to	  each	  well.	  Pooled	  peptides	  were	  added	  at	  a	  concentration	  of	  15	  mg/mL.	  For	  tests	  using	  tumour	  lysate	  or	  peptides,	  background	  activity	  was	  assessed	  on	  wells	  with	  PBMC	  alone.	  Positive	  controls	  were	  wells	  of	  PBMC	  supplemented	  with	  1	  μg/mL	  agonistic	  anti-­‐CD3	  mAb,	  or	  a	  pool	  of	  MHC	  class	  I-­‐restricted	  viral	  peptides	  known	  to	  elicit	  recall	  responses	  in	  90	  %	  of	  normal	  adults	  (Currier	  et	  al.	  2002).	  In	  this	  study	  seven	  of	  nine	  tested	  patients	  (78	  %)	  responded	  to	  the	  viral	  peptides,	  in	  line	  with	  expectations.	  Plates	  were	  incubated	  at	  37	  0C	  for	  48	  hours	  and	  developed	  according	  to	  the	  manufacturer’s	  instructions.	  Spots	  were	  counted	  using	  an	  automated	  ELISpot	  plate	  reader	  (Autoimmun	  Diagnostika,	  Strassberg,	  Germany)	  subject	  to	  visual	  audit,	  and	  spot	  counts	  were	  calculated	  by	  subtracting	  the	  mean	  of	  background	  wells	  from	  the	  mean	  of	  test	  wells.	  A	  positive	  response	  to	  in	  vitro	  stimulation	  was	  defined	  as	  a	  mean	  spot	  count	  greater	  than	  the	  mean	  +	  2	  standard	  deviations	  (SD)	  of	  background	  control	  wells,	  with	  this	  count	  also	  having	  to	  be	  greater	  than	  50	  tumour-­‐specific	  spots	  per	  106	  PBMC	  (Slota	  et	  al.	  2011).	  An	  alteration	  in	  a	  specific	  immune	  response	  over	  the	  course	  of	  therapy	  was	  defined	  as	  a	  greater	  than	  two-­‐fold	  difference	  from	  baseline	  (after	  subtraction	  of	  background	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activity)	  for	  any	  antigen,	  which	  was	  sustained	  over	  two	  or	  more	  consecutive	  time	  points.	  Background	  activity	  was	  generally	  low	  in	  wells	  containing	  PBMC	  only	  (median	  4	  spot	  forming	  units/106	  PBMC)	  and	  somewhat	  higher	  in	  wells	  containing	  PBMC	  +	  unloaded	  DC	  (median	  40).	  Unusually	  high	  background	  activity	  was	  observed	  in	  two	  assays,	  neither	  of	  which	  met	  the	  criteria	  for	  the	  presence	  of	  a	  tumour-­‐specific	  response.	  ELISpot	  assays	  using	  antigen-­‐loaded	  DC	  or	  tumour	  lysate	  for	  stimulation	  were	  performed	  by	  the	  author.	  ELISpot	  assays	  using	  peptides	  for	  stimulation	  were	  performed	  by	  Olivier	  Gasser.	  	  Immune	  cell	  populations	  in	  the	  PBMC	  of	  trial	  participants	  were	  enumerated	  before	  and	  after	  vaccination	  using	  flow	  cytometry.	  PBMCs	  were	  labelled	  with	  the	  following	  anti-­‐human	  antibodies:	  CD56-­‐BV605	  (HCD56),	  CD33-­‐APC	  (WM53),	  NKG2D-­‐PeCy7	  (1D11),	  CD11b-­‐PE	  (ICRF44),	  HLA-­‐DR-­‐PerCP	  (L243),	  CD45RA-­‐FITC	  (HI100),	  CD3-­‐Alexa	  Fluor	  700	  (UCHT1),	  CD4-­‐BV510	  (OKT4),	  CD8α-­‐PerCP/Cy5.5	  (HIT8a),	  CCR7-­‐BV605	  (G043H7)	  and	  CD19-­‐BV510	  (HIB19)	  (all	  BioLegend,	  San	  Diego,	  CA).	  FoxP3	  staining	  was	  performed	  using	  an	  anti-­‐human	  FoxP3-­‐PE	  Flow	  Kit	  (BioLegend)	  according	  to	  the	  manufacturer’s	  instructions.	  Live	  cells	  were	  discriminated	  using	  a	  LIVE/DEAD	  Fixable	  Blue	  Dead	  Cell	  Stain	  Kit	  (Molecular	  Probes,	  Eugene,	  OR).	  Data	  were	  acquired	  on	  an	  LSRII	  flow	  cytometer	  (BD	  Biosciences,	  Franklin	  Lakes,	  NJ).	  The	  author	  was	  responsible	  for	  experiment	  design	  and	  data	  analysis.	  Staining	  and	  flow	  cytometry	  was	  performed	  by	  Brigitta	  Mester.	  	  	  
3.2.8	   Analysis	  of	  MGMT	  expression	  Total	  RNA	  was	  isolated	  from	  single	  cell	  suspensions	  of	  resected	  GBM	  tumours	  using	  a	  NucleoSpin	  RNA	  kit	  (Macherey-­‐Nagel,	  Düeren,	  Germany),	  and	  cDNA	  was	  synthesized	  with	  iScript	  (Bio-­‐Rad,	  Hercules,	  CA)	  according	  to	  the	  manufacturer’s	  instructions.	  	  Real-­‐time	  PCR	  was	  performed	  with	  using	  MGMT	  and	  18s	  rRNA	  primers	  (QuantiTect	  primer	  assay,	  Qiagen,	  Hilden,	  Germany),	  and	  SensiMix	  SYBR	  Low-­‐ROX	  kit	  (Bioline,	  London,	  UK)	  on	  the	  ABI	  7500	  platform	  (Applied	  Biosystems,	  Foster	  City,	  
 128 
CA).	  The	  exponential	  phase	  of	  the	  amplification	  curves	  were	  used	  to	  calculate	  cycle	  threshold	  and	  each	  Ct	  was	  normalized	  to	  18s	  rRNA	  (∆Ct).	  	  Efficiency	  of	  amplification	  of	  each	  QuantiTect	  primer	  assay	  is	  equivalent,	  so	  the	  ∆∆Ct	  method	  was	  used	  to	  determine	  fold	  change	  from	  control.	  The	  median	  MGMT	  mRNA	  expression	  of	  29	  tumour	  samples	  was	  used	  as	  the	  threshold	  value	  to	  define	  high	  and	  low	  MGMT	  mRNA	  expression.	  This	  analysis	  was	  performed	  by	  Lindsay	  Ancelet.	  	  	  
3.2.9	   Statistics	  Feasibility	  and	  clinical	  outcomes	  are	  presented	  as	  descriptive	  data	  with	  95	  %	  confidence	  intervals.	  	  	  
3.3	  	   RESULTS	  
3.3.1	   Feasibility	  and	  safety	  	  Fourteen	  patients	  were	  provisionally	  enrolled	  over	  36	  months	  from	  February	  2009.	  The	  entry	  requirement	  for	  prior	  completion	  of	  at	  least	  three	  cycles	  of	  adjuvant	  TMZ	  was	  intended	  to	  avoid	  enrolling	  patients	  with	  pseudo-­‐progression	  (Bartholomae	  et	  al.	  2004;	  Chamberlain	  et	  al.	  2007).	  One	  patient	  (A11)	  who	  had	  just	  completed	  the	  6th	  cycle	  of	  adjuvant	  TMZ	  was	  found	  to	  have	  a	  ring-­‐enhancing	  lesion	  on	  MRI	  typical	  of	  recurrence	  but	  histology	  revealed	  necrosis	  and	  a	  cellular	  infiltrate	  dominated	  by	  macrophages.	  This	  patient	  was	  withdrawn	  from	  the	  trial	  and	  is	  not	  included	  in	  the	  remainder	  of	  the	  analysis.	  The	  remaining	  13	  patients	  were	  confirmed	  histologically	  to	  have	  recurrent	  GBM.	  Demographic	  data	  and	  details	  of	  previous	  treatment	  are	  summarised	  in	  Table	  3.1.	  	  Although	  validation	  exercises	  in	  healthy	  volunteers	  suggested	  that	  a	  single	  leukapheresis	  procedure	  should	  suffice,	  DC	  yields	  were	  highly	  variable	  and	  often	  not	  	  





























































































































































































































































































































































































































































































sufficient	  for	  the	  intended	  regimen.	  This	  was	  addressed	  either	  by	  reducing	  the	  dose	  of	  the	  priming	  vaccinations	  and/or	  by	  harvesting	  additional	  PBMC	  by	  peripheral	  venesection.	  The	  second	  PBMC	  harvest	  was	  performed	  before	  the	  first	  dose	  of	  TMZ	  and	  was	  only	  undertaken	  when	  a	  single	  venesection	  was	  realistically	  expected	  to	  make	  up	  the	  full	  complement	  of	  vaccines.	  Detail	  on	  vaccine	  yield	  is	  shown	  in	  Table	  3.2.	  	  In	  three	  cases	  (A03,	  A04,	  A07)	  insufficient	  vaccine	  was	  produced	  after	  the	  first	  PBMC	  harvest	  to	  warrant	  venesection	  and	  these	  patients	  were	  withdrawn.	  In	  two	  cases	  (A03,	  A04),	  age	  and	  corticosteroid	  exposure	  may	  have	  been	  factors.	  Although	  every	  effort	  was	  made	  to	  reduce	  dexamethasone	  prior	  to	  leukapheresis,	  it	  proved	  difficult	  to	  wean	  the	  drug	  off	  completely	  and	  these	  two	  patients	  were	  both	  still	  taking	  8	  mg	  per	  day.	  In	  the	  third	  case	  (A07),	  very	  recent	  exposure	  to	  TMZ	  was	  a	  possible	  factor.	  	  In	  the	  remaining	  10	  patients	  there	  was	  sufficient	  vaccine	  to	  proceed	  with	  vaccination,	  albeit	  at	  a	  reduced	  dose	  in	  two.	  Three	  of	  these	  required	  an	  additional	  venesection	  to	  allow	  the	  full	  course	  of	  six	  booster	  vaccines	  to	  be	  made.	  In	  four	  cases	  it	  was	  necessary	  to	  deviate	  from	  protocol	  and	  perform	  urgent	  surgical	  debulking	  before	  leukapheresis.	  This	  did	  not	  appear	  to	  disadvantage	  vaccine	  production	  (Table	  3.2).	  In	  summary,	  accepting	  that	  two	  patients	  received	  priming	  vaccines	  at	  lower	  doses	  than	  intended,	  the	  proportion	  of	  patients	  in	  whom	  vaccine	  was	  successfully	  produced	  was	  77	  %	  (95	  %	  CI:	  46	  –	  95	  %).	  The	  majority	  of	  cells	  in	  the	  final	  vaccine	  expressed	  the	  dendritic	  cell	  marker	  CD209	  (median	  89.2	  %,	  IQR	  10.3)	  and	  were	  typically	  CD86+	  CD83+	  with	  little	  to	  no	  expression	  of	  CD14.	  Median	  viability	  of	  the	  thawed	  vaccine	  assessed	  by	  Trypan	  Blue	  staining	  in	  a	  post-­‐hoc	  analysis	  was	  82.5	  %	  (IQR	  26.6).	  	  In	  one	  case	  (A10),	  the	  tumour	  progressed	  rapidly	  after	  enrolment,	  with	  invasion	  into	  the	  basal	  ganglia	  detected	  on	  MRI	  on	  the	  day	  of	  surgery.	  Only	  50	  %	  of	  the	  tumour	  mass	  could	  be	  safely	  removed.	  The	  patient’s	  clinical	  state	  continued	  to	  rapidly	  deteriorate	  after	  surgery	  and	  treatment	  was	  discontinued	  after	  the	  first	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Table 3.3: Adverse Events 
Adverse Event Grade n 
Bilateral cataracts secondary to corticosteroid III 1 
Syncopal event III 1 
Thrombocytopenia requiring dose delay II 1 
Thrombocytopenia requiring dose delay I 1 
Thrombocytopenia requiring dose reduction I 1 
Worsening of existing deficit after surgery II 1 
Seizure II 3 
Headache II 1 
Headache I 1 
Vomiting  II 1 
Nausea I 1 




3.3.2	   Clinical	  outcome	  A	  summary	  of	  treatment	  and	  clinical	  outcome	  is	  presented	  in	  Table	  3.4.	  Two	  patients	  had	  a	  PR	  (A08,	  A12)	  yielding	  an	  objective	  response	  rate	  in	  the	  nine	  treated	  patients	  of	  22	  %	  (95	  %	  CI:	  0	  -­‐	  49	  %).	  In	  both	  cases	  the	  radiological	  response	  occurred	  after	  starting	  retreatment	  with	  TMZ.	  One	  patient	  (A01)	  had	  a	  long	  period	  of	  SD	  lasting	  31.5	  months.	  Four	  additional	  patients	  (44	  %)	  experienced	  brief	  periods	  of	  SD	  lasting	  2-­‐3	  months.	  	  After	  priming	  vaccinations	  but	  before	  TMZ,	  four	  patients	  had	  SD	  and	  five	  had	  progressed.	  The	  PFS6mo	  for	  all	  enrolled	  patients	  with	  GBM	  was	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Fig 3.1 Responses of treated patients to questions 29 and 30 of the EORTC 
QLQ-C30 version 3 self-assessment questionnaire. Patients rated their 
general health (A) and overall quality of life (B) on a scale of 1-7. Shown are 
individual patients over time (solid lines) and group means (dotted line). 
A
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15	  %	  and	  for	  the	  nine	  treated	  patients	  was	  22	  %	  (95	  %	  CI:	  0	  –	  49	  %).	  Prolonged	  progression-­‐free	  survival	  was	  observed	  in	  two	  patients,	  A01	  and	  A08,	  one	  of	  who	  also	  experienced	  a	  radiological	  response	  (Table	  3.4;	  Figs	  3.2	  and	  3.3).	  Median	  survival	  from	  the	  original	  diagnosis	  of	  GBM	  for	  the	  treated	  patients	  was	  23	  months.	  	  	  
	  
Enrolment Immediate post-operation
Pre-vaccination baseline (3 weeks) 13 months
Figure 3.2. Magnetic resonance imaging of Trial Participant A01. Gadolinium-
enhanced T1-weighted axial MRI head scan at enrolment, immediately after surgery, at 
pre-vaccination baseline, and at the indicated times after enrolment. After complete resec-
tion of enhancing tissue, a region of new enhancement was seen 3 weeks later on the 
pre-vaccination baseline scan (arrow) that resolved over time leaving an area of gliosis. 
The possibility that this enhancement was due to reactive change could not be excluded 
and the patient was categorised as having stable disease.  
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3.3.3	   Immunological	  assessments	  	  DTH	  tests	  were	  negative	  in	  all	  the	  treated	  patients.	  The	  IFN-­‐γ	  ELISpot	  results	  are	  presented	  in	  Table	  3.5.	  All	  patients	  were	  tested	  for	  responses	  to	  tumour-­‐loaded	  DC	  and	  to	  the	  panel	  of	  peptides	  from	  glioma-­‐associated	  antigens.	  Insufficient	  material	  meant	  that	  not	  all	  patients	  could	  be	  tested	  for	  responses	  to	  autologous	  tumour	  lysate.	  Baseline	  immune	  responses	  to	  antigens	  in	  tumour	  material	  were	  observed	  prior	  to	  vaccination	  in	  2	  patients	  [A01,	  A08].	  The	  magnitude	  of	  these	  responses	  was	  higher	  at	  some	  subsequent	  time	  points	  but	  fell	  short	  of	  reaching	  the	  strict	  criteria	  for	  a	  treatment-­‐induced	  response	  (Table	  3.5;	  Figs	  3.4	  and	  3.5).	  Limited	  material	  restricted	  the	  number	  of	  time	  points	  that	  could	  be	  assessed	  in	  this	  way.	  One	  of	  these	  patients	  [A01]	  developed	  de	  novo	  responses	  to	  the	  selected	  tumour-­‐associated	  antigens,	  with	  responses	  to	  TRP-­‐2,	  survivin	  and	  SOX-­‐2	  being	  sustained	  over	  at	  least	  two	  consecutive	  time	  points.	  
Enrolment Pre-vaccination baseline (3 weeks) 5 months
Figure 3.3. Magnetic resonance imaging of Trial Participant A08. Gadolinium-enhanced 
T1-weighted coronal MRI head scan at enrolment, pre-vaccination baseline, and 5 months 
after enrolment, showing partial response after combined treatment. Arrows indicate mea-
sureable disease at pre-vaccination baseline.
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Figure 3.4. ELISpot results for trial patient A01. PBMC were stimulated with unloaded 
DC (in triplicate) or with DC pulsed with autologous tumour cells (single wells per time 
point due to limited patient material). 2 x 105 PBMC and 6 x 103 DC per well. Positive 
control wells were stimulated with a viral peptide pool (CEF) or with an agonistic anti-
CD3 antibody. The response to loaded DC at baseline is > mean of the unloaded DC con-
trol wells + 2 SD. Although the spot count (after subtraction of background) is higher at 
the 5 month time point, this did not meet the criteria for a treatment-induced response.
Figure 3.5. ELISpot results for trial patient A08. 2 x 105 PBMC were stimulated in 
duplicate with crude tumour lysate at a ratio of 4 PBMC:3 tumour cells (equivalent). Posi-
tive control wells as for Fig 3.4. The response to tumour lysate at baseline is > mean of the   
PBMC only control wells + 2 SD. Although the spot count (after subtraction of back-
ground) is higher at subsequent time points, this did not meet the criteria for a treatment-
induced response.
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Patients	  A01	  and	  A08	  both	  experienced	  long	  periods	  of	  disease	  stability,	  despite	  the	  fact	  that	  both	  patients	  expressed	  high	  levels	  of	  MGMT	  mRNA	  in	  tumour	  tissue	  (Fig	  3.6).	  One	  additional	  patient,	  A09,	  developed	  a	  response	  to	  survivin	  over	  the	  course	  of	  therapy	  but	  exhibited	  only	  transient	  SD	  over	  the	  priming	  phase	  of	  immunotherapy.	  Thus	  2	  of	  9	  patients	  (22	  %)	  met	  the	  strict	  criteria	  for	  a	  treatment-­‐induced	  immune	  response	  (Table	  3.5;	  Fig	  3.7).	  	  
	  
Fig.3.6. Relative expression of MGMT mRNA in recurrent tumours at time of enrolment. 
The median MGMT mRNA expression of 29 tumour samples, indicated by line, was used as the 






effects.	  Interestingly,	  the	  two	  patients	  with	  the	  most	  favourable	  clinical	  course	  (defined	  arbitrarily	  as	  PFS	  >	  6	  months)	  had	  a	  comparatively	  high	  proportion	  of	  CD8+	  T	  cells	  with	  effector	  phenotype	  at	  baseline	  that	  persisted	  at	  subsequent	  time	  points	  (Fig	  3.9),	  a	  finding	  consistent	  with	  the	  ELISpot	  results	  in	  these	  two	  patients.	  One	  of	  these	  (A08)	  also	  had	  an	  unusually	  high	  proportion	  of	  CD4+	  effector	  cells	  at	  baseline	  (14.2	  %	  of	  total	  CD4+	  T	  cells;	  mean	  of	  other	  treated	  patients	  2.2	  %,	  range	  0.2	  –	  4.3	  %).	  No	  consistent	  trends	  were	  observed	  for	  the	  number	  of	  total	  CD4	  cells,	  total	  CD8	  cells,	  B	  cells	  or	  NK	  cells,	  or	  for	  selected	  NK	  cell	  activation	  markers	  (Fig	  3.9;	  Appendix	  A,	  Fig	  A1;	  and	  data	  not	  shown).  
 
	  
Fig.3.7. Combined clinical and immunological data. (A) Radiological response, as determined 
by experienced independent neuroradiologist, and time to progression. (B) Immune response 
determined by IFN-γ ELISpot, where "pre" is positive ELISpot at baseline, "post” is retention of 
pre-existing response at at least one time point after treatment, and "induced" meets criteria for 
treatment-induced response (greater than two-fold difference from baseline for any antigen that 






Figure 3.8.  Analysis of proportion of Treg and putative MDSC in PBMC of trial 
participants at the baseline pre-vaccination time point. A, Flow cytometric gating strategy for 
enumerating regulatory T cells. Left: Representative plot of live CD3+ lymphocytes from a trial 
participant. For each participant the gate for FoxP3+ cells was set using the patients’ own CD4- 
population as negative control. Right: The gating strategy was validated by staining PBMC from 
a healthy volunteer with the same panel minus FoxP3. B, Flow cytometric gating strategy for a 
subset of CD11b+ CD33+/int HLA-DR- putative MDSC Representative plots from one trial 
participant. Plot on left was gated first on live PBMC. For each participant the gate for HLA-DR- 
cells was set using the patient’s own HLA-DR- PBMC as negative control. C, Treg and putative 
MDSC populations in the PBMC of trial participants at the baseline pre-vaccination time-point. 
Regulatory T cells defined as FoxP3+ CD4+ CD3+ lymphocytes are plotted according to the left 
hand Y-axis. CD11b+ CD33+/int HLA-DR- putative MDSC are plotted according to the right hand 
Y-axis. Open symbols show the two patients that met the criteria for a vaccine-induced response. 
Small subgroup size precluded statistical analysis.  







































































Figure 3.9.  Analysis of CD4+ and CD8+ T cell phenotype in PBMC of trial participants. A. 
Gating strategy for enumerating T cell subsets in PBMC of trial participants. Shown are 
representative plots of CD4+ (left) and CD8+ (right) live CD3+ lymphocytes. Naïve, effector, 
effector memory and central memory cells were defined as CCR7+CD45RA+, CCR7-CD45RA+, 
CCR7-CD45RA- and CCR7+CD45RA- respectively. B. Left: Proportion of CD8+ T cells with 
CCR7-CD45RA+ effector phenotype. The two “best clinical responders” (defined as progression 
free survival > 6 months) are compared with the other 7 vaccinated participants. Bars show mean 
and range. The small subgroup size precluded statistical analysis. Right: Proportion of live CD3+ 
lymphocytes that were CD8+ in the same subgroups as A. Bars show means and range.   
	  
 
3.4	   DISCUSSION	  This	  phase	  I	  trial	  has	  shown	  that	  retreating	  previously	  TMZ-­‐exposed	  GBM	  patients	  with	  a	  combination	  of	  surgery,	  a	  DC-­‐based	  vaccine	  and	  TMZ	  is	  safe	  and	  well-­‐
















Best clinical responders Non/Poor clinical responders







+ Effector T cells 



















CD8+ T cells 





















tolerated.	  Previous	  studies	  have	  demonstrated	  the	  safety	  and	  feasibility	  of	  DC-­‐based	  immunotherapies	  for	  recurrent	  GBM	  (reviewed	  in	  X.	  Xu	  et	  al.	  2012)	  but	  this	  is	  the	  first	  study	  to	  explore	  the	  feasibility	  of	  manufacturing	  autologous	  monocyte-­‐derived	  DC-­‐based	  vaccines	  in	  GBM	  patients	  in	  which	  previous	  exposure	  to	  TMZ	  was	  an	  entry	  criterion.	  Many	  of	  the	  trial	  participants	  underwent	  monocyte	  harvest	  within	  a	  few	  weeks	  of	  TMZ	  exposure	  (Table	  3.1).	  Feasibility	  of	  this	  treatment	  regimen	  proved	  to	  be	  marginal.	  In	  three	  cases	  we	  were	  unable	  to	  produce	  sufficient	  vaccine	  to	  proceed	  with	  treatment.	  The	  reasons	  for	  this	  are	  not	  clear	  but	  recent	  exposure	  to	  TMZ	  may	  have	  been	  an	  important	  factor.	  It	  has	  been	  shown	  that	  human	  monocytes,	  but	  not	  DC,	  are	  highly	  sensitive	  to	  TMZ-­‐induced	  apoptosis	  in	  vitro	  (M.	  Bauer	  et	  al.	  2012).	  Other	  possible	  factors	  include	  older	  age	  and	  treatment	  with	  dexamethasone	  at	  doses	  greater	  than	  4	  mg/day.	  Glucocorticoids	  have	  been	  shown	  to	  induce	  apoptosis	  in	  monocytes	  in	  vitro	  in	  a	  time	  and	  dose-­‐dependent	  manner	  (M.	  Schmidt	  et	  al.	  1999).	  	  A	  unique	  feature	  of	  this	  trial	  protocol	  was	  that	  leukapheresis	  was	  performed	  prior	  to	  surgical	  debulking.	  The	  reason	  for	  this	  was	  to	  minimize	  delay	  in	  starting	  treatment	  after	  surgery	  so	  that	  participants	  could	  be	  exposed	  to	  both	  components	  of	  the	  combined	  regimen	  when	  tumor	  burden	  was	  still	  minimal.	  In	  practice,	  nearly	  half	  the	  treated	  patients	  underwent	  surgery	  before	  leukapheresis	  because	  of	  clinical	  necessity.	  We	  saw	  no	  statistically	  significant	  differences	  in	  DC	  yield	  or	  phenotype	  between	  these	  two	  groups	  (data	  not	  shown).	  Nevertheless,	  we	  cannot	  rule	  out	  the	  possibility	  that	  harvesting	  monocytes	  prior	  to	  debulking	  might	  have	  compromised	  optimum	  yield	  or	  function	  of	  the	  final	  product	  (Ogden	  et	  al.	  2006).	  	  Objective	  responses	  were	  observed	  in	  22	  %	  of	  treated	  patients	  with	  a	  period	  of	  SD	  in	  another	  56	  %.	  PFS6mo	  was	  22	  %.	  These	  results	  are	  similar	  to	  those	  of	  Wick	  and	  colleagues	  (A.	  Wick	  et	  al.	  2009)	  who	  reported	  objective	  responses	  in	  17.2	  %	  of	  patients,	  SD	  in	  51.7	  %	  and	  28.6	  %	  PFS6mo	  in	  15	  GBM	  patients	  retreated	  with	  an	  MTD	  regimen	  of	  TMZ.	  Patients	  with	  high	  grade	  glioma	  can	  be	  prognostically	  stratified	  at	  first	  presentation	  using	  recursive	  partitioning	  analysis	  (RPA)	  (W.	  J.	  Curran	  et	  al.	  1993)	  which	  was	  recently	  updated	  to	  reflect	  contemporary	  practice	  (Paravati	  et	  al.	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2011).	  According	  to	  this	  revised	  system,	  all	  patients	  in	  our	  study	  were	  retrospectively	  assigned	  to	  RPA	  class	  III	  at	  first	  presentation,	  a	  group	  with	  a	  median	  survival	  of	  21.3	  months	  in	  that	  study.	  Median	  overall	  survival	  for	  treated	  patients	  in	  our	  study	  was	  23	  months.	  Thus,	  although	  this	  trial	  was	  not	  designed	  to	  assess	  efficacy	  as	  a	  primary	  endpoint,	  the	  combination	  of	  TMZ	  and	  DCV	  does	  not	  appear	  to	  be	  more	  promising	  than	  retreatment	  with	  TMZ	  alone.	  	  Despite	  this	  disappointing	  result	  for	  the	  group	  as	  a	  whole,	  we	  did	  find	  a	  broad	  correlation	  between	  clinical	  outcome	  and	  anti-­‐tumour	  immunity.	  Sustained	  progression-­‐free	  survival	  in	  two	  patients	  was	  associated	  with	  a	  baseline	  response	  and	  a	  treatment-­‐induced	  response	  in	  one	  [A01]	  and	  a	  baseline	  response	  that	  trended	  upwards	  in	  the	  other	  [A08].	  The	  fact	  that	  these	  two	  patients	  had	  progressed	  on,	  or	  immediately	  after,	  standard	  TMZ	  treatment,	  coupled	  with	  relatively	  high	  MGMT	  expression	  in	  their	  tumour	  tissue,	  makes	  it	  highly	  unlikely	  that	  retreatment	  with	  TMZ	  alone	  accounted	  for	  their	  better	  clinical	  course.	  It	  is	  therefore	  possible	  that	  the	  vaccine	  had	  a	  chemo-­‐potentiating	  effect,	  consistent	  with	  the	  hypothesis	  underpinning	  this	  study.	  However,	  when	  treatments	  are	  combined	  it	  becomes	  difficult	  to	  assess	  the	  contribution	  of	  individual	  components.	  It	  is	  also	  possible,	  for	  example,	  that	  the	  improved	  outcomes	  in	  these	  two	  patients	  were	  due	  to	  the	  vaccine	  alone.	  Both	  were	  relatively	  young,	  had	  good	  performance	  status	  and	  had	  undergone	  complete	  or	  near-­‐complete	  radiological	  resection,	  factors	  known	  to	  be	  associated	  with	  favourable	  clinical	  course	  after	  DCV	  for	  recurrent	  GBM	  (De	  Vleeschouwer	  et	  al.	  2012;	  Linda	  M	  Liau	  et	  al.	  2005).	  Other	  possibilities	  are	  that	  TMZ	  had	  a	  potentiating	  effect	  on	  the	  booster	  vaccines	  (C.-­‐H.	  Kim	  et	  al.	  2007;	  Sampson	  et	  al.	  2011)	  or,	  since	  an	  anti-­‐tumour	  immune	  response	  was	  detected	  prior	  to	  vaccination	  in	  both	  cases,	  surgical	  debulking	  alone	  may	  have	  allowed	  endogenous	  responses	  to	  become	  more	  effective	  by	  attenuating	  tumour-­‐induced	  immunosuppression.	  In	  one	  patient,	  A14,	  responses	  to	  two	  selected	  tumour	  antigens	  were	  present	  at	  baseline,	  but	  became	  undetectable	  at	  subsequent	  time	  points,	  raising	  the	  discomforting	  possibility	  that	  the	  vaccine	  had	  a	  tolerising	  effect	  in	  this	  patient.	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However,	  the	  phenotype	  of	  the	  infused	  DC	  in	  this	  patient	  did	  not	  reveal	  any	  obvious	  differences	  in	  maturation	  state	  (levels	  of	  CD83	  and	  CD86)	  compared	  to	  the	  other	  vaccines	  generated	  in	  the	  trial.	  An	  alternative	  possibility	  is	  that	  this	  endogenous	  response	  was	  ultimately	  overwhelmed	  by	  tumour-­‐induced	  immunosuppressive	  mechanisms.	  	  To	  our	  knowledge	  this	  is	  the	  first	  report	  of	  a	  vaccine-­‐induced	  response	  to	  SOX2	  in	  a	  glioma	  patient.	  	  Normally	  expressed	  in	  developing	  brain	  and	  neural	  stem	  cells,	  this	  transcription	  factor	  is	  reportedly	  overexpressed	  by	  putative	  cancer	  stem	  cells	  (CSC)	  in	  GBM	  tumours	  (Gangemi	  et	  al.	  2009;	  Y.-­‐P.	  Yang	  et	  al.	  2012).	  We	  speculate	  that	  the	  prolonged	  period	  of	  SD	  observed	  in	  patient	  A01	  may	  have	  been	  due	  to	  vaccine-­‐induced	  immune	  responses	  targeting	  the	  aggressive	  CSC	  phenotype.	  In	  conclusion,	  treating	  GBM	  patients	  relapsing	  after	  TMZ	  with	  a	  combination	  of	  surgery,	  autologous	  DC-­‐based	  vaccines	  and	  further	  TMZ	  is	  safe	  but	  is	  hampered	  by	  uncertainty	  in	  achieving	  the	  required	  vaccine	  yield.	  In	  contrast,	  several	  recent	  studies	  have	  demonstrated	  the	  feasibility	  of	  integrating	  DC-­‐based	  vaccination	  into	  standard	  treatment	  for	  newly	  presenting	  patients	  (Ardon	  et	  al.	  2012;	  Phuphanich	  et	  al.	  2012;	  Prins	  et	  al.	  2013).	  Although	  reported	  efficacy	  remains	  modest,	  recent	  advances	  in	  our	  capacity	  to	  attenuate	  tumour-­‐induced	  immunosuppression	  and	  target	  T	  cell	  checkpoint	  molecules	  has	  the	  potential	  to	  considerably	  improve	  the	  efficacy	  of	  DC-­‐based	  vaccines	  (Sabado	  and	  Bhardwaj	  2013).	  Although	  the	  findings	  reported	  here	  offer	  some	  encouragement	  for	  the	  idea	  of	  using	  immunotherapy	  to	  attenuate	  resistance	  of	  GBM	  tumours	  to	  retreatment	  with	  TMZ,	  DC-­‐based	  approaches	  seem	  more	  likely	  to	  achieve	  their	  full	  potential	  in	  the	  newly-­‐presenting	  setting.	  	  In	  the	  recurrent	  setting,	  a	  better	  strategy	  might	  be	  to	  use	  a	  vaccine	  that	  delivers	  antigen	  and	  adjuvant	  to	  the	  patients’	  endogenous	  DC.	  Ideally,	  such	  a	  vaccine	  would	  retain	  many	  of	  the	  theoretical	  advantages	  of	  whole	  tumour	  antigen-­‐pulsed	  DC	  vaccines	  including	  the	  provision	  of	  a	  broad	  range	  of	  personalised	  antigens	  and	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applicability	  to	  patients	  of	  all	  HLA	  types.	  A	  novel	  vaccine	  with	  these	  attributes	  is	  described	  in	  the	  next	  chapter.	  
 147 
CHAPTER	  FOUR:	  THERAPEUTIC	  VACCINATION	  FOR	  MURINE	  
GLIOMA	  USING	  AN	  ADJUVANT	  THAT	  STIMULATES	  NKT	  
CELLS	  	  
4.1	   INTRODUCTION	  The	  aim	  of	  therapeutic	  cancer	  vaccines	  is	  to	  generate	  a	  potent	  systemic	  anti-­‐tumour	  immune	  response	  with	  long-­‐lasting	  memory.	  Unless	  APC	  such	  as	  DC	  are	  properly	  licensed	  to	  initiate	  effector	  T	  cell	  responses,	  vaccination	  will	  be	  ineffective	  or	  even	  risk	  inducing	  a	  state	  of	  immunological	  tolerance	  (R	  M	  Steinman	  et	  al.	  2000).	  One	  way	  to	  ensure	  optimal	  activity	  of	  DCs	  is	  to	  include	  a	  potent	  immune	  adjuvant	  in	  the	  vaccine.	  The	  glycolipid	  α-­‐GalCer	  has	  been	  shown	  to	  specifically	  stimulate	  invariant	  iNKT	  cells,	  a	  population	  of	  T	  cells	  with	  innate-­‐like	  function	  found	  in	  high	  numbers	  in	  spleen,	  liver	  and	  bone	  marrow	  (MacDonald	  1995).	  In	  addition	  to	  expressing	  a	  variety	  of	  cell	  surface	  markers	  typically	  observed	  on	  NK	  cells,	  iNKT	  cells	  express	  a	  semi-­‐invariant	  αβ	  T	  cell	  receptor	  that	  recognizes	  glycolipid	  antigens	  (including	  α-­‐GalCer)	  bound	  to	  the	  non-­‐polymorphic	  MHC	  I-­‐like	  molecule	  CD1d.	  CD1d	  is	  expressed	  at	  high	  levels	  on	  APC	  including	  DC,	  so	  that	  inclusion	  of	  an	  iNKT	  cell	  ligand	  such	  as	  α-­‐GalCer	  in	  a	  vaccine	  can	  induce	  interactions	  between	  DC	  and	  iNKT	  cells	  that	  enhance	  innate	  and	  adaptive	  immune	  responses	  (Cerundolo	  et	  al.	  2009;	  Fujii	  et	  al.	  2003;	  Hermans	  et	  al.	  2003b).	  	  Anti-­‐cancer	  vaccines	  exploiting	  the	  adjuvant	  function	  of	  activating	  iNKT	  cells	  with	  α-­‐GalCer	  have	  been	  shown	  to	  be	  highly	  effective	  in	  animal	  studies,	  with	  long-­‐lasting	  immunity	  induced	  in	  response	  to	  co-­‐administration	  of	  tumour	  antigens	  and	  α-­‐GalCer	  (Chung	  et	  al.	  2007;	  C.	  Hong	  et	  al.	  2006;	  Petersen	  et	  al.	  2010b;	  Shimizu	  et	  al.	  2007a).	  This	  approach	  has	  yet	  to	  be	  tested	  in	  a	  glioma	  model	  or	  in	  cancer	  patients.	  One	  potential	  obstacle	  to	  clinical	  translation	  is	  the	  observation	  that	  iNKT	  cell	  numbers	  appear	  to	  be	  reduced	  in	  many	  cancer	  patients	  (Crough	  et	  al.	  2004;	  Giaccone	  et	  al.	  2002).	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Aims	  of	  the	  study:	  1. Establish	  a	  murine	  model	  of	  glioma	  2. Assess	  the	  efficacy	  of	  a	  vaccine	  consisting	  of	  irradiated	  tumour	  cells	  pulsed	  with	  α-­‐GalCer	  	  3. Characterise	  the	  effector	  arms	  of	  the	  vaccine-­‐induced	  immune	  response	  4. Assess	  whether	  the	  effectors	  required	  for	  the	  success	  of	  α-­‐GalCer-­‐based	  vaccines	  are	  present	  and	  competent	  in	  a	  cohort	  of	  typical	  GBM	  patients.	  	  
 
 
4.2	   THE	  GL261	  MOUSE	  MODEL	  OF	  GLIOMA	  The	  first	  aim	  of	  this	  project	  was	  to	  establish	  a	  murine	  model	  of	  glioma	  suitable	  for	  assessing	  active	  immunotherapies	  in	  vivo.	  GL261	  is	  a	  commercially-­‐available	  methylcholanthrene-­‐induced	  murine	  glioma	  cell	  line	  that	  can	  be	  surgically	  implanted	  into	  the	  brain	  of	  syngeneic,	  immunocompetent	  C57BL/6	  hosts	  (Ausman	  et	  al.	  1970;	  Wim	  Maes	  and	  Van	  Gool	  2010;	  Seligman	  et	  al.	  1939;	  Szatmari	  et	  al.	  2006).	  GL261	  is	  also	  capable	  of	  forming	  tumours	  after	  s.c.	  implantation.	  Although	  genetically-­‐engineered	  autochthonous	  models	  may	  represent	  some	  aspects	  of	  human	  glioma	  biology	  more	  accurately	  (de	  Vries	  et	  al.	  2009;	  Dranoff	  2011;	  Huszthy	  et	  al.	  2012),	  implantable	  models	  are	  more	  practical	  and	  allow	  progress	  to	  be	  made	  quickly.	  	  GL261	  is	  considered	  to	  be	  moderately	  immunogenic	  (Wim	  Maes	  and	  Van	  Gool	  2010).	  Vaccines	  containing	  peptides	  derived	  from	  the	  melanoma-­‐associated	  antigens	  TRP-­‐2	  and	  gp100	  (Prins	  et	  al.	  2003),	  or	  from	  survivin	  (Ciesielski	  et	  al.	  2008),	  have	  been	  shown	  to	  have	  some	  activity	  against	  GL261	  but	  the	  immunodominant	  antigens	  mediating	  the	  anti-­‐tumour	  activity	  of	  whole	  tumour	  antigen-­‐based	  vaccines	  have	  not	  been	  characterised	  (Grauer	  et	  al.	  2008).	  	  
 149 
	  
Figure 4.1. The GL261 mouse model of glioma.  A, Photomicrograph of the GL261 cell line growing 
as an adherent monolayer in standard culture medium. B, Photomicrograph of haematoxylin and eosin-
stained section of formalin-fixed paraffin-embedded brain tissue harvested from a C57BL/6 mouse 3 
weeks after intracranial implantation of 5 x 103 GL261 tumour cells. Tumour is at left, normal brain 
parenchyma at right. C, Dose finding study. Mice were implanted intracranially with different numbers 
of GL261 tumour cells and weighed every 1-2 days. 1 mouse per group. Those mice implanted with 
10,000 or 20,000 cells became symptomatic and were euthanased on day 23. The remaining mice were 
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GL261	  is	  customarily	  cultured	  in	  DMEM	  supplemented	  with	  FCS	  and	  antibiotics	  and	  grows	  as	  an	  adherent	  monolayer	  (Fig	  4.1A).	  	  Intracranial	  (i.c.)	  implantation	  is	  performed	  by	  injecting	  a	  single	  cell	  suspension	  into	  the	  right	  striatum	  of	  anaesthetised	  mice	  using	  a	  syringe	  mounted	  on	  a	  stereotactic	  frame.	  On	  histological	  examination,	  i.c.	  tumours	  are	  highly	  cellular,	  highly	  pleomorphic	  and	  may	  contain	  areas	  of	  necrosis	  (Fig	  4.1B).	  	  Tumours	  typically	  have	  a	  well	  demarcated	  border	  and	  do	  not	  exhibit	  the	  endothelial	  proliferation	  typical	  of	  human	  GBM	  tumours	  (Fig	  4.1B,	  see	  also	  Fig	  5.3E).	  After	  sectioning,	  brain	  tumours	  are	  usually	  visible	  to	  the	  naked	  eye	  (Fig	  4.1D).	  	  After	  obtaining	  consent	  from	  the	  VUW	  Animal	  Ethics	  Committee,	  titration	  studies	  were	  performed	  (Fig	  4.1C).	  Injection	  of	  5000	  tumour	  cells	  was	  selected	  for	  i.c.	  implantation	  experiments	  because	  this	  number	  led	  to	  tumour	  formation	  with	  almost	  100	  %	  penetrance	  in	  3-­‐4	  weeks,	  creating	  a	  suitable	  window	  for	  testing	  therapeutic	  vaccination.	  Mice	  were	  weighed	  and	  inspected	  daily	  and	  culled	  as	  soon	  as	  they	  developed	  unequivocal	  symptoms	  according	  to	  an	  Ethics	  Committee-­‐approved	  grading	  system.	  In	  practice,	  the	  first	  objective	  symptom	  in	  the	  great	  majority	  of	  mice	  was	  10	  %	  weight	  loss,	  so	  that	  mice	  were	  euthanased	  before	  the	  appearance	  of	  other	  overt	  symptoms	  (Fig	  4.1C).	  Subcutaneous	  implantation	  was	  used	  for	  some	  experiments	  in	  this	  study,	  particularly	  for	  large	  experiments	  with	  multiple	  groups.	  
 
4.3	   RESULTS	  
4.3.1	   Prophylactic	  treatment	  with	  an	  α-­‐GalCer-­‐loaded	  whole	  tumour	  vaccine	  
prevents	  glioma	  growth	  in	  a	  mouse	  model.	  To	  generate	  a	  vaccine,	  tumour	  cells	  were	  pulsed	  overnight	  with	  α-­‐GalCer,	  irradiated,	  and	  then	  washed	  to	  remove	  excess	  α-­‐GalCer	  (hereafter	  termed	  “Glioma-­‐Gal”	  vaccine).	  Because	  iNKT	  cells	  are	  found	  predominantly	  in	  spleen	  and	  liver,	  the	  vaccine	  was	  delivered	  i.v.	  to	  provide	  access	  to	  these	  populations.	  When	  used	  in	  a	  prophylactic	  setting,	  the	  Glioma-­‐Gal	  vaccine	  conferred	  significant	  protection	  against	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an	  s.c.	  challenge	  with	  GL261	  tumour	  cells	  (Fig.	  4.2A).	  Injection	  of	  free	  α-­‐GalCer,	  or	  irradiated	  tumour	  cells	  alone,	  did	  not	  confer	  any	  significant	  protection,	  suggesting	  that	  activation	  of	  iNKT	  cells	  with	  α-­‐GalCer	  co-­‐ordinates	  an	  improved	  response	  to	  the	  tumour	  antigens	  in	  the	  Glioma-­‐Gal	  vaccine	  (Fig.	  4.2A	  and	  B).	  The	  chemotherapeutic	  agent	  doxorubicin	  has	  been	  reported	  to	  increase	  the	  immunogenicity	  of	  dying	  tumour	  cells	  (Casares	  et	  al.	  2005).	  To	  exploit	  this	  phenomenon,	  the	  α-­‐GalCer-­‐pulsed	  tumour	  cells	  were	  treated	  with	  doxorubicin	  prior	  to	  vaccination.	  While	  there	  was	  a	  consistent	  trend	  for	  this	  “Glioma-­‐Gal-­‐Dox”	  vaccine	  to	  provide	  improved	  protection	  (Fig.	  4.2C),	  this	  did	  not	  reach	  statistical	  significance	  over	  the	  already	  highly	  effective	  Glioma-­‐Gal	  vaccine.	  Regardless,	  the	  doxorubicin	  treated	  version	  of	  the	  vaccine	  was	  used	  in	  all	  i.c.	  tumour	  experiments.	  Accordingly,	  the	  Glioma-­‐Gal-­‐Dox	  vaccine	  was	  shown	  to	  confer	  protection	  against	  subsequent	  i.c.	  tumour	  challenge	  (Fig.	  1D).	  
 
4.3.2	   The	  α-­‐GalCer-­‐loaded	  whole	  tumour	  vaccine	  is	  dependent	  on	  the	  
adjuvant	  function	  of	  activated	  iNKT	  cells.	  	  The	  activation	  of	  iNKT	  cells	  was	  required	  for	  the	  Glioma-­‐Gal	  vaccine	  to	  confer	  tumour	  immunity,	  as	  protection	  from	  tumour	  challenge	  was	  not	  observed,	  or	  was	  severely	  attenuated,	  in	  CD1d-­‐/-­‐	  mice	  that	  do	  not	  have	  iNKT	  cells	  (Fig	  4.3A).	  It	  has	  been	  shown	  that	  after	  i.v.	  treatment	  with	  free	  α-­‐GalCer,	  the	  glycolipid	  is	  acquired	  by	  resident	  APCs	  and	  then	  presented	  via	  CD1d	  to	  activate	  iNKT	  cells	  (Kitamura	  et	  al.	  1999;	  Tomura	  et	  al.	  1999).	  Activation	  of	  iNKT	  cells	  provokes	  an	  early	  release	  of	  cytokines	  including	  IL-­‐4,	  IL-­‐13	  and	  IFN-­‐γ	  into	  the	  serum.	  The	  interaction	  with	  APCs	  is	  reciprocal,	  with	  the	  activated	  iNKT	  cells	  in	  turn	  stimulating	  the	  APCs	  to	  release	  IL-­‐12p70.	  This	  interaction,	  which	  involves	  CD40/CD40L	  interactions,	  also	  promotes	  cross-­‐presentation	  and	  stimulation	  of	  conventional	  T	  cells	  (Fujii	  et	  al.	  2003;	  Hermans	  et	  al.	  2003b).	  To	  examine	  whether	  a	  similar	  profile	  of	  intercellular	  interactions	  takes	  place	  after	  i.v.	  administration	  of	  Glioma-­‐Gal,	  serum	  was	  collected	  at	  different	  time	  points	  after	  vaccination	  to	  analyse	  cytokine	  secretion,	  and	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  compared	  to	  animals	  that	  received	  free	  α-­‐GalCer	  (Fig.	  4.3B).	  As	  expected,	  in	  wild-­‐type	  mice	  administered	  free	  α-­‐GalCer,	  high	  levels	  of	  IL-­‐4,	  IL-­‐12p70	  and	  IFN-­‐γ	  were	  detected	  that	  peaked	  at	  2,	  12	  and	  approximately	  24	  hours	  respectively.	  In	  contrast,	  after	  infusion	  of	  Glioma-­‐Gal	  the	  systemic	  release	  of	  these	  cytokines	  was	  much	  lower,	  and	  peaked	  later	  in	  the	  case	  of	  IL-­‐4	  and	  IL-­‐12p70.	  	  Similar	  observations	  have	  been	  made	  by	  others	  who	  have	  compared	  the	  serum	  cytokine	  profiles	  of	  free	  versus	  cell-­‐associated	  α-­‐GalCer	  (Fujii	  et	  al.	  2002).	  Notably,	  cytokine	  secretion	  after	  Glioma-­‐Gal	  infusion	  was	  absent	  in	  serum	  in	  CD1d-­‐/-­‐	  mice,	  confirming	  that	  iNKT	  activation	  triggered	  the	  cytokine	  release	  observed	  in	  WT	  animals	  (Fig.	  4.3C).	  Although	  	  
A B
C


























































































Figure 4.2. Glioma-Gal vaccine prevents glioma growth in a mouse model. A, Mice were vaccinated i.v. with  
Glioma-Gal cells, treated i.v. with unpulsed irradiated tumour cells or not treated, and then challenged with subcu-
taneous GL261 7 days later. 4-5 mice per group. One of two experiments with similar results is shown. In WT mice 
receiving prophylactic vaccination followed by s.c. challenge, mean long term tumour-free survival was 78% over 
18 experiments, range 60 - 100% (excepting one outlying experiment in which long term survival was 20%). B, 
0LFHZHUHWUHDWHGRUQRWWUHDWHGZLWKQJIUHHĮ*DO&HULYDQGWKHQFKDOOHQJHGZLWKVXEFXWDQHRXV*/
GD\VODWHU2QHRIWZRH[SHULPHQWVZLWKVLPLODUUHVXOWVLVVKRZQ&0LFHZHUHYDFFLQDWHGZLWK*OLRPD*DOFHOOV
Glioma-Gal-Dox cells, or not treated, and then challenged with subcutaneous GL261 7 days later. 5 mice per 
group. One of two experiments with similar results is shown. Two additional s.c. challenge experiments included a 
prophylactic Glioma-Gal-Dox vaccine arm. Mean long term tumour-free survival over the four experiments was 
95%, range 80 - 100%. D, Mice were vaccinated with 5 x 105 Glioma-Gal-Dox cells or not treated and then 
challenged intracranially with GL261 7 days later. 5 mice per group. One of two independent experiments with 
similar results is shown.






























































































DFWLYDWHGL1.7FHOOVA, CD1d-/- mice or their CD1d+/- littermates were vaccinated with Glioma-Gal and 
challenged with GL261 s.c. 7 days later. 5 mice per group. One of 3 independent experiments with similar 
results is shown. Considering these three experiments together, long term survival was observed in 13/15 
(87 %) CD1d-sufficient mice compared with 2/15 (13 %) CD1d-deficient mice (p < 0.0001, Fisher’s exact 
WHVW%6HUXPF\WRNLQHOHYHOVDIWHULYDGPLQLVWUDWLRQRIQJIUHHĮ*DO&HU[5 Glioma-Gal cells, 
or 1 x 105 irradiated tumour cells; 5 mice per group. Statistical analysis was with the Krusskal Wallis test 
at each time point, with Dunn’s post-test. Results of comparisons with the Irradiated Cells group are 
shown. C, Serum cytokine levels after 5 x 105 Glioma-Gal cells were administered i.v. to WT or CD1d-/- 
mice; 3-5 mice per group. Statistical analysis was with the Mann Whitney test at each time point. D, 
Splenocytes were harvested from WT mice 7 days after i.v. infusion of Glioma-Gal vaccine, unpulsed 
LUUDGLDWHGWXPRXUFHOOVRUQJRIĮ*DO&HU and replated in 96-well plates in complete media without 
restimulation. Cytokine levels in the supernatant of splenocyte cultures were assessed 48 hours later; 3 
mice per group. Statistical analysis with the Kruskal Wallis test showed no significant differences between 
groups.  E, CD1d surface expression by cultured GL261 tumour cells assessed by flow cytometry. Positive 
and negative controls are WT CD11c+ splenocytes and a fibrosarcoma cell line raised in a CD1d-/- mouse. 







































































the	  levels	  of	  IL-­‐12p70	  were	  lower	  after	  Glioma-­‐Gal	  compared	  to	  free	  α-­‐GalCer	  (Fig.	  4.3B),	  the	  ratio	  of	  peak	  IL-­‐12p70	  to	  IL-­‐4	  was	  higher	  (approximately	  100:1	  compared	  to	  3:1),	  possibly	  indicating	  more	  efficient	  vaccine-­‐induced	  APC	  activation	  with	  proportionately	  lower	  systemic	  iNKT	  cell	  activation.	  Cytokines	  were	  still	  being	  secreted	  in	  splenic	  tissue	  isolated	  from	  mice	  one	  week	  after	  vaccination,	  which	  was	  not	  the	  case	  in	  mice	  that	  had	  received	  free	  α-­‐GalCer	  (Fig.	  4.3D).	  All	  of	  these	  observations	  suggest	  that	  α-­‐GalCer	  is	  presented	  in	  a	  qualitatively	  different	  manner	  
in	  vivo	  when	  incorporated	  into	  the	  vaccine.	  As	  GL261	  tumour	  cells	  do	  not	  express	  CD1d	  (Fig.	  4.3E),	  and	  are	  therefore	  incapable	  of	  stimulating	  iNKT	  cells	  directly,	  other	  CD1d+	  cell	  types	  must	  have	  acquired	  α-­‐GalCer	  from	  the	  vaccine	  for	  presentation	  to	  iNKT	  cells.	  	  	  
4.3.3	   The	  α-­‐GalCer-­‐loaded	  whole	  tumour	  vaccine	  elicits	  a	  CD4+	  T	  cell-­‐
mediated	  immune	  response.	  	  Next,	  the	  important	  effector	  arms	  responsible	  for	  protection	  from	  tumour	  challenge	  were	  defined.	  Depletion	  of	  NK	  cells	  after	  vaccination	  in	  the	  host	  with	  antibody	  to	  NK1.1	  did	  not	  abrogate	  protection	  (Fig.	  4.4A)	  suggesting	  that	  these	  cells,	  which	  are	  typically	  activated	  immediately	  downstream	  of	  iNKT	  cell	  stimulation,	  were	  not	  important	  anti-­‐tumour	  effectors.	  Transfer	  of	  serum	  to	  naïve	  mice	  from	  vaccinated	  mice	  that	  had	  survived	  a	  tumour	  challenge	  did	  not	  confer	  protection,	  indicating	  that	  antibodies	  were	  not	  likely	  to	  be	  playing	  a	  major	  role	  in	  protection	  (Fig	  4.4B).	  The	  Glioma-­‐Gal	  vaccine	  was	  not	  capable	  of	  protecting	  against	  challenge	  with	  the	  unrelated	  Lewis	  Lung	  Carcinoma	  cell	  line	  (Fig.	  4.5A),	  indicating	  that	  vaccine-­‐induced	  immunity	  was	  tumour-­‐specific.	  Experiments	  conducted	  in	  animals	  depleted	  of	  specific	  T	  cell	  subsets	  showed	  that	  protection	  was	  lost	  in	  the	  absence	  of	  CD4+	  T	  cells	  (Fig	  4.5B),	  but	  retained	  in	  the	  absence	  of	  CD8+	  T	  cells	  (Fig.	  4.5C).	  This	  was	  confirmed	  in	  knockout	  mice,	  with	  protection	  lost	  in	  MHC	  class	  II-­‐/-­‐	  hosts	  which	  lack	  CD4+	  T	  cells,	  and	  retained	  in	  TAP1-­‐/-­‐	  hosts	  which	  lack	  CD8+	  T	  cells	  (Fig.	  4.5D).	  It	  was	  independently	  shown	  that	  iNKT	  cells	  are	  present	  and	  able	  to	  respond	  to	  α-­‐GalCer	  in	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  these	  MHC	  II-­‐/-­‐	  mice	  (Appendix	  B,	  Fig	  B3.1).	  	  As	  further	  supporting	  evidence	  for	  a	  lack	  of	  significant	  involvement	  of	  CD8+	  T	  cells	  in	  this	  vaccination	  strategy,	  protection	  was	  retained	  in	  the	  absence	  of	  langerin+	  antigen-­‐presenting	  cells	  (Fig.	  4.5E),	  a	  cell	  type	  that	  has	  recently	  been	  shown	  to	  be	  critically	  involved	  in	  cross-­‐presentation	  of	  blood-­‐borne	  antigens	  to	  CD8+	  T	  cells	  (Farrand	  et	  al.	  2009;	  C.-­‐H.	  Qiu	  et	  al.	  2009).	  	  Given	  the	  requirement	  for	  CD4+	  T	  cells	  in	  conferring	  protection,	  it	  is	  notable	  that	  expression	  of	  MHC	  class	  II	  molecules	  by	  GL261	  was	  negligible	  in	  the	  steady	  state,	  but	  induced	  after	  a	  brief	  exposure	  to	  IFN-­‐γ	  (Fig.	  4.5F).	  It	  is	  therefore	  at	  least	  possible	  that	  CD4+	  T	  cells	  directly	  target	  tumour	  cells	  via	  MHC	  class	  II,	  as	  has	  recently	  been	  suggested	  (Quezada	  et	  al.	  2010).	  





















Figure 4.4. Tumour protection after Glioma-Gal vaccination is not mediated by NK cells or 
circulating antibodies. A. Mice vaccinated with Glioma-Gal on Day 0 were challenged on Day 7 with 
GL261 s.c. Some mice were also treated with NK1.1-depleting antibody on Days 4, 6, and then every 
3-4 days until the completion of the experiment. 5 mice per group. One of two independent experi-
PHQWVZLWKVLPLODUUHVXOWVLVVKRZQ%ȝ/RIVHUXPIURPQDwYHPLFHRUIURP*OLRPD*DOYDFFL-
QDWHGPLFHWKDWKDGVXUYLYHGDWXPRXUFKDOOHQJHZHHNVSUHYLRXVO\ZHUHLQMHFWHGLYLQWRQDwYHPLFH
that were challenged the following day with GL261 s.c. 5 mice per group. One of 2 independent 




























UHVSRQVH A, Glioma-Gal vaccinated mice were challenged s.c.7 days later with 1 x 106 Lewis Lung 
Carcinoma cells. One of three independent experiments with similar results is shown. B, Mice vacci-
nated with Glioma-Gal on Day 0 were challenged s.c. on Day 7 with GL261. Some mice were also 
treated with CD4-depleting antibody on Days 2 and 4 and then every 3-4 days. 5 mice per group. One 
of two independent experiments with similar results is shown. Over two experiments, long term 
tumour-free survival was observed in 1/10 depleted mice compared with 9/10 undepleted mice (p < 
0.01, Fisher’s exact test). See Appendix B, Fig B2.2 for validation of depletion method. C, Mice 
vaccinated with Glioma-Gal on Day 0 were challenged s.c. on Day 7 with GL261. Some mice were 
also treated with CD8-depleting antibody on Days -2 and -1 and then every 3-4 days until the comple-
tion of the experiment. 5 mice per group. One of three independent experiments with similar results is 
shown. Over three experiments, long term survival was observed in 10/15 (67 %) mice in both 
depleted and undepleted groups. See Appendix B, Fig B2.3 for validation of depletion method. D, 
WT, MHC class II-deficient, or TAP1-deficient mice were challenged s.c. 7 days after Glioma-Gal 
vaccination. 5 mice per group. The ability of GL261 to form tumours in naive TAP1-deficient mice 
was confirmed separately (data not shown). E. Langerin-DTREGFP mice were depleted of Langerin+ 
cells by administering Diphtheria toxin (DT) on Days -2, -1, 1 and 3, and were challenged s.c. on Day 
7. Some mice were vaccinated with Glioma-Gal on Day 0. One of two independent experiments with 
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4.3.4	   The	  α-­‐GalCer-­‐loaded	  whole	  tumour	  vaccine	  primes	  adaptive	  responses	  
in	  the	  lung-­‐draining	  lymph	  nodes.	  	  Interestingly,	  the	  Glioma-­‐Gal	  vaccine	  was	  fully	  effective	  in	  conferring	  protection	  against	  tumour	  challenge	  after	  splenectomy	  (Fig.	  4.6A).	  Thus,	  this	  lymphoid	  organ	  was	  not	  required	  for	  effective	  immunity.	  Different	  anatomic	  sites	  were	  therefore	  screened	  for	  cytokine	  production	  to	  identify	  possible	  alternative	  locations	  of	  antigen-­‐presenting	  cells	  mediating	  the	  protective	  immune	  response.	  	  Significant	  levels	  of	  cytokine	  production	  were	  detected	  in	  the	  mediastinal	  lymph	  nodes	  (MdLNs)	  of	  vaccinated	  mice,	  but	  not	  in	  inguinal	  LN	  or	  liver	  (Figs.	  4.6B	  and	  C).	  There	  was	  an	  increase	  in	  the	  overall	  size	  of	  MdLNs	  and	  a	  significant	  increase	  in	  the	  proportion	  of	  CD4+	  T	  cells	  expressing	  the	  activation	  marker	  CD44	  in	  the	  MdLNs	  of	  immunized	  mice	  that	  was	  not	  seen	  in	  inguinal	  LN	  (Fig.	  4.6D	  and	  E).	  In	  addition,	  we	  observed	  an	  increase	  in	  the	  proportion	  of	  MHC	  II+	  CD11c+	  cells	  in	  the	  MdLNs	  of	  vaccinated	  mice	  (Fig.	  4.6F).	  It	  is	  possible,	  therefore,	  that	  the	  infused	  tumour	  cells	  are	  filtered	  by	  the	  lung	  capillary	  bed	  where	  they	  are	  taken	  up	  by	  other	  lung-­‐resident	  or	  circulating	  cells	  that	  traffic	  to	  lung-­‐draining	  LN.	  
 
4.3.5	   The	  α-­‐GalCer-­‐loaded	  whole	  tumour	  vaccine	  is	  effective	  against	  












































































































































































GUDLQLQJO\PSKQRGHV A, Splenectomised mice were vaccinated with Glioma-Gal, or mice were not 
vaccinated, and challenged s.c. 7 days later with GL261. 5 mice per group. B, In vitro cytokine secre-
tion without further stimulation by cells harvested from mice vaccinated 7 days previously, or from 
naive mice, as in Fig 4.3D. MdLN = mediastinal lymph node; IngLN = inguinal lymph nodes; Liver = 
liver lymphocytes. Shown are means (+ SEM) of results from 3 vaccinated and 3 naive mice. Statistical 
comparison of vaccinated and naive groups was performed at each site using the Mann Whitney test. 
No significant differences were observed. C, Experiment similar to B. In vitro cytokine secretion by 
cells harvested from the MdLN and inguinal LN of mice vaccinated with 5 x 105 Glioma-Gal 7 days 
previously, or from naive mice. 4-5 mice per group. Statistical analysis at each site was with the Mann 
Whitney test. D, Absolute number of live cells in MdLN and inguinal LN from naïve mice and from 
mice vaccinated 7 days previously with 5 x 105 Glioma-Gal. Plots show individual mice. Pooled data 
from 4 experiments all showing the same trend. Statistical analysis at each site was with the Mann-
Whitney test. D, CD44 expression by CD3+CD4+ cells in MdLN and inguinal LN from naïve mice or 
from mice vaccinated 7 days previously with Glioma-Gal, assessed by flow cytometry. C. Representa-
tive histograms (left) and summary of 4-5 mice per group (right). Statistical analysis was with the 
Krusskal Wallis test with Dunn’s post-test. One of 2 independent experiments with similar results is 
shown. E, Flow cytometry  of MdLN cells from naïve mice and from mice vaccinated 7 days previously 
with Glioma-Gal, gated on live B220 cells. Complete gating strategy is shown in Appendix A, Figure 
A3.  Concatenated plots (above) and summary of 3 mice per group (below). Statisitical analysis was 






GUDLQLQJO\PSKQRGHV A, Splenectomised mice were vaccinated with Glioma-Gal or not vaccinated 
and challenged s.c. 7 days later with GL261. 5 mice per group. B, In vitro cytokine secretion without 
further stimulation by cells harvested from mice vaccinated 7 days previously, or from naive mice, as 
in Fig 4.3D. MdLN = mediastinal lymph node; IngLN = inguinal lymph nodes; Liver = liver lympho-
cytes. Shown are means (+ SEM) of results from 3 vaccinated and 3 naive mice. Statistical compari-
son of vaccinated and naive groups was performed at each site using the Mann Whitney test. No 
significant differences were observed. C, Experiment similar to B. In vitro cytokine secretion by cells 
harvested from the MdLN and inguinal LN of mice vaccinated with 5 x 105 Glioma-Gal 7 days 
previously, or from naive mice. 4-5 mice per group. Statistical analysis at each site was with the Mann 
Whitney test. D, Absolute number of live cells in MdLN and inguinal LN from naïve mice and from 
mice vaccinated 7 days previously with 5 x 105 Glioma-Gal. Plots show individual mice. Pooled data 
from 4 experiments all showing the same trend. Statistical analysis at each site was with the Mann-
Whitney test. D, CD44 expression by CD3+CD4+ cells in MdLN and inguinal LN from naïve mice or 
from mice vaccinated 7 days previously with Glioma-Gal, assessed by flow cytometry. C. Representa-
tive histograms (left) and summary of 4-5 mice per group (right). Statistical analysis was with the 
Krusskal Wallis test with Dunn’s post-test. One of 2 independent experiments with similar results is 
shown. E, Flow cytometry  of MdLN cells from naïve mice and from mice vaccinated 7 days previ-
ously with Glioma-Gal, gated on live B220 cells. Complete gating strategy is shown in Appendix A, 
Figure A3.  Concatenated plots (above) and summary of 3 mice per group (below). Statisitical analy-
sis was with the Mann Whitney test. One of two independent experiments with similar results is 
shown.
)LJXUH7KHĮ*DO&HUORDGHGZKROHWXPRXUYDFFLQHLVHIIHFWLYHDJDLQVWHVWDEOLVKHGLQWUDFUDQLDO
WXPRXUVEXWUHTXLUHVGHSOHWLRQRIUHJXODWRU\7FHOOV A-D. Mice were implanted intracranially with 5 
x 103 GL261 cells and vaccinated 6 days later with 5 x 105 Glioma-Gal-Dox cells (Vaccine). Some mice 
also received PC61, an anti-CD25 depleting antibody, i.p. on the day of tumour implantation (Vaccine + 
Treg depletion). Some mice were only treated with PC61 (Treg depletion). 4 independent experiments are 
shown. 4-7 mice per group. Over 3 experiments (A,B,C) mean long-term tumour-free survival was 43%. 
E, Gadolinium-enhanced T1-weighted MRI scans of a vaccinated mouse from the experiment depicted in 









































































































(Figs.	  4.7B	  and	  D).	  MRI	  scans	  at	  20	  days	  post-­‐implantation	  (14	  days	  post-­‐vaccination)	  showed	  enhancing	  mass	  lesions	  in	  most	  vaccinated	  mice	  that	  were	  radiologically	  similar	  to,	  but	  smaller	  than,	  those	  seen	  in	  unvaccinated	  mice	  (Fig.	  4.8),	  and	  complete	  resolution	  of	  the	  enhancing	  lesion	  was	  documented	  in	  one	  vaccinated	  mouse	  that	  exhibited	  long-­‐term	  survival	  (Fig.	  4.7E).	  To	  confirm	  that	  the	  radiological	  abnormalities	  in	  the	  vaccinated	  mice	  were	  tumours,	  some	  vaccinated	  mice	  were	  sacrificed	  on	  Day	  20	  for	  histological	  examination	  (Fig.	  4.8).	  	  Overall,	  these	  data	  confirm	  that	  the	  vaccine	  is	  effective	  in	  prolonging	  survival	  and,	  in	  some	  cases,	  eradicating	  established	  i.c.	  tumours.	  	  
 
4.3.6	   Patients	  with	  GBM	  have	  functional	  iNKT	  cells	  that	  can	  respond	  to	  α-­‐























Fig 4.8. Therapeutic Glioma-Gal vaccination prolongs survival by eradicating established 
tumours or by suppressing tumour growth. A, Mice were implanted i.c. with 5 x 103 GL261 cells 
and vaccinated 6 days later with 5 x 105 Glioma-Gal-Dox cells. Anti-CD25 depleting antibody 
(PC61) was administered i.p. on the day of tumour implantation. Symptom-free survival for this 
experiment is shown in Fig 4.7C. T1-weighted (post-gadolinium) and T2-weighted MR images were 
obtained on Day 20 post-implantation (14 days post-vaccination). Mouse #7 is the same as that 
depicted in Fig 4.7E. B, In a separate experiment, mice underwent intracranial tumour implantation 
followed by therapeutic PC61 + Glioma-Gal-Dox vaccination as in A. Two asymptomatic mice with 
enhancing mass lesions on Day 20 MRI scans were culled on the same day as the scan. A representa-
tive haematoxylin and eosin-stained section of formalin-fixed, paraffin-embedded brain tissue is 




























































































































































LQ*%0SDWLHQWVA, Flow cytometry of peripheral blood from patients with histologically-proven 
GBM and from an age-matched population of healthy volunteers, showing iNKT cells as a percent of 
total CD3+CD19- lymphocytes. Mean ages of the patient and control groups were 56.1 years (range 
44-74) and 58.6 years (range 27-78) respectively. Gating strategy is shown in Appendix A, Figure A4. 
B, Automated lymphocyte counts in the peripheral blood of the same subjects as in A. C, Absolute 
iNKT cell number in GBM patients and an age-matched population of healthy volunteers, estimated 
by multiplying % iNKT of total lymphocytes (on flow cytometry) and a contemporaneous automated 
peripheral blood lymphocyte count. Mean ages of the patient and control groups were 59.8 (range 
44-74) and 61.1 (range 48-70) years respectively. D, Absolute number of myeloid dendritic cells 
(mDC) in peripheral blood from GBM patients and healthy volunteers (all subjects with sufficient 
PBMC available for FC), estimated by multiplying % mDC of total live PBMC (on flow cytometry) 
and a contemporaneous automated peripheral blood count of lymphocytes + monocytes. Myeloid DC 
were defined as lineage marker low, CD11c high, HLA-DR high cells. Mean ages of the patient and 
control groups were 58 and 64 years respectively. Gating strategy is shown in Appendix A, Figure 
A5. E, Automated monocyte counts in the peripheral blood of the same subjects as in A. F, CD1d 
expression on circulating mDC and CD14++ monocytes in the peripheral blood of a subgroup of GBM 
patients and healthy volunteers, assessed by flow cytometry. Gating strategy for identifying CD14++ 
monocytes is shown in Appendix A, Figure A6. E, PBMC from GBM patients and healthy volunteers 
were cultured in vitroLQWKHSUHVHQFHRIĮ*DO&HUIRUGD\V$EVROXWHL1.7FHOOQXPEHUEHIRUHDQG
after co-culture (left and centre); fold change in absolute iNKT cell number (right).  In G, statistical 
analysis was performed using a Wilcoxon matched pairs test. A Mann Whitney test was used for all 




































































































































































































LQ*%0SDWLHQWVA, Flow cytometry of peripheral blood from patients with histologically-proven 
GBM and from an age-matched population of healthy volunteers, showing iNKT cells as a percent of 
total CD3+CD19- lymphocytes. Mean ages of the patient and control groups were 56.1 years (range 
44-74) and 58.6 years (range 27-78) respectively. Gating strategy is shown in Appendix A, Figure A4. 
B, Automated lymphocyte counts in the peripheral blood of the same subjects as in A. C, Absolute 
iNKT cell number in GBM patients and an age-matched population of healthy volunteers, estimated 
by multiplying % iNKT of total lymphocytes (on flow cytometry) and a contemporaneous automated 
peripheral blood lymphocyte count. Mean ages of the patient and control groups were 59.8 (range 
44-74) and 61.1 (range 48-70) years respectively. D, Absolute number of myeloid dendritic cells 
(mDC) in peripheral blood from GBM patients and healthy volunteers (all subjects with sufficient 
PBMC available for FC), estimated by multiplying % mDC of total live PBMC (on flow cytometry) 
and a contemporaneous automated peripheral blood count of lymphocytes + monocytes. Myeloid DC 
were defined as lineage marker low, CD11c high, HLA-DR high cells. Mean ages of the patient and 
control groups were 58 and 64 years respectively. Gating strategy is shown in Appendix A, Figure 
A5. E, Automated monocyte counts in the peripheral blood of the same subjects as in A. F, CD1d 
expression on circulating mDC and CD14++ monocytes in the peripheral blood of a subgroup of GBM 
patients and healthy volunteers, assessed by flow cytometry. Gating strategy for identifying CD14++ 
monocytes is shown in Appendix A, Figure A6. E, PBMC from GBM patients and healthy volunteers 
were cultured in vitroLQWKHSUHVHQFHRIĮ*DO&HUIRUGD\V$EVROXWHL1.7FHOOQXPEHUEHIRUHDQG
after co-culture (left and centre); fold change in absolute iNKT cell number (right).  In G, statistical 
analysis was performed using a Wilcoxon matched pairs test. A Mann Whitney test was used for all 
















































































































































4.4	  DISCUSSION	  This	  study	  has	  shown	  that	  a	  simple	  vaccine	  composed	  of	  irradiated	  autologous	  tumour	  cells	  pulsed	  with	  α-­‐GalCer,	  an	  adjuvant	  that	  stimulates	  iNKT	  cells,	  is	  an	  effective	  treatment	  against	  tumours	  in	  a	  murine	  glioma	  model.	  The	  vaccine	  depends	  on	  the	  reciprocal	  activation	  of	  iNKT	  cells	  and	  APCs	  and	  elicits	  an	  adaptive	  immune	  response	  dominated	  by	  CD4+	  T	  cells	  that	  is	  tumour-­‐specific	  and	  long-­‐lasting.	  While	  evidence	  of	  cellular	  activation	  was	  observed	  in	  the	  spleen,	  the	  mediastinal	  lymph	  node	  was	  shown	  to	  be	  an	  important	  anatomical	  site	  of	  T	  cell	  priming.	  It	  has	  also	  been	  shown	  that	  the	  principal	  effector	  arms	  necessary	  for	  the	  success	  of	  such	  a	  vaccine	  are	  present	  and	  functional	  in	  a	  typical	  cohort	  of	  patients	  with	  high-­‐grade	  glioma.	  	  In	  some	  animal	  models	  α-­‐GalCer	  has	  been	  shown	  to	  have	  significant	  anti-­‐tumour	  effects	  when	  injected	  intravenously	  as	  a	  sole	  agent	  (E.	  Kobayashi	  et	  al.	  1995).	  These	  effects	  were	  shown	  to	  be	  largely	  due	  to	  stimulation	  of	  the	  innate	  immune	  system,	  particularly	  NK	  cells	  (Hayakawa	  et	  al.	  2002),	  but	  enhancement	  of	  spontaneous	  adaptive	  responses	  were	  also	  observed	  in	  some	  tumour-­‐bearing	  animals	  (Carnaud	  et	  al.	  1999;	  Nishimura	  et	  al.	  2000).	  However,	  most	  clinical	  trials	  in	  human	  cancer	  patients,	  using	  either	  free	  α-­‐GalCer	  or	  α-­‐GalCer	  loaded	  onto	  DC,	  have	  achieved	  limited	  clinical	  benefit	  despite	  evidence	  of	  iNKT	  activation	  (Cerundolo	  et	  al.	  2009;	  Richter	  et	  al.	  2013;	  Schneiders	  et	  al.	  2011;	  van	  den	  Heuvel	  et	  al.	  2011).	  In	  all	  of	  these	  clinical	  trials	  α-­‐GalCer	  has	  been	  used	  without	  co-­‐administration	  of	  antigen.	  Thus	  the	  adjuvant	  function	  of	  stimulating	  iNKT	  cells	  has	  yet	  to	  be	  tested	  directly	  in	  patients.	  	  In	  animal	  models	  it	  has	  been	  reported	  that	  simple	  co-­‐administration	  of	  α-­‐GalCer	  with	  microbial	  products	  (Gonzalez-­‐Aseguinolaza	  et	  al.	  2002)	  or	  soluble	  antigens	  (Fujii	  et	  al.	  2003;	  Hermans	  et	  al.	  2003b)	  can	  significantly	  enhance	  antigen-­‐specific	  T	  cell-­‐	  and	  antibody-­‐mediated	  responses.	  There	  have	  also	  been	  previous	  reports	  that	  injection	  of	  α-­‐GalCer	  with	  whole	  tumour	  cells	  can	  provoke	  effective	  anti-­‐tumour	  responses,	  although	  different	  effector	  arms	  were	  invoked	  depending	  on	  the	  model	  studied.	  As	  reported	  here	  for	  glioma,	  a	  previous	  report	  of	  an	  α-­‐GalCer-­‐pulsed	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lymphoma	  cell	  vaccine	  showed	  that	  efficacy	  was	  dependent	  on	  CD4+	  T	  cells,	  and	  did	  not	  require	  CD8+	  T	  cells	  (Chung	  et	  al.	  2007).	  Similarly,	  CD4+	  T	  cells	  could	  independently	  mediate	  full	  immunity	  to	  a	  vaccine	  consisting	  of	  irradiated	  B16	  melanoma	  cells	  administered	  i.p.	  with	  free	  α-­‐GalCer,	  although	  CD8+	  T	  cells	  were	  important	  effectors	  in	  fully	  T	  cell-­‐replete	  animals	  (C.	  Hong	  et	  al.	  2006).	  In	  contrast,	  it	  was	  reported	  that	  the	  anti-­‐tumour	  activity	  of	  an	  α-­‐GalCer-­‐pulsed	  live	  B16	  tumour	  cell	  vaccine	  was	  abrogated	  in	  both	  MHC	  class	  I-­‐/-­‐	  and	  MHC	  class	  II-­‐/-­‐	  animals	  	  (Shimizu	  et	  al.	  2007a).	  These	  contradictory	  findings	  could	  be	  reconciled	  if	  the	  type	  of	  response	  induced	  is	  a	  consequence	  of	  the	  tumour	  antigens	  presented	  and/or	  the	  timing	  and	  manner	  in	  which	  the	  infused	  tumour	  cells	  die.	  Shimizu	  and	  colleagues’	  mechanistic	  analysis	  of	  their	  live	  tumour	  cell	  vaccine	  showed	  that	  the	  injected	  α-­‐GalCer-­‐loaded	  tumour	  cells	  were	  killed	  by	  iNKT	  cells	  and	  NK	  cells,	  thereby	  providing	  a	  reservoir	  of	  antigens	  for	  uptake	  by	  resident	  antigen-­‐presenting	  cells,	  with	  CD8α+	  DCs	  in	  spleen	  being	  important	  for	  cross-­‐presentation	  (Shimizu	  et	  al.	  2007a;	  Shimizu	  et	  al.	  2007b).	  This	  mode	  of	  antigen	  delivery	  could	  be	  enhanced	  by	  transducing	  the	  tumour	  cells	  to	  express	  higher	  levels	  of	  CD1d,	  thereby	  making	  the	  injected	  cells	  more	  susceptible	  to	  attack	  by	  iNKT	  cells.	  In	  contrast,	  in	  the	  glioma	  study	  presented	  here,	  the	  tumour	  cells	  in	  the	  Glioma-­‐Gal	  vaccine	  were	  CD1d-­‐negative	  and,	  as	  a	  consequence	  of	  γ-­‐irradiation,	  were	  likely	  to	  already	  be	  in	  the	  process	  of	  dying.	  These	  different	  pathways	  to	  cell	  death	  are	  likely	  to	  result	  in	  differences	  in	  the	  expression	  of	  danger-­‐associated	  molecular	  patterns	  and	  ligands	  for	  phagocytosis	  receptors,	  and	  these	  in	  turn	  may	  determine	  the	  location,	  subset	  and	  maturation	  state	  of	  the	  antigen-­‐presenting	  cells	  that	  take	  up	  the	  tumour	  cells	  and	  shape	  the	  immune	  response.	  	  The	  manner	  in	  which	  α-­‐GalCer	  is	  acquired	  from	  the	  vaccine	  and	  presented	  to	  iNKT	  cells	  in	  vivo	  may	  also	  have	  a	  significant	  bearing	  on	  the	  outcome	  of	  vaccination.	  Irradiated	  whole	  tumour	  cells	  pulsed	  with	  α-­‐GalCer	  may	  be	  an	  efficient	  way	  of	  delivering	  “antigen	  plus	  adjuvant”	  to	  the	  same	  phagocytic	  cell.	  It	  has	  previously	  been	  shown	  that	  a	  vaccine	  composed	  of	  DC	  pulsed	  with	  antigen	  and	  α-­‐GalCer	  remains	  effective	  even	  when	  the	  infused	  DC	  are	  CD1d-­‐deficient,	  demonstrating	  that	  the	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glycolipid	  must	  be	  transferred	  to	  host	  cells	  (Petersen	  et	  al.	  2011).	  As	  tumour	  cells	  in	  the	  Glioma-­‐Gal	  vaccine	  do	  not	  express	  CD1d,	  transfer	  of	  α-­‐GalCer	  to	  host	  APC	  must	  also	  occur.	  Quite	  how	  α-­‐GalCer	  becomes	  physically	  associated	  with	  tumour	  cells	  in	  the	  Glioma-­‐Gal	  vaccine	  is	  not	  clear.	  One	  possibility	  is	  that	  the	  lipophilic	  sphingosine	  tail	  of	  the	  molecule	  adheres	  to,	  or	  becomes	  integrated	  into,	  the	  plasma	  membrane	  (Moody	  et	  al.	  2002).	  While	  only	  modest	  amounts	  of	  glycolipid	  are	  likely	  to	  be	  incorporated,	  analysis	  of	  the	  cytokines	  released	  in	  vivo	  following	  vaccination	  suggests	  that,	  consistent	  with	  a	  previous	  report	  comparing	  free	  α-­‐GalCer	  with	  α-­‐GalCer	  pulsed	  onto	  DC	  (Fujii	  et	  al.	  2002),	  stimulation	  of	  iNKT	  cells	  by	  tumour	  cell-­‐associated	  α-­‐GalCer	  is	  sustained	  over	  many	  days,	  perhaps	  suggesting	  slow	  release	  of	  vaccine	  material	  from	  an	  anatomical	  or	  cellular	  site	  of	  sequestration.	  	  Because	  the	  Glioma-­‐Gal	  vaccine	  was	  infused	  into	  the	  circulation,	  a	  role	  for	  antigen-­‐presenting	  cells	  in	  the	  spleen,	  and	  for	  CD8α+	  DC	  in	  particular,	  was	  anticipated	  as	  these	  APC	  have	  been	  shown	  to	  have	  a	  selective	  capacity	  to	  take	  up	  and	  present	  antigen	  from	  circulating	  dying	  cells	  (Iyoda	  et	  al.	  2002;	  Shimizu	  et	  al.	  2007a).	  	  Surprisingly,	  in	  the	  model	  used	  in	  this	  study	  splenic	  DC	  were	  redundant.	  Instead	  the	  evidence	  suggested	  that	  the	  MdLN	  was	  an	  important	  site	  of	  T	  cell	  priming.	  Two	  major	  CD11c+	  DC	  subsets	  have	  been	  described	  in	  the	  lung	  with	  recent	  studies	  suggesting	  the	  two	  populations	  have	  distinct	  functional	  roles	  (Jakubzick	  et	  al.	  2008).	  CD11blo	  CD103+	  DCs,	  which	  are	  also	  langerin+,	  are	  specialized	  in	  presenting	  antigen	  to	  CD8+	  T	  cells.	  In	  contrast,	  CD11bhi	  CD103−	  DCs	  preferentially	  induce	  proliferation	  of	  CD4+	  T	  cells	  (del	  Rio	  et	  al.	  2007;	  Jakubzick	  et	  al.	  2008).	  Given	  that	  anti-­‐tumour	  responses	  to	  Glioma-­‐Gal	  were	  not	  abrogated	  when	  langerin+	  cells	  were	  depleted,	  we	  speculate	  that	  apoptotic	  tumour	  cells	  of	  the	  vaccine	  lodging	  in	  the	  pulmonary	  capillary	  bed	  might	  be	  preferentially	  taken	  up	  by	  CD11bhi	  CD103−	  DCs	  that	  in	  turn	  generate	  the	  predominantly	  CD4+	  T	  cell-­‐mediated	  response	  observed.	  However,	  a	  role	  for	  other	  cell	  types	  of	  the	  monocyte/macrophage/DC	  lineage,	  either	  circulating	  in	  the	  blood	  or	  resident	  in	  the	  MdLNs,	  cannot	  be	  excluded.	  It	  was	  recently	  shown	  that	  CD169+	  macrophages	  in	  the	  subcapsular	  sinus	  of	  LN	  are	  able	  to	  take	  up	  α-­‐GalCer	  and	  activate	  iNKT	  cells	  (P.	  Barral	  et	  al.	  2010).	  It	  has	  also	  been	  shown	  that	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these	  cells	  have	  the	  capacity	  to	  phagocytose	  dead	  tumour	  cells	  arriving	  via	  afferent	  lymphatics,	  and	  act	  as	  antigen-­‐presenting	  cells	  to	  initiate	  anti-­‐tumour	  immune	  responses	  (Asano	  et	  al.	  2011).	  	  The	  CD4+	  T-­‐cell-­‐mediated	  mechanisms	  responsible	  for	  anti-­‐tumour	  immunity	  remain	  to	  be	  established.	  It	  is	  likely	  that	  CD4+	  T	  cells	  act	  at	  the	  tumour	  site,	  either	  indirectly	  by	  secreting	  cytokines	  and	  promoting	  the	  anti-­‐tumour	  effects	  of	  innate	  cells,	  or	  by	  a	  direct	  granzyme	  B-­‐dependent	  cytolytic	  mechanism,	  as	  recently	  described	  (Quezada	  et	  al.	  2010).	  With	  respect	  to	  the	  latter	  possibility,	  MHC	  class	  II	  expression	  can	  be	  induced	  by	  IFN-­‐γ	  in	  GL261	  cells	  (and	  in	  human	  GBM	  cell	  lines),	  thereby	  providing	  a	  plausible	  mechanism	  by	  which	  “cytotoxic	  CD4	  T	  cells”	  might	  recognize	  tumour	  cells.	  	  There	  is	  evidence	  that	  Treg	  play	  a	  major	  role	  in	  mediating	  glioma-­‐induced	  immunosuppression,	  both	  in	  human	  patients	  and	  in	  mouse	  models	  (Dix	  et	  al.	  1999;	  Fecci	  et	  al.	  2006a;	  Fecci	  et	  al.	  2006b;	  Raychaudhuri	  et	  al.	  2011).	  In	  our	  model,	  established	  tumours	  were	  resistant	  to	  therapeutic	  vaccination	  unless	  supported	  by	  treatment	  with	  an	  anti-­‐CD25	  depleting	  antibody.	  Attenuation	  of	  immuno-­‐suppressive	  mechanisms	  is	  likely	  to	  be	  a	  vital	  component	  of	  successful	  glioma	  immunotherapies	  in	  the	  future.	  Whole	  tumour	  preparation-­‐based	  vaccines	  have	  some	  theoretical	  advantages	  over	  vaccines	  directed	  at	  one,	  or	  a	  few,	  predetermined	  antigens.	  There	  is	  still	  a	  paucity	  of	  identified	  glioma-­‐associated	  antigens	  that	  are	  consistently	  expressed	  and/or	  capable	  of	  eliciting	  strong	  anti-­‐tumour	  responses.	  For	  this	  reason,	  vaccines	  based	  on	  whole	  autologous	  tumour	  extracts	  have	  been	  the	  most	  common	  immunotherapeutic	  strategy	  tested	  in	  glioma	  patients.	  Other	  theoretical	  benefits	  of	  personalized	  whole	  tumour-­‐based	  vaccines	  include	  applicability	  to	  all	  HLA	  types,	  the	  provision	  of	  both	  MHC	  class	  I	  and	  II	  epitopes,	  and	  the	  stimulation	  of	  a	  broad	  polyclonal	  response	  that	  reduces	  the	  risk	  of	  immune-­‐escape.	  Most	  human	  studies	  of	  whole	  tumour-­‐based	  glioma	  vaccines	  have	  involved	  loading	  antigen	  onto	  autologous	  monocyte-­‐derived	  DC.	  However,	  as	  in	  the	  clinical	  trial	  described	  in	  Chapter	  3,	  generating	  DC	  from	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patients	  with	  advanced	  disease	  can	  be	  problematic,	  and	  there	  are	  many	  uncertainties	  surrounding	  the	  optimum	  phenotype	  of	  the	  infused	  DC	  (Melief	  2008).	  There	  is	  also	  increasing	  evidence	  that	  antigen-­‐pulsed	  DC	  administered	  as	  a	  vaccine	  may	  simply	  serve	  as	  couriers	  that	  deliver	  antigen	  to	  endogenous	  APC	  (Kleindienst	  and	  Brocker	  2003;	  Petersen	  et	  al.	  2011).	  Thus,	  a	  vaccine	  that	  aims	  to	  deliver	  whole	  tumour-­‐derived	  antigens	  to	  endogenous	  DC	  may	  be	  a	  better	  approach	  than	  classical	  DC-­‐based	  therapy,	  and	  intact	  autologous	  tumour	  cells	  constitute	  a	  ready-­‐made	  vehicle	  for	  this	  purpose.	  	  The	  use	  of	  irradiated	  whole	  tumour	  cells	  in	  anti-­‐cancer	  vaccines	  raises	  some	  theoretical	  concerns	  such	  as	  the	  possibility	  of	  inducing	  auto-­‐immunity,	  particularly	  if	  the	  treatment	  also	  includes	  deliberate	  attenuation	  of	  self-­‐tolerance.	  However,	  immune	  cell	  infiltration	  was	  not	  seen	  in	  the	  normal	  brain	  parenchyma	  of	  treated	  mice	  in	  this	  study	  (data	  not	  shown).	  Another	  concern	  is	  the	  risk	  of	  acute	  toxicity	  associated	  with	  the	  i.v.	  infusion	  of	  apoptotic	  tumour	  cells.	  Toxicity	  encountered	  in	  this	  study	  at	  higher	  doses	  of	  the	  vaccine	  was	  effectively	  abrogated	  by	  pre-­‐treating	  mice	  with	  i.v.	  heparin,	  suggesting	  that	  tissue	  factor	  or	  another	  procoagulant	  factor	  was	  probably	  responsible	  (Bastida	  et	  al.	  1984;	  Fernandes	  et	  al.	  2006).	  	  Reduced	  numbers	  of	  iNKT	  cells	  and	  functional	  iNKT	  cell	  defects	  have	  been	  reported	  in	  patients	  with	  advanced	  solid	  cancers	  (Crough	  et	  al.	  2004;	  Giaccone	  et	  al.	  2002;	  Tahir	  et	  al.	  2001)	  that	  could	  impact	  on	  the	  utility	  of	  α-­‐GalCer	  as	  a	  useful	  immune	  adjuvant.	  However,	  GBM	  appears	  to	  be	  an	  exception	  in	  this	  regard.	  A	  small	  study	  of	  iNKT	  cells	  in	  the	  blood	  of	  nine	  patients	  with	  gliomas	  of	  various	  grades	  (Kavita	  M	  Dhodapkar	  et	  al.	  2004)	  reported	  no	  difference	  in	  iNKT	  cell	  function	  or	  number	  (expressed	  as	  percentage	  of	  total	  lymphocytes)	  compared	  to	  control	  subjects.	  Here	  a	  much	  larger	  and	  more	  homogeneous	  group	  of	  patients	  was	  examined,	  with	  iNKT	  cell	  number	  and	  function	  compared	  to	  age-­‐matched	  healthy	  controls.	  All	  patients	  had	  a	  histological	  diagnosis	  of	  GBM,	  and	  the	  great	  majority	  was	  taking	  moderate	  to	  high	  doses	  of	  lymphotoxic	  corticosteroid.	  Importantly,	  we	  found	  no	  difference	  in	  the	  absolute	  iNKT	  cell	  count	  in	  peripheral	  blood	  in	  patients	  compared	  to	  controls,	  even	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CHAPTER	  FIVE:	  TARGETING	  CANCER	  STEM	  CELLS	  TO	  
IMPROVE	  IMMUNOTHERAPY	  FOR	  GLIOMA	  	  
 
5.1	   INTRODUCTION	  AND	  AIMS	  
5.1.1	   Introduction	  to	  Cancer	  Stem	  Cells	  	  In	  recent	  decades,	  major	  improvements	  in	  outcome	  have	  been	  realised	  for	  some	  forms	  of	  cancer.	  For	  patients	  with	  GBM,	  the	  prognosis	  remains	  bleak.	  One	  of	  the	  reasons	  for	  relapse	  after	  cancer	  treatment	  is	  that	  tumours	  are	  heterogeneous,	  consisting	  of	  diverse	  tumour	  cell	  phenotypes	  with	  differing	  susceptibilities	  to	  treatment	  (Marusyk	  et	  al.	  2012).	  The	  “clonal	  selection”	  theory	  attributes	  this	  heterogeneity	  to	  random	  genetic	  and	  epigenetic	  events	  (Nowell	  1976).	  	  The	  “cancer	  stem	  cell”	  (CSC)	  theory	  offers	  a	  fundamentally	  different	  explanation	  for	  tumour	  heterogeneity	  that	  has	  attracted	  intense	  interest	  as	  a	  plausible	  explanation	  for	  the	  failure	  of	  conventional	  therapy	  and	  a	  framework	  for	  the	  design	  of	  new	  treatments	  (Dick	  2008;	  J.	  C.	  Y.	  Wang	  and	  Dick	  2005).	  	  The	  CSC	  model	  was	  first	  described	  in	  the	  context	  of	  haematological	  malignancies	  and	  is	  still	  most	  firmly	  established	  in	  this	  field.	  Dick	  and	  colleagues	  (Bonnet	  and	  Dick	  1997;	  Lapidot	  et	  al.	  1994),	  sorted	  peripheral	  blood	  leucocytes	  from	  patients	  with	  acute	  myeloid	  leukaemia	  and	  showed	  that	  only	  a	  small	  subset	  of	  leukaemic	  cells	  was	  able	  to	  re-­‐establish	  the	  human	  leukaemia	  when	  transplanted	  into	  immunodeficient	  mice.	  Limiting	  dilution	  studies	  showed	  the	  frequency	  of	  the	  leukaemia-­‐initiating	  cell	  to	  be	  1	  in	  250,000	  (Lapidot	  et	  al.	  1994).	  These	  cells	  resided	  within	  a	  CD34++CD38-­‐	  population	  that	  constituted	  less	  than	  0.2	  %	  of	  leukaemic	  cells	  (Bonnet	  and	  Dick	  1997).	  After	  transplanting	  purified	  CD34++CD38-­‐	  cells	  into	  mice,	  cells	  with	  this	  surface	  marker	  phenotype	  made	  up	  only	  2	  %	  of	  the	  reconstituted	  human	  leukaemia	  cells	  in	  the	  recipients,	  indicating	  an	  ability	  of	  these	  cells	  to	  give	  rise	  to	  the	  more	  differentiated	  progeny	  making	  up	  the	  bulk	  of	  the	  leukaemic	  population,	  while	  at	  the	  same	  time	  maintaining	  their	  own	  numbers.	  Because	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leukaemic	  blasts	  making	  up	  the	  bulk	  tumour	  population	  have	  limited	  proliferative	  capacity,	  further	  evidence	  of	  the	  ability	  of	  these	  “leukaemia	  stem	  cells”	  to	  “self-­‐renew”	  was	  provided	  by	  the	  ability	  to	  serially	  transplant	  the	  leukaemia	  to	  secondary	  recipient	  mice	  (Bonnet	  and	  Dick	  1997).	  These	  findings	  together	  implied	  the	  existence	  of	  a	  hierarchy	  within	  the	  leukaemic	  cell	  population	  reminiscent	  of	  normal	  haematopoiesis,	  in	  which	  a	  small	  subset	  of	  oncologically-­‐transformed	  self-­‐sustaining	  stem	  cell	  (SC)-­‐like	  cells	  have	  the	  capacity	  to	  give	  rise	  to	  a	  large	  number	  of	  more	  differentiated	  cells	  with	  a	  finite	  capacity	  for	  proliferation.	  Following	  the	  initial	  description	  of	  CSC	  in	  leukaemia,	  putative	  CSC	  have	  subsequently	  been	  described	  in	  several	  solid	  tumours	  including	  breast	  cancer	  (Al-­‐Hajj	  et	  al.	  2003),	  glioma	  (S.	  K.	  Singh	  et	  al.	  2003),	  colon	  cancer	  (O'Brien	  et	  al.	  2007),	  prostate	  cancer	  (Collins	  et	  al.	  2005)	  and	  melanoma	  (Monzani	  et	  al.	  2007;	  Schatton	  et	  al.	  2008).	  There	  is	  also	  evidence	  that	  CSC	  are	  particularly	  resistant	  to	  chemotherapy	  and	  radiotherapy	  (Bao	  et	  al.	  2006a;	  J.	  Chen	  et	  al.	  2012).	  The	  concept	  of	  a	  small	  subset	  of	  quiescent	  tumorigenic	  cells	  that	  are	  particularly	  resistant	  to	  treatment	  provides	  an	  attractive	  explanation	  for	  late	  relapse	  in	  cancer	  patients,	  and	  implies	  that	  progress	  towards	  better	  outcomes	  will	  require	  an	  understanding	  of	  CSC	  biology	  rather	  than	  measuring	  the	  success	  of	  novel	  treatments	  by	  the	  extent	  to	  which	  they	  reduce	  the	  bulk	  tumour	  population	  (Reya	  et	  al.	  2001).	  	  	  
5.1.2	   Evidence	  for	  CSC	  in	  glioma	  	  	  In	  1992	  Reynolds	  and	  Weiss	  cultured	  adult	  murine	  brain	  cells	  in	  specialised	  media	  that	  was	  serum-­‐free	  and	  supplemented	  with	  EGF,	  bFGF	  and	  other	  factors	  that	  together	  were	  intended	  to	  promote	  proliferation	  but	  inhibit	  differentiation	  (B.	  A.	  Reynolds	  and	  Weiss	  1992b).	  The	  surviving	  cells	  lacked	  lineage	  markers	  and	  grew	  as	  non-­‐adherent	  spheroidal	  aggregations	  that	  they	  termed	  neurospheres.	  When	  placed	  back	  into	  media	  containing	  serum,	  these	  sphere	  cells	  gave	  rise	  to	  more	  differentiated	  cells	  expressing	  neuronal	  and	  glial	  markers.	  This	  study	  showed	  for	  the	  first	  time	  that	  multipotent	  neural	  stem	  cells	  (NSC)	  persist	  in	  the	  adult	  mouse	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brain	  and	  the	  “neurosphere	  assay”	  has	  become	  widely	  adopted	  as	  a	  method	  of	  detecting,	  selecting,	  and	  enriching	  for	  neural	  stem	  cells.	  In	  2004	  Sanai	  and	  colleagues	  identified	  NSC	  in	  the	  subventricular	  zone	  and	  hippocampus	  of	  the	  adult	  human	  brain	  (Sanai	  et	  al.	  2004).	  	  In	  1997,	  Miraglia	  et	  al	  discovered	  CD133,	  a	  surface	  protein	  with	  a	  unique	  structure	  consisting	  of	  5	  transmembrane	  domains	  that	  was	  found	  to	  be	  expressed	  on	  CD34+	  haematopoietic	  stem	  cells	  and	  on	  some	  leukaemic	  cells	  (Miraglia	  et	  al.	  1997).	  Uchida	  and	  colleagues	  subsequently	  used	  an	  antibody	  to	  CD133	  to	  directly	  isolate	  neural	  stem	  cells	  from	  human	  foetal	  brain	  tissue	  (N.	  Uchida	  et	  al.	  2000).	  	  In	  2003,	  Peter	  Dirks	  and	  colleagues	  first	  reported	  the	  presence	  of	  “Brain	  Tumour	  Stem	  Cells”	  in	  human	  primary	  brain	  tumours	  (S.	  K.	  Singh	  et	  al.	  2003).	  Using	  a	  serum-­‐free	  media	  supplemented	  with	  growth	  factors	  similar	  to	  that	  described	  by	  Weiss	  and	  Reynolds,	  they	  found	  that	  dissociated	  human	  primary	  brain	  tumour	  cells	  grew	  as	  non-­‐adherent	  aggregations	  resembling	  neurospheres.	  The	  sphere	  cells	  expressed	  CD133	  and	  nestin,	  an	  intermediate	  filament	  transiently	  expressed	  by	  NSC	  in	  the	  developing	  CNS	  (Lendahl	  et	  al.	  1990).	  When	  placed	  into	  serum-­‐containing	  media,	  the	  cells	  grew	  as	  an	  adherent	  monolayer,	  lost	  expression	  of	  CD133	  and	  nestin,	  and	  began	  to	  express	  glial	  or	  neuronal	  markers	  depending	  on	  the	  original	  tumour	  type.	  After	  magnetic	  bead	  sorting,	  only	  the	  CD133+	  cells	  were	  able	  to	  form	  spheres	  in	  
vitro.	  Thus	  culture	  in	  SC	  media	  selected	  for,	  or	  induced,	  a	  more	  stem	  cell-­‐like	  tumour	  cell.	  In	  2004,	  two	  other	  groups	  reported	  that	  sphere	  cells	  derived	  from	  human	  GBM	  formed	  tumours	  when	  injected	  orthotopically	  into	  immunodeficient	  mice	  (Galli	  et	  al.	  2004;	  Yuan	  et	  al.	  2004)	  whereas	  adherent	  cells	  grown	  in	  standard	  media	  containing	  foetal	  bovine	  serum	  did	  not	  (Yuan	  et	  al.	  2004).	  These	  early	  studies	  represent	  the	  beginning	  of	  the	  common	  practice	  of	  equating	  the	  neurosphere	  assay	  with	  the	  “isolation”	  of	  CSC.	  	  Dirks’	  group	  subsequently	  extended	  their	  in	  vitro	  findings	  to	  show	  that	  as	  few	  as	  100	  CD133+	  human	  GBM	  cells	  were	  able	  to	  form	  tumours	  when	  injected	  orthotopically	  into	  immunodeficient	  NOD/SCID	  mice,	  whereas	  1	  x	  105	  CD133-­‐	  cells	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engrafted	  but	  did	  not	  form	  tumours	  (S.	  K.	  Singh	  et	  al.	  2004).	  By	  showing	  that	  fresh	  tumour	  tissue	  could	  be	  directly	  sorted	  into	  tumourigenic	  and	  non-­‐tumourigenic	  fractions	  using	  a	  SC-­‐associated	  surface	  marker,	  Dirks	  and	  colleagues	  provided	  compelling	  evidence	  in	  support	  of	  the	  existence	  of	  CSC	  in	  human	  glioma.	  	  Following	  this	  landmark	  study,	  CD133	  expression	  has	  been	  widely	  used	  to	  identify	  and	  isolate	  putative	  CSC	  from	  primary	  tumour	  tissue	  in	  glioma,	  colon	  cancer	  (O'Brien	  et	  al.	  2007),	  prostate	  cancer	  (Collins	  et	  al.	  2005)	  and	  melanoma	  (Monzani	  et	  al.	  2007).	  Many	  studies	  (Colman	  et	  al.	  2010;	  Metellus	  et	  al.	  2011;	  Rebetz	  et	  al.	  2008;	  Zeppernick	  et	  al.	  2008;	  M.	  Zhang	  et	  al.	  2008),	  though	  not	  all	  (K.-­‐J.	  Kim	  et	  al.	  2011;	  Pallini	  et	  al.	  2011),	  have	  found	  a	  correlation	  between	  CD133	  expression	  and	  worse	  outcome	  in	  patients	  with	  high	  grade	  glioma	  and,	  consistent	  with	  the	  idea	  that	  treatment-­‐resistant	  CSC	  are	  the	  cause	  of	  relapse,	  CD133	  expression	  has	  been	  reported	  to	  be	  increased	  in	  recurrent	  GBM	  compared	  with	  the	  original	  tumour	  (G.	  Liu	  et	  al.	  2006;	  Pallini	  et	  al.	  2011).	  	  	  	  
5.1.3	   CSC	  in	  glioma:	  complexities	  and	  controversies	  	  After	  this	  promising	  start	  to	  the	  CSC	  story,	  it	  has	  subsequently	  become	  clear	  that	  the	  situation	  is	  far	  more	  complex	  than	  first	  thought	  and	  controversy	  reigns	  in	  almost	  every	  area	  of	  the	  field.	  Many	  studies	  have	  now	  reported	  that	  CD133-­‐	  GBM	  cells	  are	  capable	  of	  tumour-­‐initiation	  in	  xenotransplanation	  assays	  (D.	  Beier	  et	  al.	  2007;	  Clément	  et	  al.	  2009;	  Joo	  et	  al.	  2008;	  Nishide	  et	  al.	  2009;	  Ogden	  et	  al.	  2008;	  Piccirillo	  et	  al.	  2009;	  Jian	  Wang	  et	  al.	  2008).	  	  Also,	  when	  antibodies	  are	  used	  to	  determine	  the	  proportion	  of	  CD133+	  cells	  in	  GBM	  primary	  tumour	  samples,	  the	  proportion	  has	  variously	  been	  reported	  to	  be	  19-­‐29	  %	  (S.	  K.	  Singh	  et	  al.	  2004),	  10-­‐70	  %	  (G.	  Liu	  et	  al.	  2006),	  0.01-­‐46	  %	  (Joo	  et	  al.	  2008),	  0.01-­‐1.0	  %	  (Clément	  et	  al.	  2009),	  and	  0	  %	  (Osmond	  et	  al.	  2010).	  The	  reason	  for	  these	  widely	  differing	  results	  is	  not	  clear.	  One	  possibility	  is	  that	  these	  differences	  reflect	  technical	  difficulties	  in	  detecting	  the	  CD133	  protein.	  The	  commonly	  used	  antibodies	  AC133	  and	  AC144	  are	  sensitive	  to	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the	  glycosylation	  state	  of	  the	  CD133	  molecule	  which	  itself	  is	  sensitive	  to	  exposure	  of	  cells	  to	  serum	  and	  trypsin	  (Campos	  and	  Herold-­‐Mende	  2011;	  Wan	  et	  al.	  2010).	  Also,	  it	  has	  also	  been	  shown	  that	  CD133	  is	  often	  intracellular	  and	  that,	  due	  to	  alternative	  splicing,	  several	  variants	  of	  the	  CD133	  protein	  exist	  that	  are	  not	  all	  recognised	  by	  commonly-­‐used	  commercially-­‐available	  antibodies	  (Osmond	  et	  al.	  2010;	  Wan	  et	  al.	  2010)	  so	  that	  immunoreactivity	  does	  not	  necessarily	  reflect	  CD133	  protein	  levels.	  An	  alternative	  explanation	  is	  that	  some	  CSC	  are	  indeed	  CD133-­‐	  and	  that	  the	  CSC	  phenotype	  of	  a	  given	  tumour	  may	  depend	  on	  the	  cell-­‐of-­‐origin	  and/or	  molecular	  subtype	  of	  the	  tumour	  (D.	  Beier	  et	  al.	  2007;	  Günther	  et	  al.	  2008;	  Lottaz	  et	  al.	  2010).	  Adding	  to	  the	  uncertainty	  about	  the	  reliability	  of	  CD133	  as	  a	  marker	  of	  glioma	  CSC	  is	  the	  fact	  that	  the	  physiological	  function	  of	  CD133	  remains	  unknown	  (Campos	  and	  Herold-­‐Mende	  2011;	  Wan	  et	  al.	  2010).	  One	  study	  found	  that	  CD133	  expression	  by	  melanoma	  and	  colon	  cancer	  cells	  was	  dependent	  on	  DNA	  content	  and	  was	  therefore	  a	  marker	  of	  actively	  cycling	  cells	  (Jaksch	  et	  al.	  2008).	  Griguer	  and	  colleagues	  found	  that	  CD133	  expression	  by	  a	  glioma	  cell	  line	  was	  reversibly	  induced	  by	  severe	  hypoxia	  or	  depletion	  of	  mitochondria	  and	  suggested	  that	  CD133	  is	  a	  marker	  of	  bio-­‐energetic	  stress	  (Griguer	  et	  al.	  2008).	  To	  my	  knowledge,	  no	  study	  has	  yet	  reported	  failure	  of	  CD133+	  GBM	  cells	  to	  form	  tumours	  in	  immunodeficient	  mice.	  Thus,	  while	  CD133	  surface	  expression	  appears	  to	  be	  sufficient	  for	  tumourigenesis	  in	  xenotransplantation	  assays,	  it	  is	  not	  absolutely	  required	  and	  therefore	  does	  not,	  by	  itself,	  define	  CSC	  in	  glioma.	  	  	  Uncertainty	  also	  surrounds	  the	  neurosphere	  assay	  as	  a	  method	  for	  selecting	  CSC.	  	  The	  proportion	  of	  CSC-­‐like	  cells	  in	  glioma	  spheres	  is	  said	  to	  be	  3-­‐20	  %	  (Wan	  et	  al.	  2010)	  so	  that	  the	  neurosphere	  assay	  would	  not	  appear	  to	  be	  an	  ideal	  method	  for	  purifying	  these	  cells.	  However,	  there	  are	  more	  fundamental	  concerns	  than	  this.	  Sphere	  formation	  in	  SC	  media	  is	  not	  unique	  to	  NSC	  and	  CNS	  tumours	  but	  has	  now	  been	  described	  in	  several	  other	  solid	  tumours	  (Liao	  et	  al.	  2007;	  Ricci-­‐Vitiani	  et	  al.	  2007).	  It	  has	  been	  proposed	  that	  the	  neurosphere	  assay	  does	  not	  select	  stem	  cells	  
per	  se,	  but	  rather	  cells	  that	  express	  EGFR	  (Pastrana	  et	  al.	  2011).	  It	  is	  possible	  that	  the	  superior	  tumourigenicity	  of	  sphere	  cells	  in	  xenotransplantation	  assays	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compared	  to	  tumour	  cells	  grown	  in	  standard	  media	  is	  an	  artefact	  of	  exposure	  to	  potent	  mitogenic	  factors	  in	  the	  SC	  media	  that	  promote	  tumour	  cell	  survival	  and	  proliferation	  (Kelly	  et	  al.	  2009).	  Furthermore,	  it	  has	  been	  reported	  that	  culture	  in	  SC	  media	  preserves	  the	  genotype	  and	  phenotype	  of	  the	  original	  tumour	  more	  faithfully,	  and	  should	  be	  used	  for	  this	  purpose,	  whereas	  culture	  in	  serum-­‐containing	  media	  induces	  a	  loss	  of	  tumourigenicity	  that	  is	  not	  representative	  of	  the	  original	  tumour	  (Fael	  Al-­‐Mayhani	  et	  al.	  2009;	  J.	  Lee	  et	  al.	  2006b).	  For	  all	  these	  reasons,	  it	  may	  be	  hazardous	  to	  assume	  that	  culture	  in	  SC	  medium	  is	  a	  way	  of	  selecting	  a	  CSC	  subset.	  	  Another	  challenge	  to	  the	  CSC	  model	  comes	  from	  reports	  that	  the	  SC-­‐like	  phenotype	  is	  not	  a	  fixed	  intrinsic	  property	  of	  certain	  glioma	  tumour	  cells	  but	  can	  be	  induced	  by	  the	  tumour	  microenvironment	  (Rosen	  and	  Jordan	  2009).	  As	  already	  mentioned	  above,	  a	  CD133-­‐	  GBM	  cell	  line	  can	  reversibly	  become	  CD133+	  in	  response	  to	  hypoxia	  
in	  vitro	  (Griguer	  et	  al.	  2008).	  In	  other	  studies,	  CD133-­‐	  GBM	  cells	  exposed	  to	  hypoxia	  
in	  vitro	  upregulated	  SC-­‐associated	  genes	  and	  exhibited	  an	  increased	  ability	  to	  form	  spheres	  (Heddleston	  et	  al.	  2009),	  and	  CD133+	  GBM	  cells	  cultured	  in	  7	  %	  02	  increased	  their	  expression	  of	  neural	  stem	  cell	  markers	  CD133	  and	  nestin	  and	  stem	  cell	  markers	  OCT4	  and	  SOX2,	  these	  changes	  mostly	  reversing	  when	  the	  cells	  were	  restored	  to	  20	  %	  O2	  (McCord	  et	  al.	  2009b).	  In	  an	  in	  vivo	  study,	  Wang	  and	  colleagues	  reported	  that	  CD133–	  cells	  implanted	  into	  immunodeficient	  mice	  formed	  tumours	  that	  eventually	  contained	  CD133+	  cells	  (Jian	  Wang	  et	  al.	  2008).	  	  This	  plasticity,	  where	  tumour	  cells	  appear	  to	  be	  able	  to	  move	  between	  stem-­‐like	  and	  non	  stem-­‐like	  states	  in	  response	  to	  their	  environment,	  has	  similarities	  with	  the	  phenomenon	  of	  Epithelial-­‐Mesenchymal	  Transition	  (EMT),	  a	  process	  central	  to	  embryogenesis	  and	  believed	  to	  play	  a	  major	  role	  in	  invasion	  and	  metastasis	  in	  some	  solid	  tumours	  (Gupta	  et	  al.	  2009).	  Mani	  and	  colleagues	  (Mani	  et	  al.	  2008)	  showed	  that	  experimental	  induction	  of	  EMT	  in	  an	  immortal	  human	  mammary	  epithelium	  cell	  line	  was	  associated	  with	  acquisition	  of	  a	  CD44hiCD24lo	  surface	  marker	  phenotype	  and	  the	  ability	  to	  form	  mammospheres,	  both	  features	  of	  putative	  CSC	  in	  breast	  cancer.	  Also	  pertinent	  is	  the	  recent	  report	  of	  Gupta	  and	  colleagues	  (Gupta	  et	  al.	  2011)	  in	  which	  sorted	  cell	  populations	  from	  human	  breast	  tumours	  were	  transplanted	  into	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immunodeficient	  mice	  along	  with	  irradiated	  “feeder”	  cells	  to	  promote	  tumourigenesis.	  As	  predicted	  by	  the	  CSC	  model,	  CD44+CD24lo	  “CSC”	  cells	  formed	  tumours	  that	  also	  included	  other	  non-­‐CSC	  tumour	  cell	  phenotypes.	  Less	  expected	  was	  the	  finding	  that	  tumours	  forming	  after	  implantation	  of	  purified	  “non-­‐CSC”	  subsets	  were	  found	  to	  include	  a	  subset	  of	  cells	  with	  the	  “CSC”	  phenotype,	  with	  the	  same	  proportion	  of	  CSC	  to	  non-­‐CSC	  cells	  as	  the	  CSC-­‐derived	  tumours.	  This	  suggests	  the	  existence	  of	  an	  equilibrium	  between	  CSC	  and	  non-­‐CSC	  phenotypes	  within	  tumour	  cell	  populations	  in	  vivo.	  At	  the	  present	  time,	  it	  is	  unclear	  whether	  heterogeneity	  in	  GBM	  tumours	  is	  the	  result	  of	  stochastic	  events,	  hierarchical	  events,	  or	  both.	  Until	  this	  is	  resolved,	  it	  may	  be	  hazardous	  to	  focus	  therapeutic	  efforts	  entirely	  on	  the	  putative	  CSC	  compartment.	  	  One	  of	  the	  most	  attractive	  aspects	  of	  the	  CSC	  model	  is	  the	  concept	  that	  properties	  of	  CSC	  render	  them	  particularly	  resistant	  to	  radiation	  and	  chemotherapy	  thereby	  explaining	  the	  failure	  of	  standard	  treatments.	  	  Putative	  glioma	  CSC	  have	  been	  reported	  to	  express	  higher	  levels	  of	  anti-­‐apoptotic	  molecules	  (G.	  Liu	  et	  al.	  2006),	  reduced	  levels	  of	  caspase-­‐8	  (Capper	  et	  al.	  2009)	  and	  exhibit	  enhanced	  DNA	  damage	  repair	  (Bao	  et	  al.	  2006a),	  conferring	  a	  general	  resistance	  to	  radiation	  and	  chemotherapeutic	  agents.	  A	  feature	  of	  normal	  haematopoietic	  stem	  cells	  is	  their	  relative	  chemoresistance	  which	  is	  thought	  to	  be	  at	  least	  partly	  due	  to	  the	  rapid	  expulsion	  of	  xenobiotics	  by	  membrane-­‐bound	  transporter	  proteins	  (Reya	  et	  al.	  2001).	  Increased	  expression	  of	  these	  ATP-­‐binding	  cassette	  (ABC)	  transporters	  proteins	  has	  also	  been	  reported	  to	  be	  a	  feature	  of	  putative	  CSC	  in	  several	  solid	  cancers	  including	  GBM	  (Bleau	  et	  al.	  2009b;	  G.	  Liu	  et	  al.	  2006).	  	  However,	  this	  does	  not	  explain	  the	  failure	  of	  chemotherapy	  to	  cure	  patients	  with	  GBM	  because	  TMZ,	  currently	  the	  standard	  chemotherapy	  agent	  for	  this	  condition,	  is	  not	  a	  substrate	  for	  ABC	  transporters	  (Bleau	  et	  al.	  2009b).	  Instead,	  TMZ	  resistance	  is	  closely	  associated	  with	  expression	  of	  the	  DNA	  repair	  enzyme	  MGMT.	  Silencing	  of	  MGMT	  expression	  by	  promoter	  methylation	  is	  associated	  with	  improved	  outcome	  after	  standard	  treatment	  (Weller	  et	  al.	  2010).	  Consistent	  with	  the	  idea	  that	  glioma	  CSC	  are	  more	  resistant	  to	  TMZ,	  Liu	  and	  colleagues	  found	  that	  CD133+	  cells	  from	  primary	  GBM	  cell	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lines	  contained	  higher	  levels	  of	  MGMT	  mRNA	  than	  CD133-­‐	  cells	  (G.	  Liu	  et	  al.	  2006).	  However,	  the	  evidence	  for	  this	  is	  contradictory,	  with	  some	  studies	  reporting	  that	  CSC	  in	  glioma	  are	  actually	  more	  susceptible	  to	  TMZ	  (D.	  Beier	  et	  al.	  2008)	  and	  that	  GBM	  sphere	  cells	  exhibit	  higher	  levels	  of	  MGMT	  promoter	  methylation	  (Sciuscio	  et	  al.	  2011).	  Similarly,	  whereas	  one	  influential	  study	  showed	  that	  sorted	  CD133+	  GBM	  cells	  were	  more	  resistant	  to	  radiation	  (Bao	  et	  al.	  2006a),	  a	  contradictory	  study	  reported	  that	  GBM	  sphere	  cells	  were	  more	  sensitive	  to	  ionising	  radiation	  (McCord	  et	  al.	  2009a).	  Thus,	  treatment	  resistance	  of	  putative	  glioma	  CSC	  remains	  controversial.	  	  
5.1.4	   Definition	  of	  Cancer	  Stem	  Cells	  (CSC)	  and	  Stem-­‐like	  Cancer	  Cells	  (SLCC)	  In	  2006	  an	  expert	  panel	  defined	  CSC	  as	  “a	  cell	  within	  a	  tumour	  that	  possesses	  the	  
capacity	  to	  self-­‐renew	  and	  to	  cause	  the	  heterogeneous	  lineages	  of	  cancer	  cells	  that	  
comprise	  the	  tumour”	  and	  stated	  “cancer	  stem	  cells	  can	  thus	  only	  be	  defined	  
experimentally	  by	  their	  ability	  to	  recapitulate	  the	  generation	  of	  a	  continuously	  
growing	  tumour”	  (Clarke	  et	  al.	  2006).	  More	  recently,	  an	  authoritative	  review	  described	  CSC	  as	  “a	  biologically	  distinct	  subset	  within	  the	  total	  malignant	  cell	  
population”	  that	  have	  “the	  ability	  to	  give	  rise	  to	  progeny	  with	  limited	  proliferative	  
capacity”	  and	  stated	  that	  “this	  model	  precludes	  the	  concept	  of	  reversibility	  between	  
intrinsically	  determined	  states	  of	  unrestricted	  and	  limited	  proliferative	  potential”	  (Nguyen	  et	  al.	  2012).	  To	  put	  this	  slightly	  differently,	  in	  the	  practical	  clinical	  context	  of	  established	  tumours	  in	  patients,	  the	  defining	  characteristic	  of	  putative	  CSC	  is	  the	  exclusive	  ability	  to	  maintain	  the	  existing	  tumour.	  The	  definition	  of	  CSC	  above	  implies	  both	  heterogeneity	  and	  hierarchy,	  requiring	  the	  presence	  of	  at	  least	  one	  other	  tumour	  cell	  phenotype	  that	  does	  not	  having	  tumour-­‐maintaining	  capacity	  or	  the	  capacity	  to	  acquire	  tumour-­‐maintaining	  ability.	  The	  capacity	  to	  indefinitely	  maintain	  tumours	  in	  patients	  also	  requires	  the	  CSC	  compartment	  to	  indefinitely	  maintain	  itself	  or	  “self-­‐renew”.	  Defined	  in	  this	  way,	  it	  follows	  that	  elimination	  of	  the	  CSC	  compartment	  should	  be	  both	  necessary	  and	  sufficient	  to	  achieve	  cure	  (Nguyen	  et	  al.	  2012).	  These	  definitions	  also	  recognise	  the	  practical	  need	  to	  use	  tumour-­‐
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initiation	  in	  animal	  models	  as	  a	  surrogate	  for	  tumour-­‐maintenance	  in	  human	  patients.	  In	  practice,	  an	  improved	  capacity	  for	  tumour	  initiation,	  rather	  than	  an	  exclusive	  capacity,	  is	  often	  accepted	  on	  the	  grounds	  that	  small	  numbers	  of	  CSC	  may	  contaminate	  non-­‐CSC	  populations	  during	  sorting.	  	  It	  is	  generally	  accepted	  that	  many	  features	  of	  the	  original	  CSC	  model	  described	  in	  leukaemia	  may	  not	  necessarily	  apply	  to	  solid	  tumours.	  As	  discussed	  above,	  cells	  with	  tumour-­‐initiating	  ability	  in	  glioma	  tumours	  are	  not	  necessarily	  rare	  or	  quiescent	  (S.	  K.	  Singh	  et	  al.	  2004),	  do	  not	  necessarily	  express	  normal	  stem	  cell	  markers	  (D.	  Beier	  et	  al.	  2007;	  Read	  et	  al.	  2009)	  and	  have	  not	  been	  proven	  to	  arise	  from	  transformed	  neural	  stem	  cells.	  Although	  proof-­‐of-­‐principle	  studies	  have	  shown	  that	  oncogenically-­‐transformed	  NSC	  are	  capable	  of	  initiating	  tumours	  in	  experimental	  systems	  (Jacques	  et	  al.	  2010;	  Y.	  Zhu	  et	  al.	  2005),	  the	  cell-­‐of-­‐origin	  of	  GBM	  still	  remains	  uncertain	  (Shackleton	  et	  al.	  2009).	  However,	  the	  definition	  of	  CSC	  does	  not	  require	  an	  origin	  from	  transformed	  normal	  stem	  cells	  (Clarke	  et	  al.	  2006;	  Dick	  2008;	  Gupta	  et	  al.	  2009).	  Although	  importance	  is	  often	  placed	  on	  the	  ability	  of	  CSC	  to	  recapitulate	  the	  morphology	  of	  the	  original	  tumour,	  this	  may	  be	  too	  stringent	  a	  requirement	  for	  xenotransplantation	  assays	  where	  the	  recipient	  stroma	  is	  very	  different	  to	  the	  original	  host.	  	  Also,	  although	  the	  term	  CSC	  implies	  an	  ability	  to	  give	  rise	  to	  at	  least	  one	  other	  more	  differentiated	  phenotype	  with	  reduced	  tumourigenic	  capacity,	  the	  capacity	  for	  multilineage	  differentiation	  is	  not	  a	  mandatory	  part	  of	  the	  definition	  (Finocchiaro	  and	  Pellegatta	  2011;	  Vescovi	  et	  al.	  2006).	  	  	  Although	  the	  exclusive	  ability	  to	  initiate	  tumours	  is	  regarded	  as	  the	  cardinal	  requirement	  for	  the	  operational	  definition	  of	  CSC,	  a	  persistent	  concern	  remains	  over	  the	  need	  to	  infer	  this	  property	  from	  behaviour	  in	  immunodeficient	  mice.	  In	  studies	  on	  melanoma,	  the	  size	  of	  the	  tumourigenic	  fraction	  depended	  on	  the	  degree	  of	  immunodeficiency	  of	  the	  recipient	  mouse	  strain	  (Quintana	  et	  al.	  2010),	  raising	  the	  possibility	  that	  transplantation	  into	  commonly-­‐used	  NOD/SCID	  mice	  (that	  still	  have	  NK	  cells	  and	  other	  innate	  immune	  effector	  cells)	  may	  underestimate	  the	  true	  size	  of	  the	  tumourigenic	  population	  (Shackleton	  et	  al.	  2009).	  Also,	  interactions	  between	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tumour	  cells	  and	  stromal	  cells	  are	  critical	  in	  determining	  behaviour	  in	  vivo	  (Bonavia	  et	  al.	  2011;	  Charles	  et	  al.	  2011).	  In	  the	  study	  of	  breast	  cancer	  cell	  subsets	  by	  Gupta	  and	  colleagues	  mentioned	  above	  (Gupta	  et	  al.	  2011),	  whereas	  only	  CD44+CD24lo	  putative	  CSC	  were	  tumourigenic	  when	  transplanted	  alone	  into	  immunodeficient	  mice,	  all	  subsets	  were	  tumourigenic	  when	  co-­‐transplanted	  with	  irradiated	  stromal	  cells.	  Calabrese	  and	  colleagues	  also	  reported	  that	  the	  tumourigenicity	  of	  medulloblastoma	  cells	  implanted	  into	  mice	  was	  enhanced	  by	  the	  co-­‐transplantation	  of	  human	  endothelial	  cells	  (Calabrese	  et	  al.	  2007).	  	  Thus,	  it	  is	  possible	  that	  the	  proportion	  of	  GBM	  cells	  considered	  to	  be	  “tumourigenic”	  would	  increase	  substantially	  if	  yet-­‐to-­‐be-­‐defined	  human	  stromal	  cells	  and/or	  human	  growth	  factors	  were	  included	  in	  these	  xenotransplantation	  models	  (Bonavia	  et	  al.	  2011).	  If	  the	  bulk	  tumour	  population	  is	  in	  fact	  capable	  of	  tumourigenesis	  in	  its	  original	  syngeneic	  host,	  the	  CSC	  model	  cannot	  be	  said	  to	  apply.	  The	  term	  CSC	  should	  be	  used	  cautiously	  while	  this	  concern	  still	  exists.	  As	  a	  minimum,	  a	  tumour-­‐initiating	  cell	  should	  not	  be	  called	  a	  CSC	  without	  also	  demonstrating	  heterogeneity	  and	  hierarchy.	  This	  general	  principle	  is	  often	  violated	  in	  the	  literature,	  where	  cells	  expressing	  stem	  cell	  markers	  or	  exhibiting	  stem	  cell-­‐like	  behaviours	  such	  as	  sphere	  formation	  or	  multipotency,	  are	  often	  referred	  to	  as	  CSC	  without	  confirming	  the	  existence	  of	  a	  mixed	  population	  of	  tumourigenic	  and	  non-­‐tumourigenic	  cells.	  If	  these	  	  “stem	  cell-­‐like	  cancer	  cells”	  (SLCC)	  are	  not	  a	  subset	  of	  a	  heterogeneous	  tumour	  cell	  population	  that	  otherwise	  consists	  of	  their	  non-­‐tumourigenic	  progeny,	  they	  are	  not	  CSC	  by	  definition.	  However,	  SLCC	  may	  still	  be	  legitimate	  targets	  for	  novel	  therapies.	  	  The	  literature	  suggests	  that	  almost	  every	  adverse	  characteristic	  of	  malignant	  glioma	  is	  amplified	  in	  these	  more	  stem	  cell-­‐like	  tumour	  cells	  including	  invasion	  (Ye	  et	  al.	  2012),	  induction	  of	  angiogenesis	  (Bao	  et	  al.	  2006b;	  Folkins	  et	  al.	  2009;	  Heddleston	  et	  al.	  2009;	  Ricci-­‐Vitiani	  et	  al.	  2010;	  R.	  Wang	  et	  al.	  2010b),	  resistance	  to	  radiation	  (Bao	  et	  al.	  2006a)	  and	  chemotherapy	  (G.	  Liu	  et	  al.	  2006),	  and	  immunosuppression	  (Wei	  et	  al.	  2010;	  Wei	  et	  al.	  2011).	  Thus	  treatments	  that	  specifically	  target	  SLCC	  may	  improve	  survival	  by	  suppressing	  a	  particularly	  aggressive	  and	  therapy-­‐resistant	  phenotype.	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5.1.5	   Targeting	  Glioma	  CSC/SLCC	  with	  immunotherapy	  	  Already,	  diverse	  ways	  of	  targeting	  SLCC	  and	  putative	  CSC	  in	  patients	  with	  high	  grade	  glioma	  and	  other	  solid	  tumours	  have	  been	  tested	  in	  animal	  models	  and	  some	  of	  these	  are	  now	  reaching	  the	  clinic.	  This	  topic	  is	  fully	  discussed	  in	  recent	  reviews	  (Alison	  et	  al.	  2012;	  Frosina	  2011).	  Conceptually,	  CSC-­‐directed	  treatments	  aim	  to	  either	  eliminate	  CSC	  directly,	  to	  increase	  the	  sensitivity	  of	  CSC	  to	  standard	  treatments,	  or	  to	  attenuate	  some	  property	  of	  CSC	  that	  is	  driving	  tumour	  progression.	  For	  example,	  inhibition	  of	  the	  Notch	  pathway	  has	  been	  proposed	  both	  as	  a	  way	  of	  reducing	  the	  proliferative	  and	  invasive	  properties	  of	  CSC	  and	  as	  a	  way	  of	  sensitising	  CSC	  to	  radiation	  treatment	  (Fan	  et	  al.	  2010;	  Jialiang	  Wang	  et	  al.	  2010a;	  Jianpeng	  Wang	  et	  al.	  2012).	  	  Bevacizumab,	  an	  anti-­‐VEGF	  monoclonal	  antibody	  currently	  being	  evaluated	  in	  patients	  with	  GBM,	  is	  considered	  by	  some	  to	  be	  a	  form	  of	  CSC-­‐targeted	  treatment	  (Li	  et	  al.	  2012)	  on	  the	  grounds	  that	  glioma	  CSC	  are	  claimed	  to	  induce	  angiogenesis	  through	  VEGF	  secretion	  (Bao	  et	  al.	  2006b)	  that	  in	  turn	  induces	  the	  formation	  of	  a	  perivascular	  niche	  that	  supports	  maintenance	  of	  a	  stem	  cell-­‐like	  state	  (Calabrese	  et	  al.	  2007).	  Some	  groups	  have	  explored	  the	  idea	  of	  combining	  an	  SLCC-­‐targeted	  therapy	  with	  a	  therapy	  targeting	  the	  non-­‐SLCC	  compartment.	  For	  example,	  using	  breast	  cancer	  cell	  lines,	  Hirsch	  and	  colleagues	  showed	  that	  the	  additive	  effects	  of	  metformin	  and	  doxorubicin	  were	  due	  to	  selective	  targeting	  of	  the	  CD44hiCD24lo	  CSC	  and	  CD44loCD24hi	  non-­‐CSC	  compartments	  respectively	  (Hirsch	  et	  al.	  2009).	  Support	  for	  this	  approach	  was	  also	  provided	  by	  a	  recent	  study	  in	  a	  genetically	  engineered	  mouse	  model	  of	  glioma	  in	  which	  treatment	  with	  TMZ	  and	  conditional	  ablation	  of	  nestin-­‐expressing	  cells	  had	  an	  additive	  effect	  (J.	  Chen	  et	  al.	  2012).	  The	  potential	  for	  improving	  the	  efficacy	  of	  glioma	  immunotherapy	  by	  targeting	  the	  putative	  CSC	  subset	  has	  been	  quickly	  recognised.	  In	  2006	  Pellegatta	  and	  colleagues	  reported	  that	  the	  GL261	  murine	  glioma	  cell	  line	  grew	  as	  unattached	  spheres	  when	  cultured	  in	  SC	  media	  and	  that	  mice	  implanted	  orthotopically	  with	  sphere	  cells	  became	  symptomatic	  more	  quickly	  than	  mice	  implanted	  with	  GL261	  grown	  in	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standard	  media	  (Pellegatta	  et	  al.	  2006b).	  In	  this	  study,	  vaccination	  with	  DC	  pulsed	  with	  a	  sphere	  cell	  lysate	  was	  more	  effective	  against	  intracranial	  tumours	  than	  DC	  pulsed	  with	  parental	  tumour	  lysate.	  	  In	  2009	  Xu	  and	  colleagues	  reported	  similar	  results	  in	  the	  9L	  rat	  glioma	  model	  using	  DC	  loaded	  with	  peptides	  acid-­‐eluted	  from	  sphere	  cells	  or	  cells	  cultured	  in	  standard	  media	  (Q.	  Xu	  et	  al.	  2009).	  This	  study	  also	  reported	  that	  a	  range	  of	  known	  glioma-­‐associated	  antigens	  were	  expressed	  at	  higher	  levels	  in	  human	  GBM	  sphere	  cell	  lines	  relative	  to	  tumour	  cells	  cultured	  in	  standard	  media,	  and	  that	  human	  DC	  pulsed	  with	  peptides	  acid-­‐eluted	  from	  a	  human	  GBM	  sphere	  cell	  line	  elicited	  stronger	  T	  cell	  responses	  to	  these	  antigens	  in	  vitro	  than	  DC	  pulsed	  with	  peptides	  eluted	  from	  the	  same	  cell	  line	  cultured	  in	  standard	  media.	  The	  authors	  further	  reported	  that	  this	  was	  not	  due	  to	  differences	  in	  DC	  maturation	  or	  antigen	  uptake.	  However,	  some	  of	  the	  TAA	  identified	  in	  this	  study	  as	  being	  overexpressed	  by	  sphere	  cells	  relative	  to	  standard	  cells,	  such	  as	  the	  melanoma-­‐associated	  differentiation	  antigen	  TRP-­‐2,	  have	  no	  known	  association	  with	  a	  stem-­‐like	  phenotype,	  suggesting	  the	  superior	  performance	  of	  the	  sphere	  cells	  in	  this	  study	  may	  have	  been	  due	  to	  some	  unexplained	  general	  effect	  of	  the	  SC	  medium	  on	  TAA	  expression.	  These	  studies	  in	  immunocompetent	  rodents	  suggest	  that	  sphere	  cells	  may	  be	  a	  superior	  source	  of	  antigens	  for	  DC	  vaccines	  but	  it	  is	  not	  clear	  that	  the	  vaccines	  necessarily	  acted	  by	  selectively	  targeting	  CSC.	  As	  previously	  mentioned,	  it	  has	  been	  proposed	  that	  culturing	  human	  glioma	  tissue	  in	  SC	  medium	  on	  laminin-­‐coated	  plates	  preserves	  the	  phenotype	  and	  genotype	  of	  the	  original	  tumour	  more	  faithfully	  than	  culture	  in	  standard	  conditions	  (J.	  Lee	  et	  al.	  2006b).	  If	  confirmed,	  this	  would	  suggest	  that	  sphere	  cells	  might	  supply	  antigens	  that	  align	  more	  closely	  with	  the	  antigens	  presented	  by	  the	  target	  tumour	  than	  cell	  lines	  raised	  in	  standard	  culture	  conditions.	  Vik-­‐Mo	  and	  colleagues	  have	  recently	  published	  the	  results	  of	  a	  Phase	  I	  trial	  in	  which	  newly-­‐presenting	  GBM	  patients	  were	  vaccinated	  with	  DC	  loaded	  with	  RNA	  extracted	  from	  autologous	  tumour	  sphere	  cultures	  (Vik-­‐Mo	  et	  al.	  2013).	  Progression-­‐free	  survival	  in	  7	  treated	  patients	  was	  reported	  to	  be	  prolonged	  compared	  with	  matched	  historical	  controls.	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Several	  preclinical	  studies	  have	  assessed	  the	  feasibility	  of	  targeting	  glioma	  CSC	  in	  patients	  with	  immunotherapy.	  Bertrand	  and	  colleagues	  (Bertrand	  et	  al.	  2009)	  used	  the	  U87	  immortal	  human	  glioma	  cell	  line	  to	  show	  that	  CD133+	  cells	  were	  more	  resistant	  to	  Fas-­‐mediated	  apoptosis	  than	  CD133-­‐	  cells.	  However,	  Brown	  and	  colleagues	  (C.	  E.	  Brown	  et	  al.	  2009)	  compared	  sphere	  cells	  derived	  from	  human	  GBM	  tumours	  with	  their	  serum-­‐cultured	  counterparts	  and	  found	  both	  were	  competent	  to	  process	  and	  present	  endogenous	  antigen	  and	  detected	  no	  differences	  in	  MHC	  class	  I	  expression,	  ICAM-­‐1	  expression,	  susceptibility	  to	  perforin,	  or	  ability	  to	  trigger	  degranulation	  of	  CTL.	  They	  also	  showed	  that	  CTL	  adoptively	  transferred	  into	  immunodeficient	  mice	  were	  able	  to	  eliminate	  human	  “CSC”	  in	  vivo.	  Wu	  and	  colleagues	  (Anhua	  Wu	  et	  al.	  2007b)	  compared	  CD133+	  and	  CD133-­‐	  tumour	  cells	  from	  two	  GBM	  tumours	  and	  found	  low	  expression	  of	  MHC	  class	  I	  molecules	  and	  NK	  activating	  receptor	  ligands	  by	  both	  cell	  types	  that	  could	  be	  significantly	  upregulated	  by	  treatment	  with	  IFN-­‐γ	  in	  vitro	  and	  IFN-­‐γ-­‐treatment	  restored	  susceptibility	  of	  CD133+	  cell	  to	  NK	  cell	  lysis.	  	  Avril	  and	  colleagues	  (Avril	  et	  al.	  2011)	  showed	  that	  SLCC	  from	  GBM	  tumours	  were	  more	  sensitive	  to	  lysis	  by	  IL-­‐2-­‐activated	  NK	  cells	  and	  CTL	  than	  serum-­‐cultured	  cells.	  Castriconi	  and	  colleagues	  (Castriconi	  et	  al.	  2009)	  also	  showed	  that	  GBM	  SLCC	  were	  sensitive	  to	  lysis	  by	  IL-­‐2-­‐activated	  NK	  cells.	  Di	  Tomaso	  and	  colleagues	  (Di	  Tomaso	  et	  al.	  2010)	  compared	  GBM-­‐derived	  sphere	  cell	  lines	  with	  their	  respective	  serum-­‐cultured	  cell	  lines	  and	  found	  defects	  in	  antigen-­‐processing	  machinery	  and	  low	  expression	  of	  ligands	  for	  NK	  cell	  activating	  receptors	  that	  were	  similar	  for	  both	  cell	  types.	  MHC	  class	  I	  expression	  tended	  to	  be	  lower	  in	  sphere	  cells	  but	  could	  be	  induced	  by	  IFN-­‐γ	  and	  T	  cell	  lines	  could	  be	  raised	  against	  autologous	  sphere	  cell	  lines	  from	  patient	  PBMC.	  They	  concluded	  that	  sphere	  cells	  were	  poorly	  immunogenic	  but	  no	  more	  so	  than	  serum-­‐cultured	  cells.	  Wei	  and	  colleagues	  (Wei	  et	  al.	  2010)	  found	  that	  GBM	  sphere	  cells	  expressed	  normal	  levels	  of	  MHC	  class	  I.	  Overall,	  preclinical	  studies	  using	  primary	  cell	  lines	  from	  human	  GBM	  tumour	  tissue	  have	  not	  found	  striking	  differences	  in	  susceptibility	  to	  lysis	  by	  competent	  effector	  cells	  between	  SC-­‐like	  and	  non	  SC-­‐like	  tumour	  cells.	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T	  cell	  antigens	  that	  are	  differentially	  expressed	  by	  putative	  CSC	  and	  that	  could	  potentially	  be	  used	  to	  selectively	  target	  these	  cells	  have	  been	  described	  in	  glioma	  and	  other	  cancers.	  Schmitz	  and	  colleagues	  (Schmitz	  et	  al.	  2007)	  used	  microarray	  data	  to	  compare	  GBM	  tumours	  with	  normal	  brain	  tissue	  and	  found	  that	  the	  transcription	  factor	  SOX2,	  normally	  only	  expressed	  in	  the	  developing	  brain,	  was	  overexpressed	  in	  9	  of	  10	  tumours.	  Using	  epitope	  prediction	  software,	  they	  created	  SOX2	  peptides	  that	  were	  able	  to	  elicit	  T	  cell	  responses	  from	  the	  PBMC	  of	  healthy	  volunteers	  that	  in	  turn	  were	  capable	  of	  lysing	  HLA-­‐compatible	  tumour	  cells	  in	  vitro.	  Ueda	  and	  colleagues	  (Ueda	  et	  al.	  2004)	  identified	  SOX6,	  also	  a	  transcription	  factor	  normally	  expressed	  transiently	  in	  the	  developing	  brain,	  as	  another	  potential	  glioma-­‐associated	  antigen	  by	  screening	  the	  serum	  of	  GBM	  patients	  for	  antibodies	  against	  a	  testis	  cDNA	  library.	  Vaccination	  of	  C57BL/6	  mice	  against	  full-­‐length	  SOX6	  protein	  provided	  protective	  and	  therapeutic	  immunity	  against	  GL261	  murine	  glioma	  (Ueda	  et	  al.	  2008)	  and	  SOX6	  peptide	  epitopes	  were	  capable	  of	  expanding	  SOX6-­‐specific	  CTL	  from	  the	  PBMC	  of	  healthy	  volunteers	  and	  patients	  that	  were	  able	  to	  lyse	  HLA-­‐compatible	  tumour	  cells	  in	  vitro,	  including	  a	  “CSC”	  line	  (Ueda	  et	  al.	  2010).	  	  Dhodapkar	  and	  colleagues	  (K.	  M	  Dhodapkar	  et	  al.	  2010)	  detected	  T	  cells	  specific	  for	  the	  protein	  product	  of	  the	  normal	  stem	  cell-­‐associated	  gene	  OCT4	  in	  the	  serum	  of	  healthy	  volunteers	  and	  observed	  an	  increase	  in	  OCT4-­‐specific	  T	  cells	  in	  the	  serum	  of	  patients	  with	  germ	  cell	  tumours	  after	  treatment	  with	  chemotherapy.	  As	  mentioned	  above,	  one	  group	  identified	  antigens	  (Her2/Neu,	  AIM-­‐2	  and	  TRP-­‐2)	  that	  were	  overexpressed	  by	  GBM	  cells	  grown	  in	  SC	  medium	  relative	  to	  cells	  grown	  in	  standard	  media	  and	  termed	  these	  “Cancer	  Stem-­‐like	  Cell-­‐associated	  antigens”	  (Q.	  Xu	  et	  al.	  2009).	  Subsequently,	  this	  group	  has	  reported	  the	  results	  of	  a	  clinical	  trial	  in	  which	  newly-­‐presenting	  GBM	  patients	  were	  vaccinated	  with	  DC	  loaded	  with	  HLA	  A2-­‐restricted	  peptides	  derived	  from	  these	  antigens	  along	  with	  three	  other	  known	  glioma-­‐associated	  antigens	  (Phuphanich	  et	  al.	  2012).	  The	  results	  of	  this	  Phase	  1	  trial	  were	  described	  in	  Chapter	  1.	  Briefly,	  vaccine-­‐induced	  CD8	  T	  cell	  responses	  were	  detected	  in	  a	  third	  of	  patients.	  In	  the	  few	  patients	  who	  underwent	  further	  surgery	  after	  vaccination,	  loss	  of	  CD133	  expression	  was	  observed	  in	  4	  of	  4	  patients	  who	  had	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CD133+	  tumours	  prior	  to	  vaccination.	  This	  may	  indicate	  editing	  of	  SLCC	  although	  peptide-­‐specific	  CD8	  T	  cell	  responses	  were	  not	  seen	  in	  some	  of	  these	  patients.	  	  The	  use	  of	  monoclonal	  antibodies	  to	  target	  putative	  CSC	  surface	  markers	  has	  been	  explored	  in	  preclinical	  models	  of	  non-­‐CNS	  malignancies.	  Dick	  and	  colleagues	  (Jin	  et	  al.	  2006)	  found	  that	  an	  anti-­‐CD44	  mAb	  prevented	  human	  acute	  myeloid	  leukaemia	  CSC	  from	  engrafting	  in	  NOD/SCID	  mice	  at	  least	  in	  part	  by	  interfering	  with	  leukaemic	  stem	  cell	  trafficking	  to	  supportive	  niches.	  	  An	  anti-­‐CD133	  mAb	  conjugated	  to	  a	  cytotoxic	  drug	  potently	  induced	  apoptosis	  in	  a	  human	  CD133+	  hepatocellular	  cancer	  cell	  line	  and	  delayed	  tumour	  growth	  in	  immunodeficient	  mice	  (Smith	  et	  al.	  2008).	  This	  approach	  has	  not	  yet	  been	  tested	  in	  glioma	  patients.	  Although	  the	  in	  vitro	  studies	  described	  above	  suggest	  CSC	  should	  be	  susceptible	  to	  T	  cell-­‐mediated	  cytotoxicity,	  a	  potential	  problem	  for	  immunotherapies	  targeting	  CSC	  
in	  vivo	  is	  raised	  by	  reports	  that	  these	  cells	  are	  particularly	  immunosuppressive.	  Heimberger	  and	  colleagues	  (Wei	  et	  al.	  2010)	  found	  that	  sphere	  cell	  lines	  derived	  from	  human	  GBM	  tumours	  suppressed	  T	  cell	  proliferation	  and	  cytokine	  elaboration,	  induced	  T	  cell	  apoptosis,	  and	  induced	  regulatory	  T	  cells	  in	  vitro.	  These	  effects	  were	  mediated	  by	  direct	  cell-­‐to-­‐cell	  contact	  via	  the	  co-­‐inhibitory	  factor	  PD-­‐L1	  (B7-­‐H1)	  and	  by	  the	  secretion	  of	  soluble	  factors	  TGF-­‐β1,	  PGE2	  and	  CCL-­‐2,	  a	  chemoattractant	  for	  Treg.	  In	  other	  studies,	  this	  group	  has	  also	  shown	  that	  sphere	  cells	  recruit	  macrophages	  and	  polarise	  macrophages	  and	  microglial	  cells	  towards	  an	  immunosuppressive	  M2	  phenotype	  by	  secreting	  soluble	  Colony-­‐Stimulating	  Factor,	  TGF-­‐β1	  and	  Macrophage	  Inhibitory	  Factor-­‐1	  (A	  Wu	  et	  al.	  2010).	  The	  immunosuppressive	  properties	  of	  sphere	  cells	  were	  regulated	  by	  expression	  of	  STAT-­‐3	  and	  potentiated	  by	  hypoxia	  (Wei	  et	  al.	  2011).	  Di	  Tomaso	  and	  colleagues	  (Di	  Tomaso	  et	  al.	  2010)	  also	  found	  that	  sphere	  cells,	  but	  not	  the	  corresponding	  serum-­‐cultured	  lines,	  secreted	  soluble	  factors	  that	  inhibited	  allogeneic	  T	  cell	  proliferation.	  	  Contrary	  to	  Heimberger’s	  study,	  this	  effect	  did	  not	  appear	  to	  be	  due	  to	  TGF-­‐β1,	  or	  to	  TGF-­‐β2	  or	  IL-­‐10.	  	  Wolpert	  and	  colleagues	  (Wolpert	  et	  al.	  2012)	  reported	  that	  sphere	  cell	  lines	  express	  significantly	  higher	  levels	  of	  the	  atypical	  HLA	  molecule	  HLA-­‐E,	  a	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ligand	  for	  inhibitory	  receptors	  on	  NK	  cells,	  than	  GBM	  tumour	  cells	  cultured	  in	  serum-­‐containing	  media.	  	  
5.1.6	   Hypothesis	  and	  Aims	  Two	  groups	  have	  reported	  the	  use	  of	  active	  immunotherapy	  to	  selectively	  target	  CSC	  in	  rodent	  models	  of	  glioma.	  Both	  studies	  used	  a	  vaccine	  consisting	  of	  DC	  loaded	  with	  unselected	  antigens	  derived	  from	  whole	  sphere	  cells	  (Pellegatta	  et	  al.	  2006b;	  Q.	  Xu	  et	  al.	  2009).	  DC-­‐based	  vaccines	  require	  complex	  laboratory	  production	  steps	  and	  the	  optimum	  phenotype	  of	  the	  infused	  DC	  is	  uncertain.	  The	  Phase	  1	  clinical	  trial	  described	  in	  Chapter	  3	  showed	  that	  feasibility	  of	  DC-­‐based	  immunotherapy	  in	  the	  recurrent	  setting	  is	  marginal.	  In	  Chapter	  4	  it	  was	  shown	  that	  a	  relatively	  simple	  vaccine	  consisting	  of	  irradiated	  autologous	  whole	  tumour	  cells	  pulsed	  with	  an	  adjuvant	  that	  stimulates	  iNKT	  cells	  was	  effective	  in	  a	  glioma	  model.	  The	  work	  in	  this	  chapter	  tested	  the	  hypothesis	  that	  the	  Glioma-­‐Gal	  vaccine	  would	  be	  even	  more	  effective	  if	  modified	  to	  selectively	  target	  CSC	  or	  SLCC.	  	  	  Reports	  from	  the	  literature	  suggested	  that	  the	  syngeneic	  immunocompetent	  GL261	  murine	  glioma	  cell	  line	  would	  be	  an	  appropriate	  model	  for	  this	  investigation.	  As	  described	  above,	  Pellegatta	  and	  colleagues	  have	  shown	  that	  spheres	  can	  be	  grown	  in	  SC	  media	  and	  that	  sphere	  cells	  are	  more	  tumourigenic	  in	  mice	  than	  GL261	  grown	  in	  standard	  media	  (Pellegatta	  et	  al.	  2006b).	  Wu	  and	  colleagues	  reported	  that	  GL261	  contained	  a	  small	  0.5	  %	  CD133+	  fraction	  that	  can	  be	  isolated	  by	  FACS	  and	  that	  this	  subset	  was	  tumourigenic	  at	  titrations	  100	  times	  smaller	  than	  CD133-­‐	  cells	  when	  implanted	  in	  mice,	  suggesting	  the	  preservation	  of	  a	  true	  CSC	  cell	  sub-­‐population	  within	  this	  cell	  line	  (Anhua	  Wu	  et	  al.	  2008).	  	  In	  a	  different	  rodent	  glioma	  model,	  Kondo	  and	  colleagues	  (Kondo	  et	  al.	  2004)	  reported	  that	  ABC	  transporter	  activity	  could	  be	  used	  to	  distinguish	  a	  subset	  of	  cells	  within	  the	  C6	  rat	  glioma	  line	  that	  was	  more	  efficient	  at	  initiating	  tumours	  in	  nude	  mice.	  These	  studies	  together	  support	  the	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intuitively	  unlikely	  possibility	  that	  an	  immortalised	  tumour	  cell	  line	  maintained	  for	  many	  years	  in	  serum-­‐containing	  media	  can	  retain	  a	  true	  CSC	  subset.	  	  	  	  
Aims	  of	  the	  study:	  	   1. Assess	  the	  feasibility	  of	  isolating,	  enriching	  for,	  or	  inducing	  CSC	  (or	  SLCC)	  from	  the	  GL261	  murine	  glioma	  cell	  line	  2. Characterise	  the	  cell	  populations	  obtained	  in	  (1)	  3. Compare	  the	  efficacy	  of	  a	  whole	  tumour	  cell	  vaccine	  made	  from	  CSC	  (or	  SLCC)	  with	  the	  standard	  vaccine	  in	  vivo	  	  
5.2	   RESULTS	  
5.2.1	   Surface	  markers	  do	  not	  identify	  a	  discrete	  population	  of	  stem-­‐like	  cells	  
within	  GL261	  cell	  line	  cultures.	  	  A	  theoretically	  attractive	  way	  of	  isolating	  CSC	  in	  the	  clinic	  would	  be	  to	  sort	  fresh	  tumour	  tissue	  using	  a	  surface	  marker	  expressed	  uniquely	  by	  CSC.	  CD133	  is	  an	  obvious	  candidate	  marker	  for	  glioma	  CSC.	  However,	  in	  contrast	  to	  the	  report	  by	  Wu	  et	  al	  (Anhua	  Wu	  et	  al.	  2008),	  I	  could	  not	  detect	  surface	  expression	  of	  CD133	  on	  GL261	  cells	  cultured	  in	  standard	  media	  (Fig	  5.1A).	  The	  B16	  melanoma	  cell	  line,	  also	  reported	  to	  have	  a	  CD133+	  subset	  (Dou	  et	  al.	  2007),	  was	  used	  as	  a	  positive	  control	  (Fig	  5.1A).	  It	  was	  possible	  that	  long-­‐term	  culture	  in	  vitro	  had	  induced	  a	  CD133-­‐	  phenotype	  in	  tumour	  cells	  capable	  of	  CD133	  expression.	  CD133	  expression	  was	  therefore	  assessed	  under	  different	  conditions.	  Culture	  in	  serum-­‐free	  media	  supplemented	  with	  EGF	  and	  bFGF	  (SC	  medium)	  resulted	  in	  growth	  of	  GL261	  as	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  detached	  floating	  spheres	  as	  previously	  described	  (Pellegatta	  et	  al.	  2006b)	  but	  did	  not	  induce	  CD133	  expression	  (Fig	  5.1B).	  Next,	  it	  was	  hypothesised	  that	  tumour	  cells	  growing	  in	  vivo	  might	  encounter	  niches	  conducive	  to	  the	  induction	  of	  an	  SLCC	  phenotype.	  However,	  I	  saw	  no	  significant	  CD133	  expression	  in	  single	  cell	  suspensions	  freshly	  prepared	  from	  subcutaneous	  tumours	  (Fig	  5.1B).	  It	  has	  been	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Figure 5.1. Surface expression of putative CSC surface markers by GL261 assessed by 
antibody staining and flow cytometry. A, CD133 expression by in vitro cultures of the  GL261 
and the B16 murine melanoma cell lines. Figures are percentages of total cells. B, CD133 expres-
sion by GL261 spheres cultured in SC media, by GL261 cells retrieved from subcutaneous 
tumours, and from GL261 cultured in vitro under hypoxic conditions. C, CD15 expression by in 
vitro cultured GL261. D, CD44 expression by in vitro cultured GL261. E, Left panel: CD200 
expression by in vitro cultured GL261. Middle panel: CD200 expression by GL261 spheres 
cultured in SC media. Using the Kolmogorov-Smirnov method, the probability of the CD200+ 
and CD200- populations not being drawn from the same population was 0%. Expression of each 
marker was assessed at least twice.
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shown	  that	  CD133	  expression	  is	  induced	  when	  tumour	  cells	  are	  subjected	  to	  bioenergetic	  stress	  such	  as	  hypoxia	  (Griguer	  et	  al.	  2008).	  Others	  have	  reported	  that	  hypoxia	  promotes	  glycosylation	  of	  CD133	  epitopes	  that	  in	  turn	  increases	  detection	  by	  anti-­‐CD133	  antibodies	  (Bidlingmaier	  et	  al.	  2008).	  In	  accordance	  with	  this,	  culture	  of	  GL261	  under	  hypoxic	  conditions	  did	  induce	  some	  CD133	  surface	  expression	  but	  only	  in	  0.16	  %	  of	  cells	  (Fig	  5.1B).	  It	  was	  felt	  that	  this	  proportion	  was	  too	  low	  to	  realistically	  conduct	  immunotherapy	  experiments	  in	  mice	  using	  a	  Glioma-­‐Gal	  vaccine	  manufactured	  from	  tumours	  cells	  purified	  by	  FACS.	  Expression	  by	  GL261	  cells	  of	  a	  number	  of	  other	  putative	  markers	  of	  glioma	  CSC	  was	  also	  assessed.	  CD15	  surface	  expression	  has	  been	  shown	  to	  distinguish	  the	  only	  cells	  capable	  of	  initiating	  tumours	  in	  an	  implantable	  murine	  model	  of	  medulloblastoma	  (Read	  et	  al.	  2009;	  Ward	  et	  al.	  2009).	  	  GL261	  did	  not	  express	  CD15	  under	  standard	  culture	  conditions	  (Fig	  5.1C).	  CD44	  is	  a	  well-­‐established	  marker	  of	  tumour-­‐initiating	  cells	  in	  breast	  cancer	  models	  and	  has	  been	  proposed	  as	  a	  glioma	  CSC	  marker	  in	  GBM	  tumours	  (G.	  Liu	  et	  al.	  2006;	  Q.	  Liu	  et	  al.	  2009).	  CD44	  was	  highly	  expressed	  by	  virtually	  all	  GL261	  tumour	  cells	  (Fig	  5.1D),	  a	  finding	  that	  was	  interesting	  but	  excluded	  CD44	  as	  a	  way	  of	  discriminating	  CSC	  in	  this	  model.	  CD200	  is	  a	  “don’t	  eat	  me”	  membrane-­‐bound	  protein	  related	  to	  the	  B7	  family	  that	  is	  normally	  expressed	  on	  lymphocytes,	  neurons	  and	  endothelial	  cells	  and	  delivers	  an	  inhibitory	  signal	  to	  cells	  of	  the	  macrophage	  lineage	  (Kretz-­‐Rommel	  et	  al.	  2007).	  It	  is	  also	  expressed	  by	  several	  human	  tumour	  types	  and	  an	  inverse	  correlation	  between	  CD200	  expression	  and	  prognosis	  has	  been	  reported,	  suggesting	  tumours	  may	  exploit	  this	  molecule	  to	  evade	  the	  immune	  system	  (B.	  T.	  Kawasaki	  et	  al.	  2007;	  Kretz-­‐Rommel	  et	  al.	  2007).	  Co-­‐expression	  of	  CD200	  and	  putative	  CSC-­‐markers	  has	  been	  observed	  in	  human	  cancers	  including	  glioma,	  leading	  to	  the	  suggestion	  that	  CD200	  could	  be	  a	  marker	  for	  CSC	  (B.	  T.	  Kawasaki	  et	  al.	  2007;	  B.	  Kawasaki	  and	  Farrar	  2008).	  In	  this	  study,	  a	  small	  proportion	  (0.4	  -­‐	  0.6	  %)	  of	  GL261	  cells	  cultured	  in	  standard	  media	  were	  CD200+	  (Fig	  5.1E)	  but	  this	  finding	  was	  inconsistent	  (data	  not	  shown).	  Similar,	  inconsistent,	  results	  were	  obtained	  when	  cells	  were	  cultured	  in	  SC	  medium	  (Fig	  5.1E	  and	  data	  not	  shown).	  An	  expert	  opinion	  (Kylie	  Price,	  Hugh	  Green	  Flow	  Cytometry	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Fellow,	  MIMR)	  was	  sought	  regarding	  the	  feasibility	  of	  sorting	  these	  CD200+	  cells.	  Because	  the	  CD200+	  cells	  were	  not	  a	  distinct	  population,	  but	  located	  within	  the	  upper	  part	  of	  a	  normal	  distribution,	  and	  because	  of	  the	  small	  proportion	  of	  CD200+	  cells,	  magnetic	  or	  fluorescence-­‐activated	  sorting	  was	  felt	  unlikely	  to	  yield	  sufficient	  numbers	  of	  cells	  of	  acceptable	  purity	  to	  feasibly	  manufacture	  whole	  tumour	  cell-­‐based	  vaccines.	  Coupled	  with	  the	  finding	  that	  CD200+	  cells	  were	  not	  consistently	  present	  in	  all	  cultures,	  it	  was	  decided	  not	  to	  pursue	  enrichment	  of	  CD200+	  cells	  as	  a	  strategy	  for	  making	  vaccines	  targeting	  CSC.	  In	  summary,	  the	  surface	  markers	  tested	  here	  did	  not	  identify	  a	  distinct	  tumour	  cell	  subset	  or,	  if	  a	  positive	  population	  was	  seen,	  it	  was	  too	  small	  and/or	  insufficiently	  demarcated	  from	  the	  bulk	  population	  to	  be	  of	  practical	  use	  in	  the	  manufacture	  of	  a	  whole	  tumour	  cell	  vaccine.	  	  	  
5.2.2	   Side-­‐population	  cells	  isolated	  from	  GL261	  are	  less	  tumourigenic	  than	  
non-­‐SP	  cells	  ABC	  proteins	  are	  a	  family	  of	  membrane-­‐associated	  proteins	  that	  actively	  transport	  certain	  molecules	  out	  of	  the	  cell,	  including	  a	  range	  of	  chemotherapeutic	  agents	  (M	  A	  Goodell	  et	  al.	  1996).	  The	  fluorescent	  lipophilic	  dye	  Hoechst	  33342,	  which	  passively	  diffuses	  into	  all	  cells,	  is	  a	  substrate	  for	  some	  ABC	  family	  members	  so	  that	  cells	  expressing	  these	  transporters	  can	  be	  identified	  using	  flow	  cytometry	  as	  a	  population	  of	  dye-­‐negative	  cells	  termed	  the	  “side-­‐population”	  (SP)	  (Margaret	  A	  Goodell	  2005).	  The	  SP	  phenotype	  is	  strongly,	  but	  not	  exclusively,	  associated	  with	  expression	  of	  the	  ABC	  family	  member	  ABCG2,	  also	  known	  as	  Breast	  Cancer	  Resistance	  Protein-­‐1	  (BCRP-­‐1)	  (Bleau	  et	  al.	  2009b;	  Hirschmann-­‐Jax	  et	  al.	  2004;	  Kondo	  et	  al.	  2004;	  Patrawala	  et	  al.	  2005;	  S.	  Zhou	  et	  al.	  2001).	  In	  1996,	  Goodell	  and	  colleagues	  discovered	  that	  the	  SP	  contains	  the	  vast	  majority	  of	  haematopoietic	  stem	  cells	  in	  murine	  bone	  marrow	  (M	  A	  Goodell	  et	  al.	  1996).	  Subsequently,	  an	  SP	  has	  been	  demonstrated	  in	  some	  human	  solid	  cancers	  and	  several	  studies	  have	  reported	  that	  these	  SP	  cells	  are	  more	  tumourigenic	  when	  transplanted	  into	  immunodeficient	  mice	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 than	  non-­‐SP	  cells	  (Hirschmann-­‐Jax	  et	  al.	  2004;	  Ho	  et	  al.	  2007;	  Patrawala	  et	  al.	  2005).	  	  Similar	  findings	  have	  been	  reported	  in	  some	  rodent	  glioma	  models (Bleau	  et	  al.	  2009b;	  M.	  A.	  Harris	  et	  al.	  2008;	  Kondo	  et	  al.	  2004). Kondo	  and	  colleagues	  (Kondo	  et	  al.	  2004)	  found	  a	  0.4	  %	  SP	  to	  be	  present	  within	  the	  C6	  rat	  glioma	  line	  that	  was	  more	  efficient	  at	  initiating	  tumours	  in	  nude	  mice.	  Although	  SP	  cells	  could	  give	  rise	  to	  both	  
Figure 5.2. GL261 tumour cells have a side population (SP) that is less tumourigenic in vivo 
than the non-SP. A, Cultured GL261 tumour cells were incubated with Hoechst dye and the dye-
negative “side population” isolated using fluorescence-activated cell sorting. The SP gate was set 
using cells also treated with 2-deoxyglucose (2-DOG), which blocks ABC transporters, as a negative 
control. Purity of the sorted SP and non-SP fractions assessed by flow cytometry was 96% and 99% 
respectively (data not shown). One experiment by the author. At least three additonal experiments by 
K. Broadley showed similar results with a mean SP in parental cultures of 1.9%. B, 5 x 104 GL261 SP 
cells and non-SP cells from same experiment shown in A, and unsorted tumour cells, were injected 
s.c. into C57BL/6 mice. 10 mice per group, one experiment. C. GL261 cells were cultured as floating 
spheres in SC media and passaged nine times before flow cytometry to assess for the presence of a 
side population. One experiment, performed in collaboration with K. Broadley. At least three addi-
tonal experiments by K. Broadley showed similar results with a mean SP in GL261 sphere cultures of 
0.23%.

















































































SP	  and	  non-­‐SP	  cells,	  purified	  non-­‐SP	  cells	  could	  not	  reform	  SP	  cells,	  suggesting	  the	  existence	  of	  a	  hierarchy.	  It	  has	  therefore	  been	  proposed	  that	  the	  ability	  to	  exclude	  Hoescht	  dye	  and/or	  expression	  of	  ABCG2	  could	  be	  used	  as	  a	  marker	  of	  glioma	  CSC	  and	  a	  possible	  explanation	  for	  the	  chemoresistance	  of	  these	  cells	  (Bleau	  et	  al.	  2009a;	  Hirschmann-­‐Jax	  et	  al.	  2004).	  	  An	  SP	  has	  also	  been	  reported	  to	  exist	  within	  the	  GL261	  glioma	  cell	  line	  but	  the	  capacity	  of	  these	  cells	  to	  initiate	  tumours	  was	  not	  tested	  in	  that	  study	  (Anhua	  Wu	  et	  al.	  2008).	  Colleagues	  at	  the	  Malaghan	  Institute	  have	  previously	  established	  methods	  for	  undertaking	  SP	  sorting	  by	  FACS	  and	  have	  shown	  that	  GL261	  grown	  under	  standard	  culture	  conditions	  consistently	  has	  a	  small	  SP	  of	  0.01	  –	  4	  %	  that	  is	  not	  seen	  when	  cells	  are	  also	  treated	  with	  2-­‐deoxyglucose	  (2-­‐DOG),	  an	  inhibitor	  of	  ABC	  transporters	  (Broadley	  et	  al.	  2011).	  In	  this	  study,	  GL261	  cells	  grown	  under	  standard	  culture	  conditions	  were	  sorted	  by	  FACS	  into	  SP	  and	  non-­‐SP	  fractions	  (Fig	  5.2A)	  and	  implanted	  s.c.	  into	  mice.	  Whereas	  non-­‐SP	  cells	  formed	  tumours	  in	  all	  mice,	  SP	  cells	  did	  not	  always	  form	  tumours	  and	  the	  time	  to	  tumour	  appearance	  was	  delayed	  compared	  to	  non-­‐SP	  cells	  or	  unsorted	  tumour	  cells	  (Fig	  5.2B).	  	  This	  finding	  suggested	  that	  the	  GL261	  SP	  is	  not	  enriched	  for	  tumour-­‐initiating	  cells.	  Furthermore,	  culture	  of	  GL261	  in	  SC	  media,	  expected	  to	  enrich	  for	  cells	  with	  a	  SLCC	  phenotype,	  did	  not	  increase	  the	  SP	  size	  (Fig	  5.2C).	  	  Along	  with	  supportive	  data	  obtained	  by	  colleagues	  from	  human	  GBM	  tumour	  tissue	  (Broadley	  et	  al.	  2011),	  these	  findings	  discouraged	  further	  investigation	  into	  using	  SP	  cells	  as	  the	  basis	  of	  a	  vaccine	  targeting	  CSC/SLCC.	  	  	  





Figure 5.3. Tumour-initiating capacity of GL261 cultured in “stem cell medium” is similar to 
parental cells. A, Light microscopy of GL261 growing as an adherent monolayer in standard medium 
(“parental” cells). B, Light microscopy of GL261 growing in SC medium as floating spheroidal aggrega-
tions (“sphere” cells). C, 5 x 103 sphere or parental cells were implanted intracranially into the right 
striatum of C57BL/6 mice. Tumour-free survival was defined as time to symptom appearance. 4-5 mice 
per group. D, Experiment as in C. 5-6 mice per group. P-values in both figures indicate the result of a 
Log-rank test. E, F, G,  Brain tissue was collected from symptomatic mice at the completion of the 
experiments depicted in C and D. Light microscopy of formalin-fixed, paraffin-embedded, haematoxylin 
and eosin-stained sections showing margins of intracranial tumours initiated by GL261 parental cells (E) 
and sphere cells (F). Arrows indicate tumour cells infiltrating brain parenchyma. G, Pathologists indepen-
dently categorised the margin of each tumour as infiltrative or well demarcated. Infiltrative borders were 
poorly defined, with cords, clusters and individual tumour cells extending haphazardly into adjacent 
brain tissue. Well demarcated margins had a rounded, “pushing” appearance with a clearly defined 
boundary between tumour and adjacent brain. Shown are the pooled data from experiments in C and D. 
Statistical significance was assessed using a two-tailed Fisher’s exact test.   
































































spherical	  aggregations	  closely	  resembling	  the	  “neurospheres”	  that	  form	  when	  cells	  from	  the	  striatum	  of	  adult	  murine	  brain	  are	  cultured	  in	  similar	  media	  (Reynolds	  and	  Weiss	  1992a).	  The	  SC	  medium	  used	  in	  my	  study	  consisted	  of	  a	  commercially	  available	  serum-­‐free	  medium	  augmented	  with	  a	  nutritional	  supplement	  and	  the	  growth	  factors	  EGF	  and	  bFGF.	  This	  same	  SC	  medium	  has	  been	  consistently	  reported	  to	  promote	  sphere	  formation	  in	  human	  and	  rodent	  glioma	  studies	  (Ali	  Jourabchi	  Ghods	  et	  al.	  2007;	  Pellegatta	  et	  al.	  2006b;	  Yuan	  et	  al.	  2004).	  Still	  searching	  for	  a	  way to	  target	  CSC	  or	  SLCC	  with	  the	  Glioma-­‐Gal	  vaccine,	  I	  decided	  to	  explore	  this	  approach	  as	  a	  possible	  way	  of	  enriching	  for,	  or	  inducing,	  a	  CSC/SLCC	  phenotype. When	  resuspended	  in	  SC	  medium,	  GL261	  readily	  formed	  spheres	  as	  expected	  (Fig	  5.3B).	  	  These	  sphere	  cells	  could	  be	  propagated	  indefinitely	  and	  reverted	  to	  an	  adherent	  phenotype	  when	  placed	  back	  into	  standard	  medium	  (data	  not	  shown).	  In	  addition	  to	  floating	  spheres,	  some	  cells	  in	  the	  SC	  medium	  grew	  on	  the	  bottom	  of	  the	  culture	  flask	  as	  a	  patchy	  adherent	  layer.	  However,	  this	  pattern	  of	  growth	  did	  not	  appear	  to	  be	  a	  fixed	  intrinsic	  property	  of	  individual	  cells	  because	  these	  adherent	  cells,	  as	  well	  as	  purified	  sphere	  cells,	  gave	  rise	  to	  both	  cell	  types	  when	  reseeded	  into	  SC	  medium	  (data	  not	  shown).	  Furthermore,	  the	  proportion	  of	  cells	  that	  grew	  in	  this	  adherent	  way	  proved	  to	  be	  dependent	  on	  the	  supplier	  of	  the	  tissue	  culture	  flasks.	  	  	   As	  discussed	  above,	  the	  cardinal	  property	  of	  CSC	  is	  an	  increased	  ability	  to	  initiate	  tumours	  in	  vivo	  in	  comparison	  to	  bulk	  tumour	  cell	  populations.	  The	  ability	  of	  parental	  and	  sphere	  cells	  to	  initiate	  intracranial	  tumours	  was	  therefore	  compared	  in	  syngeneic	  immunocompetent	  C57BL/6	  hosts.	  Both	  cell	  types	  were	  capable	  of	  forming	  tumours	  when	  5000	  cells	  were	  implanted	  i.c.	  (Figs	  5.3C,	  D).	  There	  was	  no	  significant	  difference	  between	  sphere	  and	  parental	  cells	  with	  respect	  to	  the	  rate	  at	  which	  symptomatic	  tumours	  formed,	  a	  finding	  at	  odds	  with	  the	  previous	  report	  of	  Pellegatta	  and	  colleagues	  (Pellegatta	  et	  al.	  2006b).	  Histology	  did	  not	  reveal	  any	  obvious	  differences	  in	  the	  morphology	  of	  individual	  tumour	  cells	  but	  differences	  in	  the	  pattern	  of	  tumour	  growth	  were	  observed,	  with	  tumours	  derived	  from	  parental	  cells	  tending	  to	  be	  well	  demarcated	  and	  sphere	  cell	  tumours	  more	  likely	  to	  exhibit	  
 195 
an	  infiltrative	  growth	  pattern	  (Figs	  5.3E	  -­‐	  G).	  This	  invasive	  pattern	  of	  growth	  more	  closely	  resembles	  the	  behaviour	  of	  human	  GBM.	  	  To	  further	  assess	  the	  “stemness”	  of	  sphere	  cells	  and	  ASC,	  the	  expression	  of	  a	  panel	  of	  stem	  cell-­‐associated	  genes	  was	  assessed.	  These	  genes	  were	  selected	  because	  of	  published	  studies	  describing	  an	  association	  between	  expression	  and	  pluripotent	  stem	  cells,	  normal	  neural	  stem	  cells,	  or	  glioma	  CSC	  (Table	  5.1). To	  validate	  these	   
 
Table 5.1 Stem cell-associated gene panel 






































































Figure 5.4. Expression of stemness genes by GL261 cultured in stem cell medium. A, Foetal brain 
tissue from C57BL/6 mice was cultured in medium that supports the survival of normal neural stem cells 
(NSC). Light microscopy showing cells growing as compact spheroidal aggregations attached to the floor 
of the tissue culture flask. B, Expression of a panel of NSC- and putative glioma CSC-associated genes in 
foetal NSC cultures assessed by measuring RNA using real-time reverse transcription polymerase chain 
reaction (RT-PCR). Results are depicted as fold change on Days 11 and 28 of culture relative to baseline 
expression on Day 0 (Day 0 = 1). Graph at right shows results for Musashi-1 at different scale. Single 
H[SHULPHQW&&WYDOXHVUHODWLYHWR6U51$ǻ&WLQXQFXOWXUHGIRHWDOEUDLQFHOOVDQG'D\IRHWDO
16&FRPSDUHGZLWKWKHPHDQǻ&WRIVHYHUDOH[SHULPHQWVDVVHVVLQJH[SUHVVLRQLQ*/FXOWXUHGLQ
standard medium. D, Expression of the SC gene panel (except CD133) in GL261 sphere cells relative to 
GL261 cultured in standard medium. Top: Pooled results of six experiments by author in which some, or 
all, of the panel were assessed. Spheres were assessed after 1 - 6 passages in SC medium. No correlation 
between fold change and the number of passages was observed (data not shown). Bottom: Results of 
similar experiments by K.Farrand (with permission). Bars indicate means and SEM. E, Differences in gene 
expression between parental and sphere cells (in experiments performed by author) were analysed statisti-
FDOO\E\FRPSDULQJǻ&WYDOXHVDQGDSSO\LQJD:LOFR[RQPDWFKHGSDLUVVLJQHGUDQNWHVW1RVWDWLVWLFDOO\


































































genes	  and	  “stemness”.	  	  The	  panel	  was	  then	  used	  to	  compare	  stemness	  of	  sphere	  cells	  relative	  to	  parental	  tumour	  cells.	  With	  respect	  to	  CD133,	  expression	  of	  this	  gene	  was	  found	  to	  be	  either	  close	  to,	  or	  below,	  the	  limit	  of	  detection	  in	  both	  GL261	  cell	  types	  in	  three	  independent	  experiments	  (Fig	  5.4C	  and	  data	  not	  shown),	  a	  finding	  consistent	  with	  the	  absence	  of	  anti-­‐CD133	  antibody	  staining	  by	  parental	  and	  sphere	  cells	  (Figs	  5.1A	  and	  B).	  CD133	  expression	  was	  therefore	  not	  assessed	  in	  subsequent	  experiments.	  With	  respect	  to	  the	  other	  genes	  on	  the	  panel,	  no	  significant	  differences	  were	  detected	  between	  parental	  and	  sphere	  cells	  with	  the	  exception	  of	  Musashi-­‐1	  expression	  which	  consistently	  increased	  in	  all	  sphere	  lines	  relative	  to	  parental	  cells,	  with	  a	  mean	  fold	  increase	  of	  2.5	  (Fig	  5.4D,	  E).	  In	  support	  of	  this	  finding,	  contemporaneous	  experiments	  by	  a	  colleague	  also	  found	  a	  consistent	  rise	  in	  Musashi-­‐1	  expression	  by	  GL261	  sphere	  cells	  of	  a	  similar	  magnitude	  (Fig	  5.4D). 	  In	  summary,	  culture	  of	  GL261	  cells	  in	  SC	  medium	  did	  not	  result	  in	  an	  increased	  capacity	  to	  initiate	  tumours	  in	  vivo.	  By	  not	  meeting	  this	  key	  criterion,	  sphere	  cells	  did	  not	  meet	  the	  definition	  for	  CSC.	  However,	  culture	  in	  SC	  medium	  did	  induce	  sphere	  formation	  and	  upregulation	  of	  Musashi-­‐1,	  a	  gene	  strongly	  associated	  with	  neural	  stem	  cells,	  indicating	  at	  least	  a	  shift	  towards	  a	  more	  neural	  stem	  cell-­‐like	  phenotype	  and	  justifying	  the	  term	  SLCC.	  Sphere	  cells	  also	  gave	  rise	  to	  i.c.	  tumours	  with	  an	  infiltrative	  morphology	  more	  typical	  of	  human	  high	  grade	  glioma.	  Culture	  in	  SC	  medium	  thus	  emerged	  from	  these	  studies	  as	  a	  potentially	  useful	  way	  of	  enriching	  for	  antigens	  associated	  with	  stem-­‐like	  glioma	  cells.	  
 
5.2.4	   Designing	  a	  vaccine	  targeting	  unselected	  antigens	  from	  whole	  tumour	  
cells	  suitable	  for	  assessing	  the	  effect	  of	  qualitative	  changes	  in	  the	  antigen	  
component	  of	  the	  vaccine.	  Given	  that	  the	  aim	  of	  this	  study	  was	  to	  test	  whether	  the	  efficacy	  of	  the	  Glioma-­‐Gal	  vaccine	  could	  be	  enhanced	  by	  qualitatively	  modifying	  the	  antigen	  component	  of	  the	  vaccine,	  it	  was	  important	  to	  compare	  Glioma-­‐Gal	  vaccines	  that	  did	  not	  differ	  in	  the	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total	  quantity	  of	  antigen	  or	  in	  adjuvanticity.	  To	  try	  and	  keep	  the	  quantity	  of	  protein	  in	  the	  two	  vaccines	  constant,	  I	  first	  tried	  injecting	  the	  same	  number	  of	  morphologically-­‐intact	  cells,	  whether	  they	  were	  Trypan	  Blue	  negative	  or	  positive.	  In	  a	  pilot	  experiment,	  a	  Glioma-­‐Gal	  vaccine	  made	  from	  sphere	  cells	  was	  less	  effective	  than	  the	  parental	  vaccine	  (data	  not	  shown).	  This	  result	  was	  unexpected	  and	  contrary	  to	  previous	  DC	  vaccine	  studies	  using	  sphere	  cells	  as	  the	  antigen	  source.	  However,	  experience	  accrued	  during	  the	  preparation	  of	  Glioma-­‐Gal	  vaccines	  suggested	  several	  possible	  confounding	  factors.	  It	  was	  noted	  that	  live	  sphere	  cells	  in	  single	  cell	  suspensions	  after	  harvesting	  were	  smaller	  than	  their	  live	  parental	  counterparts,	  so	  that	  the	  per	  cell	  quantity	  of	  antigen	  and	  adjuvant	  may	  have	  been	  lower	  for	  sphere	  cells.	  One	  way	  of	  standardizing	  the	  protein	  content	  of	  the	  vaccines	  might	  have	  been	  to	  lyse	  an	  aliquot	  of	  the	  cellular	  vaccine	  and	  measure	  the	  protein	  content	  of	  a	  known	  quantity	  of	  tumour	  cells.	  The	  number	  of	  cells	  in	  each	  vaccine	  could	  then	  be	  adjusted	  to	  deliver	  an	  equivalent	  amount	  of	  protein.	  However,	  this	  would	  still	  not	  ensure	  equivalent	  delivery	  of	  adjuvant.	  The	  mechanism	  by	  which	  α-­‐GalCer	  becomes	  physically	  associated	  with	  GL261	  cells	  in	  culture	  is	  unknown.	  It	  is	  possible	  that	  differences	  in	  cell	  phenotype	  or	  the	  culture	  medium	  might	  affect	  this	  process.	  Also,	  it	  was	  consistently	  observed	  that	  the	  live-­‐to-­‐dead	  cell	  ratio	  of	  single	  cell	  suspensions	  after	  harvesting	  was	  variable,	  both	  between	  cell	  types	  and	  between	  experiments.	  Whether	  a	  tumour	  cell	  is	  live,	  dead	  or	  dying	  may	  affect	  its	  capacity	  to	  associate	  with	  α-­‐GalCer.	  For	  these	  reasons,	  even	  if	  the	  protein	  content	  could	  be	  standardised,	  it	  was	  not	  possible	  to	  safely	  assume	  that	  the	  ratio	  of	  α-­‐GalCer-­‐to-­‐protein	  would	  be	  constant	  between	  vaccines.	  It	  was	  therefore	  necessary	  to	  develop	  an	  alternative	  vaccine	  design	  to	  address	  the	  experimental	  aims.	  	  	  Accordingly,	  a	  simple	  vaccine	  was	  designed	  consisting	  of	  tumour	  cell	  lysate	  co-­‐administered	  intravenously	  with	  soluble	  α-­‐GalCer	  (Fig	  5.5A).	  Lysates	  were	  created	  using	  a	  freeze/thaw	  technique	  as	  described	  in	  Chapter	  2.	  The	  protein	  concentrations	  of	  the	  lysates	  were	  measured	  and	  volume	  adjusted	  to	  provide	  vaccines	  of	  equal	  protein	  content.	  The	  α-­‐GalCer	  dose	  of	  200	  ng	  per	  mouse	  was	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Figure 5.5. A lysate-based vaccine suitable for assessing the effect of changing antigen content 
without altering adjuvanticity.  A, Diagram showing method for making lysate vaccines (Lysate-
*DO%:LOGW\SHDQG0+&FODVV,,GHILFLHQWPLFHZHUHYDFFLQDWHGLYZLWK/\VDWH*DOȝJ
lysate) and challenged s.c. with 1 x 106 GL261 tumour cells 7 days later. 3-5 mice per group, one 
experiment. C, The effect of tumour lysate on DC maturation was assessed in vitro using the DC2114 
GHQGULWLFFHOOOLQH'&ZHUHSXOVHGIRUKRXUVLQWULSOLFDWHZLWKȝJP/RUȝJP/RISDUHQWDO
RUVSKHUHFHOOWXPRXUO\VDWH6RPH'&ZHUHSXOVHGZLWKȝJP/3RO\,&DVDSRVLWLYHFRQWURODQG
to model the effect of a strong adjuvant. CD40 and CD86 expression by DC was assessed by flow 
cytometry. Graphs show means and SEM of experimental triplicates. Statistical analysis was 
performed with a Kruskal-Wallis test with Dunn’s multiple comparison post-test.  One of two experi-








































































































selected	  based	  on	  previous	  titration	  studies	  done	  by	  others	  at	  this	  institution	  showing	  that	  this	  is	  the	  threshold	  dose	  for	  inducing	  maximal	  DC	  maturation	  (data	  not	  shown,	  I.	  Hermans).	  	  Because	  the	  main	  purpose	  of	  the	  lysate	  vaccine	  experiments	  was	  ultimately	  to	  inform	  the	  design	  of	  an	  improved	  Glioma-­‐Gal	  vaccine,	  it	  was	  important	  to	  confirm	  that	  the	  lysate	  vaccine	  acted	  by	  similar	  mechanisms	  and	  elicited	  adaptive	  immunity	  against	  protein	  antigens.	  	  Accordingly,	  it	  was	  shown	  that	  tumour	  protection	  was	  abrogated	  in	  MHC	  class	  II-­‐deficient	  mice	  (Fig	  5.5B).	  The	  vaccine	  design	  assumes	  that	  the	  lysate	  component	  does	  not	  materially	  affect	  the	  adjuvanticity	  of	  the	  vaccine.	  To	  confirm	  this,	  expression	  of	  DC	  maturation	  markers	  was	  assessed	  after	  pulsing	  with	  sphere	  or	  parental	  cell	  lysates.	  No	  effect	  on	  DC	  maturation	  was	  observed	  with	  either	  lysate	  type,	  in	  contrast	  to	  Poly	  I:C,	  a	  TLR3	  ligand	  that	  served	  as	  a	  positive	  control	  (Fig	  5.5C).	  	  
 
5.2.5	   A	  lysate	  vaccine	  made	  from	  glioma	  spheres	  does	  not	  provide	  improved	  




Figure 5.6. Vaccines made from lysates of GL261 cells grown in stem cell media are not more effective 
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5	  μg	  dose	  (Fig	  5.6D).	  The	  two	  vaccine	  types	  provided	  an	  equivalent	  level	  of	  protection	  at	  this	  dose	  in	  all	  three	  experiments.	  	  	  
5.3	   DISCUSSION	  AND	  CONCLUSIONS	  This	  study	  did	  not	  succeed	  in	  identifying	  a	  surface	  marker	  or	  functional	  property	  that	  could	  be	  used	  to	  isolate	  a	  subset	  of	  more	  stem-­‐like	  or	  more	  tumourigenic	  cells	  from	  within	  the	  parental	  GL261	  cell	  line.	  The	  finding	  that	  GL261	  under	  routine	  culture	  conditions	  lacked	  a	  CD133+	  subset	  contradicts	  the	  findings	  of	  an	  earlier	  study.	  Using	  antibody	  from	  the	  same	  clone	  as	  this	  study,	  Wu	  and	  colleagues	  (Anhua	  Wu	  et	  al.	  2008)	  reported	  CD133	  surface	  expression	  by	  0.5	  %	  of	  GL261	  tumour	  cells.	  In	  contrast	  to	  most	  studies	  of	  human	  glioma	  tumours,	  in	  which	  the	  CD133+	  fraction	  is	  depicted	  as	  a	  distinct	  and	  normally-­‐distributed	  population	  (Griguer	  et	  al.	  2008;	  Joo	  et	  al.	  2008;	  Q.	  Liu	  et	  al.	  2009;	  Lottaz	  et	  al.	  2010;	  S.	  K.	  Singh	  et	  al.	  2003),	  the	  flow	  cytometry	  plot	  in	  the	  report	  of	  Wu	  and	  colleagues	  depicts	  a	  population	  that	  is	  widely	  scattered	  both	  in	  CD133	  positivity	  and	  side	  scatter,	  perhaps	  raising	  some	  doubt	  as	  to	  whether	  this	  is	  a	  genuine	  subset	  with	  a	  consistent	  phenotype.	  Recently,	  another	  group	  also	  reported	  finding	  a	  CD133+	  subset	  in	  GL261	  using	  flow	  cytometry	  that	  could	  be	  sorted	  by	  FACS	  but	  did	  not	  include	  the	  flow	  plot	  in	  their	  report	  (Ye	  et	  al.	  2012).	  Two	  other	  studies	  have	  reported	  CD133	  expression	  by	  GL261	  to	  be	  “low”	  (Pellegatta	  et	  al.	  2006b)	  or	  absent	  (Ali	  J	  Ghods	  et	  al.	  2013)	  as	  assessed	  by	  RT-­‐PCR	  and	  immunofluorescence	  staining	  respectively.	  One	  possible	  explanation	  for	  these	  apparently	  discordant	  findings	  is	  that	  labelling	  by	  anti-­‐CD133	  antibodies	  has	  been	  shown	  to	  be	  sensitive	  to	  the	  length	  of	  the	  CD133	  protein	  and	  the	  glycosylation	  state	  of	  the	  epitope	  (Lehnus	  et	  al.	  2013;	  Osmond	  et	  al.	  2010).	  It	  is	  possible	  that	  the	  phenotype	  of	  GL261	  in	  this	  respect	  has	  diverged	  over	  the	  course	  of	  longterm	  culture	  in	  different	  laboratories.	  Several	  studies	  have	  reported	  that	  SP	  sorting	  of	  human	  glioma	  cell	  lines	  (Chua	  et	  al.	  2008;	  Hirschmann-­‐Jax	  et	  al.	  2004;	  Patrawala	  et	  al.	  2005)	  or	  rodent	  glioma	  tumours	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(Bleau	  et	  al.	  2009b;	  M.	  A.	  Harris	  et	  al.	  2008;	  Kondo	  et	  al.	  2004)	  enriches	  for	  a	  subset	  of	  tumour	  cells	  that	  are	  more	  tumourigenic.	  In	  almost	  all	  of	  these	  studies	  tumourigenicity	  was	  assessed	  in	  immunodeficient	  animals.	  An	  exception	  was	  Bleau	  and	  colleagues	  (Bleau	  et	  al.	  2009b)	  who	  used	  a	  transgenic	  PDGF-­‐driven	  glioma	  mouse	  model	  and	  showed	  enhanced	  tumourigenicity	  of	  SP	  cells	  when	  implanted	  into	  the	  cortex	  of	  syngeneic	  newborn	  pups.	  In	  the	  studies	  reported	  here,	  an	  SP	  was	  detected	  in	  GL261	  as	  previously	  described	  (Anhua	  Wu	  et	  al.	  2008)	  but	  SP	  cells	  were	  actually	  less	  tumourigenic	  than	  non-­‐SP	  or	  bulk	  cells.	  The	  converse	  finding	  in	  other	  studies	  could	  conceivably	  be	  explained	  by	  the	  fact	  that	  Hoescht	  dye	  is	  toxic	  to	  cells,	  particularly	  when	  exposed	  to	  UV	  light	  (Golebiewska	  et	  al.	  2011).	  Thus	  the	  tumourigenicity	  of	  non-­‐SP	  cells,	  that	  cannot	  efflux	  dye,	  may	  be	  sensitive	  to	  differences	  in	  SP	  methodology	  such	  as	  shielding	  from	  ambient	  light.	  	  The	  study	  of	  Bleau	  and	  colleagues	  tried	  to	  address	  this	  concern	  by	  demonstrating	  equivalent	  viability	  of	  SP	  and	  non-­‐SP	  populations	  ten	  days	  after	  sorting,	  but	  this	  does	  not	  exclude	  a	  transient	  effect	  on	  the	  tumour	  cells’	  ability	  to	  implant	  in	  vivo	  soon	  after	  sorting.	  Other	  work	  done	  in	  collaboration	  with	  colleagues	  showed	  that	  a	  panel	  of	  stem	  cell-­‐associated	  genes	  was	  not	  upregulated	  in	  the	  SP	  of	  GL261	  (Broadley	  et	  al.	  2011).	  Taken	  together,	  these	  findings	  did	  not	  support	  the	  SP	  assay	  as	  a	  way	  of	  isolating	  a	  CSC	  or	  SLCC	  subset	  in	  GL261.	  Several	  other	  reports	  have	  also	  questioned	  the	  overlap	  of	  the	  SP	  and	  the	  CSC	  compartment	  in	  a	  range	  of	  solid	  human	  cancers	  (reviewed	  in	  Broadley	  et	  al.	  2011)	  including	  GBM	  (Golebiewska	  et	  al.	  2013).	  Having	  failed	  to	  isolate	  a	  CSC	  or	  SLCC	  subset	  within	  GL261	  tumour	  cell	  populations	  cultured	  in	  standard	  medium,	  this	  study	  next	  evaluated	  the	  feasibility	  of	  using	  antigens	  derived	  from	  GL261	  cells	  cultured	  in	  SC	  medium.	  Although	  this	  technique	  enriches	  for	  a	  more	  stem	  cell-­‐like	  cell,	  it	  remains	  unclear	  whether	  this	  is	  achieved	  by	  selecting	  a	  subset	  that	  is	  intrinsically	  more	  stem-­‐like	  or	  by	  stochastically	  inducing	  this	  phenotype	  in	  a	  population	  of	  cells	  that	  are	  all	  capable	  of	  upregulating	  stem	  cell-­‐like	  characteristics	  in	  response	  to	  appropriate	  stimuli.	  Unexpectedly,	  the	  lysate	  sphere	  vaccine	  showed	  no	  benefit	  over	  the	  parental	  vaccine,	  a	  finding	  at	  odds	  with	  two	  previous	  studies	  of	  DC	  vaccines	  in	  rodent	  glioma	  models	  (Pellegatta	  et	  al.	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2006b;	  Q.	  Xu	  et	  al.	  2009)	  including	  one	  that	  used	  the	  GL261	  cell	  line	  (Pellegatta	  et	  al.	  2006b).	  This	  discordance	  with	  a	  study	  using	  the	  same	  cell	  line	  deserves	  careful	  scrutiny.	  	  It	  is	  appropriate	  to	  first	  consider	  the	  possibility	  that	  the	  cell	  lines	  used	  in	  the	  two	  studies	  were	  not	  the	  same.	  For	  the	  studies	  reported	  here,	  the	  GL261	  cell	  line	  was	  obtained	  from	  a	  respected	  tumour	  and	  cell	  line	  repository	  of	  international	  standing,	  the	  Division	  of	  Cancer	  Treatment	  and	  Diagnosis	  Tumor	  Repository,	  located	  at	  the	  National	  Cancer	  Institute	  in	  Maryland,	  USA.	  To	  rule	  out	  the	  possibility	  of	  contamination	  or	  genetic	  drift	  over	  time,	  our	  cell	  line	  was	  sent	  for	  genotyping	  by	  a	  commercial	  laboratory	  that	  specializes	  in	  cell	  line	  validation.	  Two	  specimens	  were	  sent	  for	  analysis:	  a	  sample	  of	  the	  original	  stock	  obtained	  in	  2008	  and	  stored	  since	  then	  in	  the	  vapour	  phase	  of	  liquid	  nitrogen,	  and	  a	  sample	  from	  a	  GL261	  culture	  in	  progress	  in	  2012	  at	  the	  time	  when	  many	  of	  the	  key	  experiments	  in	  this	  chapter	  were	  being	  performed.	  The	  two	  samples	  matched	  identically	  to	  each	  other	  and	  to	  the	  genetic	  profile	  established	  for	  the	  GL261	  cell	  line	  at	  that	  facility	  (Appendix	  C)	  confirming	  the	  identity	  of	  our	  cell	  line	  beyond	  any	  reasonable	  doubt.	  	  It	  is	  difficult	  to	  be	  quite	  as	  certain	  about	  the	  provenance	  of	  the	  cell	  line	  described	  in	  the	  study	  of	  Pellegatta	  and	  colleagues	  because	  the	  source	  of	  their	  cell	  line	  is	  not	  stated	  in	  their	  published	  account	  (Pellegatta	  et	  al.	  2006b),	  or	  in	  an	  earlier	  paper	  by	  the	  same	  group	  (Pellegatta	  et	  al.	  2006a).	  Since	  it	  is	  not	  possible	  to	  resolve	  this	  matter,	  the	  discussion	  will	  move	  on	  to	  consider	  other	  explanations.	  	  There	  were	  a	  number	  of	  notable	  differences	  between	  the	  vaccines	  used	  in	  the	  two	  studies,	  one	  of	  which	  was	  the	  method	  used	  to	  make	  the	  tumour	  cell	  lysate.	  In	  the	  other	  study,	  the	  lysate	  used	  to	  pulse	  DC	  was	  created	  by	  sonication	  of	  tumour	  cells.	  	  The	  lysate	  was	  then	  used	  without	  any	  further	  manipulation	  to	  pulse	  bone	  marrow-­‐derived	  DC	  (BMDC)	  in	  vitro.	  One	  possibility	  is	  that	  the	  sonication	  method	  used	  in	  that	  study,	  but	  not	  the	  vaccine	  design	  used	  in	  my	  study,	  created	  parental	  and	  sphere	  vaccines	  that	  differed	  in	  their	  antigen	  content	  or	  adjuvanticity.	  I	  considered	  trying	  to	  test	  this	  hypothesis	  by	  reproducing	  the	  methods	  used	  by	  the	  other	  group	  but	  some	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details	  for	  the	  sonication	  method	  were	  not	  clearly	  described	  in	  the	  manuscript	  or	  in	  the	  quoted	  references.	  However,	  some	  preliminary	  work	  along	  these	  lines	  yielded	  some	  interesting	  observations.	  	  Relevant	  to	  this	  discussion,	  in	  my	  hands,	  tumour	  cells	  suspended	  in	  a	  cryovial	  in	  complete	  media	  and	  sonicated	  in	  a	  water	  bath	  eventually	  became	  Trypan	  Blue	  positive	  but	  appeared	  otherwise	  morphologically	  intact.	  Secondly,	  sonication	  in	  a	  water	  bath	  for	  60	  minutes	  generated	  considerable	  heat.	  Thirdly,	  after	  60	  minutes	  of	  sonication	  a	  large	  proportion	  of	  tumour	  cells	  were	  still	  Trypan	  Blue	  negative.	  	  It	  is	  not	  possible	  to	  say	  from	  the	  information	  provided	  whether	  Pellegatta	  and	  colleagues	  controlled	  the	  temperature	  during	  sonication	  or	  checked	  cell	  viability	  at	  the	  end	  of	  the	  stated	  60	  minute	  period	  of	  sonication.	  	  In	  my	  study,	  the	  lysate	  was	  created	  by	  cycles	  of	  freeze/thaw	  followed	  by	  removal	  of	  particulate	  matter	  larger	  than	  0.2	  µm	  using	  centrifugation	  and	  filtration.	  This	  process	  may	  have	  resulted	  in	  a	  relative	  depletion	  of	  membrane-­‐associated	  proteins	  compared	  with	  the	  sonication	  method.	  If	  sphere	  cells	  and	  parental	  cells	  differ	  in	  their	  relative	  expression	  of	  an	  important	  antigen	  or	  DAMP	  that	  exists	  predominantly	  in	  membrane-­‐bound	  form	  then	  the	  comparative	  advantage	  of	  the	  sphere	  cell	  lysate	  could	  be	  lost	  if	  the	  lysates	  are	  depleted	  of	  membrane	  fragments.	  I	  considered	  the	  possibility	  of	  treating	  the	  freeze/thaw	  lysate	  with	  a	  detergent	  to	  increase	  the	  availability	  of	  membrane-­‐associated	  molecules	  but	  rejected	  this	  idea	  because	  of	  the	  possible	  toxicity	  of	  an	  i.v.	  lysate	  contaminated	  with	  detergent.	  Another	  important	  difference	  in	  vaccine	  design	  is	  that	  the	  Lysate-­‐Gal	  vaccines	  incorporated	  a	  potent	  adjuvant	  whereas,	  in	  the	  study	  by	  Pellegatta	  and	  colleagues,	  the	  only	  stimulus	  for	  DC	  maturation	  was	  delivered	  by	  the	  lysate	  itself.	  It	  has	  been	  shown	  here	  that	  the	  freeze/thaw	  lysates	  used	  in	  the	  Lysate-­‐Gal	  vaccines	  had	  neglible	  effect	  on	  DC	  maturation	  in	  vitro.	  Subtle	  differences	  in	  adjuvanticity	  between	  lysates	  likely	  become	  irrelevant	  when	  the	  vaccine	  incorporates	  a	  potent	  adjuvant	  like	  α-­‐GalCer.	  In	  contrast,	  Pellegatta	  and	  colleagues	  provide	  data	  to	  show	  that	  pulsing	  with	  the	  sonicated	  lysate	  was	  sufficient	  to	  induce	  BMDC	  to	  increase	  surface	  expression	  of	  MHC	  class	  I,	  MHC	  class	  II,	  CD80	  and	  CD86	  (Pellegatta	  et	  al.	  2006b).	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Using	  two	  different	  GL261	  parental	  cell	  lines,	  I	  also	  found	  that	  sonicated	  GL261	  tumour	  cells	  have	  the	  capacity	  to	  induce	  DC	  maturation	  (Appendix	  B,	  Fig	  B5.2).	  This	  maturation	  effect	  was	  weak	  in	  comparison	  to	  a	  TLR	  ligand	  but	  could	  perhaps	  become	  important	  when	  no	  other	  adjuvant	  is	  included	  in	  the	  system.	  Unfortunately,	  and	  perhaps	  surprisingly,	  Pellegatta	  and	  colleagues	  do	  not	  appear	  to	  have	  compared	  the	  level	  of	  DC	  maturation	  induced	  by	  the	  two	  sonicates.	  This	  raises	  the	  possibility	  that	  the	  sphere	  cell	  sonicate	  used	  in	  that	  study	  had	  a	  more	  potent	  effect	  on	  DC	  maturation	  than	  parental	  cell	  sonicate.	  	  Similar	  comments	  apply	  to	  the	  study	  of	  Xu	  and	  colleagues	  (Q.	  Xu	  et	  al.	  2009)	  who,	  using	  the	  9L	  rat	  glioma	  model,	  also	  reported	  superior	  induction	  of	  anti-­‐tumour	  immunity	  by	  BMDC	  pulsed	  with	  peptides	  acid-­‐eluted	  from	  sphere	  cells	  compared	  with	  DC	  pulsed	  with	  antigens	  eluted	  from	  tumour	  cells	  cultured	  in	  standard	  media,	  but	  did	  not	  report	  maturation	  status	  of	  the	  DC	  in	  the	  two	  vaccines.	  	  	  Another	  potentially	  relevant	  difference	  between	  the	  two	  GL261	  studies	  is	  that,	  in	  contrast	  to	  the	  freeze/thaw	  method,	  the	  sonication	  method	  of	  producing	  lysates	  has	  the	  capacity	  to	  generate	  significant	  heat.	  Sublethal	  heat	  shock	  induces	  the	  synthesis	  of	  heat	  shock	  proteins	  that	  can	  form	  complexes	  with	  proteins	  and	  act	  as	  “chaperones”	  to	  promote	  uptake	  and	  presentation	  of	  peptide	  antigens	  by	  DC	  (Crane	  et	  al.	  2013).	  To	  speculate,	  it	  is	  possible	  that	  sphere	  cells	  become	  a	  better	  source	  of	  antigens	  for	  DC	  pulsing	  after	  exposure	  to	  heat	  because	  some	  component	  of	  the	  SC	  medium,	  such	  as	  insulin	  for	  example	  (Ting	  et	  al.	  1989),	  promotes	  the	  synthesis	  of	  heat	  shock	  proteins	  (HSP),	  a	  difference	  that	  might	  not	  come	  into	  play	  when	  the	  freeze/thaw	  technique	  is	  used.	  	  Another	  way	  of	  considering	  the	  apparent	  discordance	  of	  the	  two	  studies	  is	  to	  re-­‐examine	  the	  strength	  of	  the	  conclusions	  reached	  by	  the	  earlier	  study.	  To	  begin,	  it	  seems	  possible	  that	  the	  results	  of	  some	  experiments	  in	  the	  earlier	  study	  could	  have	  been	  affected	  by	  contamination	  of	  the	  DC-­‐based	  vaccines	  by	  tumour	  cells.	  As	  mentioned	  above,	  the	  lysates	  used	  in	  that	  study	  appear	  to	  have	  been	  created	  by	  60	  minutes	  of	  sonication	  but	  no	  steps	  to	  assess	  cell	  viability	  after	  sonication	  are	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stipulated	  in	  the	  methods.	  My	  own	  preliminary	  observations	  showed	  that	  60	  minutes	  of	  sonication	  are	  not	  necessarily	  sufficient	  to	  render	  all	  tumour	  cells	  Trypan	  Blue	  positive.	  Pellegatta	  and	  colleagues	  provide	  data	  showing	  increased	  expression	  of	  MHC	  class	  II	  and	  co-­‐stimulatory	  molecules	  by	  sphere	  cells	  relative	  to	  adherent	  cells	  and	  suggested	  that	  sonicated	  sphere	  cells	  might	  therefore	  be	  more	  immunogenic.	  If	  live	  or	  dying	  whole	  tumour	  cells	  can	  act	  as	  APC	  then,	  assuming	  at	  least	  some	  tumour	  cells	  could	  survive	  co-­‐culture	  with	  BMDC	  for	  2-­‐3	  hours,	  contamination	  of	  the	  DC	  vaccines	  by	  immunogenic	  tumour	  cells	  could	  conceivably	  explain	  the	  different	  performance	  of	  the	  two	  vaccines	  in	  that	  study.	  	  Another	  factor	  to	  consider	  is	  variability	  in	  the	  behaviour	  of	  the	  GL261	  model	  between	  experiments.	  In	  my	  view,	  the	  key	  experiment	  in	  the	  paper	  of	  Pellegatta	  and	  colleagues	  was	  that	  which	  showed	  the	  sphere-­‐pulsed	  DC	  vaccine	  was	  more	  effective	  than	  the	  adherent	  (parental)	  cell-­‐pulsed	  vaccine	  against	  established	  adherent	  cell	  tumours.	  	  In	  fact,	  both	  vaccines	  had	  a	  therapeutic	  benefit	  that	  was	  statistically	  significant	  compared	  with	  untreated	  controls,	  with	  long	  term	  survival	  of	  80	  %	  	  and	  50	  %	  for	  the	  sphere	  and	  adherent	  cell	  vaccines	  respectively*.	  The	  magnitude	  of	  this	  difference	  is	  not	  dissimilar	  to	  the	  level	  of	  variation	  seen	  in	  studies	  described	  earlier	  in	  this	  thesis	  using	  parental	  cell-­‐based	  vaccines.	  It	  was	  shown	  in	  Chapter	  4	  that	  the	  level	  of	  protection	  against	  a	  s.c.	  tumour	  challenge	  afforded	  by	  the	  Glioma-­‐Gal	  vaccine	  ranged	  from	  60	  to	  100	  %	  (Fig	  4.2A).	  Similarly,	  therapeutic	  Glioma-­‐Gal-­‐based	  immunotherapy	  resulted	  in	  long	  term	  survival	  over	  three	  independent	  experiments	  in	  29	  to	  60	  %	  of	  i.c.	  tumour-­‐bearing	  mice	  (Fig	  4.7).	  Although	  several	  possible	  mechanisms	  could	  explain	  this	  variability	  from	  experiment	  to	  experiment,	  one	  that	  cannot	  be	  excluded	  is	  a	  level	  of	  variability	  in	  the	  cultured	  tumours	  cells	  used	  to	  construct	  the	  vaccines.	  Particular	  caution	  is	  therefore	  required	  when	  drawing	  conclusions	  about	  differences	  between	  vaccines	  derived	  from	  different	  GL261	  cultures.	  	  
*	  No	  direct	  statistical	  comparison	  of	  the	  two	  vaccinated	  groups	  is	  provided	  in	  this	  unrepeated	  experiment.	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To	  illustrate	  this	  point,	  in	  the	  course	  of	  this	  thesis	  it	  was	  observed	  that	  single	  cell	  suspensions	  of	  harvested	  tumour	  cells	  always	  contained	  a	  significant	  proportion	  of	  tumour	  cells	  that	  were	  Trypan	  Blue-­‐positive	  but	  otherwise	  intact.	  In	  the	  study	  by	  Pellegatta	  and	  colleagues,	  BMDC	  appear	  to	  have	  been	  pulsed	  with	  a	  defined	  number	  of	  sonicated	  cells.	  Although	  not	  stated,	  this	  may	  have	  been	  determined	  by	  counting	  live	  cells.	  Since	  the	  cell	  supensions	  almost	  certainly	  included	  a	  variable	  number	  of	  dead	  cells,	  sonicates	  derived	  from	  separate	  cell	  cultures	  could	  contain	  substantially	  different	  quantities	  of	  protein.	  Similarly,	  in	  the	  study	  of	  Xu	  and	  colleagues	  (Q.	  Xu	  et	  al.	  2009)	  peptide	  antigens	  were	  acid-­‐eluted	  from	  sphere	  and	  “daughter”	  cells	  but	  it	  is	  not	  clear	  what	  steps	  were	  taken	  to	  standardize	  the	  quantity	  of	  antigen	  used	  to	  pulse	  the	  DC	  during	  vaccine	  production.	  	  The	  potential	  for	  antigen	  quantity	  to	  influence	  the	  magnitude	  of	  a	  vaccine-­‐induced	  response	  is	  illustrated	  by	  the	  results	  of	  the	  titration	  experiment	  depicted	  in	  Fig	  5.6C.	  	  It	  is	  also	  possible	  that	  adjuvanticity	  of	  sonicated	  tumour	  cells	  varies	  from	  culture	  to	  culture	  regardless	  of	  whether	  the	  sonicated	  cells	  are	  from	  sphere	  or	  parental	  cultures	  (Appendix	  B,	  Fig	  B5.2).	  Thus,	  whereas	  the	  Lysate-­‐Gal	  vaccine	  was	  designed	  specifically	  to	  create	  vaccines	  of	  equivalent	  adjuvanticity	  and	  antigen	  quantity,	  the	  same	  cannot	  necessarily	  be	  said	  for	  the	  vaccines	  used	  in	  these	  two	  studies.	  To	  complete	  this	  re-­‐examination	  of	  the	  earlier	  GL261	  study,	  and	  with	  the	  greatest	  respect	  for	  the	  pioneering	  work	  of	  this	  group,	  I	  question	  the	  emphasis	  placed	  on	  the	  finding	  that	  the	  sphere-­‐pulsed	  DC	  vaccine	  outperformed	  the	  adherent	  (parental)	  cell-­‐derived	  vaccine	  when	  used	  to	  treat	  implanted	  sphere	  cell	  tumours.	  The	  importance	  the	  authors	  attach	  to	  this	  is	  partly	  due	  to	  their	  findings	  that	  sphere	  cell	  tumours	  were	  more	  infiltrative,	  more	  rapidly	  lethal,	  and	  more	  closely	  resembled	  human	  gliomas,	  thus	  implying	  the	  sphere	  cell	  to	  be	  of	  greater	  clinical	  relevance.	  However,	  this	  experiment	  could	  be	  interpreted	  as	  simply	  showing	  that	  whole	  tumour	  cell-­‐based	  vaccines	  are	  more	  likely	  to	  be	  protective	  when	  the	  cells	  used	  to	  make	  the	  vaccine	  and	  those	  used	  to	  seed	  the	  target	  tumour	  are	  the	  same,	  so	  that	  the	  antigens	  targeted	  by	  the	  vaccine	  most	  closely	  align	  with	  those	  expressed	  by	  the	  target	  cells.	  In	  my	  opinion,	  the	  more	  relevant	  experiment	  is	  that	  which	  tested	  the	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two	  vaccines	  against	  the	  parental	  cell	  tumour.	  Consistent	  superiority	  of	  the	  sphere-­‐pulsed	  vaccine	  in	  this	  context	  would	  have	  provided	  some	  support	  for	  the	  authors’	  conclusion	  that	  	  “targeting	  of	  GL261	  [sphere]	  cells	  depletes	  the	  tumor	  of	  its	  
hierarchically	  and	  most	  relevant	  population:	  Cancer	  Stem	  Cells”.	  	  In	  summary,	  the	  work	  presented	  in	  this	  chapter	  has	  shown	  that,	  when	  adjuvanticity	  and	  antigen	  quantity	  are	  held	  constant,	  a	  GL261	  sphere	  cell-­‐based	  vaccine	  does	  not	  provide	  superior	  protection	  against	  a	  tumour	  challenge	  than	  a	  parental	  cell-­‐based	  vaccine.	  	  While	  this	  conclusion	  at	  first	  glance	  appears	  to	  be	  discordant	  with	  that	  reached	  by	  a	  previous	  similar	  study,	  there	  were	  significant	  methodological	  differences	  between	  the	  two	  studies	  and,	  in	  my	  opinion,	  some	  of	  the	  conclusions	  reached	  by	  the	  earlier	  study	  may	  not	  have	  been	  justified.	  The	  two	  studies	  did	  find	  common	  ground	  in	  observing	  that	  culture	  of	  GL261	  in	  SC	  medium	  induces	  a	  more	  stem	  cell-­‐like	  phenotype	  that	  gives	  rise	  to	  more	  infiltrative	  tumours.	  	  	  One	  of	  the	  most	  attractive	  aspects	  of	  the	  CSC	  hypothesis	  is	  the	  proposed	  existence	  of	  a	  subset	  of	  cells	  with	  the	  unique	  capacity	  to	  initiate	  and	  maintain	  tumours.	  If	  true,	  targeting	  these	  cells	  with	  treatment	  becomes	  necessary	  but	  also	  sufficient.	  The	  failure	  of	  the	  sphere	  lysate	  vaccine	  to	  elicit	  superior	  protective	  immunity	  against	  implanted	  GL261	  tumours	  in	  this	  study	  raises	  the	  distinct	  possibility	  that	  there	  is	  no	  CSC/SLCC	  subset	  to	  target	  in	  this	  cell	  line.	  Published	  reports	  supporting	  the	  existence	  of	  a	  small	  subset	  of	  CSC	  in	  the	  GL261	  cell	  line	  (Anhua	  Wu	  et	  al.	  2008)	  and	  other	  rodent	  glioma	  cell	  lines	  (Kondo	  et	  al.	  2004)	  were	  the	  basis	  for	  selecting	  the	  GL261	  model	  for	  this	  project.	  However,	  it	  seems	  intuitively	  unlikely	  that	  a	  cell	  line	  cultured	  in	  vitro	  for	  several	  decades	  as	  an	  adherent	  monolayer	  in	  the	  presence	  of	  serum	  would	  retain	  a	  CSC	  subset	  (Zheng	  et	  al.	  2007).	  The	  findings	  presented	  here	  have	  shown	  that	  GL261	  cells	  grown	  in	  standard	  culture	  media	  are	  universally	  CD44+	  CD133-­‐	  and	  possess	  potent	  tumour	  initiation	  ability,	  with	  the	  capacity	  to	  initiate	  tumours	  after	  intracranial	  implantation	  of	  as	  few	  as	  500	  cells.	  GL261	  is	  also	  by	  definition	  capable	  of	  self-­‐renewal	  because	  it	  can	  be	  serially	  transplanted	  and	  maintained	  indefinitely	  in	  culture	  (Szatmari	  et	  al.	  2006).	  	  A	  CD44+	  CD133-­‐	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phenotype	  has	  been	  proposed	  for	  CSC	  in	  human	  GBM	  of	  mesenchymal	  type	  (Lottaz	  et	  al.	  2010).	  Thus	  GL261	  could	  be	  seen	  as	  a	  homogeneous	  population	  of	  CSC-­‐like	  cells.	  Similar	  conclusions	  have	  been	  reached	  by	  others	  with	  respect	  to	  another	  rodent	  glioma	  cell	  line.	  Whereas	  Kondo	  and	  colleagues	  had	  previously	  reported	  finding	  a	  small	  subset	  of	  exclusively	  tumourigenic	  cells	  in	  the	  C6	  glioma	  cell	  line	  (Kondo	  et	  al.	  2004),	  Zheng	  and	  colleagues	  found	  in	  the	  same	  cell	  line	  that	  100	  %	  of	  single	  cells	  formed	  colonies	  in	  vitro	  that	  in	  turn	  all	  formed	  brain	  tumours	  in	  immunodeficient	  mice	  on	  implantation	  (Zheng	  et	  al.	  2007).	  Unless	  the	  target	  tumour	  is	  heterogeneous,	  the	  concept	  of	  selectively	  targeting	  a	  CSC	  subset	  becomes	  invalid.	  	  On	  reflection,	  a	  whole	  tumour	  cell-­‐based	  vaccine	  may	  not	  be	  the	  optimal	  way	  of	  selectively	  targeting	  a	  particular	  tumour	  cell	  subset	  or	  phenotype.	  The	  immunodominant	  antigens	  responsible	  for	  the	  efficacy	  of	  vaccines	  targeting	  unselected	  antigens	  derived	  from	  whole	  GL261	  tumour	  cells	  have	  not	  been	  characterized	  (Grauer	  et	  al.	  2008).	  Although	  culturing	  cells	  in	  SC	  medium	  may	  well	  have	  resulted	  in	  a	  lysate	  skewed	  towards	  proteins	  expressed	  by	  CSC	  or	  SLCC,	  the	  proportion	  of	  protein	  in	  the	  lysate	  that	  was	  specifically	  CSC-­‐	  or	  SLCC-­‐associated	  may	  have	  been	  too	  small	  to	  materially	  alter	  the	  resulting	  immune	  response.	  Put	  another	  way,	  the	  lysates	  may	  all	  have	  included	  a	  highly	  dominant	  non-­‐CSC-­‐associated	  antigen	  common	  to	  all	  tumour	  cell	  types	  that	  negated	  any	  benefit	  of	  increasing	  the	  proportion	  of	  CSC-­‐associated	  antigens.	  Theoretically,	  a	  vaccine	  that	  only	  contained	  CSC-­‐specific	  antigens	  would	  selectively	  target	  CSC	  more	  efficiently	  but	  such	  antigens,	  if	  they	  exist,	  have	  yet	  to	  be	  defined	  in	  GL261.	  As	  discussed	  above,	  SOX2	  and	  SOX6	  are	  candidate	  CSC-­‐associated	  antigens	  for	  human	  GBM	  tumours.	  It	  is	  interesting	  to	  speculate	  that	  Musashi-­‐1,	  an	  RNA-­‐binding	  protein	  expressed	  in	  NSC	  and	  shown	  here	  to	  be	  transcriptionally	  upregulated	  by	  GL261	  sphere	  cells,	  could	  also	  potentially	  be	  a	  CSC-­‐associated	  target	  for	  glioma	  immunotherapy.	  	  Although	  this	  study	  did	  not	  produce	  “proof-­‐of-­‐principle”	  data	  to	  support	  the	  strategy	  of	  targeting	  CSC	  or	  SLCC	  with	  immunotherapy,	  this	  may	  have	  been	  due	  to	  the	  glioma	  model	  and/or	  the	  vaccine	  design.	  The	  possibility	  that	  this	  approach	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CHAPTER	  SIX:	  TARGETING	  CHEMORESISTANT	  TUMOUR	  
CELLS	  TO	  IMPROVE	  IMMUNOTHERAPY	  FOR	  GLIOMA	  
 
6.1	   INTRODUCTION	  AND	  OBJECTIVES	  
6.1.1	   Combining	  immunotherapy	  and	  chemotherapy	  for	  cancer	  High	  grade	  glioma	  tumour	  cell	  populations	  are	  highly	  heterogeneous	  in	  their	  morphology,	  genetics	  and	  biological	  behaviour	  (Bonavia	  et	  al.	  2011).	  This	  heterogeneity	  can	  arise	  from	  the	  inherent	  genetic	  instability	  of	  cancer	  cells	  or	  from	  epigenetic	  changes	  induced	  by	  the	  tumour	  microenvironment.	  Phenotypic	  differences	  contribute	  to	  variability	  in	  the	  susceptibility	  of	  tumour	  cells	  to	  different	  treatments	  such	  as	  radiotherapy,	  chemotherapy	  and	  immunotherapies.	  Single	  modality	  treatment	  often	  leads	  to	  the	  selection	  of	  resistant	  clones	  and	  clinical	  recurrence.	  Because	  of	  this,	  there	  is	  growing	  interest	  in	  combining	  different	  treatment	  modalities	  to	  exploit	  additive	  and/or	  synergistic	  effects	  (Lake	  and	  Robinson	  2005).	  	  The	  standard	  treatment	  for	  GBM	  consists	  of	  maximum	  safe	  surgical	  resection	  followed	  by	  a	  combination	  of	  external	  beam	  radiotherapy	  and	  systemic	  chemotherapy.	  TMZ	  is	  administered	  concomitantly	  with	  radiotherapy	  for	  6	  weeks,	  followed	  by	  an	  adjuvant	  phase	  of	  6	  monthly	  cycles	  of	  TMZ	  alone.	  This	  regimen	  was	  designed	  in	  part	  to	  exploit	  complementary	  effects	  of	  radiotherapy	  and	  TMZ	  observed	  in	  vitro	  (Stupp	  et	  al.	  2005;	  Wedge	  et	  al.	  1997;	  W.	  Wick	  et	  al.	  2002).	  	  The	  adoption	  of	  the	  “Stupp	  Protocol”	  as	  the	  standard	  of	  care	  has	  improved	  outcomes	  but	  5	  year	  survival	  for	  GBM	  patients	  is	  still	  under	  10	  %	  (Stupp	  et	  al.	  2009).	  There	  is	  therefore	  still	  a	  pressing	  need	  to	  find	  a	  better	  treatment.	  	  	  There	  are	  several	  reasons	  to	  consider	  a	  combination	  of	  chemotherapy	  and	  immunotherapy	  for	  the	  treatment	  of	  GBM.	  Firstly,	  there	  is	  the	  practical	  consideration	  that	  chemotherapy	  is	  already	  an	  established	  part	  of	  standard	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treatment	  for	  newly	  presenting	  patients.	  It	  has	  recently	  been	  shown	  that	  combining	  DC-­‐based	  immunotherapy	  with	  the	  adjuvant	  phase	  of	  cyclical	  TMZ	  is	  feasible	  (Ardon	  et	  al.	  2010b).	  Secondly,	  in	  the	  recurrent	  setting,	  when	  radiotherapy	  is	  no	  longer	  a	  treatment	  option,	  chemotherapies	  and	  immunotherapies	  in	  their	  current	  form	  have	  been	  generally	  disappointing	  as	  stand-­‐alone	  treatments.	  It	  is	  therefore	  logical	  to	  explore	  novel	  combinations	  of	  these	  two	  modalities.	  	  Thirdly,	  although	  combining	  cytotoxic	  chemotherapy	  with	  T	  cell-­‐based	  immunotherapy	  is	  perhaps	  counter-­‐intuitive,	  there	  is	  already	  incontrovertible	  evidence	  that	  these	  two	  modalities	  can	  have	  synergisitic	  effects	  	  (reviewed	  in	  Lake	  and	  Robinson	  2005;	  Schlom	  et	  al.	  2007;	  Schlom	  2012).	  When	  there	  is	  significant	  tumour	  burden,	  one	  role	  for	  chemotherapy	  can	  be	  simply	  to	  reduce	  surgically	  inaccessible	  tumour	  bulk	  prior	  to	  vaccination.	  It	  is	  generally	  accepted	  that	  immunotherapy	  is	  more	  likely	  to	  succeed	  in	  a	  setting	  of	  minimal	  disease	  burden,	  probably	  because	  of	  the	  many	  immunosuppressive	  mechanisms	  associated	  with	  established	  tumours	  (Bilusic	  and	  Gulley	  2012;	  Gulley	  et	  al.	  2011).	  Another	  way	  in	  which	  the	  direct	  tumouricidal	  action	  of	  chemotherapy	  can	  augment	  anti-­‐tumour	  immunity	  is	  by	  creating	  a	  large	  number	  of	  dying	  tumour	  cells	  that	  serve	  as	  a	  source	  of	  antigen	  combined	  with	  	  “danger”	  signals	  capable	  of	  priming	  or	  boosting	  anti-­‐tumour	  immune	  responses.	  Nowak	  and	  colleagues	  first	  demonstrated	  that	  the	  apoptosis-­‐inducing	  nucleoside	  analog	  gemcitabine	  could	  induce	  cross-­‐presentation	  of	  a	  model	  tumour-­‐associated	  antigen	  in	  vivo	  (Nowak	  et	  al.	  2003).	  Subsequently,	  Zitvogel	  and	  others	  have	  shown	  that	  the	  key	  to	  chemotherapy-­‐induced	  immunogenic	  tumour	  cell	  death	  is	  exposure	  or	  release	  of	  DAMPs	  including	  calreticulin	  (Obeid	  et	  al.	  2007),	  High	  Mobility	  Group	  Box	  Protein1	  (HMGB1)	  (Apetoh	  et	  al.	  2007),	  uric	  acid	  (Hu	  et	  al.	  2004),	  heat	  shock	  proteins	  (Binder	  and	  Srivastava	  2005)	  and	  ATP	  (Ghiringhelli	  et	  al.	  2009).	  	  	  This	  ability	  of	  chemotherapy	  to	  induce	  immunogenic	  cell	  death	  may	  be	  a	  major	  reason	  for	  the	  therapeutic	  benefit	  of	  some	  anti-­‐cancer	  agents	  in	  the	  clinic	  (Apetoh	  et	  al.	  2008).	  Mihich	  showed	  in	  1969	  that	  the	  ability	  of	  chemotherapy	  agents	  to	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eradicate	  tumours	  in	  several	  mouse	  models	  was	  abrogated	  by	  thymectomy	  or	  whole	  body	  irradiation	  (Mihich	  1969).	  In	  humans,	  patients	  with	  breast	  cancer	  who	  have	  a	  loss-­‐of-­‐function	  allele	  at	  the	  loci	  encoding	  TLR4	  or	  the	  P2X7	  purinergic	  receptor	  relapse	  more	  quickly	  after	  chemotherapy	  (Apetoh	  et	  al.	  2007;	  Ghiringhelli	  et	  al.	  2009)	  consistent	  with	  a	  requirement	  for	  immune	  cell	  activation	  in	  order	  for	  chemotherapy	  to	  be	  fully	  effective.	  The	  quantity	  of	  antigen	  released	  from	  dying	  cells	  in	  response	  to	  chemotherapy	  appears	  to	  be	  important.	  Hengst	  and	  colleagues	  found	  in	  an	  animal	  model	  that	  cyclophosphamide	  was	  effective	  against	  established	  plasmacytomas	  in	  vivo,	  an	  effect	  that	  required	  the	  presence	  of	  lymphocytes,	  but	  was	  not	  effective	  against	  small	  non-­‐palpable	  tumours	  (Hengst	  et	  al.	  1981).	  	  	  Applying	  the	  phenomenon	  of	  immunogenic	  cell	  death	  to	  the	  design	  of	  anti-­‐cancer	  vaccines,	  Zitvogel	  and	  colleagues	  showed	  that	  tumour	  cells	  exposed	  to	  lethal	  doses	  of	  doxorubicin	  in	  vitro	  are	  effective	  at	  protecting	  against	  tumour	  challenge	  when	  administered	  as	  a	  vaccine	  without	  any	  additional	  adjuvant	  (Casares	  et	  al.	  2005).	  Mechanistically,	  the	  authors	  showed	  that	  the	  chemotherapy-­‐treated	  cells,	  but	  not	  cells	  killed	  by	  freeze-­‐thaw,	  were	  efficiently	  phagocytosed	  by	  DC	  in	  vitro,	  and	  tumour	  protection	  in	  vivo	  was	  dependent	  on	  CD8+	  T	  cells.	  Importantly,	  the	  induction	  of	  immunogenic	  cell	  death	  is	  not	  a	  universal	  property	  of	  all	  cytotoxic	  agents.	  Although	  doxorubicin	  and	  γ-­‐irradiation	  have	  this	  effect,	  other	  DNA-­‐damaging	  agents	  such	  as	  mitomycin	  C	  and	  etoposide	  do	  not	  (Casares	  et	  al.	  2005;	  Obeid	  et	  al.	  2007).	  	  	  Chemotherapy	  does	  not	  necessarily	  need	  to	  induce	  cell	  death	  to	  render	  tumour	  cells	  more	  immunogenic.	  It	  has	  recently	  been	  shown	  that	  exposure	  in	  vitro	  to	  very	  low	  non-­‐cytotoxic	  levels	  of	  doxorubicin	  or	  paclitaxel	  increases	  the	  immunogenicity	  of	  human	  colon	  cancer	  cells	  when	  loaded	  onto	  DC	  (Kaneno	  et	  al.	  2011).	  There	  is	  also	  abundant	  evidence	  that	  sublethal	  chemotherapy	  may	  increase	  tumour	  cell	  susceptibility	  to	  CTL-­‐mediated	  killing	  in	  a	  number	  of	  ways.	  Tumour	  cells	  surviving	  exposure	  to	  doxorubicin	  in	  vitro	  have	  been	  shown	  to	  upregulate	  MHC	  class	  I	  expression	  and	  this	  in	  turn	  increased	  susceptibility	  to	  CTL-­‐mediated	  lysis	  (Fisk	  and	  Ioannides	  1998).	  Treatment	  with	  paclitaxel,	  cisplatin	  or	  doxorubicin	  upregulates	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mannose-­‐6-­‐phosphate	  receptor	  expression	  by	  tumour	  cells	  that	  in	  turn	  make	  them	  more	  permeable	  to	  granzyme	  B	  (Ramakrishnan	  et	  al.	  2010).	  In	  a	  mouse	  model	  of	  lung	  cancer,	  exposure	  to	  a	  sublethal	  dose	  of	  two	  platinum-­‐based	  agents	  caused	  tumour	  cells	  to	  downregulate	  expression	  of	  anti-­‐apoptotic	  survival	  genes	  and	  increase	  Fas	  expression,	  and	  rendered	  the	  cells	  more	  susceptible	  to	  Fas-­‐dependent	  CTL	  lysis	  in	  vitro	  (Gameiro	  et	  al.	  2011).	  Doxorubicin	  and	  an	  anti-­‐Fas	  mAb	  have	  been	  shown	  to	  have	  synergistic	  cytotoxic	  effects	  against	  bladder	  carcinoma	  cells	  (Mizutani	  et	  al.	  1997)	  and	  renal	  carcinoma	  cell	  lines	  (X.	  X.	  Wu	  et	  al.	  2000).	  Mechanistically,	  it	  was	  shown	  that	  doxorubicin	  increased	  tumour	  cell	  expression	  of	  Fas	  and	  p53,	  and	  increased	  the	  activity	  of	  caspase	  3	  (X.	  X.	  Wu	  et	  al.	  2000).	  Synergism	  with	  the	  anti-­‐Fas	  mAb	  was	  not	  seen	  with	  other	  kinds	  of	  chemotherapy,	  suggesting	  this	  mechanism	  may	  be	  specific	  to	  anthracyclines.	  	  In	  addition	  to	  direct	  effects	  on	  tumour	  cells,	  chemotherapy	  can	  also	  potentiate	  immunotherapies	  by	  modulating	  the	  immune	  system.	  The	  most	  striking	  example	  of	  this	  comes	  from	  the	  field	  of	  adoptive	  cell	  transfer.	  In	  mice,	  it	  has	  long	  been	  known	  that	  prior	  lymphodepletion	  with	  cyclophosphamide	  enhances	  the	  survival	  and	  therapeutic	  effect	  of	  adoptively	  transferred	  tumour-­‐reactive	  lymphocytes	  (Berenson	  et	  al.	  1975;	  Greenberg	  and	  Cheever	  1984;	  Proietti	  et	  al.	  1998).	  	  In	  human	  patients,	  the	  transfer	  of	  large	  numbers	  of	  ex	  vivo-­‐expanded	  tumour-­‐reactive	  T	  cells	  is	  capable	  of	  inducing	  regression	  of	  large	  solid	  tumours	  (Steven	  A	  Rosenberg	  et	  al.	  2008)	  and	  this	  treatment	  is	  more	  effective	  when	  patients	  are	  lymphodepleted	  prior	  to	  transfer	  with	  either	  cyclophosphamide	  or	  total	  body	  irradiation.	  In	  a	  series	  of	  studies	  using	  different	  lymphodepletion	  regimes	  (reviewed	  in	  Steven	  A	  Rosenberg	  and	  Dudley	  2009),	  the	  longevity	  of	  the	  transferred	  cells	  and	  the	  clinical	  response	  rate	  increased	  in	  proportion	  to	  the	  degree	  of	  lymphodepletion.	  The	  cause	  of	  these	  effects	  is	  believed	  to	  be	  a	  homeostatic	  increase	  in	  the	  levels	  of	  lymphocyte	  survival	  cytokines	  IL-­‐7	  and	  IL-­‐15	  and	  reduced	  competition	  for	  these	  cytokines	  (Gameiro	  et	  al.	  2011;	  Gattinoni	  et	  al.	  2005b),	  along	  with	  the	  elimination	  of	  immunosuppressive	  elements	  such	  as	  Treg	  (Klebanoff	  et	  al.	  2005a;	  North	  1982).	  	  
 217 
Pre-­‐treatment	  with	  chemotherapy	  has	  also	  been	  shown	  to	  augment	  active	  specific	  immunotherapies	  in	  mice	  (Gameiro	  et	  al.	  2011;	  Ghiringhelli	  et	  al.	  2004;	  J.-­‐Y.	  Liu	  et	  al.	  2007;	  Machiels	  et	  al.	  2001;	  Ramakrishnan	  et	  al.	  2010)	  and	  in	  some	  human	  studies	  (Bass	  and	  Mastrangelo	  1998;	  Berd	  et	  al.	  1986).	  	  As	  for	  adoptive	  cell	  transfer,	  a	  major	  mechanism	  of	  action	  of	  cyclophosphamide	  in	  this	  context	  is	  believed	  to	  be	  a	  selective	  reduction	  in	  the	  number	  (Ghiringhelli	  et	  al.	  2004;	  J.-­‐Y.	  Liu	  et	  al.	  2007)	  and	  function	  (Ghiringhelli	  et	  al.	  2004)	  of	  Treg.	  With	  respect	  to	  TMZ,	  currently	  the	  first	  line	  chemotherapy	  agent	  for	  GBM,	  the	  effects	  on	  Treg	  are	  complex.	  In	  a	  rat	  glioma	  model,	  Banissi	  and	  colleagues	  found	  that	  a	  regimen	  designed	  to	  mimic	  the	  adjuvant	  phase	  of	  treatment	  (maximum	  tolerated	  dose	  delivered	  over	  5	  days)	  did	  not	  alter	  the	  Treg-­‐to-­‐CD4	  T	  cell	  ratio	  but	  the	  ratio	  was	  reduced	  by	  a	  metronomic	  regimen	  (very	  low	  dose	  TMZ	  given	  daily	  for	  3	  weeks)	  (Banissi	  et	  al.	  2009).	  	  Contrary	  to	  this,	  Fadul	  and	  colleagues	  assessed	  PBMC	  in	  10	  patients	  after	  the	  concomitant	  phase	  of	  TMZ	  and	  radiotherapy	  and	  found	  that	  although	  the	  absolute	  number	  of	  CD4	  T	  cells	  decreased	  as	  expected,	  the	  absolute	  number	  of	  Treg	  was	  unchanged,	  resulting	  in	  a	  higher	  Treg-­‐to-­‐CD4	  T	  cell	  ratio	  (C.	  E	  Fadul	  et	  al.	  2011a).	  In	  a	  clinical	  trial	  of	  an	  EGFRvIII-­‐specific	  peptide	  vaccine	  for	  GBM,	  in	  which	  vaccination	  was	  alternated	  with	  adjuvant	  cycles	  of	  TMZ,	  lymphopaenia	  was	  observed	  as	  expected	  but,	  when	  assessed	  after	  the	  6th	  cycle	  of	  TMZ,	  there	  was	  no	  change	  in	  the	  proportion	  of	  T	  cells	  that	  were	  Treg	  in	  patients	  receiving	  standard	  adjuvant	  TMZ	  (200mg/m2	  for	  5	  days	  every	  28	  days).	  Patients	  randomly	  assigned	  to	  receive	  vaccine	  plus	  an	  alternative	  “dose-­‐intensified”	  regime	  (100	  mg/m2	  for	  21	  days	  every	  28	  days)	  experienced	  a	  more	  severe	  degree	  of	  lymphopaenia	  and	  the	  proportion	  of	  T	  cells	  that	  were	  Treg	  increased	  from	  6.1	  %	  to	  8.7	  %	  (Sampson	  et	  al.	  2011).	  Despite	  this,	  peptide-­‐specific	  humoral	  and	  cell-­‐mediated	  responses	  were	  of	  greater	  magnitude	  in	  the	  dose-­‐intensified	  group	  suggesting	  that	  the	  advantages	  of	  chemotherapy-­‐induced	  lymphopaenia	  outweighed	  the	  disadvantage	  of	  an	  adverse	  Treg-­‐to-­‐Effector	  T	  cell	  ratio.	  In	  addition,	  TMZ	  has	  been	  reported	  to	  inhibit	  the	  suppressive	  effects	  of	  Treg	  in	  vitro	  (Banissi	  et	  al.	  2009)	  and	  to	  inhibit	  the	  secretion	  by	  GBM	  cell	  lines	  of	  CCL2,	  a	  chemokine	  thought	  to	  play	  a	  major	  role	  in	  recruiting	  Treg	  to	  the	  tumour	  site	  (Jordan	  et	  al.	  2008).	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Chemotherapy	  can	  modulate	  the	  immune	  system	  to	  enhance	  subsequent	  immunotherapy	  in	  a	  number	  of	  other	  ways	  including	  the	  selective	  sparing	  of	  memory	  T	  cells	  (Hermans	  et	  al.	  2003a;	  Turtle	  et	  al.	  2009),	  the	  recruitment	  of	  tumour-­‐infiltrating	  γδ	  T	  cells	  that	  in	  turn	  recruit	  CTL	  (Ma	  et	  al.	  2011),	  and	  direct	  effects	  on	  DC	  such	  as	  upregulation	  of	  antigen-­‐processing	  machinery,	  expression	  of	  co-­‐stimulatory	  molecules	  and	  IL-­‐12	  production	  (Shurin	  et	  al.	  2009).	  The	  effects	  of	  chemotherapy	  on	  circulating	  MDSC	  in	  cancer	  patients	  are	  agent-­‐specific.	  Whereas	  gemcitabine	  has	  been	  reported	  to	  selectively	  deplete	  MDSC	  (E.	  Suzuki	  et	  al.	  2005),	  a	  cyclophosphamide/doxorubicin	  regimen	  has	  actually	  been	  shown	  to	  increase	  MDSC	  in	  patients	  with	  advanced	  cancer	  (Diaz-­‐Montero	  et	  al.	  2009).	  	  	  This	  discussion	  has	  so	  far	  focused	  on	  immune-­‐potentiation	  by	  chemotherapy,	  a	  mechanism	  termed	  “immunocentric	  chemoimmunotherapy”	  by	  Radfar	  and	  colleagues	  (Radfar	  et	  al.	  2009).	  There	  has	  been	  less	  emphasis	  on	  the	  inverse	  effect,	  namely	  the	  potentiation	  of	  chemotherapy	  by	  prior	  immunotherapy	  (“chemocentric	  chemoimmunotherapy”).	  There	  are	  reports	  from	  a	  range	  of	  different	  cancer	  settings	  of	  better	  than	  expected	  responses	  to	  salvage	  chemotherapy	  in	  patients	  who	  have	  relapsed	  after	  previous	  immunotherapies	  (reviewed	  in	  Ramakrishnan	  et	  al.	  2008).	  	  In	  patients	  with	  GBM	  who	  had	  previously	  participated	  in	  clinical	  trials	  of	  autologous	  tumour	  lysate-­‐pulsed	  DC	  vaccination,	  it	  was	  observed	  that	  some	  patients	  responded	  unusually	  well	  to	  salvage	  chemotherapies,	  and	  survival	  of	  patients	  receiving	  DC	  vaccination	  and	  chemotherapy	  was	  longer	  than	  patients	  treated	  with	  DC	  vaccination	  or	  chemotherapy	  alone	  (Wheeler	  et	  al.	  2004).	  Several	  groups	  have	  observed	  chemo-­‐potentiating	  effects	  of	  immunotherapy	  in	  animal	  models.	  Machiels	  and	  colleagues	  (Machiels	  et	  al.	  2001)	  used	  a	  model	  of	  a	  tumour-­‐associated	  self-­‐antigen	  in	  which	  transgenic	  mice	  ubiquitously	  expressing	  Her2/neu	  were	  implanted	  with	  a	  tumour	  also	  expressing	  Her2/neu.	  In	  this	  model,	  vaccination	  against	  the	  “self”-­‐antigen	  was	  ineffective.	  Doxorubicin	  was	  effective	  but	  only	  when	  given	  after	  the	  vaccine,	  at	  a	  dose	  that	  was	  ineffective	  as	  a	  stand-­‐alone	  treatment.	  Hermans	  and	  colleagues	  (Hermans	  et	  al.	  2003a)	  used	  a	  B16	  melanoma	  model	  in	  which	  the	  tumour	  cells	  were	  modified	  to	  express	  an	  influenza	  peptide.	  Cyclophosphamide	  or	  a	  vaccine	  targeting	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the	  influenza	  epitope	  were	  ineffective	  alone	  but	  cyclophosphamide	  became	  effective	  when	  given	  after	  the	  vaccine.	  	  One	  possible	  explanation	  for	  the	  efficacy	  of	  chemotherapy	  in	  these	  two	  studies,	  both	  of	  which	  were	  performed	  in	  a	  therapeutic	  setting	  in	  tumour-­‐bearing	  animals,	  is	  that	  immunogenic	  tumour	  cell	  death	  induced	  by	  the	  chemotherapy	  agent	  acted	  to	  boost	  a	  weak	  vaccine-­‐induced	  primary	  response.	  Radfar	  and	  colleagues	  (Radfar	  et	  al.	  2009)	  found	  that	  pre-­‐infusing	  non-­‐specifically	  activated	  polyclonal	  CD4	  T	  cells	  dramatically	  enhanced	  the	  efficacy	  of	  a	  number	  of	  chemotherapy	  agents	  including	  TMZ.	  This	  effect	  was	  found	  to	  be	  dependent	  on	  soluble	  factors	  secreted	  by	  the	  T	  cells	  including,	  but	  not	  solely	  explained	  by,	  IFN-­‐γ.	  The	  authors	  speculated	  that	  the	  synergy	  between	  these	  two	  treatments	  might	  reflect	  a	  combination	  of	  their	  pro-­‐apoptotic	  effects	  but	  also	  drew	  attention	  to	  work	  by	  others	  showing	  that	  inflammatory	  cytokines	  can	  inhibit	  DNA	  repair	  mechanisms.	  For	  example,	  Type	  1	  interferon	  has	  been	  shown	  to	  downregulate	  expression	  of	  the	  DNA	  repair	  enzyme	  MGMT	  and	  thereby	  sensitize	  glioma	  cell	  lines	  to	  TMZ	  in	  vitro	  (Natsume	  et	  al.	  2005).	  	  
	  
6.1.2	   Immunotherapy	  targeting	  chemoresistant	  glioma	  cells	  “Immunocentric”	  and	  “chemocentric”	  combinations	  use	  one	  treatment	  to	  augment	  the	  effect	  of	  another.	  Another	  model	  for	  combination	  treatment	  is	  the	  separate	  targeting	  of	  non-­‐overlapping	  subsets	  within	  a	  heterogeneous	  tumour.	  	  The	  idea	  that	  the	  immunotherapy	  component	  of	  a	  combined	  chemoimmunotherapy	  regimen	  could	  be	  used	  to	  specifically	  target	  the	  chemoresistant	  compartment	  was	  proposed	  by	  Fisk	  and	  colleagues	  (Fisk	  and	  Ioannides	  1998).	  This	  group	  first	  exposed	  tumour	  cells	  to	  doxorubicin	  in	  vitro	  to	  develop	  a	  chemoresistant	  cell	  line.	  After	  treating	  tumour	  cells	  with	  polyclonal	  CTL	  in	  vitro,	  they	  found	  that	  the	  residual	  “immuno-­‐edited”	  cells	  were	  more	  chemosensitive	  than	  before	  CTL	  treatment.	  They	  observed	  that	  chemoresistant	  cells	  expressed	  higher	  levels	  of	  MHC	  class	  I	  that	  may	  have	  rendered	  them	  more	  vulnerable	  to	  CTL-­‐mediated	  lysis	  in	  this	  model.	  Liu	  and	  colleagues	  extended	  this	  concept	  by	  proposing	  that	  immunotherapy	  could	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selectively	  delete	  chemoresistant	  cells	  by	  directly	  targeting	  the	  same	  molecules	  that	  confer	  chemoresistance	  (G.	  Liu	  et	  al.	  2005).	  This	  idea	  arose	  from	  their	  observation	  that	  vaccination	  of	  GBM	  patients	  with	  tumour	  lysate-­‐pulsed	  DC	  elicited	  T	  cell	  responses	  specific	  for	  TRP-­‐2,	  a	  protein	  implicated	  in	  mediating	  resistance	  to	  chemotherapy	  agents.	  TRP-­‐2	  is	  a	  melanoma-­‐associated	  antigen	  that	  is	  also	  expressed	  by	  many	  GBM	  tumours,	  and	  can	  be	  naturally	  processed	  and	  presented	  on	  MHC	  by	  glioma	  cells	  (G.	  Liu	  et	  al.	  2003;	  G.	  Liu	  et	  al.	  2005).	  The	  mechanism	  by	  which	  increased	  TRP-­‐2	  expression	  increases	  drug-­‐resistance	  is	  unclear.	  	  It	  does	  not	  appear	  to	  act	  indirectly	  by	  altering	  the	  levels	  of	  other	  drug-­‐resistance	  proteins	  (G.	  Liu	  et	  al.	  2005).	  	  Because	  TRP-­‐2	  transfection	  confers	  a	  broad	  resistance	  to	  both	  DNA-­‐damaging	  drugs	  and	  radiation,	  it	  has	  been	  proposed	  that	  it	  may	  act	  by	  providing	  a	  general	  protection	  against	  apoptosis	  (Chu	  et	  al.	  2000;	  Nishioka	  et	  al.	  1999;	  Pak	  et	  al.	  2001).	  Wheeler	  and	  colleagues	  provided	  evidence	  that	  in	  some	  GBM	  patients	  undergoing	  DC	  vaccination	  the	  development	  of	  a	  TRP-­‐2-­‐specific	  CTL	  response	  was	  associated	  with	  immunoediting	  of	  TRP-­‐2hi	  tumour	  cells,	  with	  tumour	  cells	  sampled	  after	  vaccination	  expressing	  lower	  levels	  of	  TRP-­‐2	  RNA	  and	  being	  more	  sensitive	  to	  chemotherapy	  in	  vitro	  than	  GBM	  cell	  lines	  derived	  from	  pre-­‐vaccination	  specimens	  from	  the	  same	  patients	  (G.	  Liu	  et	  al.	  2005).	  They	  further	  showed	  that	  transfection	  of	  a	  glioma	  cell	  line	  with	  TRP-­‐2	  increased	  resistance	  to	  TMZ	  and	  carboplatin	  and,	  when	  this	  TRP-­‐2-­‐transfected	  glioma	  cell	  line	  was	  subjected	  to	  lysis	  in	  vitro	  by	  a	  TRP-­‐2-­‐specific	  CTL	  line,	  the	  surviving	  “immunoselected”	  cells	  were	  more	  sensitive	  to	  TMZ	  and	  carboplatin	  than	  unselected	  cells.	  	  A	  number	  of	  other	  proteins	  are	  known	  to	  be	  both	  glioma-­‐associated	  antigens	  and	  implicated	  in	  mediating	  resistance	  to	  various	  chemotherapy	  agents.	  In	  theory,	  immunotherapies	  targeting	  these	  proteins	  have	  the	  potential	  to	  synergise	  particularly	  well	  with	  chemotherapy	  agents.	  	  EGFRvIII	  is	  a	  constitutively	  active	  mutant	  form	  of	  EGFR	  that	  is	  expressed	  by	  approximately	  one	  third	  of	  GBM	  tumours	  (Heimberger	  et	  al.	  2005).	  A	  clinical	  trial	  of	  TMZ	  combined	  with	  an	  EGFRvIII	  peptide	  vaccine	  recently	  reported	  improved	  outcomes	  compared	  with	  historical	  controls	  treated	  with	  TMZ	  alone	  (Sampson	  et	  al.	  2011).	  Although	  a	  specific	  role	  for	  EGFRvIII	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6.1.3	   Doxorubicin	  and	  GBM	  As	  will	  be	  seen,	  the	  experiments	  described	  in	  this	  chapter	  involved	  the	  use	  of	  doxorubicin.	  For	  this	  reason,	  a	  brief	  introduction	  to	  this	  chemotherapeutic	  agent	  follows.	  There	  is	  considerable	  interest	  in	  doxorubicin	  as	  a	  potential	  treatment	  for	  high	  grade	  glioma.	  Doxorubicin	  is	  one	  of	  the	  anthracycline	  group	  of	  drugs	  (also	  known	  as	  adriamycin)	  that	  binds	  to	  DNA	  and	  inhibits	  the	  enzyme	  topoisomerase	  II	  (Topo	  II).	  The	  role	  of	  Topo	  II	  is	  to	  induce	  temporary	  double	  strand	  DNA	  breaks	  that	  help	  “unwind”	  the	  double	  helix	  during	  DNA	  replication	  and	  RNA	  transcription.	  Anthracyclines	  stabilise	  the	  intermediate	  “cleavage	  complex”	  between	  DNA	  breakage	  and	  reunion,	  thereby	  resulting	  in	  persistent	  double	  strand	  DNA	  breaks	  (Hortobágyi	  1997;	  Nielsen	  et	  al.	  1996;	  Tewey	  et	  al.	  1984).	  This	  in	  turn	  leads	  to	  G2-­‐M	  phase	  arrest	  and	  subsequently	  to	  caspase-­‐dependent	  apoptosis	  (Opel	  et	  al.	  2008;	  Supiot	  et	  al.	  2005).	  Doxorubicin	  is	  commonly	  used	  in	  the	  clinic	  as	  a	  treatment	  for	  breast	  cancer	  and	  is	  therefore	  widely	  available.	  	  Although	  GBM	  tumours	  are	  usually	  highly	  sensitive	  to	  doxorubicin	  in	  vitro,	  the	  drug	  does	  not	  cross	  the	  blood-­‐brain	  barrier	  and	  no	  clinical	  benefit	  has	  been	  reported	  when	  doxorubicin	  has	  been	  added	  to	  the	  standard	  treatment	  for	  patients	  with	  newly	  diagnosed	  GBM	  (Ananda	  et	  al.	  2011;	  C.	  P.	  Beier	  et	  al.	  2009).	  Efforts	  to	  improve	  access	  to	  the	  CNS	  are	  ongoing,	  including	  novel	  formulations	  of	  doxorubicin	  (Cheng	  et	  al.	  2012;	  Sirova	  et	  al.	  2007;	  Wohlfart	  et	  al.	  2011)	  or	  direct	  delivery	  to	  the	  tumour	  site	  (Boiardi	  et	  al.	  2003;	  Kang	  et	  al.	  2011).	  	  The	  ability	  to	  induce	  immunogenic	  tumour	  cell	  death	  makes	  doxorubicin	  a	  promising	  candidate	  for	  inclusion	  in	  combined	  chemo-­‐immunotherapy	  approaches.	  However,	  the	  design	  of	  combined	  regimens	  need	  to	  take	  into	  account	  myelosuppressive	  effects,	  with	  dose-­‐limiting	  myelosuppression	  and	  cardiac	  toxicity	  being	  the	  most	  common	  side-­‐effects	  of	  doxorubicin	  at	  standard	  doses.	  At	  lower	  doses,	  doxorubicin	  has	  immunomodulating	  effects	  that	  have	  been	  shown	  in	  animal	  models	  to	  synergise	  with	  active	  specific	  immunotherapies	  (Eralp	  et	  al.	  2004;	  D.	  Kim	  et	  al.	  2008;	  Machiels	  et	  al.	  2001)	  and	  with	  IL-­‐2	  or	  TNF-­‐α	  cytokine	  therapy	  (Ewens	  et	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al.	  2006;	  Gautam	  et	  al.	  1991;	  Mihich	  and	  Ehrke	  2000)	  to	  evoke	  tumour-­‐specific	  T	  cell	  responses.	  The	  underlying	  mechanisms	  for	  this	  synergism	  are	  not	  entirely	  clear.	  	  In	  some	  cases,	  it	  is	  possible	  that	  sublethal	  but	  pro-­‐apoptotic	  effects	  of	  doxorubicin	  combine	  with	  signals	  from	  death	  receptors	  delivered	  by	  cytokines	  or	  immune	  cells	  to	  reach	  a	  threshold	  for	  tumour	  cell	  death.	  Doxorubicin	  has	  been	  shown	  to	  synergise	  with	  anti-­‐Fas	  antibodies	  to	  kill	  human	  cancer	  cell	  lines	  in	  vitro	  (Mizutani	  et	  al.	  1997;	  X.	  X.	  Wu	  et	  al.	  2000),	  including	  GBM	  (Herrmann	  et	  al.	  2008).	  Alternatively,	  doxorubicin	  can	  directly	  modulate	  the	  immune	  system,	  in	  ways	  that	  appear	  to	  be	  distinct	  from	  other	  immunomodulating	  chemotherapies	  such	  as	  cyclophosphamide.	  It	  is	  reported,	  for	  example,	  that	  doxorubicin	  does	  not	  significantly	  reduce	  Treg	  number	  or	  function,	  even	  at	  doses	  that	  induce	  transient	  lymphopenia	  (J.	  Y.	  Park	  et	  al.	  2009;	  Skak	  et	  al.	  2009).	  Mihich	  and	  colleagues	  (Mihich	  and	  Ehrke	  2000)	  reported	  that	  doxorubicin	  promotes	  the	  tumouricidal	  capacity	  of	  macrophages.	  	  Several	  different	  mechanisms	  for	  resistance	  to	  doxorubicin	  have	  been	  described	  in	  
vitro	  but	  so	  far	  only	  one	  has	  been	  proven	  to	  be	  clinically	  relevant	  –	  namely	  that	  mediated	  by	  p-­‐Glycoprotein,	  also	  known	  as	  ABCB1	  or	  multidrug	  resistance	  protein	  1	  (MDR1)	  (de	  Jonge-­‐Peeters	  et	  al.	  2007).	  Breast	  cancer	  that	  responds	  initially	  to	  doxorubicin	  is	  typically	  multi-­‐drug	  resistant	  at	  recurrence	  due	  to	  upregulation	  of	  this	  protein	  (Bargou	  et	  al.	  1997).	  ABCB1	  is	  a	  membrane-­‐bound	  transporter	  protein	  that	  confers	  multi-­‐drug	  resistance	  by	  expelling	  chemotherapy	  agents	  from	  the	  cell,	  including	  doxorubicin.	  Doxorubicin	  is	  also	  a	  substrate	  for	  two	  other	  members	  of	  this	  transporter	  family,	  ABCC1	  (also	  called	  multidrug	  resistance-­‐associated	  protein,	  MRP)	  and	  ABCG2	  (also	  called	  breast	  cancer	  resistance	  protein,	  BCRP),	  both	  of	  which	  have	  also	  been	  identified	  in	  tumour	  cells	  (de	  Jonge-­‐Peeters	  et	  al.	  2007;	  Nielsen	  et	  al.	  1996).	  There	  is	  already	  some	  evidence	  that	  these	  molecules	  can	  provide	  immunogenic	  epitopes.	  Niethammer	  and	  colleagues	  (Niethammer	  et	  al.	  2005)	  developed	  a	  DNA	  vaccine	  encoding	  ABCB1	  that	  conferred	  protective	  CD8	  T	  cell-­‐mediated	  immunity	  against	  multi-­‐drug	  resistant	  tumours	  in	  mice.	  Perrin	  and	  colleagues	  (Perrin	  et	  al.	  2007)	  demonstrated	  that	  a	  vaccine	  incorporating	  ABCB1	  and	  an	  adjuvant	  raised	  anti-­‐ABCB1	  antibodies	  in	  mice	  and	  serum	  from	  the	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immunized	  mice	  was	  able	  to	  restore	  chemo-­‐sensitivity	  of	  multi-­‐drug	  resistant	  cell	  lines	  in	  vitro.	  	  
	  
6.1.4	   Hypothesis	  and	  Aims	  In	  summary,	  there	  are	  good	  theoretical	  and	  practical	  reasons	  for	  combining	  immunotherapy	  and	  chemotherapy	  for	  the	  treatment	  of	  GBM.	  As	  previously	  discussed,	  the	  Glioma-­‐Gal	  vaccine	  design	  holds	  promise	  as	  a	  relatively	  simple,	  personalised	  vaccine	  that	  has	  the	  potential	  to	  provide	  a	  broad	  range	  of	  MHC	  class	  I-­‐	  	  and	  class	  II-­‐restricted	  antigens,	  and	  can	  be	  used	  in	  all	  patients	  regardless	  of	  HLA	  type.	  The	  experiments	  in	  this	  chapter	  explore	  the	  possibility	  of	  using	  a	  modified	  version	  of	  this	  vaccine	  to	  specifically	  target	  chemotherapy-­‐resistant	  tumour	  cells.	  In	  a	  combined	  regimen	  with	  chemotherapy,	  such	  a	  vaccine	  might	  be	  more	  effective	  than	  the	  standard	  vaccine	  because	  the	  vaccine	  and	  the	  chemotherapy	  agent	  may	  selectively	  target	  different	  cell	  subsets	  (chemoresistant	  and	  chemosensitive	  cells	  respectively).	  	  Although	  the	  ultimate	  aim	  of	  this	  work	  was	  to	  find	  ways	  of	  maximizing	  the	  therapeutic	  benefit	  of	  the	  Glioma-­‐Gal	  vaccine,	  in	  this	  Chapter	  the	  experiments	  used	  the	  same	  Lysate-­‐Gal	  design	  described	  in	  Chapter	  5	  in	  order	  to	  more	  accurately	  assess	  the	  effect	  of	  varying	  the	  antigen	  content	  of	  the	  vaccines.	  To	  target	  chemoresistant	  cells,	  the	  chosen	  method	  was	  to	  make	  a	  Lysate-­‐Gal	  vaccine	  using	  an	  
in	  vitro-­‐generated	  chemoresistant	  tumour	  cell	  line.	  This	  approach	  assumes	  that	  cells	  are	  drug-­‐resistant	  in	  vitro	  because	  they	  (a)	  express	  or	  upregulate	  certain	  proteins,	  (b)	  that	  the	  same	  proteins	  that	  mediate	  drug-­‐resistance	  in	  vitro	  are	  also	  responsible	  for	  drug	  resistance	  in	  vivo,	  and	  that	  (c)	  these	  proteins	  can	  serve	  as	  antigenic	  targets	  for	  an	  anti-­‐tumour	  adaptive	  immune	  response	  when	  over-­‐expressed	  on	  tumour	  cells.	  Although	  TMZ	  is	  the	  established	  first	  line	  chemotherapy	  agent	  for	  GBM,	  preliminary	  studies	  in	  our	  laboratory	  showed	  that	  the	  GL261	  line	  was	  resistant	  to	  TMZ	  in	  vitro	  (data	  not	  shown)	  making	  it	  unsuitable	  for	  use	  in	  this	  model	  system.	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GBM	  tumour	  cells	  and	  GL261	  are	  both	  sensitive	  in	  vitro	  to	  doxorubicin	  and	  this	  agent	  continues	  to	  attract	  interest	  as	  a	  possible	  treatment	  for	  GBM	  patients.	  	  Thus	  doxorubicin	  was	  chosen	  as	  the	  chemotherapy	  agent	  for	  this	  study.	  	  To	  address	  the	  research	  aims,	  it	  was	  necessary	  to	  use	  a	  model	  suitable	  for	  assessing	  the	  combination	  of	  chemotherapy	  and	  antigen-­‐specific	  immunotherapy	  in	  glioma-­‐bearing	  mice.	  GL261,	  a	  murine	  glioma	  cell	  line	  that	  can	  be	  implanted	  i.c.	  or	  s.c.	  in	  syngeneic	  immunocompetent	  hosts,	  was	  felt	  to	  be	  an	  appropriate	  model	  system	  for	  this	  study.	  Because	  the	  combined	  treatment	  would	  necessarily	  be	  tested	  in	  a	  therapeutic	  setting,	  I	  elected	  to	  first	  test	  the	  combinations	  against	  s.c.	  tumours	  so	  that	  tumour	  size	  could	  be	  tracked	  over	  time.	  	  	  
Hypothesis:	  That	  a	  whole	  tumour	  cell-­‐based	  vaccine	  targeting	  chemoresistant	  tumour	  cells	  will	  be	  more	  effective	  than	  standard	  vaccine	  when	  used	  in	  a	  combined	  treatment	  regimen	  with	  chemotherapy.	  	  
Aims:	   1.	  Generate	  and	  characterise	  a	  doxorubicin-­‐resistant	  GL261	  cell	  line.	  2.	  Construct	  a	  whole	  tumour	  cell-­‐based	  vaccine	  from	  doxorubicin-­‐resistant	  tumour	  cells.	  3.	  Compare	  the	  efficacy	  of	  this	  vaccine	  with	  the	  standard	  vaccine	  in	  vivo	  when	  used	  in	  a	  combination	  treatment	  with	  doxorubicin.	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6.2	   RESULTS	  
6.2.1	   Stable	  doxorubicin-­‐resistant	  GL261	  cell	  lines	  can	  be	  generated	  and	  


































































Figure 6.1. Characterisation of drug-tolerant expanding persister (DTEP) GL261 cell lines gener-
ated by chronic exposure to doxorubicin in vitro.  A, Proliferation rate of GL261 DTEP cell lines in 
media containing doxorubicin at the concentration appropriate for each cell line, as assessed by thymi-
dine incorporation. One experiment. c.p.m. = counts per minute. B, Proliferation rate of GL261 DTEP 0.1 
and the parental cell line in media containing varying concentrations of doxorubicin, as assessed by 
thymidine incorporation. Statistical analysis was undertaken by performing a Mann-Whitney test at each 
time point. One of three experiments with similar results is shown. C, Expression of ABC genes in DTEP 
0.1 and DTEP 5 cell lines compared to parental GL261 tumour cells, assessed by real-time reverse 
transcription polymerase chain reaction (RT-PCR). Fold change of gene expression in DTEP cells relative 
to parental cells was calculated from the means of triplicate samples. Results from one of two separate 
assays performed on the same samples with similar results is shown.  D, Expression of a panel of stem 
cell-associated genes and selected tumour-associated antigens in DTEP 0.1 cells compared to parental 





















































































































lines	  capable	  of	  growing	  in	  even	  higher	  concentrations	  but	  the	  rate	  of	  growth	  progressively	  declined	  with	  increasing	  drug	  concentration,	  making	  it	  impractical	  to	  generate	  sufficient	  quantities	  of	  tumour	  cells	  to	  make	  vaccines	  in	  a	  reasonable	  timeframe	  (Fig	  6.1A).	  Untreated	  parental	  cells	  that	  had	  not	  undergone	  this	  process	  of	  incremental	  exposure	  did	  not	  survive	  continuous	  exposure	  to	  0.1	  μM	  doxorubicin,	  demonstrating	  that	  DTEP	  0.1	  had	  indeed	  acquired	  chemoresistance.	  To	  confirm	  chemoresistance,	  parental	  and	  DTEP	  cell	  lines	  were	  exposed	  to	  different	  concentrations	  of	  doxorubicin	  and	  proliferation	  measured	  using	  thymidine	  incorporation	  over	  48	  hours.	  This	  confirmed	  the	  DTEP	  cell	  lines	  to	  be	  more	  resistant	  to	  doxorubicin	  than	  the	  parental	  line,	  with	  the	  DTEP	  0.1	  cell	  line	  having	  an	  IC50	  (the	  concentration	  of	  drug	  at	  which	  proliferation	  is	  reduced	  by	  50%)	  approximately	  ten-­‐fold	  higher	  than	  parental	  cells	  (Fig	  6.1B).	  	  	  	  Previous	  studies	  have	  reported	  a	  strong	  association	  between	  cellular	  resistance	  to	  doxorubicin	  and	  expression	  of	  the	  ABC	  transporter	  ABCB1	  (de	  Jonge-­‐Peeters	  et	  al.	  2007).	  Accordingly,	  expression	  of	  ABCB1	  was	  higher	  in	  DTEP	  cells	  compared	  with	  parental	  cells,	  a	  pattern	  not	  consistently	  observed	  for	  ABCC1	  or	  ABCG2	  (Fig	  6.1C).	  	  Because	  of	  reports	  that	  CSC	  are	  more	  chemoresistant	  than	  bulk	  tumour	  cells	  (G.	  Liu	  et	  al.	  2006),	  expression	  of	  genes	  associated	  with	  normal	  neural	  stem	  cells	  was	  also	  assessed	  to	  see	  if	  induction	  of	  chemoresistance	  had	  induced	  a	  more	  stem	  cell-­‐like	  phenotype.	  A	  striking	  increase	  in	  the	  expression	  of	  Musashi-­‐1	  was	  observed	  but	  no	  general	  upregulation	  of	  other	  	  “stemness”	  genes	  was	  seen	  (Fig	  6.1D).	  Interestingly,	  this	  pattern	  was	  similar	  to	  that	  seen	  in	  GL261	  spheres	  grown	  in	  serum-­‐free	  media	  with	  EGF	  and	  bFGF	  (see	  Chapter	  5).	  	  Expression	  of	  the	  GL261	  tumour-­‐associated	  antigens	  TRP-­‐2	  and	  gp100	  was	  also	  assessed.	  Expression	  of	  TRP-­‐2	  was	  increased	  in	  the	  DTEP	  0.1	  cell	  line	  (Fig	  6.1D).	  This	  finding	  is	  consistent	  with	  the	  claim	  by	  Liu	  and	  colleagues	  (G.	  Liu	  et	  al.	  2005)	  that	  TRP-­‐2	  also	  mediates	  chemoresistance.	  In	  summary,	  the	  DTEP	  0.1	  cell	  line	  was	  shown	  to	  be	  a	  stable	  and	  practical	  substrate	  for	  constructing	  a	  vaccine	  targeting	  antigens	  derived	  from	  tumour	  cells	  that	  are	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chemoresistant	  relative	  to	  parental	  cells	  and	  that	  have	  upregulated	  genes	  implicated	  in	  mediating	  drug-­‐resistance.	  
	  
6.2.2	   Prophylactic	  GL261	  DTEP	  vaccine	  is	  not	  more	  effective	  than	  unmodified	  
parental	  vaccine.	  	  Lysate	  vaccines	  were	  made	  from	  parental	  and	  DTEP	  0.1	  cell	  lines	  as	  previously	  described	  (Fig	  5.5A).	  The	  hypothesis	  under	  examination	  was	  that	  the	  DTEP	  lysate	  vaccine	  would	  be	  more	  effective	  against	  chemoresistant	  cells	  than	  the	  unmodified	  vaccine	  because	  the	  lysate	  would	  be	  enriched	  in	  proteins	  mediating	  chemoresistance.	  The	  DTEP	  vaccine	  should	  therefore	  be	  more	  effective	  than	  parental	  vaccine	  when	  combined	  with	  doxorubicin.	  However,	  there	  were	  several	  reasons	  why	  DTEP	  vaccine	  might	  have	  been	  a	  more	  effective	  treatment	  even	  as	  monotherapy.	  Firstly,	  doxorubicin-­‐induced	  tumour	  cell	  death	  has	  been	  shown	  to	  be	  immunogenic	  (Casares	  et	  al.	  2005).	  Although	  the	  lysates	  used	  to	  construct	  the	  vaccines	  in	  this	  study	  were	  made	  from	  a	  live	  tumour	  cell	  population,	  and	  not	  from	  dying	  cells,	  it	  was	  nevertheless	  possible	  that	  the	  expression	  of	  DAMPs	  might	  be	  higher	  in	  the	  DTEP	  lysate	  vaccine.	  Secondly,	  expression	  of	  a	  known	  tumour-­‐associated	  antigen	  (TRP-­‐2)	  was	  increased	  in	  the	  DTEP	  0.1	  line	  relative	  to	  the	  parental	  line,	  at	  least	  at	  the	  transcriptional	  level.	  Thirdly,	  the	  chemo-­‐exposed	  cells	  had	  upregulated	  at	  least	  one	  stem	  cell-­‐associated	  gene.	  If	  the	  DTEP	  vaccine	  was	  enriched	  in	  proteins	  expressed	  by	  CSC	  it	  might	  target	  this	  putative	  subset	  more	  effectively	  than	  the	  parental	  lysate	  vaccine.	  To	  compare	  the	  performance	  of	  the	  two	  vaccines	  as	  monotherapies,	  the	  vaccines	  were	  assessed	  for	  their	  capacity	  to	  protect	  against	  parental	  tumour	  challenge.	  It	  has	  already	  been	  shown	  that	  Lysate-­‐Gal	  vaccines	  containing	  100	  μg	  protein	  per	  mouse	  provided	  potent	  protection	  against	  s.c.	  tumour	  challenge	  (Fig	  5.6B).	  The	  protein	  content	  of	  was	  therefore	  reduced	  to	  make	  it	  possible	  to	  detect	  differences	  between	  the	  DTEP	  and	  parental	  vaccines.	  	  In	  one	  experiment,	  vaccines	  containing	  10	  μg	  and	  5	  μg	  of	  protein	  conferred	  similar	  levels	  of	  protection,	  with	  the	  parental	  vaccine	  performing	  better	  at	  1	  μg	  (Fig	  6.2A).	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  In	  a	  repeat	  experiment	  at	  the	  10	  μg	  dose,	  the	  parental	  vaccine	  provided	  better	  protection	  (Fig	  6.2B).	  Thus,	  the	  DTEP	  vaccine	  was	  less	  effective	  than	  the	  parental	  vaccine,	  albeit	  inconsistently	  across	  the	  two	  experiments.	  It	  seems	  reasonable	  to	  at	  least	  conclude	  that	  the	  DTEP	  vaccine	  was	  not	  more	  effective.	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Figure 6.2. GL261 DTEP vaccine is not more effective than an unmodified parental vaccine. 
A, Mice were treated i.v. with parental or DTEP Lysate-Gal vaccines containing different quanti-
ties of lysate and challenged s.c. with 1 x 106 GL261 cells 7 days later. 5 mice per group in the 10 
ȝJDUPVPLFHSHUJURXSLQWKHRWKHUDUPV7KHVDPH1R9DFFLQHFRQWUROJURXSRIPLFHLV
shown in each graph. Asterisk indicates comparison between parental and DTEP vaccine groups 
XVLQJWKH/RJUDQNWHVW%0LFHZHUHWUHDWHGLYZLWK/\VDWH*DOYDFFLQHVFRQWDLQLQJȝJRI
parental or DTEP lysate and challenged s.c. with 1 x 106 GL261 7 days later. 10 mice per group. 
Asterisk indicates comparison between parental and DTEP vaccine groups using the Log-rank test.








































6.2.3	   Establishing	  a	  model	  of	  combined	  treatment	  with	  lysate	  vaccine	  and	  
doxorubicin.	  Although	  the	  DTEP	  vaccine	  was	  not	  more	  effective	  against	  the	  parental	  tumour,	  this	  did	  not	  exclude	  the	  possibility	  that	  the	  DTEP	  lysate	  vaccine	  could	  be	  more	  effective	  against	  chemoresistant	  tumour	  cells.	  	  Theoretically,	  a	  simple	  way	  of	  testing	  this	  in	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  doxorubicin.	  These	  studies	  suggested	  that	  a	  dose	  of	  2.5	  mg/kg	  on	  Day	  3	  was	  just	  above	  the	  threshold	  for	  observable	  effects	  on	  tumour	  growth	  when	  given	  as	  monotherapy	  (data	  not	  shown	  and	  Figs	  6.3B-­‐D).	  	  This	  dose	  of	  doxorubicin	  was	  next	  tested	  in	  combination	  with	  the	  parental	  lysate	  vaccine.	  Immunotherapy	  alone	  (Lysate-­‐Gal	  preceded	  by	  Treg	  depletion)	  and	  low	  dose	  doxorubicin	  alone	  were	  partially	  effective	  (Figs	  6.3C,D).	  The	  effect	  of	  combining	  the	  two	  treatments	  was	  at	  least	  additive,	  with	  permanent	  regression	  of	  established	  tumours	  in	  all	  mice	  (Figs	  6.3B-­‐D).	  The	  performance	  of	  the	  combination	  still	  left	  room	  for	  improvement	  however,	  with	  some	  tumours	  reaching	  a	  diameter	  of	  8-­‐9	  mm	  before	  regression	  occurred.	  Thus	  the	  model	  was	  confirmed	  as	  being	  suitable	  for	  addressing	  the	  research	  aims.	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D
Figure 6.3. Validation of a model to test the combined effect of Lysate-Gal Vaccine and 
Doxorubicin. A, Model schema. Regulatory T cell depletion was achieved by i.p administration of 100 
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Figure 6.4. GL261 parental and DTEP vaccines have similar efficacy when used in combination 
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6.2.4	   The	  GL261	  DTEP	  vaccine	  is	  not	  more	  effective	  than	  parental	  vaccine	  
when	  used	  in	  combination	  with	  doxorubicin	  to	  treat	  established	  s.c.	  tumours.	  	  The	  model	  was	  next	  used	  to	  compare	  the	  performance	  of	  the	  DTEP	  and	  parental	  lysate	  vaccines	  in	  combination	  with	  doxorubicin.	  In	  both	  groups,	  all	  established	  tumours	  underwent	  rapid	  and	  permanent	  regression,	  with	  no	  major	  differences	  in	  the	  time	  course	  or	  rate	  of	  regression	  (Figs	  6.4A,	  B).	  No	  statistically	  significant	  differences	  were	  seen	  between	  the	  mean	  tumour	  sizes	  of	  the	  two	  vaccinated	  groups	  in	  two	  independent	  experiments	  (Figs	  6.4A,	  B).	  Thus,	  these	  experiments	  did	  not	  provide	  evidence	  to	  support	  the	  hypothesis	  that	  the	  DTEP	  vaccine	  would	  be	  more	  effective	  against	  tumours	  recently	  exposed	  to	  doxorubicin.	  
	  
6.2.5	   Low	  dose	  doxorubicin	  exerts	  immunomodulatory	  effects	  that	  may	  
potentiate	  Lysate-­‐Gal	  immunotherapy.	  	  Regardless	  of	  the	  lysate	  vaccine	  used,	  doxorubicin	  and	  vaccination	  (with	  prior	  Treg	  depletion)	  were	  highly	  effective	  when	  used	  sequentially	  in	  that	  order,	  and	  the	  benefits	  of	  the	  two	  treatments	  combined	  were	  supra-­‐additive	  (Appendix	  B,	  Fig	  B5.3).	  This	  was	  the	  case	  even	  though	  doxorubicin	  alone	  at	  a	  dose	  of	  2.5	  mg/kg	  does	  not	  appear	  to	  slow	  tumour	  growth	  in	  around	  half	  of	  the	  treated	  mice	  relative	  to	  untreated	  control	  mice	  (Fig	  6.3D).	  One	  possibility	  is	  that	  a	  sublethal	  dose	  of	  doxorubicin	  may	  leave	  tumour	  cells	  more	  vulnerable	  to	  subsequent	  immune	  system-­‐mediated	  apoptosis	  (Mizutani	  et	  al.	  1997;	  X.	  X.	  Wu	  et	  al.	  2000).	  To	  assess	  this	  possibility,	  GL261	  cells	  were	  exposed	  in	  vitro	  to	  doxorubicin	  at	  different	  concentrations	  (Fig	  6.5).	  Using	  Propidium	  Iodide	  staining	  as	  a	  measure	  of	  cell	  viability,	  a	  concentration	  of	  0.001	  μM	  was	  established	  as	  a	  sublethal	  dose	  just	  below	  the	  threshold	  for	  cytotoxic	  effects,	  a	  finding	  consistent	  with	  earlier	  observations	  on	  the	  effect	  of	  doxorubicin	  on	  GL261	  cell	  cultures.	  Untreated	  GL261	  cells	  already	  expressed	  high	  levels	  of	  the	  MHC	  class	  I	  molecule	  H-­‐2Kb	  and	  this	  did	  not	  change	  after	  doxorubicin	  exposure	  (Fig	  6.5).	  It	  has	  been	  shown	  previously	  that	  surface	  	  
 236 
	  




































































Figure 6.5. Doxorubicin effect on GL261 tumour cells in vitro. A, GL261 cells were exposed 
to Doxorubicin for 16 hours at different concentrations in triplicate wells and then assessed by flow 
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expression of surface molecules that might render the cells more vulnerable to T cell-mediated 





median FI relative to median FI of isotype control. No significant differences were observed 
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results is shown. 


































































expression	  of	  MHC	  class	  II	  is	  not	  detectable	  on	  GL261	  cells	  in	  culture	  unless	  stimulated	  with	  IFN-­‐γ	  (Fig	  4.5F).	  In	  this	  analysis,	  exposure	  to	  a	  sublethal	  concentration	  of	  doxorubicin	  did	  not	  induce	  surface	  expression	  of	  MHC	  class	  II	  or	  Fas	  (Fig	  6.5).	  Thus,	  no	  immunopotentiating	  effect	  of	  low	  dose	  doxorubicin	  directly	  on	  tumour	  cells	  was	  identified.	  An	  alternative	  mechanism	  for	  the	  immunopotentiating	  effect	  of	  doxorubicin	  could	  be	  modulation	  of	  one	  or	  more	  components	  of	  the	  immune	  system.	  	  Shurin	  and	  colleagues	  have	  reported	  that	  exposure	  to	  chemotherapy	  agents	  at	  low	  doses,	  including	  doxorubicin,	  induces	  changes	  in	  bone	  marrow-­‐derived	  DC	  that	  enhance	  antigen	  presentation	  to	  CD8+	  T	  cells	  including	  increased	  expression	  of	  maturation	  markers	  (Shurin	  et	  al.	  2009).	  To	  assess	  whether	  this	  was	  likely	  to	  be	  occurring	  in	  this	  model,	  cells	  of	  the	  DC2114	  dendritic	  cell	  line	  were	  exposed	  to	  doxorubicin	  in	  
vitro	  at	  different	  concentrations.	  As	  for	  GL261	  cells,	  cytotoxicity	  was	  observed	  at	  concentrations	  above	  0.001	  μM	  (Fig	  6.6A).	  Exposure	  to	  doxorubicin	  at	  this	  sub-­‐cytotoxic	  dose	  did	  not	  alter	  CD40	  or	  CD86	  expression	  by	  DC2114	  cells	  (Fig	  6.6B).	  It	  has	  been	  shown	  previously	  in	  this	  thesis	  that	  the	  Glioma-­‐Gal	  and	  Lysate-­‐Gal	  vaccines	  require	  prior	  depletion	  of	  Treg	  in	  order	  to	  be	  effective	  in	  a	  therapeutic	  setting.	  However,	  treatment	  with	  PC61	  antibody	  depletes	  only	  50	  %	  of	  FoxP3+	  CD4+	  T	  cells	  (Appendix	  B,	  Fig	  B2.1	  and	  Ataera	  et	  al.	  2011).	  To	  investigate	  whether	  doxorubicin	  might	  be	  acting	  by	  more	  completely	  depleting	  FoxP3+	  Treg,	  reporter	  mice	  that	  express	  GFP	  in	  FoxP3+	  cells	  were	  treated	  i.v.	  with	  doxorubicin	  2.5	  mg/kg	  and	  splenocytes	  analysed	  by	  flow	  cytometry	  24	  hours	  later.	  Other	  selected	  immune	  cell	  populations	  were	  also	  included	  in	  this	  analysis.	  There	  was	  no	  change	  in	  the	  total	  number	  of	  splenocytes	  (Fig	  6.7B).	  Surprisingly,	  the	  proportion	  of	  CD4+	  T	  cells	  that	  were	  Treg	  actually	  increased	  in	  the	  spleen	  after	  low	  dose	  doxorubicin	  (Fig	  6.7C	  and	  Appendix	  B,	  Fig	  B5.4).	  Absolute	  numbers	  of	  Treg	  also	  increased	  but	  this	  did	  not	  consistently	  reach	  statistical	  significance	  (Fig	  6.7C	  and	  Appendix	  B,	  Fig	  B5.4).	  	  Statistically	  significant	  differences	  were	  not	  observed	  for	  CD4+	  T	  cells,	  CD8+	  T	  cells,	  iNKT	  cells	  or	  B	  cells	  (Fig	  6.7C	  and	  data	  not	  shown).	  	  MDSC	  are	  Gr1+CD11b+	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Figure 6.6 Low dose Doxorubicin does not induce DC maturation. A, DC2114 cells were exposed 
in vitro to Doxorubicin for 16 hours at the concentrations shown and then assessed by flow cytometry. 
Cell viability progressively decreased at concentrations above 0.001 ȝ0B, Expression of maturation 
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immature	  myeloid	  cells	  that	  can	  suppress	  immune	  responses	  in	  disease	  states	  including	  in	  tumour-­‐bearing	  mice	  (Youn	  and	  Gabrilovich	  2010).	  Complete	  identification	  of	  MDSC	  requires	  demonstration	  of	  a	  functional	  capacity	  for	  immunosuppression	  and	  it	  is	  arguable	  whether	  MDSC	  even	  exist	  in	  the	  resting	  non-­‐tumour	  bearing	  state	  (Youn	  and	  Gabrilovich	  2010).	  Nevertheless,	  Gr1+CD11b+	  splenocytes	  were	  included	  in	  this	  analysis	  to	  see	  whether	  there	  was	  a	  general	  susceptibility	  of	  this	  phenotype	  to	  doxorubicin.	  No	  statistically	  significant	  changes	  were	  seen	  in	  the	  absolute	  number	  or	  proportion	  of	  these	  cells	  (Fig	  6.7C).	  	  The	  main	  conclusion	  from	  these	  findings	  is	  that	  doxorubicin	  at	  the	  dose	  used	  in	  these	  experiments	  unequivocally	  has	  some	  immunomodulating	  effect	  because	  the	  proportion	  of	  CD4+	  T	  cells	  that	  are	  Treg	  is	  increased.	  However,	  it	  is	  not	  immediately	  apparent	  how	  this	  might	  potentiate	  the	  immunotherapy	  component	  of	  the	  combined	  treatment.	  General	  lymphodepletion	  can	  be	  excluded	  as	  a	  mechanism	  by	  the	  lack	  of	  change	  in	  the	  absolute	  number	  of	  total	  splenocytes	  or	  effector	  lymphocyte	  subsets.	  The	  possible	  causes	  and	  implications	  of	  the	  observed	  changes	  in	  Treg	  cell	  numbers	  will	  be	  discussed	  below.	  	  	  
6.2.6	   A	  combined	  chemo-­‐immunotherapy	  regimen	  that	  is	  effective	  against	  
subcutaneous	  tumours	  is	  not	  effective	  in	  the	  intracranial	  setting.	  The	  combination	  of	  Treg	  depletion,	  low	  dose	  doxorubicin	  and	  the	  Lysate-­‐Gal	  vaccine	  was	  highly	  effective	  against	  established	  s.c.	  tumours.	  This	  same	  regimen	  was	  now	  tested	  against	  established	  i.c.	  tumours.	  Disappointingly,	  the	  combined	  treatment	  provided	  no	  protection	  or	  only	  weak	  protection	  (Figs	  6.8	  and	  6.9).	  One	  possible	  explanation	  for	  this	  is	  that	  the	  Blood-­‐Brain	  Barrier	  prevented	  doxorubicin	  reaching	  a	  high	  enough	  concentration	  in	  the	  CNS.	  Although	  it	  has	  been	  shown	  above	  that	  doxorubicin	  has	  some	  immunomodulatory	  activity	  in	  secondary	  lymphoid	  organs,	  the	  importance	  of	  this	  is	  unclear.	  It	  remains	  possible	  that	  the	  immunopotentiating	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Figure 6.7. Effects of low dose Doxorubicin on immune cell populations. FoxP3-GFP reporter mice 
were treated with Doxorubicin 2.5 mg/kg i.v. (Dox) or not treated (Control). Splenocytes were 
assessed by flow cytometry 24 hours later. A, Gating strategy. B, Total live splenocyte counts. C,  
Proportions (left) and absolute numbers (right) of selected immune cell types. 5 mice per group. The 
Mann Whitney test was used for statistical analysis. One of two independent experiments with similar 






















































































































































































	  effect	  of	  doxorubicin	  is	  exerted	  at	  the	  tumour	  site.	  It	  has	  been	  argued	  above	  that	  a	  direct	  cytotoxic	  effect	  on	  tumour	  cells	  seems	  unlikely	  but	  this	  leaves	  open	  the	  possibility	  of	  some	  immunomodulatory	  effect	  of	  doxorubicin	  at	  the	  tumour	  site.	  For	  example,	  it	  has	  been	  reported	  that	  doxorubicin	  can	  enhance	  the	  tumouricidal	  functions	  of	  macrophages	  (Mihich	  and	  Ehrke	  2000),	  a	  mechanism	  that	  seems	  plausible	  here	  given	  that	  the	  immunotherapy	  component	  is	  probably	  mediated	  primarily	  by	  CD4+	  effector	  T	  cells.	  To	  investigate	  whether	  improved	  access	  of	  doxorubicin	  to	  the	  tumour	  site	  would	  improve	  efficacy	  of	  the	  combined	  treatment,	  the	  chemotherapy	  component	  was	  changed	  to	  a	  form	  of	  doxorubicin	  that	  achieves	  higher	  concentrations	  in	  the	  CNS	  and	  in	  i.c.	  tumours.	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Figure 6.8 The combination treatment is less effective against intracranial tumours. Mice were 
implanted intracranially with 5 x 103 GL261 cells and treated with the same combined immunotherapy 
and chemotherapy regimen as the experiments depicted in Figs. 6.3 and 6.4.  Immunotherapy = Treg 
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Two independent experiments are shown.

























	  Liposomal	  doxorubicin	  is	  an	  alternative	  formulation	  of	  doxorubicin	  in	  which	  the	  drug	  is	  encapsulated	  within	  a	  lipid	  membrane.	  Liposomes	  may	  also	  be	  coated	  with	  polyethylene	  glycol	  to	  prolong	  half-­‐life.	  Pegylated	  liposomal	  doxorubicin	  (PEG-­‐Dox)	  persists	  longer	  in	  the	  circulation	  and	  has	  been	  shown	  to	  reach	  higher	  concentrations	  in	  intracranial	  solid	  tumours	  than	  free	  doxorubicin	  at	  equivalent	  doses	  (Siegal	  et	  al.	  1995).	  PEG-­‐Dox	  has	  an	  established	  role	  in	  the	  management	  of	  breast	  cancer	  and	  ovarian	  cancer	  (Ananda	  et	  al.	  2011;	  Pisano	  et	  al.	  2013).	  In	  glioma	  patients,	  radio-­‐labelled	  PEG-­‐Dox	  administered	  i.v.	  has	  been	  shown	  to	  reach	  a	  concentration	  in	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Figure 6.9. A pegylated liposomal formulation of Doxorubicin did not confer any advantage 
over the standard formulation.  As in Fig 6.8, mice were implanted i.c. with 5 x 103 GL261 
cells and then treated with combination immunotherapy and chemotherapy. Doxorubicin 2.5 
mg/kg was administered on Day 3 using either standard formulation or a pegylated liposomal 
formulation (PEG Dox). Two independent experiments were performed. No significant differ-
ences between groups were observed. 
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tumours	  13-­‐19	  times	  higher	  than	  in	  normal	  brain	  tissue	  (Koukourakis	  et	  al.	  2000).	  One	  of	  the	  main	  clinical	  advantages	  of	  PEG-­‐Dox	  is	  a	  reduction	  in	  the	  main	  dose-­‐limiting	  toxicities	  associated	  with	  standard	  doxorubicin	  such	  as	  cardiomyopathy	  and	  myelosuppression	  (Safra	  et	  al.	  2000;	  Waterhouse	  et	  al.	  2001).	  	  Thus,	  substituting	  PEG-­‐Dox	  for	  standard	  doxorubicin	  in	  this	  model	  offered	  a	  potential	  way	  of	  increasing	  the	  concentration	  of	  doxorubicin	  at	  the	  tumour	  site	  without	  increasing	  extra-­‐CNS	  effects.	  However,	  in	  two	  independent	  experiments,	  combining	  immunotherapy	  with	  PEG-­‐Dox	  was	  ineffective	  against	  established	  intracranial	  tumours	  (Fig	  6.9).	  	  
	  
6.3	   DISCUSSION	  AND	  CONCLUSIONS	  The	  hypothesis	  tested	  in	  this	  chapter	  was	  (a)	  that	  a	  whole	  tumour	  cell-­‐based	  vaccine	  incorporating	  antigens	  derived	  from	  doxorubicin-­‐resistant	  tumour	  cells	  would	  better	  target	  doxorubicin-­‐resistant	  tumour	  cells	  than	  a	  vaccine	  made	  from	  chemotherapy-­‐naïve	  tumour	  cells	  and	  (b)	  that	  this	  vaccine	  would	  in	  turn	  be	  more	  effective	  when	  used	  in	  a	  combination	  regimen	  with	  doxorubicin.	  The	  experiments	  reported	  here	  did	  not	  provide	  support	  for	  that	  hypothesis.	  The	  DTEP	  vaccine	  offered	  no	  advantage	  over	  the	  standard	  vaccine	  when	  used	  in	  combination	  with	  doxorubicin	  to	  treat	  established	  GL261	  s.c.	  tumours.	  	  One	  possible	  reason	  for	  this	  is	  that	  the	  DTEP	  vaccine	  did	  not,	  in	  fact,	  target	  doxorubicin-­‐exposed	  cells	  any	  better	  than	  the	  standard	  vaccine.	  Unfortunately,	  it	  was	  not	  possible	  to	  directly	  test	  the	  two	  vaccines	  against	  doxorubicin-­‐resistant	  target	  cells	  because	  DTEP	  cells	  would	  not	  reliably	  form	  tumours	  after	  s.c.	  implantation.	  The	  tumour	  cells	  used	  to	  make	  the	  two	  vaccines	  undoubtedly	  differed	  in	  their	  resistance	  to	  doxorubicin	  and	  their	  pattern	  of	  gene	  expression	  but	  the	  extent	  to	  which	  this	  was	  reflected	  in	  the	  protein	  content	  of	  the	  two	  lysates	  was	  not	  fully	  assessed.	  A	  strong	  vaccine-­‐potentiating	  effect	  of	  doxorubicin	  could	  have	  masked	  the	  impact	  of	  differences	  between	  the	  antigen	  content	  of	  the	  vaccines.	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Alternatively,	  the	  dose	  of	  doxorubicin	  used	  in	  this	  model	  of	  combined	  treatment	  may	  have	  been	  too	  low	  to	  have	  a	  direct	  effect	  on	  tumour	  cells.	  Unless	  doxorubicin	  directly	  modified	  the	  target	  tumour	  cell	  population	  in	  some	  way	  to	  render	  it	  more	  susceptible	  to	  a	  DTEP	  vaccine-­‐induced	  immune	  response,	  there	  would	  be	  no	  reason	  to	  expect	  any	  advantage	  from	  the	  DTEP	  vaccine.	  Designing	  and	  optimizing	  a	  model	  of	  combination	  treatment	  proved	  difficult.	  The	  rapid	  growth	  of	  GL261	  s.c.	  tumours	  left	  a	  narrow	  therapeutic	  window	  in	  which	  to	  administer	  the	  combination	  of	  treatments.	  A	  number	  of	  preliminary	  studies	  were	  needed	  to	  titrate	  both	  components	  of	  the	  treatment	  so	  that	  each	  contributed	  to	  the	  therapeutic	  outcome	  yet	  were	  not	  so	  effective	  together	  that	  the	  capacity	  to	  detect	  differences	  was	  lost.	  In	  the	  model	  finally	  selected,	  doxorubicin	  was	  administered	  i.v.	  three	  days	  post-­‐implantation	  at	  a	  relatively	  low	  dose	  of	  2.5	  mg/kg.	  Doses	  higher	  than	  this,	  at	  this	  time	  point,	  prevented	  tumours	  from	  growing	  (data	  not	  shown)	  suggesting	  that	  the	  dose	  of	  2.5	  mg/kg	  was	  close	  to	  the	  threshold	  for	  direct	  tumour	  cytotoxicity.	  Consistent	  with	  this,	  there	  was	  a	  non-­‐significant	  trend	  towards	  slower	  tumour	  growth	  in	  mice	  treated	  with	  doxorubicin	  alone	  (Figs	  6.3B-­‐D).	  However,	  these	  data	  fall	  short	  of	  proving	  direct	  tumour	  cytotoxicity.	  Some	  spontaneous	  tumour	  regressions	  were	  observed	  after	  s.c.	  implantation	  in	  untreated	  control	  mice	  (Fig	  6.3D)	  consistent	  with	  the	  induction	  of	  a	  spontaneous	  endogenous	  anti-­‐tumour	  immune	  response.	  The	  weak	  therapeutic	  benefit	  of	  low	  dose	  doxorubicin	  alone	  could	  therefore	  have	  been	  due	  to	  an	  immunomodulating	  effect	  that	  promoted	  the	  endogenous	  anti-­‐tumour	  response,	  rather	  than	  to	  direct	  tumour	  cytotoxicity.	  Also	  arguing	  against	  a	  tumouricidal	  effect	  of	  doxorubicin	  in	  this	  model	  is	  that	  some	  tumours	  in	  mice	  treated	  with	  doxorubicin	  alone	  continued	  to	  grow	  exponentially	  in	  a	  manner	  similar	  to	  untreated	  controls	  (Fig	  6.3D).	  Conversely,	  the	  combination	  of	  doxorubicin	  and	  Lysate-­‐Gal	  (with	  Treg	  depletion)	  was	  curative	  in	  100	  %	  of	  mice	  treated,	  suggesting	  direct	  tumour	  cell	  killing	  by	  doxorubicin	  was	  not	  required	  for	  the	  synergistic	  effect	  of	  the	  combination.	  If	  the	  predominant	  action	  of	  low	  dose	  doxorubicin	  in	  this	  model	  was	  on	  immune	  cells	  rather	  than	  tumour	  cells	  then	  one	  would	  not	  expect	  any	  advantage	  from	  a	  vaccine	  that	  was	  designed	  to	  target	  tumour	  cells	  modified	  in	  vivo	  by	  exposure	  to	  doxorubicin.	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On	  reflection,	  the	  method	  used	  to	  generate	  a	  vaccine	  intended	  to	  target	  chemoresistant	  cells	  may	  have	  been	  optimistic.	  As	  discussed	  above,	  significant	  differences	  in	  the	  DTEP	  and	  parental	  cells	  must	  have	  existed	  to	  account	  for	  the	  difference	  in	  doxorubicin	  resistance.	  However,	  these	  differences	  may	  not	  have	  been	  reflected	  in	  the	  protein	  content	  of	  the	  two	  lysates.	  Changes	  in	  gene	  expression	  do	  not	  necessarily	  translate	  to	  proportional	  changes	  in	  protein	  synthesis	  (Appendix	  B,	  Fig	  B5.5).	  It	  is	  possible	  that	  differences	  in	  chemoresistance	  could	  occur	  because	  of	  differences	  in	  the	  location	  of	  a	  certain	  protein	  within	  an	  individual	  cell	  rather	  than	  in	  the	  total	  quantity	  of	  that	  protein	  per	  cell.	  For	  example,	  ABCB1	  is	  likely	  to	  mediate	  chemoresistance	  most	  efficiently	  when	  located	  on	  the	  cell	  surface.	  Even	  if	  the	  total	  quantity	  of	  a	  particular	  protein	  such	  as	  ABCB1,	  for	  example,	  was	  increased	  in	  DTEP	  cells,	  the	  method	  used	  to	  make	  the	  lysates	  in	  this	  study	  may	  have	  led	  to	  an	  under-­‐representation	  of	  membrane-­‐bound	  molecules.	  Assuming	  ABC	  transporters	  and	  other	  proteins	  mediating	  doxorubicin	  resistance	  were	  indeed	  increased	  in	  the	  DTEP	  lysate	  as	  intended,	  the	  amount	  of	  such	  protein	  as	  a	  proportion	  of	  the	  total	  lysate	  may	  have	  been	  too	  small	  to	  skew	  the	  vaccine-­‐induced	  response	  towards	  these	  targets.	  And	  finally,	  it	  is	  not	  known	  whether	  the	  mechanisms	  conferring	  resistance	  of	  chemotherapy-­‐naïve	  tumour	  cells	  to	  a	  single	  dose	  of	  doxorubicin	  in	  vivo	  are	  necessarily	  the	  same	  as	  those	  upregulated	  by	  tumour	  cells	  chronically	  exposed	  to	  the	  drug	  in	  vitro	  (Ades	  et	  al.	  2006)	  raising	  the	  possibility	  that	  the	  DTEP	  lysate	  may	  have	  been	  enriched	  for	  the	  wrong	  proteins	  in	  this	  context.	  To	  conclude	  this	  part	  of	  the	  discussion,	  this	  study	  did	  not	  provide	  support	  for	  the	  simple	  idea	  of	  exposing	  tumour	  cells	  to	  chemotherapy	  in	  vitro	  before	  incorporating	  them	  into	  a	  whole	  tumour	  cell-­‐based	  vaccine	  for	  use	  in	  combination	  with	  the	  same	  chemotherapy	  agent.	  A	  similar	  idea	  underpinned	  the	  clinical	  trial	  described	  in	  Chapter	  3	  except	  that	  the	  tumour	  cells	  incorporated	  into	  the	  DC	  vaccine	  in	  the	  trial	  study	  had	  been	  exposed	  to	  TMZ	  in	  vivo	  during	  the	  course	  of	  treatment.	  The	  approach	  is	  clinically	  attractive	  because	  it	  is	  simple,	  does	  not	  require	  prior	  knowledge	  of	  the	  particular	  proteins	  mediating	  chemoresistance,	  and	  retains	  all	  of	  the	  advantages	  of	  whole	  tumour	  cell-­‐based	  vaccines	  including	  the	  potential	  to	  target	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multiple	  chemoresistance	  pathways	  at	  the	  same	  time.	  However,	  the	  approach	  may	  be	  too	  imprecise	  to	  achieve	  its	  aim.	  	  A	  vaccine	  with	  a	  defined	  target	  might	  be	  a	  better	  strategy.	  Additive	  effects	  have	  been	  reported	  in	  animal	  models	  of	  immunotherapy-­‐chemotherapy	  regimens	  in	  which	  the	  immunotherapy	  targeted	  a	  single	  protein	  implicated	  in	  mediating	  chemoresistance	  (C.-­‐H.	  Kim	  et	  al.	  2007;	  H.	  Zhang	  et	  al.	  2012)	  (although,	  similar	  to	  the	  study	  reported	  here,	  these	  studies	  did	  not	  provide	  any	  evidence	  that	  the	  vaccine	  selectively	  targeted	  chemoresistant	  cells).	  There	  is	  evidence	  in	  vitro	  that	  the	  immunoediting	  of	  TRP-­‐2+	  (G.	  Liu	  et	  al.	  2005)	  and	  ABCB1+	  (Perrin	  et	  al.	  2007)	  cells	  can	  restore	  chemosensitivity	  of	  tumour	  cell	  populations.	  However,	  in	  human	  cancer	  patients,	  targeting	  a	  single	  antigen	  runs	  the	  risk	  of	  immune-­‐escape	  or	  of	  selecting	  tumour	  cells	  that	  resist	  chemotherapy	  by	  a	  different	  mechanism.	  To	  speculate,	  the	  optimum	  approach	  may	  be	  to	  target	  several	  or	  a	  few	  defined	  chemoresistance-­‐related	  TAA,	  accepting	  that	  this	  would	  require	  prior	  definition	  of	  the	  important	  chemoresistance	  mechanisms	  operating	  in	  a	  particular	  clinical	  context.	  	  Although	  the	  main	  aim	  of	  the	  study	  described	  in	  this	  chapter	  was	  not	  achieved,	  an	  interesting	  and	  potentially	  valuable	  finding	  was	  that	  the	  combination	  of	  low	  dose	  doxorubicin	  and	  the	  Lysate-­‐Gal	  vaccine	  (with	  prior	  Treg	  depletion)	  had	  a	  supra-­‐additive	  effect	  that	  eradicated	  established	  s.c.	  tumours	  in	  all	  treated	  mice.	  	  In	  contrast,	  the	  combination	  treatment	  was	  ineffective,	  or	  only	  weakly	  effective,	  against	  i.c.	  tumours.	  This	  should	  not	  discourage	  interest	  in	  the	  synergistic	  effect.	  It	  should	  be	  remembered	  that	  the	  lysate	  vaccines	  used	  in	  this	  model	  were	  purposefully	  attenuated	  to	  facilitate	  comparison	  of	  the	  DTEP	  and	  parental	  lysates.	  It	  has	  been	  shown	  here,	  and	  in	  the	  preceding	  chapter,	  that	  the	  level	  of	  tumour	  protection	  afforded	  by	  the	  lysate	  vaccines	  is	  sensitive	  to	  the	  quantity	  of	  lysate.	  It	  is	  therefore	  possible	  that	  a	  similar	  synergistic	  anti-­‐tumour	  effect	  would	  have	  been	  observed	  in	  the	  i.c.	  tumour	  experiments	  if	  the	  vaccine	  had	  been	  used	  at	  a	  higher	  dose.	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Initial	  efforts	  to	  elucidate	  the	  mechanism	  underlying	  the	  supra-­‐additive	  effect	  were	  inconclusive.	  The	  inability	  of	  the	  combination	  treatment	  to	  eradicate	  i.c.	  tumours	  raises	  the	  possibility	  that	  low	  dose	  doxorubicin	  in	  this	  model	  requires	  access	  to	  the	  tumour	  site	  that	  is	  prevented	  by	  poor	  penetration	  of	  doxorubicin	  into	  the	  CNS.	  However,	  as	  discussed	  above,	  the	  data	  reported	  here	  suggests	  that	  the	  efficacy	  of	  the	  combined	  treatment	  may	  not	  have	  been	  dependent	  on	  a	  direct	  tumouricidal	  effect	  of	  doxorubicin.	  Furthermore,	  changing	  doxorubicin	  to	  an	  alternative	  formulation	  known	  to	  substantially	  increase	  CNS	  tissue	  concentration	  without	  increasing	  systemic	  toxicity	  did	  not	  restore	  efficacy	  against	  i.c.	  tumours.	  The	  possibility	  that	  low	  dose	  doxorubicin	  might	  have	  some	  sublethal	  immune-­‐potentiating	  effect	  on	  tumour	  cells	  was	  considered.	  No	  change	  in	  MHC	  molecule	  or	  Fas	  expression	  was	  detected	  in	  this	  study.	  Although	  this	  does	  not	  comprehensively	  exclude	  all	  the	  ways	  in	  which	  sublethal	  chemotherapy	  might	  render	  tumour	  cells	  more	  sensitive	  to	  killing	  by	  CTLs	  (Hodge	  et	  al.	  2013),	  temporal	  considerations	  make	  this	  an	  unlikely	  mechanism	  in	  this	  model.	  Tumours	  that	  were	  impalpable	  at	  the	  time	  of	  doxorubicin	  treatment	  continued	  to	  grow	  for	  10-­‐14	  days	  and	  reached	  a	  size	  of	  at	  least	  20	  mm2	  	  before	  eventually	  regressing.	  It	  seems	  unlikely	  that	  changes	  in	  tumour	  cells	  induced	  by	  a	  single,	  brief,	  non-­‐toxic	  exposure	  to	  doxorubicin	  would	  have	  persisted	  for	  this	  length	  of	  time	  and	  after	  multiple	  rounds	  of	  division.	  	  Although	  evidence	  for	  a	  direct	  effect	  on	  tumour	  cells	  was	  lacking,	  this	  does	  not	  exclude	  the	  possibility	  that	  doxorubicin	  had	  some	  other	  important	  effect	  at	  the	  tumour	  site	  such	  as,	  for	  example,	  depletion	  or	  functional	  suppression	  of	  an	  immunosuppressive	  cell	  population	  or	  activation	  of	  an	  effector	  cell	  type.	  However,	  the	  same	  objection	  raised	  in	  opposition	  to	  a	  direct	  effect	  on	  tumour	  cells	  also	  applies	  here	  -­‐	  it	  seems	  unlikely	  that	  a	  single	  brief	  exposure	  to	  doxorubicin	  would	  continue	  to	  exert	  a	  major	  influence	  on	  immune	  cells	  in	  tumours	  that	  continue	  to	  develop	  and	  expand	  for	  10-­‐14	  days	  after	  treatment	  before	  regressing.	  From	  this	  temporal	  perspective,	  a	  more	  likely	  explanation	  would	  seem	  to	  be	  that	  low	  dose	  doxorubicin	  has	  an	  immunomodulating	  action	  that	  impacts	  on	  the	  priming	  phase	  of	  the	  vaccine-­‐induced	  immune	  response.	  As	  a	  starting	  point,	  evidence	  for	  this	  possibility	  was	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sought	  by	  exposing	  naïve	  animals	  to	  low	  dose	  doxorubicin	  and	  assessing	  immune	  cell	  populations	  in	  the	  spleen.	  Doxorubicin	  at	  this	  dose	  did	  not	  deplete	  lymphocytes	  in	  general	  or	  Treg	  in	  particular,	  consistent	  with	  a	  previous	  report	  that	  assessed	  lymphocytes	  in	  peripheral	  blood	  (J.	  Y.	  Park	  et	  al.	  2009).	  In	  fact,	  doxorubicin	  unexpectedly	  increased	  the	  proportion	  of	  Treg	  in	  the	  spleen,	  demonstrating	  at	  least	  some	  effect	  on	  immune	  cells.	  One	  scenario	  that	  seems	  plausible	  is	  that	  doxorubicin	  administered	  i.v.	  is	  transiently	  toxic	  to	  some	  host	  cells,	  possibly	  circulating	  leucocytes,	  with	  filtration	  of	  dying	  cells	  in	  the	  spleen	  leading	  to	  increased	  presentation	  of	  self-­‐antigens	  by	  splenic	  APC,	  leading	  in	  turn	  to	  a	  relative	  accumulation	  of	  Treg	  in	  the	  spleen	  as	  they	  recognize	  cognate	  antigen.	  Along	  with	  this,	  it	  is	  possible	  that	  exposure	  to	  DAMPs	  released	  by	  the	  dying	  doxorubicin–exposed	  cells	  could	  have	  an	  activating	  effect	  on	  splenic	  DC.	  In	  the	  combined	  treatment	  model,	  the	  increase	  in	  Treg	  would	  likely	  be	  largely	  abrogated	  by	  the	  prior	  administration	  of	  Treg-­‐depleting	  antibody,	  leaving	  DC	  activation	  as	  the	  dominant	  effect.	  Further	  studies	  to	  assess	  the	  effects	  of	  doxorubicin	  on	  DC	  in	  vivo	  and	  on	  the	  magnitude	  of	  the	  vaccine-­‐induced	  response	  in	  this	  model	  would	  be	  informative.	  	  A	  scenario	  in	  which	  doxorubicin	  acts	  indirectly	  to	  activate	  APC	  by	  immunogenically	  killing	  host	  cells	  is	  consistent	  with	  the	  finding	  that	  exposure	  to	  sublethal	  doxorubicin	  in	  vitro	  did	  not	  directly	  induce	  maturation	  of	  DC2114,	  a	  murine	  DC	  cell	  line	  that	  has	  been	  shown	  to	  retain	  all	  the	  major	  features	  of	  wild-­‐type	  CD8α+	  splenic	  DC	  (Fuertes	  Marraco	  et	  al.	  2012).	  Similar	  findings	  have	  been	  reported	  using	  another	  murine	  DC	  cell	  line	  (J.	  Y.	  Park	  et	  al.	  2009).	  Caution	  is	  required,	  however,	  because	  the	  effects	  of	  doxorubicin	  may	  depend	  on	  the	  type	  of	  DC.	  	  Shurin	  and	  colleagues	  (Shurin	  et	  al.	  2009)	  reported	  increased	  expression	  of	  CD40,	  CD80,	  and	  MHC	  class	  II	  by	  murine	  BMDC	  following	  exposure	  for	  48	  hours	  in	  vitro	  to	  a	  non-­‐cytotoxic	  2	  nM	  dose	  of	  doxorubicin,	  although	  the	  magnitude	  of	  these	  statistically-­‐significant	  differences	  was	  relatively	  small	  (the	  proportion	  of	  CD11c+	  cells	  that	  were	  CD40+,	  for	  example,	  increased	  from	  9	  %	  to	  11	  %).	  In	  another	  study,	  exposure	  of	  murine	  BMDC	  to	  sub-­‐cytotoxic	  doxorubicin	  for	  24	  hours	  induced	  increased	  expression	  of	  CD40	  but	  not	  CD80,	  CD86,	  or	  MHC	  class	  II	  (H.	  Tanaka	  et	  al.	  2009).	  Similar	  in	  vitro	  studies	  have	  
 250 
been	  performed	  using	  human	  DC.	  Exposure	  of	  human	  monocyte-­‐derived	  DC	  to	  a	  non-­‐toxic	  10	  nM	  dose	  of	  doxorubicin	  induced	  increased	  expression	  of	  CD83	  but	  not	  CD40,	  CD80,	  CD86	  or	  MHC	  class	  II	  and	  did	  not	  enhance	  antigen	  presentation	  in	  a	  mixed	  lymphocyte	  reaction	  (Kaneno	  et	  al.	  2009).	  Another	  study	  exposed	  a	  DC	  subset	  isolated	  from	  human	  PBMC	  to	  the	  same	  10	  nM	  dose	  of	  doxorubicin	  and	  found	  no	  evidence	  of	  DC	  maturation.	  These	  studies,	  considered	  together	  with	  my	  own	  findings,	  do	  not	  provide	  strong	  support	  for	  direct	  activation	  of	  DC	  by	  low	  dose	  doxorubicin	  being	  a	  likely	  mechanism	  in	  the	  combined	  treatment	  model.	  	  	  The	  fact	  that	  low	  dose	  doxorubicin	  did	  not	  alter	  CD4	  or	  CD8	  T	  cell	  numbers	  in	  the	  spleen	  or	  deplete	  Treg	  does	  not	  exclude	  the	  possibility	  that	  doxorubicin	  modulated	  the	  function	  of	  these	  cell	  types.	  Kim	  and	  colleagues	  (D.	  Kim	  et	  al.	  2008)	  found	  that	  pretreatment	  with	  doxorubicin	  at	  a	  higher	  dose	  of	  5	  mg/kg	  i.v.	  enhanced	  the	  response	  to	  a	  vaccine	  designed	  to	  induce	  a	  CD4	  T	  cell	  response	  but	  inhibited	  a	  vaccine	  designed	  to	  induce	  	  CD8	  T	  cell	  responses.	  The	  same	  group	  subsequently	  showed	  that,	  whereas	  CD4	  and	  CD8	  T	  cells	  both	  upregulated	  CD40L	  and	  FasL	  after	  doxorubicin	  exposure	  in	  vitro,	  only	  CD4	  T	  cells	  upregulated	  the	  co-­‐stimulatory	  receptor	  4-­‐1BB	  (J.	  Y.	  Park	  et	  al.	  2009).	  These	  authors	  concluded	  that	  pretreatment	  with	  doxorubicin	  may	  be	  particularly	  useful	  in	  augmenting	  vaccines	  mediated	  predominantly	  by	  CD4	  T	  cells.	  	  In	  summary,	  a	  vaccine	  constructed	  from	  chemotherapy-­‐resistant	  cells,	  used	  in	  conjunction	  with	  chemotherapy,	  provided	  no	  advantage	  over	  a	  standard	  vaccine.	  However,	  this	  finding	  may	  be	  specific	  to	  this	  experimental	  model	  and	  does	  not	  necessarily	  invalidate	  the	  concept	  in	  general.	  A	  vaccine	  that	  targets	  chemoresistant	  cells	  more	  efficiently	  could	  warrant	  further	  investigation.	  This	  study	  did	  highlight	  a	  synergy	  between	  the	  vaccine	  and	  low	  dose	  doxorubicin.	  More	  work	  is	  needed	  to	  characterize	  the	  underlying	  mechanism	  but	  these	  initial	  studies	  point	  towards	  doxorubicin	  having	  some	  systemic	  vaccine-­‐potentiating	  effect.	  A	  more	  precise	  understanding	  of	  this	  phenomenon	  could	  make	  a	  valuable	  contribution	  towards	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CHAPTER	  7:	  FINAL	  DISCUSSION	  	  
	  This	  thesis	  was	  motivated	  by	  the	  need	  to	  develop	  a	  better	  treatment	  for	  patients	  with	  GBM.	  Although	  immunotherapy	  has	  yet	  to	  make	  a	  major	  impact	  in	  neuro-­‐oncology,	  lessons	  learned	  from	  clinical	  trials	  such	  as	  the	  one	  described	  in	  Chapter	  3,	  together	  with	  data	  obtained	  from	  animal	  models,	  will	  hopefully	  lead	  to	  the	  development	  of	  more	  effective	  immunotherapy	  strategies	  in	  the	  future.	  	  	  The	  main	  finding	  of	  the	  Phase	  I	  trial	  was	  that	  the	  combined	  treatment	  regimen	  was	  safe	  but	  that	  feasibility	  of	  the	  DC-­‐based	  immunotherapy	  in	  the	  recurrent	  setting	  was	  marginal.	  The	  main	  reason	  for	  this	  was	  a	  catastrophic	  failure	  of	  DC	  vaccine	  production	  in	  three	  patients.	  It	  seems	  very	  possible	  that	  previous	  exposure	  to	  TMZ	  compromised	  the	  ability	  of	  monocytes	  to	  differentiate	  and	  survive	  in	  vitro.	  Age	  and	  corticosteroid	  use	  may	  have	  been	  factors.	  An	  adverse	  impact	  of	  harvesting	  PBMC	  (and/or	  the	  autologous	  serum	  used	  in	  cell	  culture)	  before	  tumour	  debulking	  surgery	  also	  cannot	  be	  excluded.	  	  Although	  the	  trial	  was	  not	  designed	  to	  assess	  clinical	  efficacy	  or	  immunological	  outcomes	  as	  primary	  endpoints,	  improved	  clinical	  outcome	  broadly	  correlated	  with	  the	  presence	  of	  an	  anti-­‐tumour	  immune	  response	  at	  the	  time	  of	  TMZ	  retreatment.	  Nevertheless,	  marginal	  feasibility	  discourages	  pursuing	  this	  approach	  in	  the	  recurrent	  setting.	  To	  further	  support	  this	  conclusion,	  very	  few	  patients	  in	  the	  trial	  could	  be	  weaned	  off	  corticosteroids	  before	  vaccination,	  despite	  the	  fact	  that	  ≥	  90	  %	  tumour	  debulking	  was	  achieved	  in	  13	  of	  the	  14	  enrolled	  patients.	  In	  contrast,	  it	  is	  common	  for	  newly	  presenting	  patients	  to	  be	  successfully	  weaned	  off	  steroids	  completely	  and	  to	  experience	  a	  window	  of	  general	  good	  health	  after	  standard	  treatment.	  This	  would	  seem	  to	  be	  the	  optimum	  time	  to	  introduce	  immunotherapies.	  	  In	  accordance	  with	  the	  trial	  protocol,	  treatment	  was	  discontinued	  as	  soon	  as	  radiological	  progression	  was	  detected.	  This	  was	  done	  to	  give	  participants	  the	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opportunity	  to	  explore	  other	  treatment	  options	  if	  they	  wished.	  However,	  there	  is	  a	  strengthening	  viewpoint	  that	  radiological	  progression,	  widely	  used	  to	  define	  the	  failure	  of	  chemotherapy	  agents,	  may	  not	  be	  an	  appropriate	  endpoint	  for	  immunotherapies	  that	  are	  capable	  of	  conferring	  survival	  benefits	  without	  ever	  meeting	  commonly-­‐used	  criteria	  for	  objective	  response	  (Hoos	  et	  al.	  2010;	  Izumoto	  et	  al.	  2008;	  Wolchok	  et	  al.	  2009).	  Furthermore,	  the	  survival	  benefits	  of	  immunotherapies	  may	  only	  become	  apparent	  after	  several	  months	  of	  treatment	  (Bilusic	  and	  Gulley	  2012;	  Hoos	  et	  al.	  2010;	  Izumoto	  et	  al.	  2008).	  	  In	  future	  trials,	  vaccination	  should	  probably	  continue	  for	  at	  least	  12	  months.	  In	  fact,	  if	  overall	  survival	  is	  selected	  as	  the	  primary	  clinical	  endpoint,	  an	  argument	  can	  be	  made	  for	  continuing	  treatment	  even	  in	  the	  face	  of	  radiological	  progression	  as	  long	  as	  the	  patient	  remains	  clinically	  well,	  particularly	  while	  effective	  salvage	  treatment	  options	  are	  lacking.	  The	  assessments	  of	  vaccine-­‐induced	  immune	  responses	  in	  trial	  patients	  were	  more	  difficult	  to	  perform	  and	  to	  interpret	  than	  anticipated.	  ELISpot	  tests	  using	  vaccine	  or	  tumour	  lysate	  for	  stimulation	  suffer	  from	  an	  inability	  to	  precisely	  control	  for	  non-­‐specific	  activity	  induced	  by	  dead	  and	  dying	  autologous	  tumour	  cells	  and	  the	  possibility	  that	  innate	  cells,	  such	  as	  NK	  cells,	  were	  a	  source	  of	  IFN-­‐γ	  in	  these	  assays	  cannot	  be	  excluded.	  These	  tests	  were	  also	  hampered	  by	  a	  shortage	  of	  patient	  material,	  a	  situation	  exacerbated	  further	  by	  the	  need	  to	  prioritise	  patient	  treatment.	  Recovery	  of	  viable	  PBMC	  from	  frozen	  samples	  also	  declined	  as	  the	  number	  of	  cycles	  of	  TMZ	  received	  by	  the	  patient	  increased	  (data	  not	  shown).	  These	  problems	  led	  the	  investigators	  to	  use	  the	  limited	  stock	  of	  PBMC	  in	  a	  different	  way,	  by	  assessing	  responsiveness	  to	  pools	  of	  overlapping	  long	  peptides.	  Although	  the	  results	  of	  ELISpot	  tests	  done	  in	  this	  way	  are	  intrinsically	  cleaner	  and	  more	  reliable,	  a	  method	  that	  tests	  only	  a	  few	  selected	  antigens	  clearly	  has	  the	  potential	  to	  underestimate	  the	  proportion	  of	  vaccine-­‐responders.	  This	  could	  be	  addressed	  to	  some	  extent	  by	  expanding	  the	  size	  of	  the	  antigen	  panel	  but	  important	  responses	  to	  unique	  neo-­‐antigens	  would	  still	  be	  missed.	  The	  two	  forms	  of	  stimulus	  are	  therefore	  
 255 
complementary	  and,	  with	  some	  adjustments	  to	  trial	  protocol,	  should	  both	  be	  retained	  in	  future	  similar	  trials	  if	  possible.	  	  No	  single	  immunological	  test	  of	  vaccine-­‐induced	  response	  currently	  correlates	  with	  clinical	  benefit	  in	  cancer	  vaccine	  studies	  (Hoos	  et	  al.	  2010),	  a	  fact	  that	  appears	  to	  be	  discouraging	  some	  groups	  from	  even	  attempting	  the	  assessment	  (Ardon	  et	  al.	  2012).	  However,	  until	  we	  have	  a	  clear	  understanding	  of	  how	  cancer	  vaccines	  work,	  the	  optimum	  approach	  in	  my	  view	  is	  to	  assess	  cell-­‐mediated	  anti-­‐tumour	  immune	  responses	  in	  as	  many	  different	  ways	  as	  practicably	  possible	  and	  to	  include	  also	  assessments	  of	  humoral	  and	  innate	  cell	  responses.	  Where	  possible,	  immune	  parameters	  should	  be	  assessed	  at	  the	  tumour	  site	  as	  well	  as	  in	  peripheral	  blood.	  Treating	  newly	  presenting	  patients	  would	  make	  this	  more	  feasible	  because	  many	  patients	  currently	  undergo	  re-­‐operation	  at	  relapse	  as	  part	  of	  their	  usual	  treatment.	  	  Although	  median	  PFS6mo	  for	  the	  treated	  patients	  in	  the	  trial	  was	  no	  better	  than	  published	  reports	  of	  TMZ	  alone,	  there	  was	  encouraging	  evidence	  of	  treatment-­‐induced	  immune	  responses	  is	  some	  patients.	  However,	  these	  cases	  were	  few	  and	  all	  patients	  ultimately	  progressed.	  The	  fact	  that	  all	  the	  trial	  participants	  have	  now	  died	  serves	  to	  emphasise	  the	  devastating	  nature	  of	  this	  disease.	  The	  challenge	  facing	  this	  field	  is	  how	  to	  increase	  the	  proportion	  of	  responding	  patients	  and	  to	  increase	  the	  amplitude	  and	  duration	  of	  clinical	  and	  immunological	  responses.	  	  One	  way	  of	  doing	  this	  is	  to	  develop	  a	  more	  potent	  vaccine.	  In	  Chapter	  4,	  it	  was	  shown	  that	  the	  iNKT	  cell	  agonist	  α-­‐GalCer	  provides	  a	  strong	  adjuvant	  effect	  when	  incorporated	  into	  a	  simple	  vaccine	  based	  on	  irradiated	  tumour	  cells,	  and	  that	  iNKT	  cells	  are	  both	  present	  and	  functional	  in	  GBM	  patients.	  However,	  the	  adjuvanticity	  of	  α-­‐GalCer	  in	  patients	  remains	  untested.	  A	  crucial	  question	  is	  whether	  some	  patients	  simply	  have	  too	  few	  iNKT	  cells	  to	  benefit	  from	  the	  adjuvant	  effect	  of	  α-­‐GalCer.	  Adoptive	  transfer	  of	  an	  expanded	  iNKT	  cell	  population	  (East	  et	  al.	  2012)	  prior	  to	  vaccination	  could	  conceivably	  circumvent	  this	  problem.	  	  Alternatively,	  the	  Glioma-­‐Gal	  vaccine	  could	  be	  modified	  to	  increase	  DAMP	  expression	  (B.	  M.	  Andersen	  and	  Ohlfest	  2012)	  or	  incorporate	  additional	  adjuvants	  to	  promote	  DC	  licensing	  through	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multiple	  pathways.	  	  On	  a	  cautionary	  note,	  this	  thesis	  showed	  that	  irradiated	  whole	  glioma	  cells	  injected	  i.v.	  into	  mice	  are	  toxic	  at	  high	  doses.	  Toxicity	  was	  largely,	  but	  not	  completely,	  mitigated	  by	  pre-­‐treatment	  with	  heparin,	  suggesting	  that	  pro-­‐coagulant	  Tissue	  Factor	  may	  have	  been	  the	  cause	  (Bastida	  et	  al.	  1984;	  Fernandes	  et	  al.	  2006).	  Any	  move	  to	  translate	  the	  Glioma-­‐Gal	  vaccine	  to	  the	  clinic	  would	  require	  prior	  in	  vitro	  assessment	  of	  the	  effects	  of	  the	  vaccine	  on	  human	  blood	  components	  followed	  by	  a	  careful	  Phase	  I	  dose	  escalation	  study	  performed	  in	  an	  ICU	  setting.	  It	  is	  very	  likely	  that	  toxicity	  could	  be	  substantially	  reduced	  by	  administering	  the	  vaccine	  s.c.	  or	  i.d.	  but	  this	  might	  impact	  adversely	  on	  efficacy	  by	  reducing	  access	  to	  iNKT	  cells	  and/or	  by	  leading	  to	  priming	  in	  skin-­‐draining	  lymph	  nodes	  rather	  than	  in	  those	  secondary	  lymphoid	  organs	  where	  T	  cell	  priming	  may	  induce	  a	  homing	  phenotype	  more	  conducive	  to	  entering	  the	  CNS	  (Ferguson	  and	  Engelhard	  2010;	  Odoardi	  et	  al.	  2012;	  Sasaki	  et	  al.	  2007).	  Both	  the	  vaccine	  designs	  used	  in	  this	  thesis	  were	  capable	  of	  eliciting	  anti-­‐tumour	  immune	  responses	  in	  vivo.	  However,	  one	  of	  the	  potential	  advantages	  of	  the	  Glioma-­‐Gal	  vaccine	  over	  the	  simpler	  Lysate-­‐Gal	  design	  is	  that	  the	  Glioma-­‐Gal	  vaccine	  may	  be	  less	  prone	  to	  inducing	  iNKT	  cell	  anergy.	  Fujii	  and	  colleagues	  showed	  in	  mice	  that	  an	  injection	  of	  DC	  pulsed	  with	  α-­‐GalCer	  did	  not	  prevent	  iNKT	  cells	  from	  responding	  to	  a	  second	  injection	  of	  α-­‐GalCer-­‐pulsed	  DC	  30	  days	  later	  (Fujii	  et	  al.	  2002).	  A	  single	  dose	  of	  Glioma-­‐Gal	  vaccine	  also	  did	  not	  completely	  abrogate	  the	  capacity	  of	  a	  second	  α-­‐GalCer–mediated	  vaccine	  to	  elicit	  an	  immune	  response	  2	  weeks	  later	  (albeit	  in	  a	  single	  experiment:	  Appendix	  B,	  Fig	  B5.1).	  Thus,	  it	  may	  be	  feasible	  to	  use	  the	  Glioma-­‐Gal	  vaccine	  in	  a	  prime-­‐boost	  regimen.	  Further	  studies	  are	  needed	  to	  test	  this.	  Also	  relevant	  to	  the	  potential	  use	  of	  Glioma-­‐Gal	  in	  prime-­‐boost	  regimens	  is	  the	  recent	  discovery	  that	  repeated	  i.v.	  administration	  of	  α-­‐GalCer	  in	  mice	  can	  induce	  or	  expand	  a	  population	  of	  immunoregulatory	  IL-­‐10-­‐secreting	  	  iNKT	  cells	  (Sag	  et	  al.	  2014).	  The	  dose	  of	  free	  α-­‐GalCer	  used	  in	  that	  study,	  4	  μg,	  was	  20	  times	  greater	  than	  that	  used	  in	  the	  Lysate-­‐Gal	  experiments	  described	  in	  this	  thesis.	  Nevertheless,	  it	  would	  be	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important	  to	  assess	  whether	  tumour	  cell-­‐associated	  α-­‐GalCer	  has	  the	  same	  effect	  at	  doses	  required	  for	  therapeutic	  benefit.	  These	  concerns	  aside,	  the	  Glioma-­‐Gal	  vaccine	  has	  much	  to	  recommend	  it	  including	  the	  practical	  advantage	  of	  avoiding	  the	  need	  to	  generate	  autologous	  DC	  ex	  vivo,	  application	  to	  patients	  of	  all	  HLA	  types,	  the	  provision	  of	  epitopes	  for	  both	  CD4	  and	  CD8	  T	  cells	  and	  the	  provision	  of	  a	  broad	  range	  of	  personalised	  antigens.	  This	  last	  point	  may	  be	  particularly	  important.	  Evidence	  in	  the	  literature	  favours	  a	  broad	  multivalent	  approach	  in	  cancer	  vaccines	  over	  targeting	  one	  or	  a	  few	  selected	  antigens	  (Neller	  et	  al.	  2008).	  	  In	  addition,	  a	  personalised	  vaccine	  incorporating	  whole	  tumour	  antigens	  has	  the	  potential	  to	  target	  unique	  neo-­‐antigens.	  Recent	  studies	  suggest	  that	  a	  major	  reason	  for	  the	  striking	  success	  of	  checkpoint	  inhibitors	  may	  be	  the	  promotion	  of	  responses	  to	  tumour-­‐specific	  neo-­‐antigens	  rather	  than	  to	  over-­‐expressed	  shared	  antigens	  (Kvistborg	  et	  al.	  2014;	  Snyder	  et	  al.	  2014).	  It	  seems	  likely	  that	  significant	  progress	  in	  defining	  the	  optimum	  target	  antigens	  for	  cancer	  vaccines	  will	  be	  made	  in	  the	  coming	  years.	  Mass	  spectrometry	  and	  automated	  data	  analysis	  have	  been	  used	  to	  characterise	  entire	  “peptidomes”	  eluted	  from	  MHC	  molecules	  of	  GBM	  tumour	  cells	  leading	  to	  the	  discovery	  of	  antigens	  currently	  being	  tested	  in	  clinical	  trials	  (Dutoit	  et	  al.	  2012).	  	  The	  development	  of	  high	  throughput	  gene	  sequencing	  coupled	  with	  advances	  in	  bioinformatics	  means	  it	  is	  becoming	  feasible	  to	  define	  “mutanomes”	  of	  tumours	  from	  individual	  patients	  in	  a	  rapid	  time	  frame,	  potentially	  allowing	  the	  design	  of	  personalised	  vaccines	  targeting	  neo-­‐epitopes	  (Boisguérin	  et	  al.	  2014).	  In	  the	  meantime,	  autologous	  tumour	  cells	  remain	  a	  readily	  available	  source	  of	  personalised	  antigens.	  	  Unexpectedly,	  the	  anti-­‐tumour	  effect	  of	  the	  Glioma-­‐Gal	  vaccine	  did	  not	  require	  CD8	  T	  cells	  or	  NK	  cells	  but	  was	  dependent	  on	  CD4	  T	  cells.	  Two	  other	  groups	  have	  also	  described	  anti-­‐tumour	  immune	  responses	  in	  GL261-­‐bearing	  mice	  that	  were	  dependent	  on	  CD4,	  but	  not	  CD8,	  T	  cells	  (Belcaid	  et	  al.	  2014;	  Leach	  et	  al.	  1996).	  Although	  many	  studies	  have	  focused	  on	  the	  role	  of	  CD8	  T	  cells	  in	  mediating	  anti-­‐
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cancer	  immune	  responses,	  the	  potential	  for	  exploiting	  CD4	  T	  cells	  is	  attracting	  increasing	  interest	  (Tran	  et	  al.	  2014).	  	  CD4	  T	  cells	  are	  capable	  of	  exerting	  anti-­‐tumour	  effects	  in	  a	  number	  of	  ways	  that	  are	  independent	  of	  CTL	  including	  the	  promotion	  of	  effector	  functions	  of	  innate	  cells	  at	  the	  tumour	  site,	  anti-­‐angiogenic	  effects	  of	  IFN-­‐γ	  and	  TNF-­‐α,	  direct	  tumour	  cell	  cytotoxicity,	  and	  provision	  of	  help	  to	  B	  cells	  (Corthay	  et	  al.	  2005;	  Flynn	  and	  Stockinger	  2003;	  H.-­‐J.	  Kim	  and	  Cantor	  2014;	  Mumberg	  et	  al.	  1999;	  Quezada	  et	  al.	  2010).	  Recently,	  it	  has	  been	  shown	  that	  the	  presence	  of	  tumour-­‐infiltrating	  TFH	  CD4	  T	  cells	  is	  associated	  with	  an	  improved	  prognosis	  in	  patients	  with	  breast	  cancer	  (Gu-­‐Trantien	  et	  al.	  2013).	  In	  this	  study,	  the	  adoptive	  transfer	  of	  serum	  from	  Glioma-­‐Gal	  vaccinated	  mice	  did	  not	  confer	  tumour	  protection,	  arguing	  against	  a	  role	  for	  humoral	  immunity	  in	  this	  model.	  However,	  a	  mechanism	  that	  involves	  B	  cell	  help	  should	  perhaps	  not	  be	  completely	  excluded	  because	  the	  anti-­‐tumour	  effect	  of	  circulating	  antibodies	  might	  also	  be	  dependent	  on	  some	  effect	  of	  the	  vaccine	  on	  Fc	  receptor+	  cells,	  such	  as	  tumour-­‐associated	  macrophages	  for	  example.	  As	  mentioned	  earlier	  in	  this	  thesis,	  one	  of	  the	  theoretical	  advantages	  of	  personalised	  whole	  tumour	  cell-­‐based	  vaccines	  is	  the	  possibility	  of	  targeting	  unique	  neo-­‐antigens.	  Recently,	  it	  has	  been	  shown	  that	  human	  CD4	  T	  cells	  have	  the	  capacity	  to	  recognise	  mutated	  tumour	  neo-­‐antigens	  (Linnemann	  et	  al.	  2015;	  Tran	  et	  al.	  2014).	  It	  is	  interesting	  to	  speculate	  that	  the	  immunodominant	  antigens	  targeted	  by	  the	  Glioma-­‐Gal	  vaccine	  might	  be	  MHC	  class	  II-­‐restricted	  epitopes	  derived	  from	  mutated	  proteins.	  	  Although	  the	  ability	  of	  whole	  tumour	  cell-­‐based	  vaccines	  to	  target	  a	  broad	  range	  of	  personalised	  antigens	  is	  a	  theoretical	  advantage,	  a	  weakness	  of	  this	  type	  of	  vaccine	  is	  the	  fact	  that	  the	  targets	  are	  undefined,	  making	  it	  much	  more	  difficult	  to	  accurately	  assess	  vaccine-­‐induced	  responses	  than	  when	  the	  specificity	  of	  the	  vaccine	  is	  predetermined.	  A	  way	  must	  be	  found	  to	  reconcile	  these	  two	  competing	  needs	  because	  the	  ability	  to	  accurately	  measure	  the	  magnitude	  and	  specificity	  of	  immune	  responses	  induced	  by	  cancer	  vaccines	  in	  clinical	  trials	  is	  fundamental	  to	  making	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progress	  in	  this	  field.	  	  As	  mentioned	  already	  above,	  one	  way	  to	  improve	  assessment	  of	  Glioma-­‐Gal	  vaccine-­‐induced	  immune	  responses	  in	  a	  clinical	  trial	  setting	  might	  be	  to	  expand	  the	  pool	  of	  TAA	  tested	  for	  T	  cell-­‐reactivity.	  However,	  this	  approach	  will	  always	  tend	  to	  underestimate	  vaccine-­‐induced	  responses.	  An	  alternative,	  but	  complementary,	  approach	  might	  be	  to	  “spike”	  the	  Glioma-­‐Gal	  vaccine	  with	  a	  defined	  antigen.	  Incorporation	  of	  a	  control	  antigen	  could	  conceivably	  be	  done	  using	  techniques	  such	  as	  retroviral	  transfection	  or	  electroporation	  but	  this	  would	  negate	  one	  of	  the	  main	  advantages	  of	  Glioma-­‐Gal,	  namely	  the	  lack	  of	  complex	  in	  vitro	  steps	  required	  for	  manufacture.	  A	  different	  way	  of	  achieving	  this	  might	  therefore	  be	  to	  pulse	  tumour	  cells	  with	  a	  conjugate	  of	  α-­‐GalCer	  and	  a	  control	  protein,	  similar	  to	  conjugates	  recently	  described	  by	  Hermans	  and	  colleagues	  (Anderson	  et	  al.	  2014),	  thereby	  exploiting	  the	  same	  unidentified	  mechanism	  by	  which	  α-­‐GalCer	  associates	  with	  tumour	  cells	  and	  preserving	  the	  simple	  overnight	  pulsing	  method	  used	  to	  make	  the	  Glioma-­‐Gal	  vaccine.	  Validation	  studies	  would	  be	  needed	  to	  check	  that	  this	  did	  not	  impact	  adversely	  on	  the	  adjuvant	  effect	  of	  α-­‐GalCer.	  If	  a	  full	  length	  protein	  antigen,	  or	  perhaps	  a	  pool	  of	  overlapping	  SLPs	  covering	  the	  full	  protein,	  could	  be	  incorporated	  in	  this	  way	  then	  the	  vaccine	  would	  remain	  applicable	  to	  patients	  of	  all	  HLA-­‐types	  thereby	  preserving	  another	  of	  the	  other	  attractive	  properties	  of	  Glioma-­‐Gal.	  	  In	  studies	  of	  DC-­‐based	  vaccines,	  antigens	  used	  as	  controls	  have	  included	  MHC	  class	  I-­‐restricted	  viral	  peptide	  antigens	  and	  the	  large	  protein	  molecule	  keyhole	  limpet	  haemocyanin	  (Aarntzen	  et	  al.	  2013;	  Banchereau	  et	  al.	  2001;	  J.	  R.	  Harris	  and	  Markl	  1999).	  A	  concern	  with	  this	  approach	  is	  the	  possibility	  that	  the	  “marker”	  antigen	  might	  come	  to	  dominate	  the	  vaccine-­‐induced	  response.	  This	  could	  be	  addressed	  to	  some	  extent	  by	  using	  an	  “on-­‐target”	  glioma-­‐associated	  antigen.	  	  Chapters	  5	  and	  6	  explored	  the	  possibility	  of	  extracting	  additional	  therapeutic	  benefit	  from	  the	  Glioma-­‐Gal	  platform	  by	  modifying	  the	  vaccine	  to	  target	  a	  putative	  tumour	  cell	  subset	  or	  phenotype.	  In	  Chapter	  5,	  it	  was	  shown	  that	  growing	  GL261	  tumour	  cells	  in	  stem	  cell	  medium	  prior	  to	  incorporation	  into	  vaccine	  did	  not	  improve	  the	  efficacy	  of	  a	  lysate-­‐based	  vaccine.	  However,	  this	  negative	  finding	  in	  the	  GL261	  model	  cannot	  be	  said	  to	  invalidate	  the	  approach	  in	  general	  because	  an	  immortalised	  cell	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line	  does	  not	  necessarily	  accurately	  represent	  the	  biology	  of	  heterogeneous	  tumour	  cell	  populations	  in	  human	  patients.	  The	  CSC	  hypothesis	  continues	  to	  attract	  intense	  interest.	  As	  previously	  mentioned,	  Vik-­‐Mo	  and	  colleagues	  recently	  reported	  the	  results	  of	  a	  Phase	  I	  clinical	  trial	  in	  which	  7	  GBM	  patients	  vaccinated	  with	  DC	  pulsed	  with	  neurospheres	  cultured	  from	  autologous	  GBM	  tumour	  tissue	  survived	  longer	  than	  matched	  historical	  controls	  (Vik-­‐Mo	  et	  al.	  2013).	  While	  encouraging,	  the	  study	  was	  not	  designed	  to	  show	  whether	  or	  not	  the	  vaccine	  actually	  targeted	  CSC.	  There	  are	  other	  reasons	  why	  such	  a	  vaccine	  might	  be	  more	  effective	  than	  DC	  pulsed	  with	  tumour	  cells	  cultured	  in	  serum,	  such	  as,	  for	  example,	  a	  more	  faithful	  preservation	  of	  the	  genotype	  and	  phenotype	  of	  the	  original	  tumour	  (Fael	  Al-­‐Mayhani	  et	  al.	  2009;	  J.	  Lee	  et	  al.	  2006b).	  A	  number	  of	  other	  trials	  based	  on	  the	  concept	  of	  glioma	  CSC	  are	  either	  planned	  or	  in	  progress	  (Esparza	  et	  al.	  2015).	  	  In	  Chapter	  6,	  modifying	  the	  lysate	  vaccine	  with	  the	  intention	  of	  targeting	  chemoresistant	  tumour	  cells	  did	  not	  improve	  therapeutic	  benefit	  when	  used	  in	  combination	  with	  doxorubicin.	  	  Again,	  failure	  to	  show	  proof-­‐of-­‐principle	  in	  this	  particular	  model	  clearly	  does	  not	  invalidate	  the	  concept	  of	  targeting	  chemoresistance	  with	  immunotherapy	  altogether	  but	  does	  at	  least	  discourage	  pursuing	  this	  aim	  with	  the	  Glioma-­‐Gal	  vaccine	  design.	  An	  interesting	  observation	  made	  in	  Chapters	  5	  and	  6	  was	  that	  Musashi-­‐1	  gene	  expression	  was	  upregulated	  both	  by	  culture	  in	  SC	  media	  and	  by	  doxorubicin	  exposure.	  Musashi-­‐1	  is	  an	  RNA-­‐binding	  protein	  that	  binds	  to	  and	  represses	  translation	  of	  certain	  mRNAs.	  In	  normal	  neural	  stem	  cells	  it	  inhibits	  differentiation	  but	  also	  activates	  Notch	  and	  Wnt	  pathway	  signalling,	  thereby	  promoting	  progression	  through	  the	  cell-­‐cycle	  while	  at	  the	  same	  time	  maintaining	  the	  stem	  cell-­‐state	  (Glazer	  et	  al.	  2008;	  Okano	  et	  al.	  2002).	  Expression	  is	  required	  for	  normal	  nervous	  system	  development	  in	  mammals	  (Glazer	  et	  al.	  2008).	  In	  adults,	  Musashi-­‐1	  expression	  in	  the	  CNS	  is	  negligible	  except	  in	  normal	  neural	  stem	  cells	  (Okano	  et	  al.	  2002).	  It	  is	  also	  expressed	  in	  stem	  cells	  and	  early	  progenitors	  in	  some	  other	  tissues	  such	  as	  breast	  and	  colon	  (Vo	  et	  al.	  2012).	  It	  is	  aberrantly	  over-­‐expressed	  by	  astrocytic	  tumours	  in	  humans	  (Kanemura	  et	  al.	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2001;	  Thon	  et	  al.	  2010;	  Vo	  et	  al.	  2012)	  and	  the	  level	  of	  expression	  correlates	  with	  tumour	  grade	  (Dahlrot	  et	  al.	  2013;	  Kanemura	  et	  al.	  2001;	  Thon	  et	  al.	  2010).	  	  It	  is	  not	  clear	  whether	  the	  doxorubicin-­‐induced	  increase	  in	  Musashi-­‐1	  expression	  was	  directly	  involved	  in	  the	  acquired	  chemoresistance	  of	  tumour	  cells	  or	  merely	  an	  epiphenomenon.	  Johannessen	  and	  colleagues	  (Johannessen	  et	  al.	  2009)	  showed	  that	  inhibition	  of	  PI3K/Akt	  signalling	  in	  GBM	  sphere	  cells	  reduced	  Musashi-­‐1	  expression	  and	  increased	  sensitivity	  to	  doxorubicin.	  Since	  the	  PI3K/Akt	  pathway	  lies	  downstream	  of	  EGFR	  (T.	  T.	  Huang	  et	  al.	  2009),	  it	  seems	  likely	  that,	  in	  the	  case	  of	  sphere	  cells,	  the	  increase	  in	  Musashi-­‐1	  expression	  was	  stimulated	  by	  EGF	  in	  SC	  medium.	  In	  DTEP	  cells,	  it	  is	  conceivable	  that	  Musashi-­‐1	  expression	  was	  also	  due	  to	  PI3K/Akt	  signalling.	  PI3K/Akt	  pathway	  activity	  is	  upregulated	  by	  exposure	  to	  certain	  chemotherapy	  agents	  including	  doxorubicin	  and	  this	  increased	  activity	  is	  strongly	  associated	  with	  chemoresistance	  (reviewed	  in	  W.-­‐C.	  Huang	  and	  Hung	  2009).	  Thus	  upregulation	  of	  PI3K/Akt	  activity	  in	  DTEP	  cells	  in	  response	  to	  doxorubicin	  could	  potentially	  explain	  both	  an	  increase	  in	  Musashi-­‐1	  expression	  and	  the	  acquisition	  of	  chemoresistance.	  	  	  	  There	  is	  also	  a	  line	  of	  evidence	  linking	  expression	  of	  Musashi-­‐1	  with	  ABCB1	  expression.	  Doxorubicin	  exposure	  induced	  nuclear	  localisation	  of	  the	  transcription/translation	  factor	  Y-­‐box	  binding	  protein-­‐1	  (YB-­‐1)	  and	  the	  upregulation	  of	  ABCB1	  in	  a	  human	  breast	  cancer	  cell	  line	  (Bargou	  et	  al.	  1997).	  Forced	  expression	  of	  YB-­‐1	  in	  a	  drug-­‐sensitive	  breast	  epithelial	  cell	  line	  induced	  resistance	  to	  doxorubicin	  (Bargou	  et	  al.	  1997).	  Silencing	  YB-­‐1	  reduced	  the	  protein	  level	  of	  Musashi-­‐1,	  SOX2	  and	  Nestin	  in	  a	  human	  GBM	  cell	  line	  (Fotovati	  et	  al.	  2011).	  Thus	  doxorubicin-­‐induced	  nuclear	  translocation	  of	  YB-­‐1	  is	  a	  plausible	  explanation	  at	  the	  molecular	  level	  for	  the	  increased	  expression	  of	  both	  Musashi-­‐1	  and	  ABCB1	  in	  DTEP	  cells.	  	  Neither	  of	  these	  two	  speculative	  scenarios	  imply	  a	  direct	  role	  for	  Musashi-­‐1	  in	  mediating	  chemoresistance.	  I	  am	  not	  aware	  of	  any	  studies	  that	  have	  directly	  assessed	  this.	  However,	  it	  seems	  possible	  that	  Musashi-­‐1	  itself	  could	  confer	  a	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general	  resistance	  to	  apoptosis	  by	  way	  its	  known	  property	  of	  inducing	  a	  downstream	  increase	  in	  Notch	  pathway	  activity	  (Artavanis-­‐Tsakonas	  et	  al.	  1999;	  Fassl	  et	  al.	  2012;	  McAuliffe	  et	  al.	  2012).	  In	  Chapter	  5,	  I	  speculated	  that	  Musashi-­‐1	  could	  be	  a	  potential	  antigen	  for	  selectively	  targeting	  SCLC.	  To	  speculate	  further,	  if	  Musashi-­‐1	  is	  a	  mediator	  of	  chemoresistance	  in	  tumour	  cells	  then	  a	  vaccine	  targeting	  this	  protein	  could	  potentially	  perform	  particularly	  well	  in	  a	  combination	  regimen	  with	  chemotherapy.	  	  	  It	  is	  pertinent	  to	  reflect	  here	  on	  the	  strengths	  and	  weaknesses	  of	  the	  animal	  model	  used	  in	  Chapters	  4-­‐6.	  Created	  in	  1939	  by	  the	  intracerebral	  implantion	  of	  carcinogenic	  methylcholanthrene	  pellets	  (Ausman	  et	  al.	  1970;	  Seligman	  et	  al.	  1939),	  the	  GL261	  cell	  line	  forms	  lethal	  tumours	  after	  implantation	  into	  the	  brain	  of	  the	  syngeneic	  immunocompetent	  C57BL/6	  mouse	  with	  almost	  100	  %	  penetrance	  making	  it	  a	  reliable	  and	  relatively	  inexpensive	  model	  for	  studies	  of	  glioma	  immunotherapy	  (Wim	  Maes	  and	  Van	  Gool	  2010).	  Intracranial	  GL261	  tumours	  have	  several	  features	  in	  common	  with	  their	  human	  high	  grade	  glioma	  counterparts.	  Histologically,	  they	  are	  highly	  cellular	  and	  pleomorphic	  and	  areas	  of	  necrosis	  are	  often	  present	  (Doblas	  et	  al.	  2010).	  GL261	  is	  reported	  to	  exhibit	  point	  mutations	  of	  the	  K-­‐ras	  oncogene	  and	  p53	  tumour	  suppressor	  gene	  (Wim	  Maes	  and	  Van	  Gool	  2010;	  Szatmari	  et	  al.	  2006)	  and	  express	  high	  levels	  of	  VEGF	  (Doblas	  et	  al.	  2010).	  PDGF	  signalling	  has	  been	  shown	  to	  play	  an	  important	  role	  in	  GL261	  tumour	  progression	  (Y.	  Huang	  et	  al.	  2014).	  Immunologically,	  GL261	  tumours	  exhibit	  a	  number	  of	  features	  relevant	  to	  the	  human	  setting.	  Treg	  are	  progressively	  recruited	  to	  the	  i.c.	  tumour	  site	  from	  an	  early	  stage	  (Grauer	  et	  al.	  2007)	  and	  play	  an	  important	  role	  in	  both	  preventing	  rejection	  (Onizuka	  et	  al.	  1999;	  Sutmuller	  et	  al.	  2001)	  and	  in	  suppressing	  experimental	  immunotherapies	  (Grauer	  et	  al.	  2007).	  TGF-­‐β	  has	  also	  been	  implicated	  in	  suppressing	  anti-­‐tumour	  immune	  responses	  in	  this	  model	  (Hülper	  et	  al.	  2011;	  Ueda	  et	  al.	  2009).	  Microglia,	  macrophages,	  and	  immature	  myeloid	  cells	  accumulate	  within	  GL261	  tumours	  (Gabrusiewicz	  et	  al.	  2011)	  and	  have	  been	  implicated	  in	  mediating	  invasion	  (Ye	  et	  al.	  2012)	  and	  immunosuppression	  (Chae	  et	  al.	  2014).	  Shown	  in	  this	  thesis	  and	  by	  others	  (Akbasak	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et	  al.	  1991;	  Wim	  Maes	  and	  Van	  Gool	  2010),	  MHC	  class	  I	  and	  class	  II	  expression	  is	  constitutive	  or	  inducible,	  rendering	  tumour	  cells	  susceptible	  to	  T	  cell	  recognition.	  A	  number	  of	  TAA	  have	  been	  described	  for	  GL261,	  including	  TRP-­‐2	  and	  gp100	  (Prins	  et	  al.	  2003),	  survivin	  (Ciesielski	  et	  al.	  2008),	  AN2	  (A.	  K.	  Paul	  et	  al.	  2009),	  GARC-­‐1	  (Iizuka	  et	  al.	  2006),	  and	  EphA2	  (Ueda	  et	  al.	  2009)	  but	  the	  immunodominant	  antigens	  mediating	  responses	  to	  whole	  tumour	  antigen-­‐based	  vaccines	  are	  unknown	  (Grauer	  et	  al.	  2008).	  The	  model	  has	  been	  used	  extensively	  to	  assess	  active	  immunotherapies	  for	  glioma	  and	  has	  been	  described	  as	  the	  “gold	  standard”	  for	  this	  purpose	  (Wim	  Maes	  and	  Van	  Gool	  2010).	  There	  are,	  however,	  several	  ways	  in	  which	  GL261	  tumours	  differ	  from	  human	  GBM.	  Although	  considered	  “moderately”	  invasive	  by	  some	  (Doblas	  et	  al.	  2010),	  in	  this	  study	  parental	  tumours	  had	  relatively	  distinct	  borders	  on	  histological	  sections	  and	  on	  MRI.	  GL261	  tumours	  are	  angiogenic	  (Doblas	  et	  al.	  2010)	  but	  tumour	  vessels	  do	  not	  have	  the	  striking	  endothelial	  proliferation	  typical	  of	  human	  GBM.	  Individual	  cells	  have	  well-­‐defined	  plasma	  membranes,	  a	  morphology	  not	  typical	  for	  the	  high	  grade	  astrocytic	  tumours	  most	  commonly	  found	  in	  humans	  and	  considered	  by	  some	  to	  more	  closely	  resemble	  ependymoblastoma	  (Ausman	  et	  al.	  1970).	  Unlike	  most	  GBM	  tumours,	  GL261	  does	  not	  express	  the	  glial	  differentiation	  marker	  GFAP	  (Pellegatta	  et	  al.	  2006a;	  Szatmari	  et	  al.	  2006)	  except	  perhaps	  under	  special	  conditions	  (Pellegatta	  et	  al.	  2006b;	  Anhua	  Wu	  et	  al.	  2008).	  Consistent	  with	  this,	  no	  GFAP	  protein	  was	  detected	  in	  GL261	  tumour	  cells	  cultured	  in	  standard	  medium	  in	  our	  laboratory	  (M.	  McConnell,	  data	  not	  shown).	  	  A	  feature	  of	  this	  model	  seems	  to	  be	  variability	  in	  reported	  behavior	  between	  laboratories.	  In	  a	  review	  of	  the	  literature,	  Maes	  and	  colleagues	  found	  a	  two	  log	  difference	  in	  the	  number	  of	  cells	  required	  for	  full	  penetrance	  after	  i.c.	  implantation	  (Wim	  Maes	  and	  Van	  Gool	  2010).	  	  These	  authors	  speculated	  that	  differences	  between	  research	  groups	  might	  be	  due,	  in	  part,	  to	  variation	  in	  immunological	  features	  of	  the	  cell	  line	  during	  longterm	  culture.	  Adding	  further	  weight	  to	  this	  possibility	  is	  that,	  whereas	  GL261	  was	  initially	  maintained	  by	  serial	  passage	  in	  vivo,	  it	  appears	  a	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number	  of	  GL261	  cell	  lines	  capable	  of	  immortal	  growth	  in	  vitro	  were	  established	  in	  parallel	  by	  separate	  research	  groups	  in	  the	  1990s	  (Szatmari	  et	  al.	  2006).	  As	  discussed	  in	  Chapter	  5,	  this	  might	  explain	  why	  some	  of	  the	  findings	  in	  this	  thesis	  were	  discordant	  with	  some	  of	  the	  literature.	  	  A	  valid	  criticism	  of	  implantable	  models	  is	  that	  the	  implantation	  procedure	  itself	  induces	  local	  inflammation	  that	  can	  boost	  anti-­‐tumour	  immune	  responses.	  Another	  is	  that	  rapid	  tumour	  growth,	  while	  convenient,	  does	  not	  allow	  the	  extensive	  interactions	  between	  tumour	  cells,	  stromal	  cells,	  and	  immune	  cells	  that	  has	  taken	  place	  in	  symptomatic	  human	  tumours	  (Sughrue	  et	  al.	  2009).	  Autochthonous	  models,	  in	  which	  brain	  tumours	  arise	  spontaneously	  in	  genetically	  modified	  rodents,	  circumvent	  some	  of	  these	  concerns.	  Genetically	  modified	  mouse	  models	  commonly	  involve	  introducing	  genetic	  alterations	  known	  to	  be	  present	  in	  the	  corresponding	  human	  tumour	  of	  interest	  and	  are	  therefore	  theoretically	  more	  similar	  to	  their	  human	  counterparts	  than	  carcinogen-­‐induced	  tumours.	  A	  serious	  concern	  with	  germline	  genetic	  modification	  is	  the	  possibility	  of	  off	  target	  effects,	  such	  as	  effects	  on	  the	  immune	  cells.	  Conditional	  models,	  that	  allow	  genetic	  modifications	  to	  be	  tissue-­‐specific	  and/or	  induced	  in	  a	  time-­‐controlled	  manner,	  have	  been	  developed	  to	  try	  and	  address	  this	  (Dranoff	  2011;	  Huszthy	  et	  al.	  2012).	  However,	  genetically	  modified	  mouse	  models	  have	  significant	  practical	  limitations	  including	  higher	  cost,	  variable	  time	  to	  tumour	  appearance	  (creating	  a	  need	  for	  some	  way	  of	  detecting	  tumours	  before	  they	  are	  too	  advanced)	  and	  variation	  in	  tumour	  histology.	  Another	  concern	  with	  many	  genetically	  engineered	  models	  is	  the	  incorporation	  of	  viral	  protein	  that	  may	  itself	  be	  immunogenic	  (Sughrue	  et	  al.	  2009).	  Immunodeficient	  xenograft	  models	  are	  not	  suitable	  for	  testing	  active	  immunotherapies.	  “Humanised”	  rodent	  models	  can	  be	  useful	  in	  certain	  circumstances,	  such	  as,	  for	  example,	  testing	  adoptively	  transferred	  genetically-­‐engineered	  human	  T	  cells	  against	  human	  tumours,	  but	  it	  is	  not	  yet	  possible	  to	  recapitulate	  the	  entirety	  of	  a	  human	  immune	  response	  in	  mouse	  since	  this	  involves	  interactions	  with	  stromal	  cells	  (Dranoff	  2011).	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Although	  genetically	  engineered	  models	  theoretically	  recapitulate	  the	  biology	  of	  their	  human	  counterparts	  more	  faithfully	  (de	  Vries	  et	  al.	  2009;	  Dranoff	  2011;	  Huszthy	  et	  al.	  2012),	  it	  remains	  to	  be	  seen	  whether	  they	  are	  better	  at	  predicting	  the	  performance	  of	  novel	  treatments	  in	  human	  patients.	  While	  far	  from	  perfect,	  implantable	  models	  are	  nevertheless	  capable	  of	  providing	  proof-­‐of-­‐principle	  and	  mechanistic	  insights.	  Studies	  in	  implantable	  models	  have	  paved	  the	  way	  for	  some	  of	  the	  most	  significant	  recent	  advances	  in	  clinical	  cancer	  immunotherapy	  including	  checkpoint	  inhibition	  (Dranoff	  2011).	  Indeed,	  it	  has	  recently	  been	  suggested	  that	  the	  higher	  mutational	  load	  generally	  present	  in	  carcinogen-­‐induced	  tumours	  might	  make	  them	  better	  models	  for	  testing	  immune	  checkpoint	  blockade	  than	  genetically	  engineered	  tumour	  models	  (Robert	  Schreiber,	  oral	  presentation,	  Keystone	  Symposium,	  Banff	  2015).	  In	  my	  opinion,	  a	  rational	  approach	  is	  to	  tailor	  the	  choice	  of	  model	  to	  the	  particular	  research	  question,	  taking	  into	  account	  practical	  considerations	  such	  as	  time	  and	  cost.	  Large	  rodent	  models	  may	  be	  more	  suitable	  for	  experiments	  that	  involve	  post-­‐implantation	  surgical	  interventions	  at	  the	  tumour	  site	  such	  as,	  for	  example,	  intra-­‐tumoural	  administration	  of	  drugs,	  cytokines	  or	  cells.	  Genetically	  modified	  autochthonous	  models	  are	  probably	  optimal	  for	  studying	  some	  aspects	  of	  tumour	  biology,	  including	  tumour	  initiation,	  progression	  and	  invasion,	  angiogenesis,	  and	  immunoediting.	  Models	  based	  on	  known	  genetic	  modifications	  with	  predictable	  molecular	  downstream	  effects	  may	  also	  be	  highly	  suitable	  for	  testing	  treatments	  targeting	  specific	  molecules	  or	  pathways.	  Orthotopic	  models	  involving	  implantation	  of	  immortal	  cell	  lines	  into	  wild-­‐type	  immunocompetent	  mice,	  while	  far	  from	  perfect,	  remain	  a	  valid	  tool	  for	  investigating	  many	  aspects	  of	  tumour	  immunotherapy.	  Thus,	  in	  this	  thesis,	  GL261	  proved	  useful	  in	  developing	  and	  characterising	  a	  therapeutic	  cancer	  vaccine	  but,	  in	  hindsight,	  may	  have	  been	  a	  flawed	  model	  for	  investigating	  cancer	  stem	  cells.	  	  The	  capacity	  of	  GL261	  to	  form	  tumours	  after	  i.c.	  or	  s.c.	  implantation	  proved	  to	  be	  both	  an	  advantage	  and	  a	  potential	  hazard.	  One	  of	  the	  great	  disadvantages	  of	  the	  i.c.	  model	  is	  an	  inability	  to	  track	  tumour	  size	  over	  time,	  leaving	  time	  to	  symptom	  appearance	  as	  the	  only	  readout	  in	  therapeutic	  experiments.	  	  Serial	  MRI	  scanning	  
 266 
would	  have	  been	  impractical	  and	  costly	  and	  there	  is	  evidence	  that	  Ketamine	  and	  other	  general	  anaesthetic	  drugs	  can	  be	  immunosuppressive	  (F.-­‐L.	  Liu	  et	  al.	  2012).	  GL261	  can	  be	  modified	  to	  permit	  in	  vivo	  bioluminescence	  imaging	  (W	  Maes	  et	  al.	  2009a)	  but	  the	  technique	  is	  only	  semi-­‐quantitative	  and	  susceptible	  to	  errors	  (W	  Maes	  et	  al.	  2009a).	  Reports	  by	  colleagues	  of	  low	  sensitivity	  in	  detecting	  i.c.	  tumours	  (Lai-­‐Ming	  Ching,	  personal	  communication)	  and	  difficulties	  in	  achieving	  stable	  luciferase	  expression	  (David	  Walker,	  personal	  communication)	  dissuaded	  us	  from	  this	  approach.	  Another	  drawback	  of	  i.c.	  implantation	  is	  that	  it	  is	  relatively	  demanding	  and	  time-­‐consuming,	  making	  it	  difficult	  to	  ensure	  homogeneous	  tumour	  challenge	  in	  large	  experiments.	  The	  ability	  of	  GL261	  to	  form	  s.c.	  tumours	  offered	  a	  way	  around	  these	  two	  problems.	  However,	  the	  experience	  reported	  here	  has	  emphasised	  important	  differences	  in	  behaviour	  between	  s.c.	  and	  i.c.	  tumours.	  After	  i.c.	  implantation,	  tumours	  formed	  in	  almost	  100	  %	  of	  untreated	  mice	  at	  a	  consistent	  rate,	  whereas	  s.c.	  tumours	  often	  did	  not	  grow	  exponentially	  and	  sometimes	  regressed	  spontaneously	  or	  even	  failed	  to	  form,	  even	  though	  the	  number	  of	  implanted	  cells	  was	  100	  times	  greater.	  Variable	  behaviour	  after	  s.c.	  implantation	  of	  GL261	  leading	  to	  wide	  error	  bars	  is	  evident	  in	  other	  studies	  (Hülper	  et	  al.	  2011).	  The	  most	  likely	  explanation	  for	  spontaneous	  regression	  is	  that	  s.c.	  implantation	  elicits	  an	  endogenous	  immune	  response.	  GL261	  s.c.	  tumours	  grow	  more	  rapidly	  and	  in	  an	  exponential	  manner	  when	  implanted	  in	  immunodeficient	  mice	  (data	  not	  shown	  and	  Hülper	  et	  al.	  2011).	  Volovitz	  and	  colleagues	  (Volovitz	  et	  al.	  2011)	  coined	  the	  term	  “split	  immunity”	  to	  describe	  their	  observation	  in	  two	  implantable	  rat	  glioma	  models	  that	  i.c.	  tumours	  were	  invariably	  lethal	  but	  s.c.	  tumours	  all	  spontaneously	  regressed,	  an	  event	  that	  conferred	  protection	  against	  subsequent	  i.c.	  challenge.	  Although	  s.c.	  GL261	  is	  clearly	  not	  as	  immunogenic	  as	  these	  cell	  lines,	  the	  findings	  reported	  here	  do	  point	  to	  quantitative	  and/or	  qualitative	  differences	  in	  the	  endogenous	  immune	  response	  according	  to	  site	  of	  implantation.	  In	  Chapter	  6,	  a	  therapy	  effective	  against	  established	  s.c.	  tumours	  was	  not	  effective	  against	  tumours	  in	  the	  brain.	  It	  may	  be	  that	  the	  magnitude	  of	  the	  systemic	  therapy-­‐induced	  anti-­‐tumour	  immune	  response	  was	  greater	  when	  tumours	  were	  s.c.	  because	  a	  spontaneous	  response	  to	  implanted	  tumour	  cells	  was	  boosted	  by	  the	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immunotherapy	  whereas,	  when	  tumours	  were	  implanted	  into	  the	  relatively	  immune-­‐privileged	  CNS,	  the	  magnitude	  of	  the	  systemic	  immune	  response	  was	  determined	  solely	  by	  the	  immunotherapy.	  Alternatively,	  or	  perhaps	  in	  addition,	  the	  systemic	  immune	  response	  may	  have	  been	  more	  effective	  at	  the	  s.c.	  tumour	  site	  because	  of	  easier	  access	  for	  effector	  cells	  or	  a	  lower	  level	  of	  immunosuppression	  than	  at	  the	  i.c.	  site.	  	  Elucidating	  the	  reasons	  for	  	  “split	  immunity”	  has	  the	  potential	  to	  yield	  valuable	  insight	  into	  mechanisms	  hampering	  immunotherapies	  directed	  at	  tumours	  situated	  in	  the	  brain.	  In	  the	  meantime,	  although	  experiments	  involving	  s.c.	  tumour	  challenge	  served	  a	  useful	  purpose	  in	  this	  thesis,	  the	  data	  presented	  here	  illustrate	  a	  need	  for	  caution	  in	  extrapolating	  findings	  to	  the	  orthotopic	  setting.	  	  	  Common	  to	  both	  the	  Glioma-­‐Gal	  and	  Lysate-­‐Gal	  vaccines	  was	  a	  need	  for	  prior	  depletion	  of	  Treg	  to	  obtain	  therapeutic	  benefit.	  Success	  in	  the	  clinic	  also	  seems	  unlikely	  unless	  GBM-­‐induced	  immunosuppression	  can	  also	  be	  attenuated.	  This	  study	  and	  others	  have	  shown	  that	  Treg	  are	  a	  major	  source	  of	  immunosuppression	  in	  mouse	  models	  of	  glioma	  and	  there	  are	  strong	  grounds	  to	  believe	  that	  this	  is	  also	  the	  case	  in	  patients	  with	  GBM	  tumours	  (discussed	  in	  detail	  in	  Chapter	  1,	  Section	  1.3.4.3).	  The	  relative	  importance	  of	  other	  immunosuppressive	  mechanisms	  in	  the	  GBM	  setting	  is	  still	  not	  entirely	  clear.	  TAM,	  abundant	  in	  GBM,	  almost	  certainly	  contribute	  to	  local	  immunosuppression	  (Section	  1.3.4.4)	  but	  the	  role	  of	  MDSC	  and	  plasmacytoid	  DC,	  both	  strongly	  implicated	  as	  suppressor	  cells	  in	  animal	  models	  or	  other	  cancer	  types	  in	  humans,	  requires	  further	  study.	  Rather	  than	  targeting	  certain	  cell	  types,	  a	  more	  efficient	  strategy	  might	  be	  to	  target	  molecules	  that	  have	  broad	  immunosuppressive	  effects	  such	  TGF-­‐β	  or	  IDO.	  There	  is	  still	  much	  to	  be	  done	  to	  understand	  the	  many	  immunosuppressive	  mechanisms	  in	  play,	  how	  they	  interact	  with	  each	  other,	  and	  how	  to	  block	  these	  mechanisms	  in	  the	  most	  effective	  and	  efficient	  way.	  	  Checkpoint-­‐inhibiting	  antibodies	  directed	  at	  CTLA-­‐4,	  PD-­‐1	  and	  PD-­‐L1	  are	  now	  achieving	  striking	  results	  in	  patients	  with	  metastatic	  melanoma	  (Brahmer	  et	  al.	  2012;	  Hodi	  et	  al.	  2010;	  Topalian	  et	  al.	  2012).	  Importantly,	  these	  studies	  are	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powerfully	  validating	  the	  concept	  of	  immunotherapy	  for	  cancer.	  However,	  melanoma	  is	  a	  relatively	  immunogenic	  tumour	  characterised	  by	  high	  levels	  of	  tumour-­‐infiltrating	  lymphocytes	  and	  associated	  with	  occasional	  spontaneous	  remissions	  (Kalialis	  et	  al.	  2009).	  In	  GBM	  patients,	  the	  potential	  of	  checkpoint	  inhibitors	  seems	  more	  likely	  to	  be	  fully	  realised	  if	  used	  in	  combination	  with	  a	  treatment	  that	  generates	  increased	  numbers	  of	  effector	  cells,	  such	  as	  a	  vaccine.	  Anti-­‐CTLA-­‐4	  antibodies	  may	  prove	  to	  be	  a	  particularly	  useful	  in	  the	  GBM	  setting	  because	  they	  have	  been	  shown	  to	  act	  both	  by	  checkpoint	  inhibition	  and	  by	  depleting	  Treg	  at	  the	  tumour	  site	  (Peggs	  et	  al.	  2009;	  Simpson	  et	  al.	  2013).	  In	  support	  of	  this,	  colleagues	  at	  the	  Malaghan	  Institute	  have	  recently	  extended	  the	  work	  reported	  in	  this	  thesis	  to	  show	  that	  the	  Glioma-­‐Gal	  vaccine	  combined	  with	  an	  anti-­‐CTLA-­‐4	  antibody	  can	  eradicate	  80-­‐100	  %	  of	  established	  intracranial	  GL261	  tumours	  in	  mice	  (Cameron	  Field,	  personal	  communication).	  	  The	  studies	  in	  Chapter	  6	  demonstrated	  marked	  efficacy	  of	  therapeutic	  vaccination	  preceeded	  by	  anti-­‐CD25	  depleting	  antibody	  and	  an	  immunomodulatory	  dose	  of	  doxorubicin.	  Other	  combinations	  of	  immunomodulatory	  treatments	  such	  as	  anti-­‐CTLA-­‐4	  and	  anti-­‐PD-­‐1	  antibodies	  (Wolchok	  et	  al.	  2013)	  or	  anti-­‐CTLA-­‐4	  antibody	  and	  an	  IDO	  inhibitor	  (Holmgaard	  et	  al.	  2013)	  are	  also	  showing	  promise	  in	  patients	  and	  animal	  models.	  In	  this	  context,	  TMZ	  is	  firmly	  established	  as	  a	  standard	  treatment	  for	  patients	  newly	  presenting	  with	  GBM,	  making	  it	  important	  to	  understand	  and	  leverage	  any	  immunomodulatory	  properties	  this	  agent	  may	  have.	  As	  previously	  discussed,	  TMZ-­‐induced	  lymphopaenia	  appeared	  to	  promote	  the	  efficacy	  of	  a	  peptide	  vaccination	  in	  GBM	  patients	  (Sampson	  et	  al.	  2011)	  but	  TMZ	  can	  also	  unhelpfully	  increase	  the	  proportion	  of	  Treg	  (C.	  E	  Fadul	  et	  al.	  2011a;	  Mitchell	  et	  al.	  2011).	  Recent	  studies	  have	  shown	  treatment	  with	  an	  anti-­‐CD25	  antibody	  during	  TMZ-­‐induced	  lymphopenia	  selectively	  depletes	  Tregs	  in	  mice	  and	  GBM	  patients	  (Mitchell	  et	  al.	  2011;	  Sampson	  et	  al.	  2012)	  and	  the	  two	  treatments	  synergistically	  enhanced	  the	  efficacy	  of	  a	  vaccine	  in	  a	  mouse	  model	  of	  melanoma	  (Mitchell	  et	  al.	  2011).	  Combinations	  of	  complementary	  immunomodulatory	  agents	  may	  be	  a	  feature	  of	  successful	  immunotherapeutic	  strategies	  in	  the	  future.	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To	  conclude,	  a	  next-­‐generation	  immunotherapy	  for	  GBM	  could	  conceivably	  consist	  of	  a	  modified	  Glioma-­‐Gal	  vaccine	  combined	  with	  checkpoint	  inhibition	  and	  Treg	  depletion.	  Used	  in	  the	  newly	  presenting	  setting,	  this	  complex	  combination	  therapy	  would	  need	  to	  be	  designed	  around	  standard	  treatment	  to	  maximize	  the	  amplitude	  of	  the	  vaccine-­‐induced	  response.	  The	  goal	  of	  developing	  an	  effective	  treatment	  for	  patients	  with	  GBM	  remains	  a	  daunting	  one	  but,	  in	  light	  of	  recent	  advances	  in	  the	  field	  of	  cancer	  immunotherapy,	  the	  tools	  for	  making	  very	  significant	  progress	  may	  already	  exist.	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Figure A1. Flow cytometry gating strategy for enumerating B cells,  NK cells and selected
NK cell activation markers in the PBMC of clinical trial participants. B cells were defined as 
CD19+ lymphocytes (second row, right). NK cells were defined as CD56+CD3- lymphocytes (third 
row, left). Fluorescence Minus One panels in one subject were used as negative controls to guide
the setting of NK cell gates (third row, right). Bottom row shows results for Patient A08 at pre-
vaccination baseline (black lines) and 3 months post-vaccination (red lines). Solid grey histograms
show NK cells stained with FMO panels (for CD16 and NKG2D) or CD3+ lymphocytes stained 


























































































Figure A3. Flow cytometry gating strategy for identifying CD4 T cells (A) and 























































































Figure A4. Flow cytometry gating strategy for enumerating iNKT cells in the PBMC of 
























































































































Figure A5. Flow cytometry gating strategy for enumeration of myeloid DC in PBMC of 
GBM patients. Myeloid DC were defined as Lineage-CD11chiHLA-DRhi cells. Histogram at 
bottom shows CD1d surface staining of mDC from a representative patient  (black line) 





























































Figure A6. Flow cytometry gating strategy for assessment of CD1d expression on CD14++ 
monocytes in PBMC of GBM patients. Histogram at bottom right shows result from a 
representative patient (black line) compared with staining of the same PBMC with the panel minus 
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Medium only  PBMC PBMC 
+ CD3 mAb 
)LJXUH%,)1Ȗ(/,6SRWDVVD\YDOLGDWLRQ.  PBMC from a patient who had participated in a 
clinical trial of  a DC vaccine for metastatic melanoma were thawed, rested overnight, and then 

































)LJXUH%,)1Ȗ(/,6SRWDVVD\YDOLGDWLRQ PBMC from same melanoma patient and from the 
same time points as in Figure B1.2.1 x 105 PBMC per well, except CD3-stimulated wells which were 
5 x 104. Some wells were stimulated with 3 x 103 autologous tumour-pulsed DC (DCV), with a 
commercially-available pool of viral peptide antigens (CEF), or with an agonistic anti-CD3 antibody 
(CD3 mAb). This experiment confirmed low background activity from unstimulated PBMC. Responses 
WRWKH&()SHSWLGHSRROGHPRQVWUDWHGWKHFDSDFLW\RIDVVD\WRGHWHFWDQWLJHQVSHFLILF,)1ȖUHOHDVHE\
CD8 T cells. As in Figure B1.2, this experiment showed an increase in DCV-specific PBMC after 
vaccination, demonstrating consistency in the detection of DCV-elicited responses. In contrast, the 












)LJXUH%,)1Ȗ(/,6SRWDVVD\YDOLGDWLRQ PBMC from a participant in the GBM 
clinical trial. Surplus PBMC from the pre-vaccination time point were thawed, rested overnight,





















































CD4+ T cells CD4+ Lymphocytes
GFPGFP
Figure B2.1 Regulatory T-cell depletion. FoxP3-GFP mice were treated i.p. with 125 ȝg of PC61 
antibody. Peripheral blood was harvested 2 days later and analysed by flow cytometry.  Shown are 
FC plots of live CD3+ CD4+ lymphocytes (left column) and live CD4+ lymphocytes (right column) 
of a treated mouse (bottom row) and an untreated control mouse (top row). Plots are representative 
of 3 treated mice and 2 controls. 
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Control 125 μg 250 μg
Fig B2.2 CD4+ T cell depletion.  WT C57BL/6 mice were treated i.p. with a single dose of GK1.5 
antibody. Peripheral blood was harvested 13 days later and analysed by FC. Plots are gated on live 
CD3+O\PSKRF\WHVDQGDUHUHSUHVHQWDWLYHRIPLFHSHUJURXS0LFHWKDWUHFHLYHGȝJZHUH
still fully depleted at Day 13. In depletion experiments mice were vaccinated with Glioma-Gal on 






















































































































































































































































































































































































































Figure B4.1. The DC2114 dendritic cell line. A, Gating strategy for identifying DC2114 cells. B, 
CD11c expression  by DC2114 (blue line) in comparison with WT C57BL/6 splenocytes (red line). C, 








































Figure B5.1. Glioma-Gal Vaccine does not induce complete iNKT cell anergy. A, Mice were treated 









































































































































Medium GL261-8 GL261-23 Poly I:CLegend:
Figure B5.2. Effect of sonicated tumour cells on DC maturation.  Two GL261 parental tumour cell 
lines stored in the vapour phase of liquid N2 were thawed, washed, resuspended in incomplete 
medium, and sonicated for 120 minutes until all cells were Trypan Blue positive. Cells of the DC2114 
dendritic cell line were then pulsed with sonicated tumour cells at a ratio of 1:1 for 16 hours in 








































Figure B5.3 Synergistic effect of combining doxorubicin with immunotherapy. Summary of pooled 
results from experiments shown in Figure 6.3. The effect of the combined treatment on survival and 
tumour burden was greater than the sum of the effects of the two treatments as monotherapies. Survival 
was defined as no tumour, or a regressing tumour, at the conclusion of the experiment. Size < 75 mm2 




Figure B5.4. Effects of low dose Doxorubicin on immune cell populations. Proportion (left) and 
absolute number (right) of Treg in spleens of FoxP3-GFP reporter mice treated with Doxorubicin 2.5 
mg/kg i.v. (Dox) or not treated (Control), as in Figure 6.7. Splenocytes were assessed by flow cytom-
etry 24 hours after doxorubucin treatment. Gating strategy as in Figure 6.7A. 4 - 5 mice per group. The 
Mann Whitney test was used for statistical analysis. No statistically significant differences were seen 
between the total number of splenocytes in the two groups, or in the proportions or absolute numbers 
































































Figure B5.5.  Discordance between TRP-2 gene expression and protein level in tumour lysates. 
Western Blot analysis of TRP-2 protein concentration in freeze/thaw lysates of GL261 parental tumour 
cells and the Doxorubicin-tolerant DTEP 0.05 tumour cell line (left). Gene expression in the same 
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